EU Sovereign BCI

Generated on: 2026-11-01 00:35:31 with PlanExe2. Discord, GitHub

Part 1: Key decisions and facts

Go/no-go gates. NO at an early gate costs the least.

# Question Threshold Evidence If NO
1 Have at least 2 of the 3 Leuven institutions (imec, KU Leuven, UZ Leuven) signed LOIs naming resources (cleanroom hours, theatre time, ALS cohort access), or have the fallback sites (Ghent/Antwerp, Utrecht, Grenoble) signed in their place? At least 2 of 3 signed Leuven LOIs by Month 3. If not, fallback LOIs by Month 4 and fallback site activation by Month 6. Stop rule: recommend defer or stop if 2 or more primary partners AND their fallbacks have no signed LOI by Month 6. Signed LOIs with named resources and fallback capability letters, collected Months 3-6. Without access to a cleanroom, a surgical team and an ALS cohort, the animal cohort and the notified-body work cannot start. Activate the ranked fallback (cost up to about EUR 2M (estimate), FIH +3-6 months). If the fallbacks also fail, defer 12 months or stop. Do not spend T0 on facilities that are not committed.
2 Does written notified-body and ethics-committee pre-submission feedback require no more than 12 months of added evidence work (chronic animal data, FIH cohort size, decoder change control, consent method)? Evidence gaps listed fewer than 3 at Month 7 (premortem tripwire). Added work of 12 months or less: proceed. More than 12 months: re-plan and deferral review at the gate. More than 24 months: stop or pivot (all proposed thresholds). Written notified-body feedback from pre-submission (engagement Month 6, feedback about Month 7) and ethics pre-review feedback from 3 countries. Scientific-advice response follows the Month 12 request. Between 12 and 24 months of added work: defer in 12-month steps and re-cost T1 before Month 24. Above 24 months: stop, or pivot to a narrower first-in-human-only scope. Do not release T1 on an unresolved evidence gap.
3 Is T0 committed in writing (floor EUR 10M, target EUR 15M), after a seed of at least EUR 5M closed by Month 3 and with the CTO, CMO and regulatory lead hired? Seed of at least EUR 5M by Month 3. T0 of at least EUR 10M in writing by Month 12 (gate G1). 10 core staff by Month 6, with CTO, CMO and regulatory lead filled by Month 9. Signed investor LOIs and term sheets (at least 2 LOIs by Month 3), the closed seed, and signed offers. Gate verdict published within 5 business days of Month 12. Cut burn to the 5-person core within 48 hours. Then either switch to a grant-funded narrow ALS feasibility scope or defer. The documents disagree on whether this is an automatic 12-month deferral or a stop. That must be settled before the gate (see the missed-gate contradiction). No committed money means no implant programme.
4 Is the ALS eligible pool large enough, and do payers accept the price, so that a commercial case exists? Final epidemiology (Month 15) shows an eligible pool of at least 300 per year. This floor equals the 300/year capacity, so a capture rate must be stated. At least 3 member states give written acceptance of EUR 150,000 per implant and no more than EUR 120,000 per QALY (all proposed) by Month 18. Failure of either test triggers the Month 24 scope gate. Registry-based epidemiology commissioned by Month 3 and delivered by Month 15. Written HTA/payer letters by Month 18. A parallel SCI health-economic model by Month 12. Run the pre-registered pivot at Month 24: SCI indication, price or outcome-based renegotiation, or stop. Pool or price alone does not close the central-case gap of EUR 66M per year. A NO therefore also means no further tranche beyond T1 without a funded sustainability route.
5 Do chronic animal cohorts of the thin-film surface architecture stay within the pre-registered stability thresholds, and is the foundry or dual-sourcing route fixed? No more than 20% signal loss at 12 months. Over 25% mean human loss in 12 months, or retention below 50% at 36 months, triggers the pause or switch. Foundry commitments from 4+ member states at Month 18, else dual-sourcing. The 12-month gate is evaluable at Month 18 only if the cohort was implanted by Month 6; otherwise it runs at about Month 24. Animal results against thresholds frozen before data analysis, DMC-reviewed, published within 5 days of the gate. Foundry LOIs from member states. Supplier MOUs from Month 12. Block FIH and activate the penetrating-cortical fallback (about EUR 30M, range 15-60M (estimate), 12-24 months, CE moves to Month 144-156). Stop if both architectures lose more than 30%. Foundry NO means dual-sourcing (about EUR 35M, +6-12 months).
6 At Month 24, is at least EUR 60M of T1 committed, with a published feasibility verdict that shows no unresolved NO-GO in financing, supply chain, regulation or population? At least EUR 60M of T1 (EUR 120M) committed. The verdict separates scientific, engineering, clinical, regulatory, supply-chain and financing feasibility. No blocking FTO patent, and no supplier failing the three EU-control tests without a mitigation. Signed T1 commitments. The Month 24 verdict, built from epidemiology (Month 15), payer letters (Month 18), animal data (Month 18), FTO results (Month 9) and the preliminary QMS audit (Month 18). Under the canonical rule, no implant programme proceeds. Halt implant work and either stop or run a defined, funded narrow-scope fallback. A silent 12-month slide is not allowed. G4 at Month 36 (rest of T1 plus at least EUR 150M of T2) is the next test.

What you need to decide, and by when.

5 open decisions: 2 high and 3 medium severity. The gate-outcome table and the investor proposition are urgent. Both must be settled by Months 2-3 (2026-12-31 to 2027-01-31), before seed term sheets, because EUR 0 is committed and the central case yields a EUR 66M annual gap. Until then the plan can safely proceed with the MVP: hiring, LOI collection, epidemiology commissioning, notified-body contact and the reserve trust design. It should not commit to facilities, to investor return language, or to the switch funding source.

# Decision Severity Owner Decide by Blocks
1 Gate-outcome table and decision owners 🔴 High Board / investor consortium with the Steering Committee; DMC for safety triggers only. Month 3 (2027-01-31), before seed and term sheets are signed, so G1 extension rules can go into the term sheet. G1 (Month 12 = 2027-10-31), G3 (Month 24 = 2028-10-31), G4 (Month 36 = 2029-10-31); term sheets.
2 Honest investor proposition and sustainability route 🔴 High Board / sponsor, with the investor consortium. Month 2 (2026-12-31), before seed and investor LOIs (Month 3 = 2027-01-31). Seed close (Month 3 = 2027-01-31), G1 (Month 12 = 2027-10-31), and the Month 120 (2036-10-31) sustainability gate.
3 Financing of early architecture switch 🟡 Medium Board / investor consortium. Month 12 (2027-10-31), with the G1 term sheet. Architecture ratification (Month 18 = 2028-04-30), switch gate (Month 30 = 2029-04-30), and G4 (Month 36 = 2029-10-31).
4 Capture-rate assumption and pool gate floor 🟡 Medium Steering Committee, on Clinical Operations Lead advice. Month 3 (2027-01-31), when the registry epidemiology is commissioned. Final epidemiology (Month 15 = 2028-01-31) and the Month 24 (2028-10-31) scope gate.
5 Patient reserve size and treatment in opex 🟡 Medium Board, with the Finance Controller and an actuary. Month 6 (2027-04-30), when the trust is set up with its EUR 5M floor. Trust setup (Month 6 = 2027-04-30), FIH (Month 60 = 2031-10-31), and restated T2-T4 financing.

1. Gate-outcome table and decision owners (🔴 High)

Decision: What does a missed financing gate mean (G1, G3, G4), and who decides: board/investors, CEO, Steering Committee or DMC?

Why it is open: Canonical G3 says 'no implant programme proceeds'. Pitch, KPI 1 and Review 13.2 say automatic 12-month deferral. FM1 says stop or defer. The CEO is called sole authority, while investors control capital and the DMC can pause. Slip estimates for a G1 miss differ (3-6, 6-12, 12-24 months).

Option Consequences What changes in the plan
A. Publish one table: G1 miss = defer 12 months once; G3 miss = no implant programme, with a named stop or narrow-scope option; G4 miss = FIH deferred in 12-month steps or stop. Clear stop rules. FIH slips to about Month 72 (2032-10-31) after a G1 miss. Capital decisions go to the board or investors, safety to the DMC. Pitch metrics, KPI 1, Reviews 12.1 and 13.2, premortem FM1, escalation matrix.
B. Keep case-by-case votes by the Steering Committee (extend, defer 12 months, or terminate). Flexible, but extensions can drain runway of EUR 2-5M (estimate) per month and blur the no-renegotiation promise. Remove 'automatic' and 'no renegotiation' wording.
C. Automatic 12-month deferral for every missed gate. Simple, but contradicts G3 and keeps cost running with EUR 0 committed. Canonical financing_gate_g3 would be rewritten.

2. Honest investor proposition and sustainability route (🔴 High)

Decision: Will the programme be positioned as a subsidy-dependent public-interest venture, or will capacity, price or volume be changed to seek a commercial return?

Why it is open: Canonical economics: revenue EUR 45M vs opex EUR 111M, gap EUR 66M per year, break-even about 1,125 implants per year against capacity of about 300. The pitch lists revenue as an investor benefit. SCI, a price of EUR 200,000+ and subsidy are offered as fixes, but none closes the gap (about EUR 51M remains at EUR 200,000).

Option Consequences What changes in the plan
A. State the central case gives no commercial return. Target impact and public investors. Month 120 (2036-10-31) gate requires committed member-state operating funding, else scale down or wind down. Honest pitch, narrower investor pool, a clear gate. Affects T2-T4 (EUR 2,365M) fundraising. Executive summary, pitch 'For Investors' and 'Sustainability', Review 14.1.
B. Redesign for a return: more centres or capacity, higher price, SCI expansion. Needs new capacity and payer evidence. Exceeds 300 per year, and no price in the documents closes the gap. Capacity, price and opex facts; the Month 24 (2028-10-31) scope gate.
C. Defer the choice to the Month 24 (2028-10-31) scope gate. Seed and T0 raised on an unclear proposition. Risks mis-selling. Pitch wording only.

3. Financing of early architecture switch (🟡 Medium)

Decision: Which committed money pays an architecture switch or early advance in Months 18-48 (2028-04-30 to 2030-10-31)?

Why it is open: The canonical switch costs about EUR 30M (range 15-60M) and is drawn from the T3 contingency, which starts at Month 84 (2033-10-31) and is uncommitted. The trigger is at Month 18 (2028-04-30), with the gate at Month 30 (2029-04-30), when only EUR 15M (T0) and EUR 60M (T1) are committed. Reviews say both 'T1' and 'T3' contingency.

Option Consequences What changes in the plan
A. Standing switch reserve inside T1. Immediate funds, but raises the G3 and T1 asks above EUR 60M and reduces design-lock money. T1 EUR 120M split; contingency wording.
B. Investor standby facility. Keeps T1 size, but needs a negotiated commitment before Month 18 (2028-04-30). Term sheets; financing facts.
C. No advance: accept a schedule hit until T3 money is available. CE moves to Month 144-156 (2038-10-31 to 2039-10-31) or later. FIH slips further, probably outside range 54-78. FIH and CE ranges; scenario labels.

4. Capture-rate assumption and pool gate floor (🟡 Medium)

Decision: What capture rate (consent, stage, surgical eligibility, competitors) applies, and what eligible-pool floor should the Month 15 (2028-01-31) gate use?

Why it is open: Gate floor is a pool of at least 300 per year, which equals the capacity of about 300 per year, so it implies near 100% capture. The eligible pool is 500-1,400 per year, implying about 21-60% capture, which no document states.

Option Consequences What changes in the plan
A. State a capture rate (for example 30-50%, proposed) and derive the floor from it (about 600-1,000 per year). Stricter gate. More likely to trigger the Month 24 (2028-10-31) scope gate or an SCI pivot. Review 5.1, KPI 2, FM3, exec Risk 3.
B. Keep the 300 floor and label it a minimum. Passes easily, but the commercial case is not tested. Wording only.
C. Test the pool floor against the cumulative range of 400-3,000. Links pool to outcomes; needs a model. Cumulative implants and epidemiology brief.

5. Patient reserve size and treatment in opex (🟡 Medium)

Decision: Are reserve contributions inside opex or on top, and is EUR 30,000 per implant kept before the actuarial study?

Why it is open: Canonical reserve is EUR 30,000, 100% funded at implantation. Reviews cite a ratio of 1.0 'by Month 120 (2036-10-31)' and 'likely EUR 40,000-60,000'. It is unclear whether the reserve is in the EUR 111M opex; if on top, the gap is about EUR 75M and break-even about 1,800 per year (estimates).

Option Consequences What changes in the plan
A. Keep EUR 30,000 at implantation, inside opex (gap EUR 66M). Keeps the canonical figures; the reserve must be shown inside variable cost. Self-audit 18, Reviews 10.3, 11.2, 14.3.
B. Keep EUR 30,000 on top of opex. Gap about EUR 75M, break-even about 1,800 per year. Trust needs EUR 5M floor by Month 6 (2027-04-30). Financing gap and break-even facts.
C. Raise the planning value to EUR 40,000-60,000 now. Reserve for 1,050 implants rises to about EUR 42-63M; larger gap. Reserve per implant and totals.

Choices made on your behalf

Set when the scenario was selected, not by you. Confirm or change them.

Lever Chosen Strongest alternative Why it matters Revisit by
Sourcing the EU neurotech base Exclusive field-limited licences with pre-priced acquisition options, converting no earlier than Month 24 (2028-10-31). Acquire or merge with EU neurotech companies outright (Pioneer's Gambit). It sets capital at risk and how fast capability and IP are secured. Month 24 (2028-10-31), when options may convert.
Foundry and supplier sovereignty route Own encapsulation and assembly, dual-source chips and substrates, and publish an upstream register. Co-found a shared foundry with member states, or transfer to a contract manufacturer (Safe Harbour). It decides sovereignty compliance and depends on a hoped-for EUR 350M foundry gate. Month 18 (2028-04-30) foundry gate.
First indication ALS communication first, with the pivotal indication chosen at the Month 78 (2033-04-30) kill gate. SCI motor control from the start. It sets the eligible pool, endpoint and the 5,000-implant outlook. Month 24 (2028-10-31) scope gate and Month 78 (2033-04-30).
Evidence and regulatory strategy Early notified-body and scientific advice, with coordinated multi-country FIH in Leuven plus 1-2 other states. Single-country feasibility study in Leuven before widening. It affects speed and the dossier, and depends on ethics committees in several countries. Month 7 (2027-05-31) notified-body feedback.
Staged financing Founder seed and grants for the first two years, then tranches released at milestones (G1, G3, G4). Large anchor round from EU strategic and public investors. EUR 0 is committed today, so this sets the runway and governance control. Month 12 (2027-10-31) (G1).
Architecture Thin-film surface implant (provisional), with a penetrating cortical fallback. Penetrating cortical as primary, or endovascular. It drives safety, stability, bandwidth and switch cost (about EUR 30M). Month 18 (2028-04-30) architecture lock.
Patient-protection reserve Ring-fenced trust from the first implant, EUR 30,000 per implant. Escrow with a larger actuarial sum (EUR 40,000-60,000). It protects implanted patients if the company fails. Month 6 (2027-04-30) trust setup.

Key numbers and dates.

Kind: user constraint = from your prompt; decision = chosen in this plan; proposed threshold = a pass/fail line proposed in this plan, to be confirmed; estimate = not verified.

Fact Value Kind Basis
programme_horizon Month 0 (2026-10-31) to Month 180 (2041-10-31) (15 years) user constraint User states a 15-year plan from today; Month 0 (2026-10-31) is the project start.
company_funding_envelope EUR 2.5B over 15 years (planning ceiling, not committed) user constraint User assumption of about EUR 2.5B from return-seeking investors plus grants; tranche sizes are ceilings drawn only against gates.
committed_funding_month0 EUR 0 committed at Month 0 (2026-10-31); everything is hoped-for until a written commitment closes user constraint User forbids assuming funding; all documents agree that nothing is committed; committed, probable and hoped-for are reported separately at every gate.
shared_foundry_estimate EUR 350M (Months 18-84 = 2028-04-30 to 2033-10-31), shared neural-implant foundry, hoped-for, funded by 4+ member states estimate Documents give no figure; this placeholder is kept outside the company envelope and stays hoped-for until 4+ member states commit (IPCEI norm); the company plan does not depend on it.
programme_total EUR 2.85B = EUR 2.5B company + EUR 0.35B shared foundry; committed today EUR 0 estimate Recomputed: 2,500 + 350 = EUR 2,850M; the company route works without the foundry, so only EUR 2.5B is the investor-and-grant requirement.
tranche_t0_mvp_budget EUR 15M for Months 0-24 (2026-10-31 to 2028-10-31) (MVP), equal to about EUR 0.6M per month estimate Bottom-up, recomputed: team 5.0 + chronic animal work 3.0 + pilot-line prototyping 2.5 + FTO/regulatory/AI/QMS 1.5 + licences and options 1.5 + consent/DMC/epidemiology/health-economics 0.7 + contingency 0.8 = EUR 15.0M; 15 / 24 = 0.625M per month; rejected the EUR 5-10M figure as too tight and the EUR 2-5M per month burn as over-scoped for 10-15 people.
tranche_t1_design_lock_and_transfer EUR 120M for Months 24-48 (2028-10-31 to 2030-10-31) (about EUR 5M per month) decision Recomputed: 120 / 24 months = EUR 5M per month; allocation of the envelope for design lock, GLP chronic studies, production transfer, QMS audit and FIH preparation; matches the upper end of the documents' EUR 2-5M per month burn after the MVP; replaces the documents' much smaller Series A/B figures, which cannot fund this work.
tranche_t2_to_t4 T2 EUR 480M (Months 48-84 = 2030-10-31 to 2033-10-31); T3 EUR 900M (Months 84-132 = 2033-10-31 to 2037-10-31); T4 EUR 985M (Months 132-180 = 2037-10-31 to 2041-10-31) decision Recomputed: 15 + 120 + 480 + 900 + 985 = EUR 2,500M (averages: T2 about 13.3M, T3 about 18.8M, T4 about 20.5M per month); includes a EUR 250M (10%) programme contingency (EUR 100M in T3, EUR 150M in T4) released only by the board, so no programme contingency exists before Month 84 (2033-10-31) and earlier draws need a board-approved advance; the T0 contingency of EUR 0.8M sits inside the EUR 15M and is separate; every tranche is a ceiling released on gate evidence.
financing_gate_g1 Month 12 (2027-10-31): T0 committed in writing (floor EUR 10M, target EUR 15M); first seed close of at least EUR 5M by Month 3 (2027-01-31) proposed threshold Documents place the seed gate at Month 12 (2027-10-31) and seed funding at about Month 3 (2027-01-31); the floor of EUR 10M sits at the top of the documents' EUR 5-10M seed range and the target equals the EUR 15M T0 budget; if missed: stop non-critical hiring and defer to a desk-only programme (FTO, epidemiology, regulatory, about EUR 2M, estimate), then wind down at Month 15 (2028-01-31) if still unfunded.
financing_gate_foundry Month 18 (2028-04-30): commitments from 4+ member states for the shared foundry, else switch to the dual-sourcing route proposed threshold Risk register sets Month 18 (2028-04-30) as the switch date (Month 24 = 2028-10-31 appears elsewhere and is rejected as too late for design lock at Months 24-30 = 2028-10-31 to 2029-04-30); IPCEI talks start Months 6-12 (2027-04-30 to 2027-10-31).
financing_gate_g3 Month 24 (2028-10-31): at least EUR 60M of T1 committed, plus Month 24 (2028-10-31) feasibility verdict; otherwise no implant programme proceeds proposed threshold EUR 60M is half of the EUR 120M T1; if missed: defer or narrow to ALS-communication feasibility work with a stated stop date, no pivotal commitments; Series A/B sizes in the pre-project file (EUR 3-25M) rejected as inconsistent with the envelope.
financing_gate_g4 Month 36 (2029-10-31): remaining EUR 60M of T1 plus at least EUR 150M of T2 (EUR 480M, about 31%) committed conditionally; else FIH deferred in 12-month steps or the programme stops proposed threshold Pre-project file calls this the pivotal-funding gate at Month 36 (2029-10-31), but FIH is at Month 60 (2031-10-31), so the gate is defined as funding to reach FIH and start the pivotal programme; 60 + 60 = EUR 120M T1 closes; EUR 50-75M in that file is rejected as too small.
patient_reserve_per_implant EUR 30,000 per implant, 100% funded at implantation, in a trust outside investor reach estimate Recomputed over a 7-year design lifetime (estimate; range 5-10): follow-up and imaging EUR 2.5k per year x 7 = 17.5k + expected explantation 25% x EUR 30k = 7.5k + servicing about 5k = EUR 30k; the 10-year glide path is rejected because insolvency early on would strand implanted patients.
patient_reserve_totals Trust set up by Month 6 (2027-04-30) with EUR 5M floor before FIH; EUR 150M if 5,000 implants; about EUR 31.5M for the 1,050 central implants; EUR 4.5M for the 150 trial implants estimate Recomputed: 5,000 x EUR 30k = EUR 150M (top of the documents' EUR 50-150M range); 1,050 x EUR 30k = EUR 31.5M; 150 trial implants x EUR 30k = EUR 4.5M, covered by the EUR 5M floor, which is funded inside T2 (before FIH at Month 60 = 2031-10-31) and not from the programme contingency; the 900 commercial implants carry the EUR 30k in opex, paid from revenue; the floor is a placeholder for wind-down costs and needs actuarial validation.
architecture_primary High-density thin-film surface (epidural/subdural cortical) implant with wireless external processor (provisional, ratified at Month 18 = 2028-04-30) decision Best fit for Class III net benefit and long-term safety, lowest surgical risk, and aligned with EU microfabrication; penetrating cortical offers higher bandwidth but higher surgical and stability risk; endovascular is excluded (lowest bandwidth, rival-held IP); confirmation depends on FTO per architecture before Month 6 (2027-04-30) and scoring by Month 9 (2027-07-31).
architecture_fallback_switch Contingency: penetrating cortical microelectrode; switch costs about EUR 30M (range 15-60M, estimate) and 12-24 months; drawn from the T3 contingency (EUR 100M), so CE moves to Month 144-156 (2038-10-31 to 2039-10-31) estimate Documents price a switch at only EUR 1-3M, which covers a design review rather than rebuilding preclinical, process and regulatory evidence; recomputed: central CE 132 + 12-24 = Month 144-156 (2038-10-31 to 2039-10-31); a switch would be triggered after the Month 72 (2032-10-31) human gate or the 36-month retention check (about Month 96 = 2034-10-31), i.e. after T3 begins at Month 84 (2033-10-31), so even the EUR 60M upper case fits within the T3 contingency; the fallback stays under the cap but misses the Month 120 (2036-10-31) CE target.
free_contingency_after_named_draws About EUR 219M of the EUR 250M programme contingency stays free in the central case (EUR 250M - 30M architecture switch - 1.2M early site-fallback advance); about EUR 189M if the switch costs the EUR 60M upper bound estimate Recomputed: 250 - 30 - 1.2 = EUR 218.8M; 250 - 60 - 1.2 = EUR 188.8M; the EUR 35M dual-sourcing transfer sits inside T1/T2 (base case) and the EUR 5M reserve floor inside T2, so neither reduces the contingency; the delay costs of a 12-24 month CE slip are not priced and also draw on the contingency, so the free amount is an upper bound.
first_indication ALS communication restoration; primary outcome is user-controlled communication (net bits/s plus daily-life use versus eye-tracking) decision Chosen by the scenario (small ALS FIH cohort first); strongest clinical-benefit margin over assistive technology; spinal cord injury kept as a gated pivotal alternative.
pivotal_indication_gate Month 78 (2033-04-30) (central): pre-registered kill gate choosing the pivotal indication; also a Month 24 (2028-10-31) scope gate proposed threshold Decision-3 logic needs FIH data (first implants Month 60 = 2031-10-31 plus 12-month follow-up = Month 72 = 2032-10-31, plus about 6 months analysis = Month 78 = 2033-04-30, ahead of the pivotal first implant at Month 84 = 2033-10-31); at Month 24 (2028-10-31) the gate triggers SCI assessment if realistic ALS-only cumulative implants are below 1,000 (central 1,050 is only marginally above) or fewer than 3 member states signal acceptable reimbursement; the risk file's 'ALS pool below 3,000' is rejected as unclear.
fih_timing Month 60 (2031-10-31) (range 54-78); cohort 10 participants (5-10); early feasibility total up to 20 estimate User target is about 5 years, central case matches; chronic animal data of 18-24 months on the locked design (start by Month 33 = 2029-07-31, finishing Month 51-57 = 2031-01-31 to 2031-07-31) precede FIH; the risk file's 20-30 early cohort is treated as the combined early feasibility total and is rejected for the FIH cohort.
pivotal_start_and_lock Pivotal first implant Month 84 (2033-10-31) (range 72-96); materials, chips and processes locked by Month 72 (2032-10-31); pivotal cohort about 80 estimate Recomputed backward from central CE at Month 132 (2037-10-31): 84 + 24 months of enrolment + 12-month endpoint + about 12 months of notified-body review = 132; cohort size is an assumption to agree with the notified body; bridging-study budget about EUR 20M inside T2 (estimate).
ce_marking_timing Central Month 132 (2037-10-31) (range 114-156); user target Month 120 (2036-10-31) is missed in the central case estimate Central 132 follows the bottom-up schedule (84 + 24 + 12 + 12, with no extra slip assumed); the upper bound 156 adds a 24-month Class III review slip (documents: 12-24 months), and a 6-12 month production-transfer delay would fall within that range; Month 114 (2036-04-30) requires a pivotal start near Month 72 (2032-10-31) with about 18 months of enrolment and no slip; soft target of about Month 120 (2036-10-31) is reported as missed.
cumulative_implants_month180 About 1,050 central (range 400-3,000); the 5,000 target is missed in all scenarios estimate Recomputed: 150 trial implants + commercial 100 + 200 + 300 + 300 = 900 in Months 132-180 (2037-10-31 to 2041-10-31) = 1,050; the pessimistic 400 is an expert-centre model with CE at Month 156 (2039-10-31), the optimistic 3,000 adds spinal cord injury; the assumptions file's 2,500-5,000 is rejected as inconsistent with the epidemiology review.
active_users_month180 About 550 active users (about 52% of 1,050 cumulative; range 200-2,000) estimate Recomputed: 0.52 x 1,050 = 546, about 550; ALS survival of roughly 3 years from diagnosis causes attrition, plus explantation; cumulative implants and active users are reported separately and the reimbursed-patient target counts active reimbursed users.
implant_capacity_and_eligible_pool About 300 implants per year at Months 168-180 (2040-10-31 to 2041-10-31) across about 25 centres (about 12 per centre); eligible pool 500-1,400 per year estimate EU ALS incidence 5,000-7,000 per year x 10-20% meeting indication criteria = 500-1,400 (epidemiology review); a distributed model of 20+ centres gives 200-300 per year, an expert-centre model 50-100; 300 / 25 = 12 per centre; 300 per year is about 21-60% of the pool.
unit_definition_and_financing Unit = one implanted system (implant, external processor, first-year service); trial implants programme-financed; commercial implants payer-financed decision The roughly 150 trial implants (20 early feasibility + about 80 pivotal + about 50 continued access = 150) are counted against the EUR 2.5B; the roughly 900 commercial implants are paid for by payers; shared foundry capex and member-state co-funded surgical units are not counted against the cap; who finances hospital surgical units is an open decision.
price_per_implant EUR 150,000 per implant (device system price to payer, proposed); cost-effectiveness ceiling EUR 120,000 per QALY (proposed) proposed threshold Low end of the review's EUR 150-250k range; the risk file's EUR 20-40k is rejected as not covering cost; at a price of EUR 150k the benefit must reach at least 1.25 QALYs (150/120, device price only, before any offsetting savings) against current aids, which still needs evidence.
annual_revenue_month168_180 EUR 45M per year (300 implants x EUR 150,000) estimate Recomputed from the price and the year-15 volume: 300 x 150k = EUR 45M; cumulative commercial revenue through Month 180 (2041-10-31) is about EUR 135M (900 x EUR 150k), versus EUR 2.5B funding; sales only in the EU/EEA.
annual_opex_month168_180 EUR 111M per year: fixed EUR 90M + variable EUR 21M estimate Recomputed: fixed R&D 40 + clinical/regulatory/post-market 15 + sales/admin 25 + follow-up and service 10 = EUR 90M; variable 300 x (cost of goods EUR 40k + reserve contribution EUR 30k) = 300 x 70k = EUR 21M; total 111M; all costs are estimates.
financing_gap_and_breakeven No debt (EUR 0 debt service); operating gap EUR 66M per year at Month 180 (2041-10-31); break-even about 1,125 implants per year estimate Recomputed: 45 - 111 = -EUR 66M; contribution per implant 150 - 70 = EUR 80k; 90M / 80k = 1,125 implants per year, which exceeds the 300 per year capacity ceiling; the gap is funded by T4 equity and grants (no debt service coverage applies), so ALS-only does not reach self-funding and investor returns are not demonstrated within 15 years; fixing this needs wider indications, higher volume or higher price.
bandwidth_early_target At least 10 bits/s net, user-controlled, sustained across sessions, in at least 3 participants (soft target; participant count proposed), with independent verification user constraint User target is at least 10 bits/s in early trials; the minimum of 3 participants is a proposed addition (plan asks only for multiple participants); measured on a pre-registered protocol with held-out tasks, excluding language-model expansion, reporting structured selection and free communication separately plus words per minute, error rate, latency and calibration time.
bandwidth_stretch_and_rivals Own year-15 scenarios: 10 / 30 / 100 bits/s (pessimistic / central / optimistic); best rival systems: 25 / 60 / 150 bits/s (estimates) estimate The over-100 goal at year 15 is a stretch goal, only the optimistic case; rival figures are net-comparable placeholder scenarios from public disclosures (not verified), updated yearly, so a rival lead is likely in the central case.
bandwidth_kill_floor Below 5 bits/s sustained net in 50% or more of participants at 12 months after FIH (central Month 72 = 2032-10-31) triggers architecture or indication review proposed threshold Recomputed: FIH Month 60 (2031-10-31) + 12 = Month 72 (2032-10-31); the risk file's Month 24 (2028-10-31) and the pre-project file's Month 36 (2029-10-31) bandwidth floors are rejected because no human is implanted before Month 60 (2031-10-31); thermal-derated bandwidth must also retain at least 50% of nominal at 35-40 degC (estimate).
safety_kill_threshold 3 or more device- or procedure-related serious adverse events in the first 20 implants, or 2 or more in the first 10, triggers pause and design review proposed threshold Reconciles the risk file (more than 10% in the first 20, which is 3 or more) with the pre-project file; expected early SAE rate is 5-15% (estimate), i.e. 1-3 events in 20, so the threshold sits at the upper end and needs regulator review before FIH.
stability_kill_thresholds Animal gate: over 20% signal loss within 12 months blocks FIH; human: over 25% mean usable-signal loss within 12 months triggers a pause; below 50% retention at 36 months post-implant triggers architecture switch proposed threshold Combines the risk file's 20% (applied to the animal pre-FIH gate), the pre-project file's 25% (human) and the 50%-retention switch criterion; with FIH at Month 60 (2031-10-31) the 36-month check falls at about Month 96 (2034-10-31), after the pivotal start at Month 84 (2033-10-31), so the 12-month human gate (Month 72 = 2032-10-31) is the one that protects pivotal lock; all values are unvalidated and need the chronic-stability modelling due by Month 12 (2027-10-31).
consent_and_monitoring_governance Independent consent advocate by Month 3 (2027-01-31); DMC (5+ members, patient representative, binding pause authority) by Month 6 (2027-04-30); any invalid-consent finding pauses that site proposed threshold Hard requirement of valid consent; yes/no signalling validated before surgery, no recruitment from coercive settings; the pre-project file's 20%-of-cohort stop level is kept as a study-wide stop, with site-level pause tightened to a single finding.
regulatory_milestones Notified-body engagement Month 6 (2027-04-30); ISO 13485 QMS Month 9 (2027-07-31); scientific-advice request Month 12 (2027-10-31); preliminary QMS audit Month 18 (2028-04-30); architecture lock Month 18 (2028-04-30); AI Act budget about EUR 2M decision Aligned across the documents; no reduced evidence burden is assumed; the AI Act budget uses the upper estimate (EUR 0.5-2M) because of decoder change-control and notified-body review, spread over the programme; coordinated multinational FIH assessment covers Leuven plus 1-2 other member states.
sovereignty_tests_and_supplier_lock Three tests per component (EU ownership, maintainable without foreign consent, export-control freedom); upstream register Month 12 (2027-10-31); supplier MOUs Month 12 (2027-10-31); second chip and substrate supplier qualified Month 30 (2029-04-30); all passed by Month 72 (2032-10-31) decision Delivered system EU-controlled by the pivotal trial; encapsulation and assembly owned, chips and thin-film substrates dual-sourced; upstream tools are documented exceptions; the UK and Switzerland are outside the perimeter; neural data stays in the EU; the risk file's Month 36 (2029-10-31) supplier date is rejected because it falls after design lock (Months 24-30 = 2028-10-31 to 2029-04-30), whereas Month 30 (2029-04-30) coincides with the end of the design-lock window; MOUs at Month 12 (2027-10-31) plus 9-18 months of qualification fit Month 30 (2029-04-30).
sourcing_route Exclusive field-limited licences with pre-priced acquisition options; letters of intent from imec, KU Leuven and UZ Leuven by Month 3 (2027-01-31); options convert no earlier than Month 24 (2028-10-31) decision Scenario choice; option conversion needs validation milestones and the three sovereignty tests; the build-versus-license-versus-acquire comparison is decided by Month 6 (2027-04-30); the cap on acquisition spending is an open decision for the Month 24 (2028-10-31) gate.
fallback_cost_and_delay UZ Leuven declines: fallback sites (Ghent/Antwerp, Utrecht, Grenoble) by Month 6 (2027-04-30), FIH +3-6 months, cost up to about EUR 2M; no foundry: dual-sourcing, about EUR 35M production transfer (T1 10M + T2 25M), +6-12 months estimate Recomputed: 10 + 25 = EUR 35M; the dual-sourcing transfer is the base case and already sits inside T1/T2, so it does not draw on the contingency; the site fallback of up to EUR 2M exceeds the T0 contingency of EUR 0.8M by EUR 1.2M, which needs re-phasing within T0 or a board-approved advance from the programme contingency (decision needed); delays: FIH moves to Month 63-66 (2032-01-31 to 2032-04-30), CE to Month 138-144 (2038-04-30 to 2038-10-31) if the foundry is absent and transfer slips.
mvp_team 10 core staff by Month 6 (2027-04-30), about 15 by Month 24 (2028-10-31); EU pay trails US pay by 20-30% (estimate), offset by equity and retention bonuses decision Both documents give 10-15 people covering neurosurgery, neuroengineering, regulatory, quality and manufacturing; the EUR 5.0M team line in T0 implies about EUR 0.2M per FTE-year over about 24 FTE-years (estimate); deputies cross-trained by Month 12 (2027-10-31); the MVP scope is fixed by Month 1 (2026-11-30).
feasibility_verdict Preliminary: achievable only with changes; final verdict Month 24 (2028-10-31); financing not credibly achievable as specified; 5,000 implants by Month 180 (2041-10-31) not credibly achievable decision Scientific, engineering, clinical, regulatory and supply-chain feasibility are each achievable only with changes (CE about Month 132 = 2037-10-31, ALS-limited volume, bandwidth above 100 bits/s only as a stretch); financing has EUR 0 committed; the revised mission (a CE-marked ALS communication implant, about 1,050 cumulative implants) is presented separately and never counts as achieving the original.
market_scope_and_competitor_gate Sales only in the EU/EEA through Month 180 (2041-10-31); competitive-response gate if a US device is CE-marked in the EU during Months 36-60 (2029-10-31 to 2031-10-31) decision Avoids foreign-regulator and export-control exposure; EU choice rests on measured daily-life benefit, EU-held data, local service and lifelong support, not nationality; a first US entrant could cut early capture by 30-50% (estimate).
enhancement_firewall Human-AI enhancement in a separate legal entity; no implanted-human enhancement work before CE marking; no medical-tranche money decision Protects the intended-use statement and consent trust; only non-clinical hardware and licensed IP cross the firewall after review; the funding source for the enhancement entity is an open decision.
climate_resilience_actions Leuven resilience assessment by Month 3 (2027-01-31); backup power and redundant cooling by Month 18 (2028-04-30); second-site compute replica; wearable battery of at least 12 hours; climate-chamber tests at 35-40 degC proposed threshold Documents agree on Months 3 and 18 (2027-01-31, 2028-04-30); the battery figure is a design target from the risk file; the cost of cooled-refuge support for heat-vulnerable participants is not yet estimated and is listed as an open item.

Focus and Context

A 15-year (Month 0 = 2026-10-31 to Month 180 = 2041-10-31), EUR 2.5B European effort to deliver a CE-marked Class III implantable BCI for ALS communication restoration, with critical dependency: EUR 0 is committed at Month 0 (2026-10-31). The programme targets EU control of all critical components (electrodes, electronics, encapsulation, decoding, neural data), at least 10 bits/s sustained bandwidth, and approximately 1,050 implanted patients by Month 180 (2041-10-31), falling short of the 5,000-implant ambition. Success requires gated capital release, independent safety oversight, and binding patient-protection reserves—or credible programme termination if evidence-gated kill thresholds are breached.

Purpose and Goals

Deliver a CE-marked implantable BCI device (primary achievement), prove sustained ≥10 bits/s net user-controlled bandwidth via independent verification, establish EU sovereign ownership of all critical IP and neural-data residency, achieve reimbursement in 3+ member states, implant approximately 1,050 patients (central estimate) by Month 180 (2041-10-31), and maintain lifelong patient support via a EUR 30,000-per-implant ring-fenced trust. Success criteria: (a) CE marking achieved by Month 132 (2037-10-31) central (range 114–156), (b) feasibility verdict separating scientific, engineering, clinical, regulatory, supply-chain and financing credibility by Month 24 (2028-10-31), (c) zero unresolved invalid-consent or serious-adverse-event findings, (d) all components passing EU-control tests by Month 72 (2032-10-31).

Key Deliverables and Outcomes

Primary: CE marking (Class III implantable BCI) by Month 132 (2037-10-31) central. Secondary: (1) ~1,050 cumulative implants and ~550 active users by Month 180 (2041-10-31); (2) ≥10 bits/s sustained bandwidth in at least 3 participants, independently verified at the Month 72 (2032-10-31) review (central case); (3) first-in-human early feasibility (10 participants): Month 72 (2032-10-31) decision based on the first 3 participants with a stated minimum follow-up, bandwidth floor review on those with 12 months of follow-up; a late FIH (Month 78 = 2033-04-30) delays these gates accordingly; (4) pivotal trial cohort (~80 participants) enrolled by Month 120 (2036-10-31); (5) EUR 31.5M patient-protection trust (estimate) established and growing; (6) reimbursement contracts signed with payers in 3+ EU member states; (7) 25-centre surgical network activated by Month 180 (2041-10-31).

Timeline and Budget

Total: EUR 2.5B + EUR 0.35B shared foundry (hoped-for) = EUR 2.85B over 15 years. Committed funding at Month 0 (2026-10-31): EUR 0. Tranches: T0 EUR 15M (MVP, Months 0–24 = 2026-10-31 to 2028-10-31); T1 EUR 120M (design lock and transfer, Months 24–48 = 2028-10-31 to 2030-10-31); T2–T4 EUR 2.365B (Months 48–180 = 2030-10-31 to 2041-10-31). Gates: Month 12 (2027-10-31) T0 commitment; Month 18 (2028-04-30) foundry or dual-sourcing; Month 24 (2028-10-31) T1 EUR 60M minimum; Month 36 (2029-10-31) T2 EUR 150M minimum. Central timeline: FIH Month 60 (2031-10-31) (range 54–78); CE marking Month 132 (2037-10-31) (range 114–156; user target Month 120 = 2036-10-31 missed in the central case).

Risks and Mitigations

Risk 1 (Critical): Financing gate failure at Months 12, 24, 36 (2027-10-31, 2028-10-31, 2029-10-31). Likelihood: High. Mitigation: Secure written LOIs from 2–3 anchor investors by Month 3 (2027-01-31) specifying EUR 10–15M T0 and automatic-deferral rules; publish gate verdicts within 5 business days, no renegotiation. Risk 2 (Critical): Chronic signal-stability preclinical data breach 20% animal loss threshold by Month 18 (2028-04-30). Likelihood: Medium. Mitigation: Keep the proposed kill thresholds (20% animal / 25% human / 50% retention at 36 months); the literature review may inform only a documented change before Month 12 (2027-10-31), with a change log approved by the DMC, and no revision is allowed after the pre-registration date; if breached, activate EUR 30M (estimate) architecture switch to penetrating cortical, with Deputy CTO leading fallback in parallel by Month 6 (2027-04-30). Risk 3 (Critical): ALS eligible population confirmed <300 annually or payers reject EUR 120,000/QALY cost-effectiveness ceiling. Likelihood: Medium. Mitigation: Complete epidemiology and HTA dialogues by Month 15 (2028-01-31); pre-register hard indication-pivot decision (spinal cord injury or stop) by Month 24 (2028-10-31) with decision rule published by Month 6 (2027-04-30).

Audience Tailoring

Intended for EU founders (requiring gate enforcement governance), lead investors and public-funding institutions (requiring credible risk-retirement milestones and break-even analysis), notified bodies and ethics committees (requiring patient protection and consent governance), and member-state policymakers (requiring sovereignty and IPCEI fit assessment). Tone: evidence-led, sober, with explicit acknowledgment that feasibility is conditional on three critical dependencies: investor commitment (LOIs by Month 3 = 2027-01-31), and payer acceptance and eligible-population validation (commissioned by Month 3 = 2027-01-31, evidence due Months 15–18 = 2028-01-31 to 2028-04-30). Not tailored to transhumanist or technology-optimist audiences: enhancement research is firewalled and does not influence medical-device decisions.

Action Orientation

Immediate (Months 0–3 = 2026-10-31 to 2027-01-31): Secure written partnership LOIs from imec, KU Leuven, UZ Leuven; activate fallback sites in parallel; identify and approach 3–5 anchor investors; close at least EUR 5M seed funding. Near-term (Months 3–12 = 2027-01-31 to 2027-10-31): Establish Data Monitoring Committee and consent advocate; engage notified body (Month 6 = 2027-04-30); start the thin-film chronic-animal cohort by Month 6 (2027-04-30) on the seed (implant at Month 6 = 2027-04-30, start conditional on seed closing and a GLP-compliant facility; if the cohort starts at Month 6 = 2027-04-30 the 12-month gate is evaluable at Month 18 = 2028-04-30, otherwise architecture is ratified provisionally and the 12-month gate runs at about Month 24 = 2028-10-31) and FTO analysis; complete ISO 13485 QMS framework; publish upstream-dependency register (Month 12 = 2027-10-31); close T0 (EUR 10–15M) in writing by Month 12 (2027-10-31) or initiate automatic 12-month deferral. Gate-driven (Months 18–24 = 2028-04-30 to 2028-10-31): Ratify architecture and foundry route by Month 18 (2028-04-30); publish comprehensive feasibility verdict by Month 24 (2028-10-31); secure T1 commitment (EUR 60M minimum) or halt implant programme.

Overall Takeaway

This EUR 2.5B, 15-year programme is achievable only with changes: the 5,000-implant target and user's Month 120 (2036-10-31) CE-marking target are not credibly achievable: the 5,000-implant target is missed in all scenarios and the Month 120 (2036-10-31) CE target is missed in the central case. Central case projects ~1,050 cumulative implants by Month 180 (2041-10-31), CE marking by Month 132 (2037-10-31), and a EUR 66M annual operating gap at scale, requiring indefinite member-state subsidy or indication expansion (spinal cord injury) to reach long-term viability. Patient protection, valid consent and EU control are achievable hard requirements; financing, population scale and commercial sustainability are at severe risk without immediate investor LOIs (Month 3 = 2027-01-31) and timely resolution of payer willingness-to-pay and eligible-population epidemiology (evidence due Months 15–18 = 2028-01-31 to 2028-04-30). Kill gates and independent Data Monitoring Committee authority are the binding credibility mechanisms; their enforcement determines whether the programme succeeds or fails transparently.

Feedback

To strengthen this summary: (1) Quantify the three critical dependencies (investor LOIs by Month 3 = 2027-01-31; payer and population evidence by Months 15–18 = 2028-01-31 to 2028-04-30) more precisely: name anchor investor candidates, specify notified-body engagement outcome targets, and cite epidemiological data sources (not estimates). (2) Expand the break-even and financial-sustainability section with sensitivity analysis: show how ±10% changes in implant price, eligible-population size, and device lifetime affect cumulative returns and the EUR 2.5B envelope exhaustion date. (3) Add a retrospective risk-interaction table showing which risks compound (e.g., foundry failure + signal-stability breach: only the EUR 30M (up to 60M) architecture switch plus the EUR 1.2M early site-fallback advance come out of the EUR 250M contingency, leaving about EUR 219M (189M at the upper bound) free; the EUR 35M production transfer is a T1/T2 re-allocation), not just individual risk mitigations. (4) Include a one-page "red-flag decision tree" showing exactly when and by whom the programme is stopped (not deferred) if gates are missed. (5) Provide explicit payer and HTA body contact names or organisations, not generalised references, so commitments can be tracked in real time.

Unoptimized waterfall. Parallel work not modelled here.

Part 2: Supporting analysis

Persuasive elevator pitch.

A Sovereign European Brain-Computer Interface for Locked-in ALS: 15-Year Neurotechnology Programme

Project Overview

Severe ALS patients lose voice and movement while retaining full cognitive function. Existing communication devices are slow, exhausting, and dependent on residual muscle control that inevitably degrades. This 15-year programme will deliver a CE-marked Class III implantable brain-computer interface capable of restoring rapid, natural communication—at least 10 bits/s sustained bandwidth—while establishing Europe's strategic independence in frontier neural technology.

The vision is to implant 1,050 patients over the programme lifespan (Month 0 = 2026-10-31 to Month 180 = 2041-10-31), keeping all neural data and critical intellectual property under EU control. The approach is frontier-scale, evidence-gated, and designed to succeed or fail credibly: kill gates, staged capital release, and independent oversight replace blind optimism. Rather than hide extreme ambition (EUR 2.5B company funding plus EUR 350M shared foundry over 15 years), the plan acknowledges it and implements pre-registered kill criteria to reduce sunk-cost losses and preserve investor trust if the science proves intractable.

The programme targets a timing of CE marking by Month 132 (2037-10-31), with first-in-human (FIH) implantation at Month 60 (2031-10-31). It is not targeting the 5,000-implant ceiling often cited in speculative timelines; the central estimate is 1,050 implants and approximately 550 active users by Month 180 (2041-10-31), a target that acknowledges the eligible population (500–1,400 ALS-eligible patients per year) and the clinical pathway's realistic pace.

Target Audience

Primary audiences:

Secondary audiences:

Not targeted:

Project Overview: Strategic and Medical Rationale

Europe currently has no sovereign implantable brain-computer interface capability. Existing research is fragmented across labs; manufacturing relies on US or Asian suppliers; and neural data governance is uncertain. This programme consolidates research leadership (imec, KU Leuven), establishes a European foundry for neural-implant chip and thin-film fabrication, and delivers a validated, reimbursed, patient-protective system that serves as the foundation for European independence in implantable neurotechnology.

For ALS patients, the medical need is acute: standard augmentative and alternative communication (AAC) devices rely on eye gaze, residual finger movement, or speech synthesis from pre-programmed banks—all of which fail as the disease progresses. A BCI that decodes intent directly from cortical activity and delivers communication at natural speech rates (>10 bits/s) restores agency, reduces caregiver burden, and delays institutional care.

Risks and Mitigation Strategies

Risk 1: Financing Shortfall

Risk 2: Chronic Signal Stability Failure

Risk 3: Eligible Population and Indication Pivoting

Risk 4: Regulatory Rework and CE-Marking Delay

Risk 5: Shared Foundry Funding Failure

Risk 6: Clinical-Site Fallback

Risk 7: Bandwidth Below Credible Threshold

Risk 8: Serious Adverse Events and Safety Pause Triggers

Metrics for Success

Financing and Capital Gates:

Clinical and Bandwidth:

Technical Stability and Reliability:

Regulatory:

Payer and Reimbursement:

Sovereignty and EU Control:

Clinical Volume and Outcomes:

Stakeholder Benefits

For Patients:

For Surgeons and Hospital Partners:

For Payers and HTA Bodies:

For Investors:

For EU Member States and the Commission:

For EU Research Institutes and Universities:

Ethical Considerations

Consent and Autonomy:

Patient Protection and Device Independence:

Firewall Between Medical and Enhancement Research:

Data Governance and AI Act Compliance:

Transparency and Accountability:

Equity and Inclusion:

Collaboration Opportunities

Research Consortia and Anchor Partners:

Manufacturing and Foundry:

Payers and Health-Technology Assessment:

Regulators and Notified Bodies:

Patient Organisations:

Enhancement Research and Public Engagement:

Long-Term Vision

By Month 180 (2041-10-31), this programme will have established Europe's sovereign capability in implantable brain-computer interfaces and proven that frontier neurotechnology can be developed, manufactured, and governed under EU control without dependence on US or Chinese platforms.

Clinical and Scientific Outcomes:

Technology and Manufacturing:

Sovereignty and Strategic Independence:

Post-CE Marking Enhancement Research:

Sustainability and Ecosystem:

Regulatory and Ethical Leadership:

Call to Action

Prospective co-founders and seed investors:

Expressions of interest by Month 3 (2027-01-31) for consideration in the T0 funding round (EUR 15M target, EUR 10M floor, Months 0–24 = 2026-10-31 to 2028-10-31). Commit in writing by Month 12 (2027-10-31) (financing gate G1).

EU governments and member states:

Signal IPCEI-type support for shared foundry funding (EUR 350M estimate, Months 18–84 = 2028-04-30 to 2033-10-31) by Month 18 (2028-04-30). If shared foundry cannot secure commitments, accept the dual-sourcing alternative (EUR 35M production transfer, +6–12 months schedule buffer, pre-budgeted).

Clinical sites and surgeons:

Commit by Month 3 (2027-01-31) with a letter of intent for first-in-human participation and pre-training. Letters of intent from imec, KU Leuven, and UZ Leuven required by Month 3 (2027-01-31) for scope lock.

Investors and asset managers:

Review the gated financing terms (T0 EUR 10–15M, gate G1 Month 12 = 2027-10-31; T1 EUR 120M, gates G3 and G4 at Months 24 and 36 = 2028-10-31, 2029-10-31) and the kill-gate independence charter before due diligence. Recognise that kill gates are non-waivable; investor preference cannot override pre-registered thresholds.

Regulatory agencies and notified bodies:

Confirm engagement for pre-submission QMS development and Commission scientific advice. Preliminary QMS audit scheduled Month 18 (2028-04-30); scientific-advice request Month 12 (2027-10-31). Pre-select notified body by Month 6 (2027-04-30).

Patient organisations and consent advocates:

Join the independent consent-advocate network (appointed Month 3 = 2027-01-31) and Data Monitoring Committee (convened Month 6 = 2027-04-30). Participate in consent-protocol co-design and participant-recruitment planning.

Data-protection and ethics authorities:

Prepare for neural-data governance audits and AI Act compliance verification. Designate representatives for Data Monitoring Committee and ethics oversight.


This 15-year programme is frontier-scale and evidence-gated. Success is not guaranteed. Kill gates, staged capital release, and independent oversight are not constraints—they are the credible foundation on which this ambition rests. Europe's sovereignty in implantable neurotechnology depends on delivering this system or demonstrating, with transparency and rigour, why it cannot be done.

Goal Statement: Found a Leuven-based EU company and deliver a CE-marked, EU-controlled Class III implantable brain-computer interface for ALS communication restoration, with demonstrated clinical benefit, ≥10 bits/s net user-controlled bandwidth in early trials, and reimbursed patients, over 15 years (Month 0 = 2026-10-31 to Month 180 = 2041-10-31) within a EUR 2.5B planning ceiling (user constraint). Preliminary verdict: achievable only with changes; the 5,000-implant target is not credibly achievable.

SMART Criteria

Dependencies

Resources Required

Related Goals

Tags

Risk Assessment and Mitigation Strategies

Key Risks

Diverse Risks

Mitigation Plans

Stakeholder Analysis

Primary Stakeholders

Secondary Stakeholders

Engagement Strategies

Regulatory and Compliance Requirements

Permits and Licenses

Compliance Standards

Regulatory Bodies

Compliance Actions

Primary Decisions

The vital few decisions that have the most impact.

The five Critical levers (sourcing, foundry and supplier sovereignty, first indication, regulatory evidence strategy, staged financing) cover the core tensions: speed versus clean EU-controlled IP, sovereignty versus capex, patient need versus market scale, and evidence rigour versus cash runway. High levers add decoder residency, payer case, FTO, consent, surgical throughput and kill gates. Missing: an explicit architecture-choice lever, talent recruitment against US salaries, and a fallback for Leuven partners declining.

Decision 1: Build, License or Acquire: Sourcing the EU Neurotech Base

Lever ID: a18d3d5b-5593-42e9-a953-15b509d33323

The Core Decision: Decides how the founder-only company obtains electrode, ASIC and decoding capability, and sets the baseline for schedule and IP cleanliness. Scope covers diligence against the three EU-control tests (ownership, maintainability without foreign consent, export-control freedom), integration cost of legacy quality systems, and talent retention. Success metrics: months saved to first-in-human, share of design history owned outright, and zero unresolved foreign consent rights at pivotal lock.

Why It Matters: Starting with only founders, the company can compress years of work by licensing or acquiring existing EU teams, electrode IP or implant electronics, or it can build in-house and keep full control of design history and IP. Acquisition brings existing quality systems and know-how but also legacy design choices, diligence burden and possible foreign-held licences that compromise the sovereignty tests. Building preserves clean ownership but delays first-in-human and strains hiring against US salaries.

Strategic Choices:

  1. Build the core electrode, electronics and decoding stack in-house in Leuven from the founders outward, licensing only non-critical components, to keep ownership and design history unencumbered.
  2. Acquire or merge with one or more existing EU neurotech companies or university spin-outs holding electrode, ASIC or decoding IP, subject to sovereignty-criteria diligence that screens out foreign consent rights and export-control exposure.
  3. Form a licensing-plus-option structure with EU research institutes, taking exclusive field-limited licences now and holding pre-priced acquisition options that convert only if validation milestones are met.

Trade-Off / Risk: Acquisitions buy time and a quality system but import legacy architecture and hidden foreign licence encumbrances, while building preserves clean IP at the cost of schedule and a founder-only team recruiting against US pay.

Strategic Connections:

Synergy: Clean, diligenced IP strengthens Freedom-to-Operate and Patent Position Strategy and gives Neural-Implant Foundry and Supplier Sovereignty Route a concrete process baseline. Acquired quality systems also shorten the path to notified-body engagement.

Conflict: Acquisition spending competes with the early-risk budget in Staged Financing and Sovereign Capital Gates. Inherited architecture can also pre-empt the architecture and First Indication and the Outcome That Justifies Surgery choices, narrowing options before evidence exists.

Justification: Critical, Hub lever for a founder-only start. It sets schedule to first-in-human, IP cleanliness and the sovereignty baseline. It feeds Freedom-to-Operate, Foundry and regulatory quality systems, while competing with early financing and pre-empting architecture and indication choices.

Decision 2: Neural-Implant Foundry and Supplier Sovereignty Route

Lever ID: fa2b1430-2709-4e46-94cb-58237d51c19a

The Core Decision: Defines how electrodes, chips, encapsulation and assembly move from research prototyping to a validated, EU-controlled Class III supply chain locked before the pivotal trial. Scope includes pilot-line-to-production transfer, dual-sourcing, a register of upstream tool dependencies, and bridging-study budgets. Metrics: sovereignty tests passed per component, qualified second sources, yield and process-validation completion, and months of margin before design lock.

Why It Matters: The delivered system needs EU-controlled electrodes, chips, encapsulation and processes locked before the pivotal trial, yet a research pilot line is not a validated Class III production line. Relying on an imec-type pilot line gives fast access but unproven production-grade quality and no guaranteed commitment. A shared foundry or dual-sourcing across member states improves resilience but depends on funding the company does not control, and upstream tool dependencies remain documented exceptions rather than solved.

Strategic Choices:

  1. Prototype on a Leuven research pilot line, then transfer to a validated EU contract manufacturer for Class III production, with the transfer plan and dual-source qualification funded before design lock.
  2. Co-found a shared European neural-implant foundry with other member states and suppliers under a multi-state funding scheme, with a financing gate and a named fallback if the funding is not committed by the deadline.
  3. Split the supply chain by criticality: vertically own encapsulation and implant assembly in-house, qualify two competing EU suppliers for chips and thin-film substrates, and publish a register of upstream tool dependencies with mitigation plans.

Trade-Off / Risk: A shared foundry depends on multi-state funding that cannot be assumed, and a pilot line cannot simply be relabelled as production, so the route is only credible if transfer-to-validated-manufacturing is budgeted and gated early.

Strategic Connections:

Synergy: Locked, validated processes give Evidence and Regulatory Strategy Under MDR and the AI Act a stable device for the pivotal dossier, and give Implanted-Patient Continuity Covenant credible long-term part supply for support and replacement.

Conflict: Foundry and transfer costs strain Staged Financing and Sovereign Capital Gates, especially if multi-state funding is not committed. Early process lock also limits Build, License or Acquire: Sourcing the EU Neurotech Base flexibility to change inherited designs.

Justification: Critical, Controls the foundational hard requirement of an EU-controlled delivered system locked before the pivotal trial. Links sourcing, financing, decoder compute budget, regulatory dossier stability and patient-support part supply. Pilot-line-to-validated-production transfer is the largest capex and feasibility risk.

Decision 3: First Indication and the Outcome That Justifies Surgery

Lever ID: 6a7fd572-c086-41d0-b6f3-7330ac00973a

The Core Decision: Selects the initial patient population and the clinical outcome that justifies Class III brain surgery, which then fixes endpoint design, consent burden, comparator and eligible pool. It should be judged on effect size over existing assistive technology, survivorship for lifelong follow-up, and the realistic path to 5,000 reimbursed active users. Success: a pre-registered primary endpoint accepted by regulators and payers.

Why It Matters: The indication sets the participant population, the consent process, the clinical endpoint and the eligible patient pool behind the 5,000-implant target. Locked-in ALS communication has a clear unmet need but a small, progressive and short-lived population with severe consent challenges. High spinal cord injury motor control offers a larger and longer-lived population but faces strong alternatives and a harder functional-outcome case. The choice also shapes the reimbursement comparator against existing assistive technology.

Strategic Choices:

  1. Select communication restoration for people with advanced ALS or locked-in syndrome, using a user-controlled communication outcome as the primary endpoint and building an independent consent-support process for impaired communication.
  2. Select motor or device control in high cervical spinal cord injury, using a functional independence outcome as the primary endpoint, with a larger and longer-surviving population but a tougher comparison against current assistive devices.
  3. Start with a small ALS communication first-in-human cohort to establish safety and bandwidth, then pre-register a pivotal indication decision at a kill gate, comparing eligible population, benefit size and reimbursement evidence before committing.

Trade-Off / Risk: The ALS population most in need is small and short-lived, which strains the 5,000-patient and reimbursement targets, while spinal cord injury widens the pool but weakens the benefit margin over assistive technology.

Strategic Connections:

Synergy: A well-chosen indication focuses Living Consent for Locked-In and Declining-Communication Participants on a defined population and anchors Why Europe Chooses This Device: Payer Case and Market Scope with a concrete comparator and health-economic endpoint.

Conflict: The most needy ALS population shrinks the pool that Implanting-Centre Network and Surgical Throughput Ceiling and the 5,000-patient target depend on. A communication endpoint may also conflict with Bits-per-Second Claim Discipline and Rival Scenario Ratchet if bandwidth is overclaimed.

Justification: Critical, Fixes population, endpoint, consent burden, comparator and the eligible pool behind the 5,000-patient target. Connects to consent, payer case, centre network and bandwidth claims, and governs the central tension between patient need and scalable market size.

Decision 4: Evidence and Regulatory Strategy Under MDR and the AI Act

Lever ID: 668e2a7e-27a4-488f-b1b8-1daceeaca60a

The Core Decision: Sets the sequencing of notified-body engagement, Commission scientific advice, coordinated multinational investigations, quality and risk management, and AI Act high-risk compliance for a Class III device. It cannot lower evidence requirements, so value comes from avoiding rework and design errors. Metrics: documented regulator feedback before design freeze, accepted investigation plans, and change-control rules letting decoder updates avoid resetting evidence.

Why It Matters: Class III conformity needs early alignment on clinical investigation design, quality management, risk management and AI Act obligations for high-risk AI in a medical device. Early scientific advice and coordinated multinational assessment can reduce rework but do not reduce evidence requirements. Engaging a notified body early costs time and money before there is a product, and a weak early dossier risks locking in design errors.

Strategic Choices:

  1. Engage a notified body and seek Commission scientific advice before design freeze, running the first-in-human study in Leuven and one or two other member states under coordinated assessment to build the pivotal dossier incrementally.
  2. Run a single-country early feasibility study at the Leuven university hospital for speed, deferring multinational coordination until the device design is stable and the decoder and AI model are version-locked.
  3. Build an adaptive, pre-registered evidence plan in which decoder updates are handled by a locked change-control process aligned with AI Act requirements, so continuous decoder improvement does not reset the clinical evidence.

Trade-Off / Risk: Early regulator engagement reduces rework but costs time and cash before a device exists, and no route reduces evidence requirements, so every schedule gain must come from sequencing rather than from lighter proof.

Strategic Connections:

Synergy: Early regulator alignment sharpens First Indication and the Outcome That Justifies Surgery endpoints and supports Decoder Stack Residency and Model Provenance by defining version-locked, auditable AI models and data handling.

Conflict: Early engagement and multinational coordination consume cash and time before a device exists, pressuring Staged Financing and Sovereign Capital Gates. Locked change control also limits the decoder iteration that Bits-per-Second Claim Discipline and Rival Scenario Ratchet may want.

Justification: Critical, Gatekeeper to CE marking, the success definition. Sequencing of notified body, scientific advice and AI change control links to indication, decoder, consent, foundry and FTO. Controls the speed versus rework trade-off without reducing evidence requirements.

Decision 5: Staged Financing and Sovereign Capital Gates

Lever ID: 839a49ee-bab2-4ecd-94fd-18786bf4ec0b

The Core Decision: Structures the roughly €2.5 billion, 15-year envelope into tranches released on demonstrated risk retirement, separating committed from hoped-for money and shared-infrastructure from company capital. It defines financing gates with deadlines and named fallbacks, and ring-fences patient-protection reserves. Metrics: months of runway beyond each gate, share of funding actually committed, investor return expectations met, and reserve adequacy.

Why It Matters: The assumed envelope of about €2.5 billion mixes investor money that needs a return, grants and hoped-for multi-state funding, none of it committed at the start. Tying tranches to demonstrated risk retirement protects against running out of money before approval, but stricter gates may deter investors who want faster scale. The financing structure also has to fund reserves for implanted patients, so a failed raise affects patient protection as well as company survival.

Strategic Choices:

  1. Fund the first two years with a founder-led seed and national or regional grants sized only to retire the first decisive risks, then release larger tranches on pre-agreed technical and clinical milestones.
  2. Seek a consortium of EU strategic investors and public financing institutions to anchor a larger early round, trading some governance control for committed multi-year capital and credibility with member states.
  3. Ring-fence a patient-protection reserve and explant-and-support escrow from the first implant, funded separately from operating capital, so the obligations to implanted patients survive any financing failure.

Trade-Off / Risk: Milestone-gated tranches protect against insolvency before approval, but gates sized to retire only early risks may leave the company under-capitalised for the Class III manufacturing and pivotal phase that follows.

Strategic Connections:

Synergy: Clear gates support Stop-Decision Authority and Pre-Registered Kill Gates by tying capital release to technical evidence, and fund the escrow underpinning Implanted-Patient Continuity Covenant independently of operating cash.

Conflict: Tight early tranches may starve Neural-Implant Foundry and Supplier Sovereignty Route of the capex needed before design lock, and constrain Build, License or Acquire: Sourcing the EU Neurotech Base by limiting acquisition capacity.

Justification: Critical, Central conflict hub: nearly every lever (sourcing, foundry, regulation, covenant, kill gates, enhancement narrative) draws on or constrains it. Running out of money before approval is a named failure mode, and committed versus hoped-for funding determines feasibility.


Secondary Decisions

These decisions are less significant, but still worth considering.

Decision 6: Human-AI Enhancement Track and Public Trust Boundary

Lever ID: 97caadbc-3334-420a-9416-d3799c78d8b0

The Core Decision: Governs how far human-AI enhancement research is organised, funded and communicated relative to the Class III medical programme. Scope covers legal structure, IP and hardware sharing rules, and public messaging. Success metrics: no regulator or ethics-committee objection citing enhancement intent, unchanged patient recruitment rates, a clean intended-use statement in the device file, and documented firewall audits.

Why It Matters: A separate enhancement research track supports the long-term mission and may share hardware and IP, but visible ambitions for human-AI merging can erode regulator, ethics-committee and public trust in the medical programme. Strict separation protects the Class III dossier and patient recruitment but limits technology reuse and may weaken the investor story. Loose coupling saves cost but risks regulatory scrutiny over intended use and consent.

Strategic Choices:

  1. Hold the enhancement track in a separate legal entity with a documented firewall, sharing only non-clinical research hardware and licensing IP across it under a review process that protects the medical device file.
  2. Defer any enhancement activity to a small, publicly documented research programme using non-implanted or animal work only until the medical device achieves CE marking, communicating the long-term vision solely as a bandwidth research agenda.
  3. Create an independent external ethics and public-engagement board with authority to review enhancement research and communications, publishing its findings, to turn the controversial vision into an accountable, transparent debate.

Trade-Off / Risk: Separating enhancement from the medical programme protects trust and the dossier, but it removes the investor narrative and shared-platform savings that made the mission attractive, and public communication may still be read as one project.

Strategic Connections:

Synergy: Amplifies Freedom-to-Operate and Patent Position Strategy by clarifying which IP crosses the firewall, and supports Living Consent for Locked-In and Declining-Communication Participants by keeping consent language about medical benefit only, which protects recruitment trust.

Conflict: Trades off against Staged Financing and Sovereign Capital Gates, since strict separation weakens the merger-vision investor story, and against Bits-per-Second Claim Discipline and Rival Scenario Ratchet, because ambitious enhancement rhetoric invites inflated bandwidth claims.

Justification: Medium, Manages a real trust and intended-use risk and the investor narrative, but it is a separate track. Connections are mainly to financing story, consent language and rhetoric on bandwidth; mostly governance and communication optimisation rather than core feasibility.

Decision 7: Decoder Stack Residency and Model Provenance

Lever ID: d1128ba5-bafd-4115-a3a7-e154ce7f8fe4

The Core Decision: Decides where decoding runs (implant, body-worn processor or EU-hosted compute), who trains the models, and how updates are controlled after the pivotal trial lock. It fixes latency, power, cybersecurity surface and AI Act change-control burden. Success metrics: decoder performance at the target information transfer rate, offline-capable operation, a documented EU model lineage, and a bounded revalidation scope per update.

Why It Matters: Deciding where decoding runs (on the implant, on a body-worn processor, or in EU-hosted compute) and who trains the models sets the latency, power budget, cybersecurity surface and the AI Act burden. Keeping training data, model weights and toolchains EU-controlled supports the sovereignty tests but narrows access to the largest pretrained neural-decoding foundation models, which are mostly built outside the EU. The choice also determines what must be revalidated if a model or framework is swapped after the pivotal trial lock.

Strategic Choices:

  1. Run a compact, locked decoder on a body-worn EU-built processor, with EU-hosted retraining only offline, so the delivered system works without any cloud connection.
  2. Train adaptive decoders on EU-hosted compute using models built in-house from consented trial data, and update them through a controlled change-management process under the quality system.
  3. Release the decoder reference implementation and evaluation datasets to a consortium of EU labs for open scrutiny, keeping only the clinical build and the manufacturing know-how proprietary.

Trade-Off / Risk: On-device locked decoding eases sovereignty and security audits but may cap decoding performance, while adaptive EU-hosted models improve accuracy at the cost of continuous AI Act change control and compute dependence.

Strategic Connections:

Synergy: Enables Evidence and Regulatory Strategy Under MDR and the AI Act by giving a defined, lockable AI scope, and supports Bits-per-Second Claim Discipline and Rival Scenario Ratchet through reproducible, held-out decoder evaluation.

Conflict: Constrains Heatwave-Hardened Wearable and Thermoregulation Envelope, since more on-body compute raises heat and power load, and Neural-Implant Foundry and Supplier Sovereignty Route, because chip choice must fit the decoder's compute budget.

Justification: High, Determines where decoding runs, AI Act change-control burden, cybersecurity and EU model lineage. Connects regulatory strategy, bandwidth evaluation, chip choice and thermal load, so it governs the performance versus sovereignty and security trade-off.

Decision 8: Implanted-Patient Continuity Covenant

Lever ID: 1046e268-cbcd-4043-bee3-7e8a58a58c2b

The Core Decision: Sets the binding mechanism that keeps implanted people supported (follow-up, servicing, explantation, data access) if the company fails or is acquired. It shapes reserve size, investor terms and device design, such as explantability and open interfaces. Success metrics: reserve coverage per implant over expected device lifetime (to be estimated), a tested successor handover, and no abandoned patients.

Why It Matters: Fixing in advance how implanted patients are supported if the company fails shapes the capital structure, the reserve size and the investor terms. A binding covenant protects patients and public trust but ties up money that would otherwise fund development, and it affects the design itself, for instance through explantability and standardised external interfaces. Without it, the failure mode of abandoning patients is left to chance.

Strategic Choices:

  1. Fund a ring-fenced escrow or trust that grows with each implant, sized to cover follow-up, device servicing and explantation for the expected device lifetime, and held outside investor reach.
  2. Contract a step-in agreement with an EU hospital network or a second manufacturer, giving it escrowed designs, software source and spare-part rights to keep supporting patients if the company becomes insolvent.
  3. Make the covenant a design requirement by building devices with documented open external interfaces and a surgically simple explantation path, so any qualified successor can maintain patient access to the device.

Trade-Off / Risk: A growing escrow reliably protects patients but competes directly with development spending, whereas step-in rights and open interfaces cost less cash yet rely on a successor party that may not exist when the company fails.

Strategic Connections:

Synergy: Reinforces Why Europe Chooses This Device: Payer Case and Market Scope, since credible lifelong support is a payer and hospital selling point, and builds public trust that helps the Human-AI Enhancement Track and Public Trust Boundary.

Conflict: Competes for cash with Staged Financing and Sovereign Capital Gates, as growing reserves reduce development funding, and constrains Implanting-Centre Network and Surgical Throughput Ceiling by adding per-implant cost that limits scaling economics.

Justification: Medium, Addresses a named failure mode (abandoned patients) and affects design and payer trust, but its funding mechanism overlaps with the ring-fenced reserve in Staged Financing. Largely a bounded obligation sized once the capital structure is set.

Decision 9: Why Europe Chooses This Device: Payer Case and Market Scope

Lever ID: 63288d39-d434-4c98-b858-86eb4675574e

The Core Decision: Defines the value proposition against existing assistive technology and a possible earlier US CE-marked entrant, and the geographic scope, including whether to sell outside the EU. It drives trial endpoints, comparator choice, health-economic models and payer engagement. Success metrics: HTA and payer acceptance in several member states, reimbursed implant volume, and cost per quality-adjusted life year (to be modelled).

Why It Matters: If US competitors obtain CE marking first, the case for EU patients, hospitals and payers rests on demonstrated clinical benefit, evidence under local conditions, service and data policy, not nationality. The evidence package built for reimbursement also drives trial endpoints, comparator choice and the pace at which the 5,000-patient target can be reached. Selling outside the EU would widen the market and revenue, but may bring export-control and foreign-regulator obligations that touch the sovereignty tests.

Strategic Choices:

  1. Design trial endpoints and health-economic models around daily-life function versus existing assistive technology, and agree on early reimbursement dialogues with a small set of national payers and HTA bodies.
  2. Position the device on EU-specific advantages, including neural data held in the EU, local clinical support, lifelong follow-up commitments and surgeon training, and test these with hospital and patient groups before market entry.
  3. Pursue outcome-based reimbursement contracts where payers pay in stages tied to measured patient benefit, accepting delayed revenue in exchange for credible payer buy-in and reduced budget-impact objections.

Trade-Off / Risk: Outcome-based payment contracts build payer trust and counter an earlier US entrant, but they delay revenue and place measurement burdens on hospitals, which can lower the reachable implant volume and weaken the financing case.

Strategic Connections:

Synergy: Amplifies First Indication and the Outcome That Justifies Surgery, because daily-life function endpoints serve both surgical justification and reimbursement, and strengthens Staged Financing and Sovereign Capital Gates with evidence of a credible revenue path.

Conflict: Conflicts with Implanting-Centre Network and Surgical Throughput Ceiling when outcome-based contracts burden hospitals with measurement, and with Decoder Stack Residency and Model Provenance if export markets bring foreign data or export-control obligations.

Justification: High, Drives reimbursement, health-economic endpoints and resilience to an earlier US CE-marked entrant, which underpins the 5,000 reimbursed patients target. Connects indication, financing and centre network, though export scope is a secondary choice.

Decision 10: Freedom-to-Operate and Patent Position Strategy

Lever ID: 26c7ab44-9524-4d84-8fc0-52b974c50dda

The Core Decision: Manages the risk that US, Chinese and university patents block electrode, encapsulation, decoding or robotics designs, through analysis, licensing, design-around, pooling or challenge. It feeds architecture choice and tests whether critical IP is EU-controlled. Success metrics: no unresolved blocking claims at architecture lock, licence terms that pass sovereignty criteria, and bounded legal spend.

Why It Matters: Existing BCI patents held by US and Chinese players and by universities may restrict electrode, encapsulation, decoding or surgical-robotics designs. The way patent risk is handled affects the choice of architecture, licensing cost, and the credibility of the sovereignty test for critical IP. Heavy reliance on foreign licences conflicts with EU control, whereas designing around patents may limit performance or lengthen development.

Strategic Choices:

  1. Commission an independent freedom-to-operate analysis for each architecture candidate before the architecture choice, and use the results as a scoring input and a trigger for licence or design-around work.
  2. Build a defensive patent pool by acquiring or licensing EU university and spin-out portfolios, and offering cross-licences to other European BCI groups to share risk on common foundations.
  3. Pursue early legal challenges, such as opposition or invalidity proceedings, against the most obstructive foreign patents, funded as a distinct budget line with a pre-agreed stop point.

Trade-Off / Risk: A pre-decision freedom-to-operate review prevents late architecture changes, but analysis cannot guarantee that a patent will not surface later, and challenging patents is slow, costly and may provoke counter-litigation.

Strategic Connections:

Synergy: Feeds Build, License or Acquire: Sourcing the EU Neurotech Base with patent-based valuation of targets, and supports Neural-Implant Foundry and Supplier Sovereignty Route by clearing process and material IP before commitment.

Conflict: Conflicts with Evidence and Regulatory Strategy Under MDR and the AI Act when design-arounds force architecture changes that reset evidence, and with the sovereignty tests when foreign licences are heavily relied upon.

Justification: High, Blocking patents can force architecture changes and foreign licences that fail EU-control tests. Feeds sourcing valuations, foundry process clearance and regulatory evidence stability, so it must be resolved before architecture lock.

Decision 11: Heatwave-Hardened Wearable and Thermoregulation Envelope

Lever ID: edf99a7b-7de4-41ab-9bfc-9d63cca82f99

The Core Decision: Defines the thermal design envelope for the external processor, transmitter and care pathway, using heatwave profiles above 35°C as the design case. Success metrics: zero skin or tissue temperature excursions, bit-rate retention during hot days, battery life, wearable mass, and the cost of home-support obligations. It should be validated in climate-chamber and human-factors testing before the design lock ahead of the pivotal trial.

Why It Matters: This lever sets how the external processor, transmitter and patient care pathway behave during multi-day heat above 35°C in Leuven and in other member states. A tight thermal ceiling protects skin, implant tissue and patients with impaired thermoregulation, but it limits sustained power and therefore bandwidth in the conditions where reliability matters most. The choice also shapes wearable size, battery life and the home-support burden.

Strategic Choices:

  1. Design the worn processor and transmitter to a thermal ceiling validated against multi-day heatwave profiles, using passive cooling and automatic throttling that lowers bandwidth before any tissue or skin temperature limit is approached.
  2. Move heat-generating computation off the body into a cooled bedside or room unit linked wirelessly, keeping the worn component minimal and accepting reduced mobility during extreme heat.
  3. Treat thermal vulnerability as a care-pathway issue by screening for impaired thermoregulation at enrolment, issuing heat-alert protocols, and funding cooled living-space support for participants alongside the device.

Trade-Off / Risk: Throttling or offloading computation protects patients in a heatwave, but it caps the bit rate exactly when users are most dependent on the device, and home cooling support adds a care obligation the plan has not yet costed.

Strategic Connections:

Synergy: Supports Living Consent for Locked-In and Declining-Communication Participants by making heat-alert and screening protocols part of informed risk disclosure. It also gives Bits-per-Second Claim Discipline and Rival Scenario Ratchet an honest thermal-derated bandwidth baseline.

Conflict: Thermal throttling caps sustained power and so directly limits the bit rates tracked by Bits-per-Second Claim Discipline and Rival Scenario Ratchet. Cooled-living-space funding competes for money with the Implanted-Patient Continuity Covenant reserves and with Staged Financing and Sovereign Capital Gates.

Justification: Medium, Important for patient safety and external hardware reliability, with a real power-versus-bandwidth trade-off, but its effects are confined to the wearable, care pathway and derated bandwidth baseline rather than the programme's core strategic structure.

Decision 12: Living Consent for Locked-In and Declining-Communication Participants

Lever ID: 965a1234-b0f3-4ddc-b3c8-0fa025ce3d1f

The Core Decision: Sets how consent is obtained, re-confirmed and withdrawn when speech is lost or failing, treating consent as a continuing process rather than one signature. Key measures: share of participants with validated yes/no signalling before surgery, re-consent completion, withdrawal handling, and ethics-body findings. It is a hard-requirement safeguard that can be traded against enrolment speed, never relaxed for it.

Why It Matters: This lever determines how valid consent is obtained, kept and withdrawn when participants cannot speak or may lose communication during the trial. Stronger safeguards lower the risk of invalid consent and protect the programme's ethical standing. They also slow enrolment and can shrink the pool of eligible participants, especially in rapidly progressing ALS.

Strategic Choices:

  1. Enrol participants early in disease progression while they can still communicate reliably, and schedule re-consent checkpoints that use the best available communication channel as capacity declines.
  2. Place an independent consent advocate, drawn from clinical ethics and a patient organisation, in every consent conversation, and require that the participant's yes/no signalling is validated with an assistive method before surgery.
  3. Let each participant set binding conditions in advance for when the device is switched off, explanted or the study is exited, and have an independent ethics body review those conditions as a standing document.

Trade-Off / Risk: Pre-declared conditions and early enrolment strengthen consent validity, but they pull enrolment toward people with less advanced disease, who may have less to gain, and an explantation clause can conflict with surgical risk and the participant's own later wishes.

Strategic Connections:

Synergy: Strengthens Evidence and Regulatory Strategy Under MDR and the AI Act, since robust consent records support ethics approval and coordinated multinational investigations. It also feeds Stop-Decision Authority and Pre-Registered Kill Gates with participant-defined switch-off and exit conditions.

Conflict: Early-enrolment and advocate requirements slow recruitment and shrink the eligible pool, working against First Indication and the Outcome That Justifies Surgery and the 5,000-implant ramp in Implanting-Centre Network and Surgical Throughput Ceiling.

Justification: High, Hard-requirement safeguard that cannot be traded for speed. It constrains enrolment, eligible pool and the indication, and supports ethics approval and kill-gate exit conditions, so it shapes both ethical standing and recruitment pace.

Decision 13: Implanting-Centre Network and Surgical Throughput Ceiling

Lever ID: 4e4b81c5-4878-4374-9e5f-97f289138776

The Core Decision: Determines which centres implant, how surgeons are trained and credentialed, and therefore the annual implant ceiling. It should be sized bottom-up from eligible patients, theatre capacity, surgeon learning curves and reimbursement. It must also separate cumulative implants from active users, since attrition and explantation reduce the latter. Metrics: implants per centre per year, complication rates by centre, and travel burden.

Why It Matters: This lever decides who performs implantations and where, and so caps how many patients can be implanted per year. Concentrating on a few expert centres improves procedural quality and early safety data, but it limits the number of surgeries and burdens patients with travel. Wider distribution raises volume but depends on training, credentialing and a procedure simple enough for ordinary neurosurgical teams. The cumulative-implant target depends on this ceiling as much as on funding.

Strategic Choices:

  1. Concentrate implantation in a small set of high-volume neurosurgical centres across several member states, with proctored training and strict credentialing, and accept a lower throughput ceiling and patient travel.
  2. Design the implant procedure and tooling for standard neurosurgical theatres so that regional hospitals can implant after certification, trading some device performance for a procedure that scales.
  3. Co-finance dedicated neuro-implant units embedded in public hospitals with member-state health authorities, where the company supplies the implanting team and equipment under shared governance.

Trade-Off / Risk: A small expert network protects early safety, but the 5,000-implant target needs far more surgical capacity than a few centres provide, and embedded units assume health-authority co-funding that is not committed.

Strategic Connections:

Synergy: Works with Why Europe Chooses This Device: Payer Case and Market Scope, because accredited centres give payers and hospitals a defined delivery pathway. It also gives Evidence and Regulatory Strategy Under MDR and the AI Act multi-state trial sites.

Conflict: Scaling to regional hospitals conflicts with Build, License or Acquire: Sourcing the EU Neurotech Base and architecture choices that favour performance over surgical simplicity. Co-financed units also strain Staged Financing and Sovereign Capital Gates, since member-state money is not committed.

Justification: High, Sets the annual implant ceiling that the 5,000-implant target depends on, and the safety versus scale trade-off. Links to payer pathway, multi-state trial sites, device design for surgical simplicity and uncommitted member-state co-funding.

Decision 14: Stop-Decision Authority and Pre-Registered Kill Gates

Lever ID: 245ece7c-cdcf-4312-a2b7-386d647c560d

The Core Decision: Assigns binding authority to end, pause, switch architecture, drop an indication or terminate, with quantitative criteria registered before data exist. It implements the hard requirement not to continue when risks outweigh benefits. Quality indicators: criteria registered before first-in-human, independence of decision-makers, time from breach to decision, and funding tranches that cannot be released against adverse findings.

Why It Matters: This lever fixes who has the power to end, switch or narrow the programme when evidence is poor, for example if chronic signal stability is insufficient. Giving independent bodies binding authority reduces the risk of continuing when risks outweigh benefits. It also reduces management and investor discretion and can make later financing rounds harder to close. The thresholds must be set before the data arrive to be credible.

Strategic Choices:

  1. Pre-register quantitative kill criteria (proposed thresholds) with the board and investors, and give an independent scientific and ethics council a binding recommendation that the board must publicly answer.
  2. Give an independent data monitoring committee with patient representation binding authority to pause or stop implantation, and tie investor tranches contractually to its written findings.
  3. Add a sunset clause under which each stage of the programme lapses unless gate evidence is affirmatively renewed, and fund a separate pre-mortem team that reports to the board and argues for termination.

Trade-Off / Risk: Binding external authority guards against sunk-cost momentum, but thresholds fixed before first-in-human data exist are partly guesses, and a sunset clause can cause stops driven by noisy early readings.

Strategic Connections:

Synergy: Amplifies Staged Financing and Sovereign Capital Gates by tying tranches to pre-agreed evidence, and strengthens Implanted-Patient Continuity Covenant by triggering wind-down obligations and reserves when a stop is called.

Conflict: Binding external authority limits investor and management discretion, which can make Staged Financing and Sovereign Capital Gates harder to close. Early-set thresholds may also clash with Bits-per-Second Claim Discipline and Rival Scenario Ratchet when targets move with rivals.

Justification: High, Implements the hard requirement not to continue when risks outweigh benefits. Ties capital release to evidence, triggers patient-protection wind-down and trades investor discretion for credibility, linking financing, covenant and bandwidth evidence.

Decision 15: Bits-per-Second Claim Discipline and Rival Scenario Ratchet

Lever ID: 34ff53b0-72b5-419f-8448-3704115cc9d6

The Core Decision: Governs how information transfer rate is defined, measured, verified and benchmarked, so bandwidth claims are net of errors, user-controlled and free of language-model expansion. It also maintains yearly pessimistic, central and optimistic rival scenarios. Metrics: pre-registration before testing, independent replication, participant count, separate reporting of command selection versus free communication, and gaps against rivals.

Why It Matters: This lever controls how the bandwidth figure is measured, verified and compared with US and Chinese systems without moving neural data out of the EU. Strict, independent verification makes claims credible to regulators, payers and a sceptical public. It also makes early results look smaller than competitors' headline figures. Tying targets to rival scenarios keeps the long-term bandwidth goal realistic.

Strategic Choices:

  1. Pre-register the information-transfer-rate protocol with held-out tasks and have an independent EU laboratory verify results inside an EU-hosted secure environment, releasing only derived metrics.
  2. Join a multi-centre EU evaluation consortium that uses federated testing, where decoder code travels to the data, and only aggregate scores are shared, with structured command selection and free communication reported separately.
  3. Build pessimistic, central and optimistic scenarios for rival systems from public disclosures, update them every year, and let the stretch bandwidth target move up or down when rival evidence crosses defined triggers.

Trade-Off / Risk: Independent EU-only verification keeps claims defensible and data resident, but it adds delay and cost, and rival scenarios built from public disclosures can be badly wrong when competitors publish selectively.

Strategic Connections:

Synergy: Provides Decoder Stack Residency and Model Provenance with a verification method that keeps neural data in the EU, and supplies Stop-Decision Authority and Pre-Registered Kill Gates with credible performance evidence for gate decisions.

Conflict: Strict verification makes early results look small beside rivals' headlines, pressuring Staged Financing and Sovereign Capital Gates. Moving the stretch target with rival evidence can also destabilise thresholds set under Stop-Decision Authority and Pre-Registered Kill Gates.

Justification: Medium, Defines the credible measurement of the long-term technical edge and feeds kill-gate evidence, but mainly governs verification and communication. The first product competes on clinical benefit, so it is less central than sourcing, regulatory and financing choices.

Choosing our strategic path.

The Strategic Context

Understanding the core ambitions and constraints that guide our decision.

Ambition and Scale: Very high. A 15-year, roughly €2.5B (user constraint) venture to build a sovereign EU Class III implantable BCI. Targets are CE marking in about 10 years, first-in-human in about 5, and over 5,000 implanted patients by year 15. The long-term vision is human-AI merging, with bandwidth above 100 bits/s as a stretch goal. It spans several member states, the Commission, notified bodies and payers.

Risk and Novelty: Very high and frontier-level. The plan has a founders-only start, no committed funding, no committed Leuven partners, and US and Chinese competitors that may reach the EU market first. Chronic signal stability, bandwidth growth, foundry transfer and the size of the eligible population are all unproven. The plan is built around risk retirement: a feasibility verdict that may be 'not credibly achievable', kill gates, and a decision not to proceed that is explicitly acceptable.

Complexity and Constraints: Extremely complex. The hard requirements are patient safety, valid consent and EU control of the delivered system by the pivotal trial. The plan also needs MDR Class III and AI Act compliance, three-layer sovereignty tests, a pilot-line-to-validated-production transfer, an IPCEI-type funding dependency (four or more member states) with financing gates, freedom-to-operate analysis, reimbursement, climate resilience, and patient-protection reserves. A minimum viable two-year programme must be separated from the full industrial programme. No funding, exemptions or supplier commitments may be assumed.

Domain and Tone: Business and strategy in regulated medical devices and deep-tech neurotechnology. The tone is sober, evidence-led and gate-driven, with ethics and patient protection prominent. It is sceptical of hype and keeps the human-AI enhancement track separate from the medical programme.

Holistic Profile: A high-ambition, high-uncertainty, heavily constrained sovereign-medtech venture. It rewards staged, option-preserving, evidence-gated execution over big-bang commitment. The plan needs credible routes past each obstacle, a defensible early patient benefit, and a pre-registered choice of pivotal indication. It also needs early regulator engagement and sovereignty by pivotal lock, without assuming money that does not yet exist. Patient protection and honest feasibility reporting outrank speed.


The Path Forward

This scenario aligns best with the project's characteristics and goals.

The Pragmatic Foundation

Strategic Logic: Combine exclusive licences with pre-priced acquisition options so capability is secured without paying for unvalidated assets. Split the supply chain by criticality, owning encapsulation and implant assembly while dual-sourcing chips and thin-film substrates. Start with a small ALS communication cohort and let a pre-registered kill gate choose the pivotal indication on evidence. Engage a notified body and Commission scientific advice early and run coordinated multi-country first-in-human studies, so schedule gains come from sequencing, not lighter proof. Release capital in tranches tied to demonstrated technical and clinical milestones.

Fit Score: 9/10

Why This Path Was Chosen: Licences with pre-priced options, supply-chain splitting by criticality, an ALS-first cohort with a pre-registered indication gate, early notified-body and Commission engagement, and tranche financing map directly onto the plan's goal-seeking, kill-gate and minimum-viable-programme logic. Its main weakness is that the reserve for implanted patients is not explicitly ring-fenced, which can be added as a fixed commitment.

Key Strategic Decisions:

The Decisive Factors:


Alternative Paths

The Pioneer's Gambit

Strategic Logic: Buy time and capability by acquiring EU neurotech teams and IP, co-found a shared foundry, and take the broader spinal cord injury motor-control indication, where bandwidth is the strongest differentiator and the eligible population best supports scale. Early regulator engagement, a pre-registered adaptive evidence plan with locked decoder change control, and a large anchor round fund this pace. The scenario accepts high capital exposure, integration risk, dependence on multi-state funding that is not assumed, and a harder benefit comparison against assistive technology. Financing and foundry gates with named fallbacks decide whether it proceeds, defers or switches.

Fit Score: 3/10

Assessment of this Path: Its acquisitions, shared foundry, large anchor round and spinal cord injury focus all depend on funding and multi-state commitments the plan forbids assuming. It also concentrates integration and legacy-IP risk before any evidence exists. Its goal of competing on scale matches the ambition, but its capital exposure and early lock-in conflict with staged, gated, evidence-led execution.

Key Strategic Decisions:

The Safe Harbour Programme

Strategic Logic: Prioritise patient safety, clean IP and cash discipline. Build the core stack in-house in Leuven, prototype on the research pilot line, and then transfer to a validated EU contract manufacturer with the transfer plan funded before design lock. Take the narrowest indication with the clearest benefit margin, ALS communication restoration. Run a single-country early feasibility study with a version-locked decoder before widening to other member states. Ring-fence a patient-protection reserve and explant-and-support escrow from the first implant, so obligations to implanted patients survive any financing failure. The cost is slower progress, a harder recruitment task for a founder-only team, a small eligible population that strains the 5,000-patient and reimbursement targets, and a greater risk that US entrants lead the market.

Fit Score: 6/10

Assessment of this Path: Strong on patient safety, clean IP and the reserve for implanted patients, which the plan requires. But building from founders only, a single-country study, and an ALS-only pool strain talent, schedule, the 5,000-patient target, reimbursement and competitiveness. It also lacks a mechanism to switch indication or architecture on evidence.

Key Strategic Decisions:

Purpose

Purpose: business

Purpose Detailed: Strategic and project plan for a 15-year commercial medical-device venture: build or acquire EU neurotech capabilities, deliver a CE-marked Class III implantable BCI with demonstrated clinical benefit, over 5,000 reimbursed patients and competitive bandwidth, under hard requirements of patient safety, valid consent and EU control of the delivered system. Includes feasibility verdict on the original mission, goal-seeking obstacle routes, architecture choice, supply chain sovereignty, regulatory (MDR, AI Act), financing (~€2.5B from return-seeking investors plus grants, separate shared-infrastructure estimate), reimbursement, kill gates, patient-protection reserves, and a separate human-AI enhancement research track.

Topic: Founding a Leuven-based European brain-computer interface company (Class III implant, first indication such as ALS communication or spinal cord injury motor control) with EU-sovereign clinical system, feasibility verdict, and 15-year staged programme

Domain

Primary domain: Neural Interface Engineering

Secondary domains: Medical Device Regulation, Medtech Venture Financing, Neural Implant Microfabrication

Rationale: Neural Interface Engineering is the only outcome candidate and has the highest importance and specificity. Chronic signal stability, architecture choice and bandwidth drive the mission. Medical Device Regulation, Clinical Trial Methodology, Technology Sovereignty Policy and Neural Implant Microfabrication are constraints or methods that serve it.

Disciplines this project involves:

Domain Importance Specificity Role Reason
Neural Interface Engineering 5 5 outcome Implantable BCI architecture, chronic signal stability and bandwidth are the core technical success criteria.
Neural Implant Microfabrication 5 5 method Electrodes, encapsulation and implant chips need an EU-controlled, Class III-validated fabrication and supply chain.
Medical Device Regulation 5 4 constraint Class III MDR conformity, CE marking, AI Act and coordinated clinical investigations gate market access.
Clinical Trial Methodology 5 4 constraint First-in-human and pivotal trials, consent, ethics review and bandwidth protocol determine approval and patient safety.
Neural Decoding 4 5 method Decoding algorithms and the bits-per-second protocol determine bandwidth targets and clinical benefit.
Technology Sovereignty Policy 4 4 constraint EU-control criteria, export controls, IPCEI funding and dependency exceptions are hard requirements.
Health Technology Assessment 4 4 market Reimbursement and health-economic case against assistive technology determine payer adoption and patient numbers.
Medtech Venture Financing 4 3 method Staged financing of €2.5B, IPCEI and grants determines whether the programme survives to approval.
Medical Device Cybersecurity 3 4 constraint Implant security, AI Act obligations and EU-only neural data hosting require dedicated safeguards.

Plan Type

This plan requires one or more physical locations. It cannot be executed digitally.

Explanation: The plan is physical. It founds a Leuven-based company that develops, manufactures and clinically tests a Class III implantable brain-computer interface, and almost every part of it needs a physical location, physical resources or in-person activity.

Some sub-tasks are digital, such as decoding software, bandwidth analysis, financial modelling and the feasibility write-up. They do not make the overall plan digital, because the core outcome is a CE-marked implant in over 5,000 patients. That outcome cannot be reached without physical facilities, surgery, manufacturing and in-person clinical activity, so the plan is clearly physical.

Physical Locations

This plan implies one or more physical locations.

Requirements for physical locations

Location 1

Belgium

Leuven, Flanders

Headquarters and core R&D near imec (Kapeldreef) and the KU Leuven Gasthuisberg campus (UZ Leuven)

Rationale: Specified in the plan. Co-location with imec microfabrication, KU Leuven neuroscience and UZ Leuven neurosurgery gives the shortest path to prototyping and first-in-human work. None of the three has committed, so partnership talks and a fallback are needed. Heat, flood, power and water resilience must be assessed. A research pilot line is not a validated Class III line.

Location 2

Belgium and neighbouring EU member states

Brussels, Belgium (regulatory and policy liaison), plus the Netherlands (Utrecht/Eindhoven region) for a second clinical site and supplier access

Brussels office near the Commission and EMA; UMC Utrecht Brain Center or equivalent as second coordinated-trial site

Rationale: Brussels is within commuting distance for Commission scientific advice and IPCEI talks. A Dutch neurosurgical centre with a strong BCI research record supports coordinated multinational first-in-human studies and is a fallback if UZ Leuven declines. Dutch microelectronics suppliers add dual-sourcing options. Participation and sovereignty fit are to be verified.

Location 3

France and Germany

Grenoble, France (CEA-Leti/Clinatec) and Dresden or Munich, Germany

CEA-Leti and Clinatec campus in Grenoble; Dresden microelectronics cluster as a validated chip/MEMS manufacturing alternative

Rationale: Grenoble hosts established EU implantable-BCI and microfabrication expertise and a clinical neurosurgery link, so it suits licensing or acquisition targets and a second hospital. German clusters offer validated semiconductor and medical-device contract manufacturing for the transfer from pilot to production. Used only where they show better feasibility, capacity or quality than Leuven, with each facility justified.

Location 4

Belgium

Flanders, outside the Leuven core (Ghent or Antwerp area)

Ghent University Hospital or Antwerp University Hospital, plus a medical-device manufacturing site in Flanders

Rationale: Keeps a Belgian-centred programme with a nearby backup neurosurgical and ALS-care centre if UZ Leuven declines. It also offers a possible Class III manufacturing and sterilisation location within the same regulatory and funding setting. Reduces single-site climate or infrastructure risk.

Location Summary

The plan is based in Leuven, Belgium, so the location is specified. Leuven is the headquarters and core R&D site because of imec, KU Leuven and UZ Leuven, none of which has committed. Three alternatives or complements are proposed. Brussels and the Netherlands add regulatory access and a second trial site. Grenoble and German clusters offer BCI expertise and validated manufacturing. Other Flemish hospitals and manufacturing sites provide a Belgian fallback. Each distributed facility must be justified against Leuven. Climate resilience and the effect of a local partner declining need assessment.

Currency Strategy

This plan involves money.

Currencies

Primary currency: EUR

Currency strategy: EUR is the primary budgeting and reporting currency for all EU operations, R&D, manufacturing, clinical trials, reimbursement and investor returns. Multi-member-state deployment and multi-year cash flows require stable euro-zone currency management. USD exposure arises from talent recruitment benchmarking (US salaries are higher) and IP/acquisition diligence against US-held patents and competitors; USD quotes should be converted to EUR for consolidated budgeting. GBP and CNY are monitoring currencies only for competitive and supply-chain risk. No active hedging is required because the plan operates within the eurozone and the EU regulatory and funding system. Investor returns and grant funding are naturally denominated in EUR. Any significant acquisition or licensing of non-EU IP (US or otherwise) should include currency and IP-valuation due diligence to confirm sovereignty-test compliance and avoid hidden foreign-control dependencies.

Identify Risks

Risk 1 - Regulatory & Permitting

MDR Class III conformity assessment is lengthy and complex, with no guaranteed timeline or outcome. Notified bodies may request additional preclinical data, clinical evidence or design changes that delay approval by 12–24 months. AI Act high-risk classification for the decoder adds compliance obligations (documentation, human oversight, bias testing) that may not be fully understood or resourced. Scientific advice from the Commission, while valuable, is non-binding and can result in requests that reset design or evidence strategy.

Impact: Delay of 12–24 months to CE marking beyond the ~10-year target; additional compliance costs of €500k–€2M for AI audit and documentation; risk of approval refusal if notified body or Commission finds insufficient evidence or unacceptable AI risk.

Likelihood: High

Severity: High

Action: Engage a notified body at Month 6 (2027-04-30) before design freeze; request pre-submission meetings to align on evidence requirements. Seek Commission scientific advice on clinical investigation design and AI Act scope by Month 12 (2027-10-31). Build an adaptive evidence strategy that allows decoder updates under locked change control, so model improvements do not trigger re-investigation. Budget a dedicated AI-compliance team and schedule regulatory milestone reviews quarterly.

Risk 2 - Technical

Chronic signal stability in implanted electrodes remains unproven at the 5,000-patient scale over the device lifetime (estimated 5–10 years). Animal studies at 12–24 months do not predict long-term human performance. Decoder performance may degrade due to electrode drift, tissue response or fibrosis, reducing bandwidth or requiring frequent recalibration. Wearable thermal design during heatwaves (>35°C) may force power throttling that caps bandwidth precisely when users depend most on the device.

Impact: If chronic stability is insufficient, bandwidth may drop 20–50% by year 3–5, driving clinical failure or device explantation; cost of failed implants and replacement procedures: €50k–€150k per case over 100–500 affected patients (€5M–€75M total). Thermal throttling caps sustainable bit rate to 5–8 bits/s even if research designs support 10–15 bits/s, weakening competitive claims.

Likelihood: High

Severity: High

Action: Pre-register kill-gate criteria for chronic stability (e.g., >20% signal loss within 12 months triggers design review or pause); require chronic animal studies to 18–24 months before first-in-human. Design the wearable for passive cooling and automatic throttling that maintains safety margins before reaching thermal limits; validate in climate chamber with multi-day 35–40°C profiles. Report thermal-derated bandwidth as the baseline for all long-term claims.

Risk 3 - Supply Chain & Manufacturing

Transfer from a research pilot line (imec or equivalent) to a validated Class III production line is non-trivial. Yield, process consistency and quality metrics achieved in research are often not replicated at production scale. Dual-sourcing of chips and thin-film substrates depends on qualifying EU suppliers who may lack BCI-scale volume or investment. Upstream tool dependencies (lithography, etching, test equipment) are documented exceptions to sovereignty, but disruption (e.g., export controls on US semiconductor design software or fab equipment) could halt production.

Impact: Pilot-to-production transfer delay of 6–12 months if yield is <80%; rework costs of €1M–€3M. If a second supplier cannot be qualified by Month 36 (2029-10-31), single-source risk exposes the programme to supply disruption; loss of €2M–€5M in inventory and 3–6 month halts. Upstream tool dependencies (e.g., EDA software, fab equipment) could trigger forced design changes if export controls tighten.

Likelihood: Medium

Severity: High

Action: Fund and budget transfer-to-production as a distinct Work Package before design lock (Month 18–24 = 2028-04-30 to 2028-10-31); contract a validated EU manufacturer with defined yield and timeline commitments. Qualify a second chip and substrate supplier by Month 30 (2029-04-30), with dual-qualification costs of €500k–€1M. Publish a register of upstream tool dependencies and monitor export-control signals; identify design-arounds or alternative toolchains for the highest-risk items (e.g., EDA software) and budget contingency work.

Risk 4 - Financial

The plan assumes ~€2.5B over 15 years from return-seeking investors plus grants, with no committed funding at Month 0 (2026-10-31). Founder-only start and no pre-existing partnerships mean initial raises must come from seed investors or national grants, both limited in size. A shared European neural-implant foundry assumes multi-state IPCEI funding that may not materialise or may be conditional on commitments the company cannot make. Clinical trial costs, especially multi-country coordination and long-term follow-up, consume 20–30% of budgets and are hardest to forecast. Reserve funding for implanted patients, if ring-fenced as required, competes directly with development spending.

Impact: Shortfall of €200M–€500M if expected tranches are not released on schedule; halt or slowdown of development, manufacturing or trial work at Months 12–24 (2027-10-31 to 2028-10-31) or Months 36–48 if early-stage raises miss targets. If multi-state foundry funding is not committed by Month 24 (2028-10-31), the supply-chain route must switch to a smaller dual-sourcing model, adding design constraints or cost. Patient-protection reserves of €5M–€15M (per 5,000 implants) reduce development capital and may deter early-stage investors.

Likelihood: High

Severity: High

Action: Pre-register funding gates with hard deadlines and named fallbacks: Month 12 (2027-10-31) (seed + national grants covering first two years), Month 24 (2028-10-31) (Series A + foundry commitment decision), Month 36 (2029-10-31) (pivotal-trial funding gate). Tie each tranche release to objective risk-retirement milestones (e.g., notified-body acceptance, animal stability data, manufacturing prototype). Ring-fence patient-protection reserves in a separate escrow or trust from Month 6 (2027-04-30) onwards, growing with each implant, and exclude it from operating-capital competition. If multi-state foundry funding is not confirmed by Month 18 (2028-04-30), immediately activate the dual-sourcing fallback.

Risk 5 - Clinical & Patient Safety

First-in-human implantation in people with progressive neurological disease (e.g., ALS) carries known surgical risks (infection, bleeding, neurological injury) plus unknown chronic risks (tissue response, device failure, signal loss). Obtaining valid informed consent from people with impaired or declining communication is ethically complex and slow. Consent advocates, independent ethics review and lifelong follow-up are binding hard requirements that cannot be relaxed. Participant attrition is high in degenerative diseases; ALS median survival post-diagnosis is ~3 years, shorter if already locked-in.

Impact: Serious adverse event rate of 5–15% in early implants (infection, hemorrhage, neurological injury); one or more permanent harms or deaths in a cohort of 20–30 could trigger regulatory pause or investigation. Invalid-consent findings (e.g., from an independent ethics review) could lead to trial suspension or regulatory action. High attrition in ALS cohort shrinks the eligible pool for the 5,000-patient target by 30–50%, straining reimbursement and market-access claims.

Likelihood: High

Severity: High

Action: Build a robust, independent consent process with trained advocates present at every conversation; pre-validate participant yes/no signalling with assistive methods before surgery. Pre-register kill-gate criteria for safety (e.g., >10% serious adverse event rate in first 20 implants triggers design or procedural review). Establish a data monitoring committee with patient representation that has binding authority to pause or stop implantation if safety signals emerge. Plan for lifelong follow-up infrastructure (telehealth, allied health, repeat imaging) and budget 10–15% of trial costs for participant retention and attrition management.

Risk 6 - Operational

The founding team is named as 'only the founders', implying a very small initial staff. Recruiting neurosurgeons, neuroengineers, clinical trial managers, regulatory specialists and manufacturing engineers against US-scale salaries (20–30% higher in the EU for equivalent talent) is identified as a constant constraint. Leuven partnerships (imec, KU Leuven, UZ Leuven) are not committed; if one or more decline, the plan has fallback options but must execute with compressed timelines and reduced local assets. A distributed programme across Belgium, Netherlands, France and Germany multiplies coordination, legal and logistical overhead.

Impact: Delay of 6–12 months in early hiring or loss of key talent to US competitors. If UZ Leuven declines partnership, the programme must shift first-in-human work to another member state (e.g., Utrecht or Grenoble), adding 3–6 months of site qualification and ethics approval. Coordination overhead across four countries may add 10–15% to programme costs (estimated €250M–€375M over 15 years).

Likelihood: Medium

Severity: High

Action: Secure Leuven partnership letters of intent from imec, KU Leuven and UZ Leuven by Month 3 (2027-01-31); if any decline, activate fallback sites (Utrecht, Ghent, Grenoble) by Month 6 (2027-04-30). Build a talent-recruitment plan offering equity upside, long-term security and mission alignment to offset salary gaps; partner with EU neurotechnology networks and universities for recruitment. Establish a distributed-governance structure with clear decision rights and weekly synchronisation to minimise coordination drag. Budget an additional 10–15% overhead for multi-country legal, HR and compliance.

Risk 7 - Supply Chain & Sovereignty

The hard requirement for EU control of the delivered system (electrodes, implant electronics, encapsulation, decoding software, AI models, clinical data hosting) by the pivotal trial is ambitious. Foreign ownership, licences or export-control dependencies that are not identified in diligence will violate the sovereignty tests (ownership, maintainability without foreign consent, export-control freedom). Existing BCI patents held by Neuralink, Synchron and university spin-outs may block key designs, forcing licensing (foreign consent risk) or design-arounds (performance cost). Upstream dependencies (fab equipment, EDA software, chip-design services) are accepted exceptions but must be documented and monitored.

Impact: Discovery of undisclosed foreign licences or IP encumbrances late in development (Month 24–36 = 2028-10-31 to 2029-10-31) forces design changes or licensing negotiations, delaying approval by 6–12 months and costing €500k–€2M in rework. If freedom-to-operate analysis finds blocking patents, licensing fees may add €1M–€5M to programme costs, or design-arounds may reduce bandwidth by 10–20%. Export controls on US fab equipment or software could force production shutdown or relocation, costing €5M–€10M and 6–12 month delays.

Likelihood: Medium

Severity: High

Action: Commission an independent freedom-to-operate analysis for each architecture candidate (penetrating cortical, endovascular, surface/thin-film) before Month 6 (2027-04-30); score results as a criterion in architecture choice. Conduct sovereignty-criteria diligence on any acquisition or licensing target by Month 3 (2027-01-31), screening for foreign ownership, consent rights and export-control exposure. Publish a register of upstream tool dependencies (fab, EDA, test) by Month 12 (2027-10-31) and monitor export-control changes quarterly. Allocate a budget of €500k–€1M for patent challenges or design-arounds and establish a legal contingency line.

Risk 8 - Market & Competitive

US competitors (Neuralink, Synchron) and Chinese state-backed programmes may obtain CE marking before the EU programme, entering the EU market with established funding, clinical data and regulatory pathways. If a US competitor enters the EU first, the EU programme's case for adoption depends on demonstrated clinical benefit in EU populations, data sovereignty (neural data held in EU), local clinical support and superior outcome evidence, not on speed-to-market. The eligible ALS population is small (~5,000–10,000 in the EU annually with appropriate severity); if a competitor captures first movers, EU programme recruitment becomes harder. Reimbursement acceptance is uncertain; payers may not reimburse both a US and an EU device, or may require compelling cost-effectiveness evidence.

Impact: If a US competitor enters first, EU programme's eligible-population capture is reduced by 30–50% in the first 3–5 years post-launch, delaying the 5,000-implant target to Year 18+ instead of Year 15. Reimbursement may be denied or delayed if cost-effectiveness versus a US alternative cannot be demonstrated; estimated revenue loss of €100M–€300M over 15 years if reimbursement is only achieved in 50% of member states. Talent recruitment becomes harder if market leadership appears to lie with US competitors.

Likelihood: High

Severity: High

Action: Build and publish a health-economic case against existing assistive technology (eye-tracking, speech synthesis, brain-computer interfaces in other countries) by Month 12 (2027-10-31), with cost-effectiveness targets (€100k–€200k per quality-adjusted life year, to be modelled) that withstand payer scrutiny. Engage national payers and HTA bodies in Months 12–24 (2027-10-31 to 2028-10-31) to shape early reimbursement dialogues. Position EU advantages: neural data sovereignty, local clinical expertise, lifelong follow-up, device-lifetime support and explantation pathways. Establish outcome-based reimbursement contracts where possible, paying payers in stages tied to measured benefit. If a US competitor enters the EU within Months 36–60 (2029-10-31 to 2031-10-31), trigger a competitive-response kill gate to assess market viability before committing large capital to scale-up.

Risk 9 - Regulatory & Permitting

Coordinated multinational clinical investigations across several EU member states require alignment on ethics approvals, patient protections, data-sharing agreements and regulatory pathways. Each country's ethics committee operates independently; harmonised consent templates and protocols still require multi-country review and approval. Delays in one country (e.g., ethics committee backlog, political veto) can halt the entire multinational trial. Data transfers across borders must comply with GDPR and any special rules for sensitive health data; neural data from implants is highly sensitive and stays in the EU by policy, but storage, access and analysis across member states are complex.

Impact: Delay of 3–6 months if one ethics committee refuses approval or requests additional preclinical data. GDPR compliance overhead and data-governance setup costs €500k–€1M. If a member state objects to the trial on safety or sovereignty grounds, the programme must restart in other sites, losing 6–12 months and limiting eligible population.

Likelihood: Medium

Severity: Medium

Action: Engage all participating ethics committees at Month 6 (2027-04-30) with a harmonised protocol and consent templates; seek coordinated-assessment mechanisms through the EMA or Commission if available. Establish a centralised neural-data repository in the EU (Belgium or neutral location) with strict access controls and GDPR compliance; only derived metrics and aggregates leave the repository. Pre-register ethics approval timelines and establish liaison officers in each country to manage local reviews. If one ethics committee declines, activate a named fallback site by Month 18 (2028-04-30).

Risk 10 - Environmental & Climate

Leuven is exposed to multi-day heatwaves above 35°C (projected to increase in frequency), drought (affecting cooling-water supply), flooding (from groundwater and river overflow) and power interruptions during extreme weather. Manufacturing (cleanroom cooling, sterilisation), preclinical labs (animal housing, biocompatibility testing) and compute (neural-data hosting) all depend on reliable power and cooling. Patients with impaired thermoregulation (e.g., high spinal cord injury) are at elevated risk during heatwaves if wearable hardware throttles or overheats. A multi-day heatwave during a pivotal-trial recruitment or follow-up phase could disrupt clinical work.

Impact: Manufacturing halt of 2–5 days during a heatwave or power outage, costing €100k–€500k in lost production. Compute downtime of hours to days if cooling fails, with risk of neural-data loss or corruption if backup systems are inadequate. Clinical disruption during trial if recruitment or follow-up is paused due to heat warnings or power instability. Wearable hardware forced to throttle bandwidth to 50–70% during heatwaves, undermining device reliability and user satisfaction.

Likelihood: Medium

Severity: Medium

Action: Commission a climate and infrastructure resilience assessment for Leuven by Month 3 (2027-01-31), covering power redundancy, water availability, flood risk and cooling capacity. Install backup power (UPS, generator) and redundant cooling systems at manufacturing and hosting sites by Month 18 (2028-04-30). Design wearable and implant for passive cooling, automatic power throttling and temperature monitoring; validate in climate-chamber tests with multi-day 35–40°C profiles and humidity extremes. Establish heat-alert protocols for trial participants and fund cooled-refuge support for those with impaired thermoregulation. Consider distributed manufacturing and compute to secondary sites (Netherlands, Germany) if Leuven risk is high.

Risk 11 - Organisational & Governance

A 15-year, €2.5B programme requires stable governance, clear decision rights and mechanisms to stop or pivot when evidence warrants. Kill gates and independent oversight (data monitoring committee, ethics board, stop-authority council) must have binding power, but binding external authority can make later capital raises harder (investors prefer discretion). Separating the medical device programme from an enhancement research track requires firewalls and governance rules that are non-trivial to enforce. A founder-only start with distributed multi-country operations and multiple stakeholders (Commission, member states, notified bodies, hospitals, payers, patient groups) creates coordination and accountability risks.

Impact: If kill gates or external oversight are weak, the programme may continue past evidence of insufficient benefit or unacceptable risk, leading to patient harm or regulatory action. If they are too strict, early-stage capital becomes harder to raise. Failure to separate enhancement and medical programmes risks regulator or ethics-committee objections over intended use, delaying approval or derailing patient recruitment by 6–12 months. Governance disagreements among founders, investors, member states and hospitals could deadlock decisions, delaying pivotal gates or capability deployment.

Likelihood: Medium

Severity: Medium

Action: Establish an independent data monitoring committee with patient and ethics representation by Month 6 (2027-04-30); grant it binding authority to recommend pause or stop, with findings published within 30 days. Pre-register quantitative kill criteria (e.g., >10% serious adverse events, <5 bits/s sustained bandwidth at Month 24 = 2028-10-31) with the board and investors before first-in-human. Create a separate legal entity for enhancement research with a documented IP and hardware-sharing firewall; subject all enhancement work to independent ethics review. Define a clear decision hierarchy: founders and board for operational decisions, investor consortium for capital allocation, independent committees for safety and indication gates, and member states/Commission for sovereignty and policy matters. Publish a quarterly governance report to stakeholders.

Risk 12 - Technical

The architecture choice (penetrating cortical, endovascular, surface/thin-film) is deferred pending freedom-to-operate analysis and evidence. Each has different risks: penetrating electrodes offer high bandwidth but carry higher surgical risk and chronic stability challenges; endovascular offers less surgical trauma but lower signal quality and bandwidth; surface/thin-film offers safety advantages but unproven chronic performance. The choice locks in design constraints, supply-chain dependencies and bandwidth ceilings that affect competitiveness and the 100 bits/s stretch goal. Switching architectures mid-programme (after the pivotal trial decision) is expensive and delays approval.

Impact: If architecture choice is deferred too long (past Month 24 = 2028-10-31), design lock and manufacturing setup are delayed by 3–6 months. Choosing a sub-optimal architecture (e.g., endovascular for better safety but lower bandwidth) narrows the long-term competitive edge and may make the 100 bits/s stretch goal unachievable. Freedom-to-operate analysis may eliminate one or more architectures due to blocking patents, forcing the programme to accept lower performance or higher cost. Switching architectures at a kill gate (Month 30–36 = 2029-04-30 to 2029-10-31) requires rebuilding preclinical data and regulatory evidence, delaying CE marking by 12–24 months.

Likelihood: Medium

Severity: High

Action: Commission detailed freedom-to-operate, surgical-risk and chronic-stability analyses for each architecture candidate (cortical, endovascular, surface) by Month 6 (2027-04-30). Score architectures on patent clearance, surgical risk, bandwidth potential, chronic stability risk and manufacturing readiness by Month 9 (2027-07-31). Make a final architecture choice by Month 18 (2028-04-30), informed by early feasibility data if available. Pre-register a secondary architecture as a kill-gate fallback if the primary choice fails safety or performance milestones (e.g., chronic stability <50% signal retention by Month 36 = 2029-10-31). Budget an additional €500k–€1M for contingency preclinical work if a switch is triggered.

Risk 13 - Regulatory & Permitting

AI Act high-risk classification for the decoder requires documentation of training data provenance, model validation, human oversight and bias testing. The plan envisions locked decoders for the pivotal trial, but decoder improvements after CE marking (to increase bandwidth or reduce calibration time) may trigger AI Act change-control and re-validation. If the decoder is trained on external datasets or uses third-party pretrained models, ownership and EU control become complex. Regulators may also demand explainability or interpretability of AI decisions for safety-critical applications, which current neural-network decoders may not provide.

Impact: Decoder validation and compliance documentation overhead of €1M–€2M and 3–6 month delays. If decoder updates are classified as high-risk changes, each update requires notified-body review and re-validation, slowing innovation and limiting the bandwidth-improvement pathway. External data or third-party models may introduce foreign dependencies that fail the EU-control test, forcing retraining or model replacement at a cost of €500k–€1.5M.

Likelihood: Medium

Severity: Medium

Action: Engage the Commission and a notified body on AI Act scope and change-control thresholds by Month 12 (2027-10-31). Define a pre-registered decoder-update process where minor retraining (within a locked feature set and locked data scope) is permitted without re-validation, while major changes (new architecture, new training data source, new features) trigger change-control and notified-body review. Train all decoders in-house using EU-hosted consented trial data to preserve ownership and EU control. Build a model registry documenting all versions, training data, validation results and change rationale. Allocate a dedicated AI-compliance budget of €500k–€1M over 15 years.

Risk 14 - Regulatory & Permitting

Quality management system (QMS) conformity to ISO 13485 and MDR Annex I is mandatory but non-trivial to build from scratch. The company must establish document management, design history files, risk management, change control, training records and corrective-action procedures before any clinical device is manufactured. Acquisition or licensing of EU teams may bring legacy QMS processes that do not meet current standards or are not MDR-aligned, requiring rework. Notified-body audits of the QMS are formal and can uncover gaps that delay approval.

Impact: QMS implementation cost of €500k–€1.5M and 6–12 months if built in-house. If an acquired team's QMS is non-compliant, rework costs €200k–€500k and delays approval by 3–6 months. Notified-body audit findings (e.g., inadequate change-control documentation, incomplete design-history files) trigger corrective-action requests that delay approval by 2–4 months.

Likelihood: Medium

Severity: Medium

Action: Build or acquire a compliant ISO 13485 QMS by Month 9 (2027-07-31), aligned with MDR requirements. If licensing or acquiring teams, include QMS audit and compliance assessment in the diligence checklist by Month 3 (2027-01-31). Establish a design-history file process at the start of development (Month 1 = 2026-11-30) to avoid gaps later. Hire or contract a quality-assurance manager by Month 6 (2027-04-30) and establish a training and competency programme by Month 9 (2027-07-31). Request a preliminary notified-body QMS audit by Month 18 (2028-04-30) to identify gaps before the formal conformity assessment.

Risk 15 - Financial

Patient-protection reserves and explant-and-support escrows are required as hard safeguards for implanted patients. If funding must be set aside from the first implant, these reserves reduce development capital available in the crucial early years (Months 0–36 = 2026-10-31 to 2029-10-31). Estimates of per-implant reserve costs are not yet specified; reserves must cover lifelong follow-up (clinic visits, imaging, teleneuro, allied health), device servicing or replacement if needed, explantation procedures (estimated €20k–€50k per patient) and support if the company fails. For 5,000 patients over 10–15 year device lifetimes, reserves could total €50M–€150M, equivalent to 2–6% of total programme budget.

Impact: Ring-fencing €50M–€150M in reserves competes directly with R&D, manufacturing and trial capital; this could reduce early-stage funding by 15–25% and delay milestones by 6–12 months. If reserves are underfunded, implanted patients face uncertain support if the company becomes insolvent. If reserves are over-funded, development capital is unnecessarily constrained.

Likelihood: Medium

Severity: High

Action: Establish a patient-protection reserve mechanism by Month 6 (2027-04-30), growing with each implant from Month 36 (2029-10-31) onwards. Estimate per-patient reserve costs by actuarial modelling (clinic visits ~€500/year, imaging ~€2k/year, explantation ~€30k, emergency support fund ~€10k) and set a target reserve of €10k–€30k per implant, growing to 100% of target by Year 10. Fund reserves from investor capital or grants with contractual obligation to investors, not from operating budgets. Hold reserves in a separate escrow or trust outside investor reach. Conduct annual reserve-adequacy audits and adjust targets if cost estimates change. If reserves threaten development capital, trigger a financing gate to seek dedicated reserve funding.

Risk 16 - Operational

A minimum viable two-year programme (Months 0–24 = 2026-10-31 to 2028-10-31) must be separated from the full industrial programme, but the scope of the MVP is not yet detailed. The MVP should cover founding team assembly, Leuven partnership confirmation, architecture and supplier validation, preclinical work and early funding. If the MVP is under-scoped, critical risks are not retired before larger capital is committed. If it is over-scoped, the team is stretched and early cash is consumed before learning what is needed.

Impact: Under-scoped MVP: critical gaps (e.g., no chronic animal data, no foundry pathway, no supplier lined up) emerge at Month 24–36 (2028-10-31 to 2029-10-31), triggering expensive rework or programme pause. Over-scoped MVP: cash burn of €2M–€5M per month leaves insufficient funding for the pivotal trial phase, leading to shortfalls at Month 36–48 (2029-10-31 to 2030-10-31).

Likelihood: Medium

Severity: High

Action: Define the MVP scope explicitly by Month 1 (2026-11-30): (1) founding team (10–15 core staff, including neurosurgeons, engineers, regulatory), (2) Leuven partnership letters of intent and backup sites, (3) architecture-choice analysis and freedom-to-operate review, (4) preclinical feasibility (6–12 month chronic animal study, biocompatibility) and pilot prototype, (5) supplier identification and qualification planning, (6) regulatory engagement (notified-body pre-submission, Commission scientific-advice request), (7) early funding commitment (seed + national grants €5M–€10M for Months 0–24 = 2026-10-31 to 2028-10-31). Gate release of Series A funding (Months 24–36 = 2028-10-31 to 2029-10-31) on MVP completion and risk-retirement milestones, not on timeline alone.

Risk 17 - Supply Chain

Dual-sourcing of chips and thin-film substrates assumes that at least two EU suppliers can be qualified by the design-lock date (Month 24–30 = 2028-10-31 to 2029-04-30). Many specialised neural-implant chip designers and thin-film manufacturers are concentrated in a few locations (Netherlands, Germany, France); if both targets decline to commit or go insolvent, the programme has no fallback and faces single-source supply risk. Qualification timelines for medical suppliers are 9–18 months, so delays in supplier engagement compress the schedule.

Impact: If a second supplier cannot be qualified by Month 30 (2029-04-30), single-source risk remains through the pivotal trial; loss of the single source due to financial failure, export controls or capacity issues could halt manufacturing and delay CE marking by 6–12 months and cost €2M–€5M in rework. Late supplier engagement (Month 24+) compresses qualification and may delay first-in-human by 3–6 months if prototyping is blocked.

Likelihood: Medium

Severity: High

Action: Identify two candidate chip suppliers (e.g., imec/Gent, Dresden, Eindhoven) and two thin-film substrate suppliers by Month 3 (2027-01-31). Conduct pre-qualification assessments (capacity, capability, cost, timeline, export controls, financial stability) by Month 6 (2027-04-30). Sign agreements or MOUs with both suppliers by Month 12 (2027-10-31), locking design specifications and timelines. Conduct formal qualification (process audits, sample testing, documentation review) by Months 18–24 (2028-04-30 to 2028-10-31). If a second supplier withdraws, immediately activate a tertiary option or diversify the supply chain geographically (e.g., one chip supplier in the EU, one thin-film supplier outside but with low export-control risk). Budget supplier qualification costs of €500k–€1M and maintain a contingency of €1M–€2M for rapid re-sourcing.

Risk 18 - Technical

Wearable hardware (external processor, transmitter, power, antennas) must operate reliably during daily use, heatwaves, moisture and mechanical stress. Battery life, heat dissipation, antenna efficiency and electromagnetic interference all affect bandwidth and user experience. A poorly designed wearable reduces adoption, increases support burden and undermines the clinical benefit case. There is limited precedent for high-power neural-implant wearables in the EU market.

Impact: Wearable failures or poor thermal design reduce bandwidth by 30–50% during heatwaves; user complaints and returns increase support costs by €500k–€1M annually. Poor antenna design reduces range, forcing frequent recalibration or loss of signal; calibration time increases from minutes to hours, reducing usability. Battery life <8 hours forces frequent charging, reducing adoption and user satisfaction.

Likelihood: Medium

Severity: Medium

Action: Engage a medical-device wearable specialist (e.g., Philips, Medtronic, or EU research groups) by Month 6 (2027-04-30) for design and testing guidance. Design for heatwave performance (passive cooling, automatic throttling, thermal shutdown if needed) and validate in climate-chamber tests by Month 18 (2028-04-30). Conduct human-factors testing (wearing comfort, heat perception, mechanical durability) with 10–20 non-implanted users by Month 20 (2028-06-30). Target battery life >12 hours and antenna range >10 meters; validate in field testing. Budget wearable design and testing at €500k–€1.5M.

Risk 19 - Regulatory & Permitting

The plan requires valid informed consent from people with impaired or declining communication (ALS, locked-in syndrome). Consent advocates, independent ethics review and lifelong follow-up are hard requirements. Multi-country coordination adds complexity: each country's ethics committee has different consent standards and approval timelines. If consent is deemed invalid by an ethics committee or regulator, the entire trial cohort may be invalidated, requiring restart and delaying approval by 12–24 months.

Impact: Ethics-committee rejection of consent protocols adds 3–6 months and requires protocol redesign and re-review. If consent is invalidated mid-trial, accumulated data may not be useable; loss of 12–36 months of trial data and forced restart of first-in-human with new cohort.

Likelihood: Low

Severity: High

Action: Develop consent protocols with independent ethics specialists and patient organisations by Month 3 (2027-01-31). Conduct a multi-country ethics-committee pre-submission at Month 6 (2027-04-30) to align on consent standards, advocate roles and validation methods. Engage patient organisations to review consent materials and advocate recruitment. Use harmonised consent templates across all countries and maintain detailed consent records (signed forms, video documentation, communication-method validation). Have independent ethics monitors review consent quality in each cohort of 5–10 participants.

Risk 20 - Organisational

A founder-only start with no committed partners or funding means the initial team must be small, multidisciplinary and highly skilled. Early hiring is critical to set direction and attract follow-on talent, but recruiting against US salaries and with limited early funding is difficult. Burnout and turnover risk is high in a 15-year programme; key personnel loss (especially the founder and lead neurosurgeon) can derail early work. Distributed sites across four countries multiply HR, legal and cultural coordination challenges.

Impact: Loss of a key team member within the first two years delays architecture choice or regulatory engagement by 3–6 months and costs €500k–€1M in knowledge loss and hiring rework. High turnover in early years demoralises remaining staff and signals instability to investors and partners. Coordination delays across distributed teams reduce execution speed by 10–20%.

Likelihood: Medium

Severity: Medium

Action: Recruit the core founding team (10–15 people: neurosurgeon, neuroengineers, clinical lead, regulatory, manufacturing) by Month 6 (2027-04-30), with transparent equity, mission alignment and multi-year contracts. Offer mission-driven roles and long-term advancement paths to offset salary gaps. Establish a retention bonus for key roles (payable after 3 and 5 years). Build a strong culture and flat hierarchy to maximise autonomy and engagement. Establish quarterly all-hands meetings and distributed team rituals (virtual journals, team retreats) to maintain cohesion across sites. Identify and cross-train deputies for all key roles by Month 12 (2027-10-31) to reduce single-person risk.

Risk 21 - Market & Competitive

The eligible population for the initial indication (ALS communication) is small (~5,000–10,000 annually in the EU with appropriate severity for surgery). The progression rate in ALS is rapid; median survival is ~3 years post-diagnosis and often <1 year for locked-in cases. This shrinks the recruitment pool and strains the 5,000-implant target, which assumes a 10–15 year ramp. Spinal cord injury offers a larger pool, but the benefit case against assistive technology is weaker and reimbursement acceptance is lower. Without evidence of a compelling clinical benefit, payers may decline reimbursement or offer very low rates.

Impact: If the ALS population shrinks by 20–30% due to rapid disease progression or competing treatments, the eligible pool for 5,000 implants is reduced by ~1,000 patients, extending the timeline to Year 17–18 instead of Year 15. If reimbursement is denied or is very low (€5k–€10k instead of €20k–€40k), annual revenue is €25M–€50M instead of €100M–€200M, straining long-term sustainability.

Likelihood: Medium

Severity: Medium

Action: Validate eligible populations by epidemiology studies and payer consultations by Month 12 (2027-10-31). For ALS: work with ALS societies in each member state to map disease progression, case definitions and patient flow. For spinal cord injury (if considered): model survival, rehabilitation capacity and outcome measures against assistive technology. Build a health-economic case against existing assistive technology (eye-tracking, speech synthesis) with cost-effectiveness targets by Month 15 (2028-01-31). Engage payers in pre-reimbursement dialogues by Month 18 (2028-04-30) to test price acceptability and evidence requirements. If ALS eligible population is <3,000, trigger a kill gate to consider spinal cord injury or a combination indication.

Risk 22 - Technical

The bandwidth measurement protocol (bits per second, user-controlled, excluding language-model expansion) is strict but may underestimate practical communication speed if language models and autocomplete are later allowed. Reporting structured-command selection separately from free communication complicates comparisons with competitors' claims. Independent verification and held-out tasks are essential for credibility, but add testing burden and delay result release.

Impact: Measured bandwidth (e.g., 8–12 bits/s in early trials) looks significantly lower than competitors' claims (20–30 bits/s if language models are included), weakening investor and payer confidence by 30–50%. Independent verification adds 2–3 months to result publication, allowing competitors to claim leadership. Separate reporting of commands versus free text complicates marketing and may confuse regulators or payers.

Likelihood: Low

Severity: Medium

Action: Pre-register the bandwidth protocol with held-out tasks, independent verification and structured-command/free-text separation by Month 12 (2027-10-31). Use EU-based independent verification (e.g., university lab or research institute) and maintain neural data in the EU using federated testing. Publish bandwidth results with full transparency, including error rates, calibration time and participant count. Report structured-command and free-text metrics separately, and separately report gross bandwidth (with language-model expansion) and net bandwidth (user-controlled only) to allow context-dependent comparisons. Build a public benchmarking page showing rival systems' measured bandwidth (pessimistic, central and optimistic scenarios) and update it yearly.

Risk summary

This is an ambitious, frontier-level, heavily constrained programme with very high technical, financial, regulatory and operational risk. The three most critical risks are: (1) Financing and Capital Gates – approximately €2.5 billion over 15 years, with no committed funding at start and multi-state IPCEI dependency, means the programme can run out of money at Months 12–24 (2027-10-31 to 2028-10-31) or Months 36–48 (2029-10-31 to 2030-10-31) if expected tranches are missed. Running out of money before CE marking is a named failure mode that must be prevented through staged capital gates tied to objective milestones. (2) Technical Feasibility of Chronic Signal Stability and Bandwidth – chronic electrode performance over 5–10 year device lifetimes remains unproven; if signal degrades >20% within 12 months, the bandwidth and clinical benefit claims collapse, triggering device failure or explantation. Pre-registered kill gates on stability and bandwidth by Months 18–36 (2028-04-30 to 2029-10-31) are essential. (3) Regulatory and Clinical Evidence Path under MDR and AI Act – Class III conformity assessment is lengthy and uncertain; notified bodies may request additional preclinical work or refuse approval, delaying CE marking by 12–24 months. Early scientific advice and notified-body engagement reduce rework risk, but no route avoids the evidence burden. Key mitigation strategies include: (a) explicit financing gates with hard deadlines (Months 12, 24, 36 = 2027-10-31, 2028-10-31, 2029-10-31) and named fallbacks, (b) pre-registered kill criteria for chronic stability and bandwidth by Month 18 (2028-04-30), (c) early notified-body and Commission engagement by Month 12 (2027-10-31), and (d) separation of the MVP (Months 0–24 = 2026-10-31 to 2028-10-31) from full industrial scale, with clear risk-retirement criteria for each tranche. A feasibility verdict (achievable, achievable only with changes, or not credibly achievable) should be rendered by Month 24 (2028-10-31) based on financing confirmation, partnership commitment and early preclinical data. The plan is executable if these three pillars are actively managed; without them, the programme faces high probability of halt or failure.

Make Assumptions

Question 1 - How much committed versus hoped-for money exists, and how should the ~€2.5B (user constraint) split between company capital, shared-foundry costs and patient-protection reserves, with gate deadlines?

Assumptions: Assumption: Nothing is committed at Month 0 (2026-10-31). The first 24 months need a seed plus grants of roughly €5M–€10M (estimate), which is small relative to likely burn. Gates sit at Months 12, 24 and 36 (2027-10-31, 2028-10-31, 2029-10-31). Shared foundry costs are budgeted separately and treated as hoped-for until four or more member states commit. Reserves are ring-fenced from the first implant.

Assessments: Title: Financial Feasibility Assessment Description: Tests whether staged funding can reach CE marking without assuming money. Details: The €5M–€10M MVP figure (estimate) looks tight for a 10–15 person team, chronic animal work and FTO. A burn of €2M–€5M per month (risk file estimate) would exhaust it quickly, so the MVP should be re-costed bottom-up. Gates: Month 12 (2027-10-31) seed, Month 24 (2028-10-31) Series A and foundry decision, Month 36 (2029-10-31) pivotal funding. If foundry funding is unconfirmed by Month 18 (2028-04-30), switch to dual-sourcing. Report the programme total as committed, probable and hoped-for ranges. Reserve estimate €50M–€150M (risk file estimate) needs actuarial validation. Missing a gate means stop, defer or switch to the named alternative.

Question 2 - What bottom-up schedule, with uncertainty ranges, supports first-in-human near Month 60 (2031-10-31), CE marking near Month 120 and 5,000 (2036-10-31, 2027-03-31, 2026-10-31) implants by Month 180 (2041-10-31)?

Assumptions: Assumption: Targets are soft. Central case: first-in-human at Month 60 (2031-10-31) (range 54–78), CE marking at Month 132 (2037-10-31) (range 114–156), cumulative implants about 2,500–5,000 by Month 180 (2041-10-31). Chronic animal data of 18–24 months precede first-in-human. The architecture choice is made by Month 18 (2028-04-30) and design lock by Months 24–30 (2028-10-31 to 2029-04-30).

Assessments: Title: Timeline Feasibility Assessment Description: Checks the milestone chain against clinical and regulatory durations. Details: The critical path runs through architecture choice, chronic animal studies, supplier qualification (9–18 months), a pilot-to-production transfer and a pivotal trial. Class III reviews often slip 12–24 months (risk file estimate), which pushes CE marking past Month 120 (2036-10-31). The 5,000-implant goal is the weakest target: ALS-only supply and a ramp starting after approval point to a miss, reported with ranges. Schedule gains must come from sequencing, not lighter evidence. Key decision dates: Month 6 (2027-04-30) notified-body engagement, Month 12 (2027-10-31) scientific advice, Month 24 (2028-10-31) feasibility verdict.

Question 3 - What is the minimum team and partner set for the first two years, and which capabilities will be licensed, acquired or built if imec, KU Leuven or UZ Leuven declines?

Assumptions: Assumption: The MVP team is 10–15 people (risk file figure) covering neurosurgery, neuroengineering, regulatory, quality and manufacturing. Capabilities are secured through exclusive field-limited licences with pre-priced acquisition options. Letters of intent are sought by Month 3 (2027-01-31). Fallback sites are Ghent or Antwerp, Utrecht and Grenoble, activated by Month 6 (2027-04-30).

Assessments: Title: Resources and Personnel Assessment Description: Evaluates hiring, partnerships and the build-versus-acquire comparison. Details: EU pay for equivalent talent trails US pay (risk file estimates 20–30%), so equity, mission and long retention bonuses are needed. Licences with options avoid paying for unvalidated assets but need a diligence screen on ownership, maintainability without foreign consent and export-control freedom. A refusal by UZ Leuven adds an estimated 3–6 months for site qualification. Cross-train deputies by Month 12 (2027-10-31). Compare options on months saved, share of IP owned and cost, and decide by Month 6 (2027-04-30).

Question 4 - What regulatory route and quality system will meet MDR Class III and AI Act high-risk obligations, with coordinated investigations, and without assuming reduced evidence?

Assumptions: Assumption: An ISO 13485 QMS is in place by Month 9 (2027-07-31). A notified body is engaged by Month 6 (2027-04-30) and Commission scientific advice is requested by Month 12 (2027-10-31). First-in-human runs in Leuven plus one or two other states under coordinated assessment. The decoder is version-locked with a pre-registered change-control process, and there is no reduced evidence burden.

Assessments: Title: Governance and Regulatory Assessment Description: Reviews the MDR, AI Act, GDPR and ethics pathway. Details: Early engagement reduces rework but is non-binding, and a Class III review may add 12–24 months (risk file estimate). AI Act work (documentation, oversight, bias testing) is budgeted at about €0.5M–€2M (estimate). Ethics committees differ by country, so use harmonised consent templates and pre-submission at Month 6 (2027-04-30). Neural data stays in the EU, so use federated verification. The Month 24 (2028-10-31) feasibility verdict should split scientific, engineering, clinical, regulatory, supply-chain and financing feasibility. Enhancement work sits in a separate entity so the intended-use statement stays clean.

Question 5 - Which kill gates, safety thresholds and consent safeguards will bind the programme, and who holds stop authority?

Assumptions: Assumption: An independent data monitoring committee with patient representation holds binding pause authority. Proposed thresholds, to be refined with regulators: more than 10% serious adverse events in the first 20 implants, more than 20% signal loss within 12 months, and a sustained bandwidth floor at Month 24 (2028-10-31). Independent consent advocates attend every consent conversation. Yes/no signalling is validated before surgery.

Assessments: Title: Safety and Risk Management Assessment Description: Assesses patient harm, consent validity and stop rules. Details: Early-implant serious adverse event rates of 5–15% (risk file estimate) mean thresholds must be set before data exist, then reviewed by regulators. Invalid consent could void a cohort and cost 12–36 months. Early enrolment improves consent validity but favours less advanced disease. Kill gates cover continuing, switching architecture, dropping an indication or terminating. Tie investor tranches to written monitoring-committee findings. Never recruit from coercive settings. Fund lifelong follow-up from the first implant.

Question 6 - What are Leuven's heat, drought, flood and power risks for manufacturing, compute and patients, and which sites or controls follow from them?

Assumptions: Assumption: A resilience assessment is commissioned by Month 3 (2027-01-31). Backup power and redundant cooling are installed by Month 18 (2028-04-30). The wearable is designed for multi-day 35–40°C profiles with passive cooling and throttling. Compute is replicated at a second EU site. Participants are screened for impaired thermoregulation and receive heat-alert protocols.

Assessments: Title: Environmental Impact and Resilience Assessment Description: Evaluates climate exposure of sites, hardware and patients. Details: Cleanroom cooling, sterilisation, animal housing and compute depend on power and water. Outage losses are estimated at €100k–€500k per event (risk file). Throttling during heat may cut bandwidth to 50–70% (risk file estimate), so report thermal-derated bandwidth as the baseline. High spinal cord injury raises patient heat risk and a cooled-refuge obligation, which needs costing. Also assess the footprint of manufacturing water use and animal work. Move production or compute to a secondary site if the assessment shows high risk.

Question 7 - Which stakeholders must be secured first (investors, Commission, member states, hospitals, payers, patients, public), and why would EU buyers choose this device if a US rival gets CE marking first?

Assumptions: Assumption: The value case rests on measured daily-life benefit in EU patients, EU-held neural data, local service, lifelong support and surgeon training. Payers and HTA bodies are engaged in Months 12–24 (2027-10-31 to 2028-10-31). The company does not sell outside the EU until CE marking, which avoids export-control entanglement. A freedom-to-operate review precedes the architecture choice.

Assessments: Title: Stakeholder Involvement Assessment Description: Reviews alignment, public trust and market positioning. Details: A US entrant first could cut early capture by 30–50% (risk file estimate), so the reimbursement case must rest on evidence rather than nationality. Test cost-effectiveness against eye-tracking and speech aids, using thresholds still to be modelled. Patient groups and ALS societies should review consent and endpoints. A published bandwidth protocol and honest communication of the enhancement track protect public trust. An IPCEI needs four or more member states, so start Commission and member-state talks at Months 6–12 (2027-04-30 to 2027-10-31). Patents from rivals need a freedom-to-operate review before architecture lock.

Question 8 - Which architecture, supply chain, decoder location and implant-centre network make the integrated system sovereign and scalable, and which pilot-line, supplier and surgical-capacity limits apply?

Assumptions: Assumption: The architecture is chosen at Month 18 (2028-04-30) from cortical, endovascular and thin-film options, scored on benefit, surgical risk, stability, bandwidth, scale and patent clearance. The company owns encapsulation and assembly and dual-sources chips and substrates. The decoder runs locked on a body-worn EU processor. The pilot line is not treated as production. Early implanting is limited to a few expert centres.

Assessments: Title: Operational Systems Assessment Description: Tests the design, supply and delivery systems as one coherent whole. Details: Transfer to validated production may take 6–12 months if yield falls below 80% (risk file estimate). A second supplier must be qualified by Month 30 (2029-04-30) or single-source risk persists. Sovereignty is tested by ownership, maintainability without foreign consent and export-control freedom, with upstream tools listed as exceptions. Bandwidth is net user-controlled bits per second with held-out tasks and independent verification. Reaching 5,000 active users needs bottom-up centre and theatre capacity modelling, separating cumulative implants from active users. Lock materials, chips and processes before the pivotal trial, with bridging studies budgeted.

Distill Assumptions

Review Assumptions

Domain of the expert reviewer

Medical device development, regulated product commercialisation, and deep-tech venture scaling. The review prioritises regulatory feasibility under MDR Class III and AI Act compliance, clinical evidence pathways, manufacturing sovereignty and financial viability in a capital-intensive, multi-stakeholder EU environment where committed funding is absent at start and risk is frontier-level.

Domain-specific considerations

Issue 1 - Missing Baseline Cost-of-Capital and Investor Return Assumptions for €2.5B Envelope

The plan specifies ~€2.5B total (user constraint) but does not state what return-seeking investors expect (IRR, payback period, exit horizon) or the cost of capital across seed, Series A, pivotal and scale-up phases. Investor return expectations (e.g., 3× in 10 years versus 10× in 15 years) directly determine acceptable risk, willingness to wait for CE marking, and tolerance for kill gates. Without explicit return assumptions, capital-raising risk and financing-gate credibility cannot be assessed.

Recommendation: By Month 3 (2027-01-31), define and document investor return expectations: proposed target IRR (e.g., 20-25% nominal), payback horizon (e.g., 10-12 years to first revenue), exit scenarios (IPO, strategic sale, dividend from reimbursement revenue), and how these vary by funding phase (seed 5-7 year horizon, Series A 10-12 year horizon). Model the €2.5B envelope backwards from reimbursement revenue assumptions (price per implant, volume ramp, payer-adoption timing) to confirm the return profile is achievable. Use this model to set financing gates: if a tranche cannot be raised at the proposed return terms, the gate fails and triggers a fallback (pivot indication, slower scale, additional grant funding). Publish the return model to investors with monthly updates post-funding.

Sensitivity: Return assumptions directly affect capital availability and gate credibility. If investors demand 30% IRR (higher risk premium) instead of 20%, the company must either accelerate revenue (compress trials or aggressively licence to partners) or secure larger grants. A 10-percentage-point IRR change could reduce willing investors by 50-70% and delay Series A close by 6-12 months. Revenue shortfalls (e.g., payer acceptance at 50% of member states instead of 80%) compress IRR by 5-15 percentage points, potentially invalidating early investor theses and triggering bridge-financing crisis at Months 36-48 (2029-10-31 to 2030-10-31).

Issue 2 - Unspecified Eligible-Population Epidemiology and Attrition Modelling for the 5,000-Implant Target

The plan targets 5,000 reimbursed implanted patients by Month 180 (2041-10-31) but does not quantify EU ALS incidence, survival rates, disease-progression phenotypes (people who can consent and have durable benefit), or attrition due to competing treatments. ALS median survival is ~3 years post-diagnosis and <1 year for locked-in cases. Without bottom-up eligible-population modelling, the 5,000 target is detached from reality and financing/reimbursement assumptions built on it are unreliable.

Recommendation: By Month 6 (2027-04-30), commission an epidemiology study covering (1) EU annual ALS incidence (~5,000–7,000), (2) fraction meeting indication criteria (age, disease stage, communication loss, consenting capacity), estimated at 10-20% = 500–1,400/year; (3) attrition due to disease progression (median survival <12 months in locked-in cohorts), and (4) net eligible-pool size assuming 5-year trial ramp starting at Month 60 (2031-10-31). Model cumulative implants under two scenarios: (a) expert-centre model (5-10 implants/centre/year across 10 centres = 50–100/year, reaching 250–500 by Month 180 = 2041-10-31), and (b) distributed-centre model (20+ centres, 200–300/year, reaching 1,000–1,500 by Month 180 = 2041-10-31). Report the realistic 5,000 target as unachievable under ALS-only indication unless attrition assumptions drop dramatically or definition expands. Trigger a pre-registered kill gate at Month 24 (2028-10-31) if eligible population modelling shows <1,000 realistic cumulative implants.

Sensitivity: Population size directly determines revenue ceiling and investor ROI. If ALS-only pool is 500–1,000 implants (versus the 5,000 target), cumulative revenue is €10M–€40M (at €20k–€40k per implant) instead of €100M–€200M, reducing IRR by 8-15 percentage points and invalidating the programme's financial case. Spinal cord injury offers 3–5× larger pool but weaker benefit case, so reimbursement acceptance may drop 50%, offsetting volume gains. A combined ALS-plus-SCI indication could reach 2,000–3,000 implants by Month 180 (2041-10-31), still below 5,000, and require a formal indication-switch kill gate at Month 36 (2029-10-31).

Issue 3 - Undefined Reimbursement Model and Payer-Acceptance Preconditions at Feasibility Verdict

The plan assumes payer engagement in Months 12–24 (2027-10-31 to 2028-10-31) but does not specify (1) what payers must see to approve—clinical benefit threshold, health-economic ceiling (€/QALY, cost-benefit ratio), and comparator choice—or (2) how many member states must reimburse for the 5,000-implant and revenue targets to hold. Payers evaluate based on cost-effectiveness and budget impact; without pre-negotiated thresholds and early dialogue outcomes, the financial model rests on hope. Outcome-based contracts mentioned in Decision 9 are mentioned but not specified: what outcomes, what payment steps, what financial risk does the company bear?

Recommendation: By Month 9 (2027-07-31), define payer-acceptance criteria: (a) primary comparators (eye-tracking, speech-synthesis devices, current assistive technology) and cost thresholds per indication (ALS communication: target €150k–€250k per implant for 5-year payer horizon; SCI motor: target €100k–€200k). (b) Health-economic targets: cost per quality-adjusted life year (QALY) or life-year gained (LYG) at 3× GDP per capita or lower (roughly €80k–€120k/QALY in EU). (c) Budget-impact limits: annual payer outlay <5% of neurology/rehabilitation budget in any country. By Month 15 (2028-01-31), conduct pre-reimbursement dialogues with payers in at least three large member states (Germany, France, Benelux) and publish a reimbursement-feasibility summary. At the Month 24 (2028-10-31) feasibility verdict, report which member states have signalled acceptance and at what price; if fewer than three, trigger a commercial-viability kill gate. For outcome-based contracts, specify the measurement burden on hospitals (follow-up timing, outcome metrics), the payment steps (e.g., 30% upfront, 40% at 6-month retention, 30% at 12-month benefit confirmation), and the company's financial risk (e.g., refund if retention drops below 80%).

Sensitivity: Reimbursement acceptance and pricing are the largest determinants of ROI and company viability. A 20% shortfall in payer adoption (6 member states instead of 7–8) reduces revenue by €30M–€50M and IRR by 4-8 percentage points. Outcome-based contracts delay cash inflow by 12–24 months, straining working capital at Months 60–84 (2031-10-31 to 2033-10-31) and requiring larger financing facilities, adding €2M–€5M in interest and fees. If payers demand cost per QALY >€150k (higher than assumed), the indication may be economically unviable in lower-income member states, shrinking addressable market by 30-40%.

Issue 4 - Unquantified Chronic Signal-Stability Kill-Gate Thresholds and Implications for Device Longevity Claims

The plan identifies chronic electrode signal stability as a critical risk and proposes a kill threshold of '>20% signal loss within 12 months' (proposed threshold), but does not justify this number or model its implications for device lifetime, maintenance burden or claim defensibility. If signal degrades 20% in 12 months, what happens in years 2-5? How is recalibration burden or explantation risk priced into the patient-protection reserve? What bandwidth floor at what timepoint makes the device clinically unusable? Without quantified stability trajectories, the kill gate is arbitrary and the device-lifetime claims are ungrounded.

Recommendation: By Month 12 (2027-10-31), commission a chronic-stability modelling study covering (a) preclinical data from 18–24 month animal studies: mean signal-loss trajectory, variance, distribution across electrodes, and tissue-response correlates; (b) published human data from competing BCI programmes (NIL, Neuralink, Synchron, academic cohorts if available), showing signal loss over 3–5 years; (c) degradation-mode analysis: electrode encapsulation failure, tissue fibrosis, metal migration, software drift, user fatigue/calibration non-compliance. Model forward to 5, 10 and 15 year horizons with pessimistic, central and optimistic scenarios. Define kill-gate thresholds as quantitative criteria tied to clinical unacceptability: e.g., '>30% signal loss by Month 24 (2028-10-31)' (proposed threshold), or 'sustained bandwidth drops below 5 bits/s in >20% of participants by Month 36 (2029-10-31)' (proposed threshold). Link thresholds to device-lifetime warranties (e.g., 5-year warranty if stability is central-case estimate; 3-year if pessimistic). Estimate explantation frequency and cost (€20k–€50k per case, affecting reserves) from stability projections. Report stability-sensitivity analysis: if signal loss is 1.5× worse than preclinical, what is the cost impact on reserves and scalability?

Sensitivity: Signal stability drives bandwidth sustainability and device lifetime. A 2× worse-than-expected degradation rate (30% loss in 12 months instead of 20%) would necessitate electrode replacement or device explantation in 10-20% of early cohorts by Month 48–60 (2030-10-31 to 2031-10-31), costing €1M–€2M in unexpected explantations and damaging payer trust. Such findings would likely trigger a device-design review or architectural switch at a cost of €1M–€3M and 6–12 month delay. Stability uncertainty compounds with long-term reserve adequacy: if device lifetime is 3 years instead of 5–7 years assumed, per-implant reserves must increase by €5k–€10k, raising total reserve requirement from €50M to €75M–€150M.

Issue 5 - Unspecified Patient-Protection Reserve Governance, Triggering Mechanism and Adequacy Audit Cadence

The plan mentions ring-fencing €50M–€150M (estimate) in a patient-protection reserve but does not specify (1) how much grows per implant or when, (2) what events trigger draw-down (explantation, lifelong follow-up, company insolvency), (3) who governs the escrow (independent trustee, hospital network, member states), or (4) how adequacy is audited. Without these details, the reserve is a stated goal without operational structure. Implanted patients could be left unsupported if reserve design fails or funding lapses.

Recommendation: By Month 6 (2027-04-30), establish a patient-protection reserve governance charter covering: (a) reserve account structure (separate trust, escrow or foundation outside investor reach); (b) per-implant allocation (proposed: €10k–€30k per implant, starting from Month 36 = 2029-10-31 when implants begin), growing to 100% target by Year 10 post-first-implant; (c) draw-down events: lifelong clinical follow-up (€500–€1,000/year), device servicing or replacement (€5k–€10k per episode), surgical explantation (€20k–€50k), emergency support if company insolvency (full coverage for remaining device lifetime); (d) governance: independent trustee (e.g., hospital network, member-state nominee, or professional fiduciary) with authority to approve draw-downs; (e) investment policy (conservative, low-risk vehicles to preserve capital); (f) annual adequacy audit by external actuaries, with public reporting. Tie investor terms to reserve funding: clarify that reserves are not available for operating capital and are pledged first to patient obligations. If reserves fall below adequacy levels, trigger a capital call or halt new implants until reserves recover. Publish reserve status quarterly.

Sensitivity: Reserve adequacy directly affects patient safety and company credibility. Underfunding (setting per-implant allocation at €5k instead of €10k–€30k) could leave 1,000+ implanted patients with inadequate follow-up or explantation support if device lifetime extends beyond funding reserves. Underfunding by 50% (€25M shortfall across 5,000 implants) would trigger a capital crisis at Month 120+ (2036-10-31+) when patients enter long-term follow-up phases. Conversely, over-funding (allocating €50k per implant when €10k–€20k is adequate) reduces development capital by €100M–€150M at crucial pre-approval phases, delaying Months 12–24 (2027-10-31 to 2028-10-31) milestones by 6–12 months.

Review conclusion

This 15-year, €2.5B European BCI venture is feasible in principle but depends critically on five missing assumptions being resolved before Month 24 (2028-10-31): (1) explicit investor return expectations and cost-of-capital assumptions to drive capital-raising credibility and gate discipline; (2) bottom-up eligible-population epidemiology showing whether 5,000 implants is realistic or should trigger an indication pivot; (3) quantified payer-acceptance preconditions and reimbursement-model specifications (outcome-based contracts, member-state coverage targets, cost-per-QALY thresholds); (4) chronic signal-stability kill-gate thresholds grounded in preclinical and published human data, with device-lifetime implications; and (5) patient-protection reserve governance, per-implant allocation and adequacy-audit cadence to operationalise the safeguard. The plan is strong on governance structure, kill gates and risk retirement logic, but weak on the financial and clinical foundations those gates depend on. The feasibility verdict at Month 24 (2028-10-31) must not proceed without these five assumptions resolved to quantitative certainty. If they remain unresolved, the programme should defer or switch to a narrower scope (e.g., ALS-communication first-in-human only, with a deliberate pause before pivotal-indication decision). Addressing these gaps requires €500k–€1M in early analysis and payer engagement, well worth the cost to avoid larger failures later.

Governance Audit

Audit - Corruption Risks

Audit - Misallocation Risks

Audit - Procedures

Audit - Transparency Measures

Internal Governance Bodies

1. Project Steering Committee

Rationale for Inclusion: This €2.5B, 15-year frontier-level medical device programme requires high-level strategic oversight of financing gates, partner commitments, regulatory milestones and risk-retirement decisions. A Steering Committee with investor, founder and independent representation provides the governance layer for approving tranches, pivoting indication or architecture, and escalating unresolved conflicts between operational management and external stakeholders (Commission, member states, notified bodies, hospital partners).

Responsibilities:

Initial Setup Actions:

Membership:

Decision Rights: Binding authority to approve or withhold financing tranches (T0–T4, each gated on milestones); to ratify architecture, indication and supplier choices; to approve kill-gate actions (pause, design review, programme termination); to override or escalate recommendations from operational management if they conflict with hard requirements (patient safety, valid consent, EU control). Decisions affecting more than one member state or EU policy require advance consultation with the Commission liaison. No decision to proceed with first-in-human, pivotal trial or CE submission without explicit Steering Committee written approval.

Decision Mechanism: Consensus preferred; if consensus cannot be reached on a gate decision or strategic choice, voting by simple majority (3 of 5 members), with the independent chair breaking ties. Tie-breaker rule: the chair votes in favour of stopping or pausing if any member raises a safety, consent or sovereignty concern. All decisions recorded in writing with the date, dissent noted, and reasoning captured. Gate-decision outcomes (go/defer/stop/switch) published within 5 business days to investors, the Commission and hospital partners.

Meeting Cadence: Monthly operational updates (30 mins); quarterly strategic reviews (2 hours); emergency meetings within 48 hours if a gate condition is triggered or a safety finding from the DMC emerges. Within 5 business days of each defined gate (Months 6, 12, 18, 24, 36, 60, 78, 84, 132, 180 = 2027-04-30, 2027-10-31, 2028-04-30, 2028-10-31, 2029-10-31, 2031-10-31, 2033-04-30, 2033-10-31, 2037-10-31, 2041-10-31), the Steering Committee holds a formal gate-review meeting and publishes its verdict.

Typical Agenda Items:

Escalation Path: Unresolved Steering Committee decisions (e.g., conflict between investor return requirements and patient safety safeguards, or between schedule pressure and consent rigour) escalate to the Commission and founding member states if they affect policy (IPCEI commitments, sovereignty tests) or to binding third-party mediation (external arbitrator, to be named in the Charter). Regulatory or ethics-committee deadlock (e.g., multi-country ethics approval stalled) escalates to the Commission's scientific-advice or coordinated-assessment machinery. Financing-gate failures (e.g., T1 not closed by Month 24 = 2028-10-31) automatically trigger the named fallback route within 14 days: defer FIH by 12 months, switch to dual-sourcing to avoid foundry dependency, or terminate the programme.

2. Project Management Office (PMO) and Core Execution Team

Rationale for Inclusion: Operational management of a 15-year, multi-site, multi-stakeholder medical-device development programme requires a dedicated PMO to execute day-to-day work: manage work packages, track milestones, oversee budget and supplier relationships, coordinate across Leuven HQ and distributed sites (Netherlands, France, Germany, Belgium), and escalate blockers that exceed the PMO's threshold. The PMO sits below the Steering Committee and reports monthly to it; it owns the detailed schedule, resource allocation and operational risk management.

Responsibilities:

Initial Setup Actions:

Membership:

Decision Rights: Approve work-package plans and budgets within T0–T4 allocation; approve supplier RFQs and evaluation criteria; approve changes to schedule and scope <2 months slip or <EUR 1M cost impact; approve regulatory submissions and scientific-advice responses (with Steering Committee final sign-off on major strategy shifts). Escalate to Steering Committee any decision affecting financing gates, kill-gate criteria, partnership stability or sovereignty tests. Do not approve decisions that reduce evidence requirements, defer safety oversight or weaken consent processes.

Decision Mechanism: Consensus among PMO leads; the Programme Manager has tie-breaking authority for operational decisions (schedule, budget, supplier performance) but must escalate strategic or compliance decisions to the Steering Committee. All decisions recorded in the project log with date, owner and rationale. Weekly PMO sync (30 mins) reviews blockers and escalations; major decisions documented within 24 hours.

Meeting Cadence: Weekly PMO internal sync (30 mins); bi-weekly supplier and clinical-site coordination calls (1 hour); monthly steering report to the Project Steering Committee; quarterly external reporting to the Commission, member states and hospital partners; quarterly audit of budget, schedule and risk (see Governance Audit and Transparency Measures).

Typical Agenda Items:

Escalation Path: Decisions with budget impact >EUR 1M, schedule slip >2 months, potential impact on patient safety or sovereignty tests, or conflict between cost and evidence quality escalate to the Project Steering Committee within 24 hours. Supplier or manufacturing crises (yield <80%, second-source withdrawal, export-control shock) escalate to the Steering Committee within 48 hours with recommended fallback action. Regulatory deadlock (notified-body request for rework exceeding budget or schedule buffer) escalates to Steering Committee for potential scientific-advice escalation to the Commission. Clinical safety signals (>proposed threshold for serious adverse events) escalate to the independent Data Monitoring Committee immediately; the DMC's pause recommendation is binding.

3. Independent Data Monitoring Committee (DMC) and Safety Oversight Board

Rationale for Inclusion: This is a hard-requirement safeguard for a Class III implant trial in people with severe neurological disease and impaired or declining communication. An independent DMC with patient representation and binding pause authority protects against continuing when risks outweigh benefits, ensures valid consent, monitors safety and signal-stability kill gates, and reports transparently to ethics committees, regulators and patients. The DMC answers to the Steering Committee but acts independently of operational and investor pressure.

Responsibilities:

Initial Setup Actions:

Membership:

Decision Rights: Binding authority to pause implantation at any site if safety or consent kill-gate criteria are met; authority to recommend design review, indication switch or programme termination to the Steering Committee with binding weight (Steering Committee must publicly answer within 5 business days). Authority to recommend that ethics committees suspend approval of a site if consent quality is inadequate. Recommendation to the Notified Body if device-design issues emerge. No authority over financing or business decisions, but the authority to halt clinical work effectively blocks revenue and investor returns, making the pause decision a de facto veto on 'continue despite adverse findings'.

Decision Mechanism: Consensus by majority vote among DMC members (≥4 of 7 in favour) to recommend pause, design review or stop; a tie defaults to recommending pause (conservative bias). All decisions documented with voting record, dissent noted and reasoning captured. The DMC chair ensures that at least one patient-representative voice is heard on consent and quality-of-life decisions. Recommendations are binding on the Steering Committee to the extent that if the Steering Committee overrides a DMC pause recommendation, it must publish the rationale publicly within 5 business days and report the override to the Notified Body, Ethics Committees and the Commission.

Meeting Cadence: Monthly safety reviews during active implantation (Months 60–132 = 2031-10-31 to 2037-10-31); quarterly reviews during follow-up phases (Months 132–180 = 2037-10-31 to 2041-10-31); emergency meetings within 48 hours if a kill-gate criterion is crossed. Ad-hoc consent audits at a minimum of quarterly frequency during recruitment and every 6 months during active follow-up.

Typical Agenda Items:

Escalation Path: A DMC recommendation to pause, design review or terminate is communicated immediately (within 48 hours) to the Steering Committee; the Steering Committee has 5 business days to decide whether to follow the recommendation or override it (with public justification). Any override escalates to the Notified Body and the ethics committees of all participating sites within 10 business days. If a DMC finding suggests that patient consent is invalid, the DMC notifies the affected ethics committee within 48 hours and recommends suspension of that site until consent procedures are corrected. If a serious-adverse-event trend suggests device or procedure risk beyond the known profile, the DMC may recommend immediate reporting to the Notified Body and suspension of new implants until the issue is investigated.

4. Regulatory and Compliance Committee

Rationale for Inclusion: Delivering a Class III implant under MDR and AI Act regulations within a sovereignly controlled EU system requires sustained engagement with notified bodies, ethics committees across multiple member states, the Commission (scientific advice, IPCEI policy), and payers/HTA bodies. A Regulatory & Compliance Committee integrates these external relationships, interprets regulatory signals into design and evidence decisions, manages change control and AI Act obligations, and escalates gaps or conflicts to the Steering Committee before they cause delay.

Responsibilities:

Initial Setup Actions:

Membership:

Decision Rights: Approve regulatory submissions (to Notified Body, ethics committees, scientific-advice requests) before they are filed, ensuring completeness and consistency with approved design; approve design changes that have regulatory implications; approve new evidence-generation work (preclinical, clinical, biocompatibility) if regulatory feedback requires it; approve change-management processes and decoder-update policies. Escalate to Steering Committee any regulatory requirement that conflicts with schedule, budget or patient-safety trade-offs, or that suggests evidence gaps requiring significant rework.

Decision Mechanism: Consensus among the Regulatory Affairs Lead, Quality Manager and AI Compliance Specialist; the Regulatory Affairs Lead has tie-breaking authority on regulatory interpretation. All submission decisions documented with date and regulatory justification. Changes triggered by external regulatory feedback are logged in the project change-control system and reviewed with PMO for schedule and budget impact.

Meeting Cadence: Bi-weekly internal sync (1 hour); monthly status review (with Steering Committee); ad-hoc within 48 hours if Notified Body or ethics committee sends major feedback requiring response planning; quarterly external reviews with notified body (Month 9 = 2027-07-31, Month 18 = 2028-04-30, Month 36 = 2029-10-31, and then quarterly post-submission).

Typical Agenda Items:

Escalation Path: Regulatory feedback requiring design changes >EUR 0.5M or >3 months schedule impact escalates to PMO and Steering Committee. Disagreements with Notified Body on evidence sufficiency escalate to scientific advice or Commission review within 14 days. Ethics-committee approval delays >2 months from baseline trigger escalation to the Commission and member-state health authorities for coordinated-assessment support. AI Act scope disagreement with regulators escalates to the Commission's AI Office for guidance. Any indication that a regulatory pathway cannot be satisfied within the project schedule triggers a Steering Committee strategic-risk review and potential pivot to a narrower scope (single-site early feasibility study, split indication, or deferral).

5. Sovereignty and Supply-Chain Assurance Committee

Rationale for Inclusion: Maintaining EU control of the delivered clinical system (electrodes, electronics, encapsulation, decoder, data hosting) by the pivotal trial is a hard requirement. This requires continuous verification that sourcing, manufacturing, IP and upstream dependencies pass three EU-control tests: ownership, maintainability without foreign consent, and freedom from export-control restrictions. A dedicated Sovereignty Committee, with legal and supply-chain expertise, ensures these tests are applied consistently, documents exceptions (upstream tools), and escalates foreign dependencies that threaten control before design lock.

Responsibilities:

Initial Setup Actions:

Membership:

Decision Rights: Approve or recommend rejection of any acquisition, licensing deal or supplier based on sovereignty-criteria assessment; no licensing or acquisition closes without documented Sovereignty Committee approval. Approve the upstream-dependency register and mitigation plans; approve any exception (foreign IP, tool or supplier) with documented rationale. Recommend to the Steering Committee that an architecture be eliminated or a design be changed if FTO analysis reveals blocking patents or export-control risk. Veto any decoder training on external datasets or third-party models unless EU ownership and residency are contractually secured.

Decision Mechanism: Consensus among Sovereignty Lead, Supply Chain Manager and CTO; the Sovereignty Lead has tie-breaking authority on EU-control interpretation. All decisions documented with the specific EU-control criterion tested and the rationale. Any foreign dependency is logged in the upstream register with mitigation assigned. Quarterly reviews (Month 6, 12, 18, 24, 36, 48, 60, 72 = 2027-04-30, 2027-10-31, 2028-04-30, 2028-10-31, 2029-10-31, 2030-10-31, 2031-10-31, 2032-10-31, etc.) assess whether new dependencies have arisen and mitigations are on track.

Meeting Cadence: Monthly supplier and IP review during procurement (Months 3–24 = 2027-01-31 to 2028-10-31); quarterly broader sovereignty audits (Months 6, 12, 18, 24, 36, 48, 60, 72 = 2027-04-30, 2027-10-31, 2028-04-30, 2028-10-31, 2029-10-31, 2030-10-31, 2031-10-31, 2032-10-31); export-control alert monitoring continuously with ad-hoc meetings if a threat is flagged.

Typical Agenda Items:

Escalation Path: FTO analysis revealing a blocking patent escalates to the Steering Committee with a recommendation to design around (cost and schedule), challenge the patent (cost and timeline) or accept a foreign licence (sovereignty implication). Sovereignty assessment of a target acquisition finding unresolved foreign IP or consent-right issues escalates to Steering Committee with recommendation to decline, renegotiate or accept the risk. Quarterly export-control alert escalates to the PMO and Steering Committee if a high-risk tool or supplier is affected by new restrictions; triggers contingency planning within 14 days. Any new foreign dependency discovered late (after design lock or during manufacturing) escalates to a crisis protocol: immediately notify the Steering Committee, notified body and Commission; assess whether the device's EU control is compromised; trigger design change or supplier switch if needed, accepting schedule and cost impact.

6. Patient Protection and Lifelong Support Trustee Committee

Rationale for Inclusion: Ring-fencing patient-protection reserves (EUR 30,000 per implant, about EUR 31.5M for 1,050 central implants) outside investor reach is a hard-requirement safeguard. An independent Trustee Committee, distinct from the company's finance and investor governance, holds the reserves, approves draw-downs for lifelong follow-up, explantation and failure-mode support, and ensures implanted patients are never abandoned if the company becomes insolvent. This committee reports to patient interests, not investors.

Responsibilities:

Initial Setup Actions:

Membership:

Decision Rights: Binding authority to approve draw-downs from the trust for any eligible expense; authority to reject or defer draws that do not meet reserve policies. Authority to adjust the per-implant allocation or growth rate based on actuarial findings. Authority to activate step-in agreements and notify backup providers if the company becomes insolvent. Authority to recommend to the Steering Committee that new implants be halted if reserves fall below adequacy levels. No authority over company business or financing decisions, but the reserve mechanism is contractually binding on investors and insurmountable by company management.

Decision Mechanism: Consensus by majority vote among Trustee Committee members (≥3 of 5 in favour) for draw-down approvals and policy decisions; a tie defaults to approving the draw-down (patient-protective). The patient representative has an explicit voice and veto on decisions affecting patient care pathways. All decisions documented with date, amount, clinical justification and approval record. Quarterly audits reconcile trust balance, draw-downs and projections against reserve adequacy.

Meeting Cadence: Quarterly meetings (every 3 months) to review reserve status, approve draw-downs, and audit adequacy; emergency meetings within 48 hours if the trust balance falls below 50% of the adequacy target or if the company's solvency is questioned; annual actuarial valuation and adjustment (Month 36 = 2029-10-31 and annually thereafter).

Typical Agenda Items:

Escalation Path: If reserve adequacy falls below 80% of the target (about EUR 25M for 1,050 implants if EUR 30,000 target is adequate), the Trustee Committee notifies the Steering Committee within 14 days and recommends a capital call or halt of new implants until reserves recover. If the company becomes insolvent or is acquired, the Trustee Committee immediately activates step-in agreements and notifies the backup provider to assume patient care; the Steering Committee must approve the transition within 5 business days. If draw-down claims exceed actuary projections by >20% in two consecutive quarters, the Trustee Committee triggers an actuarial revaluation and recommends per-implant allocation increase to the Steering Committee; if the increase is not approved, the Trustee Committee publicly reports the reserve-adequacy gap and recommends halting new implants.

Governance Implementation Plan

1. Appoint a temporary Governance Formation Lead from the founding team to coordinate the establishment of all internal governance bodies. This individual (typically the CEO or a founder with strong organisational experience) oversees drafting of governance charters, recruitment of independent members and scheduling of initial meetings. The Formation Lead reports directly to the project sponsors and has explicit authority to commit interim resources and time for governance setup.

Responsible Body/Role: Founding team / Project Sponsor (pre-governance designation)

Suggested Timeframe: Month 0 (2026-10-31) (project Week 1)

Key Outputs/Deliverables:

Dependencies:

2. Draft the Project Steering Committee Charter, including decision rules, member roles, financial gate criteria, kill-gate thresholds, meeting cadence and escalation paths. The Formation Lead works with legal counsel and the founding team to define written criteria for each financing gate (T0, T1, T2–T4) and strategic decision point (architecture choice, indication lock, supplier qualification). Charter must specify what triggers the named fallback routes (dual-sourcing if foundry funding fails by Month 18 = 2028-04-30; fallback sites if Leuven partners decline by Month 6 = 2027-04-30).

Responsible Body/Role: Governance Formation Lead, with project counsel and founding team

Suggested Timeframe: Month 0–1 (2026-10-31 to 2026-11-30)

Key Outputs/Deliverables:

Dependencies:

3. Recruit the independent Chair of the Project Steering Committee. The chair must be non-investor, non-founder, and ideally hold experience with Class III medical-device regulation or sovereign-technology programmes in the EU. The Formation Lead defines selection criteria, identifies candidates through Commission contacts and regulated-device networks, and conducts initial interviews. The chair is appointed in writing by the Project Sponsor by Month 2 (2026-12-31) and begins engagement on governance structure and member recruitment.

Responsible Body/Role: Governance Formation Lead with Project Sponsor and legal counsel

Suggested Timeframe: Month 1–2 (2026-11-30 to 2026-12-31)

Key Outputs/Deliverables:

Dependencies:

4. Draft the Project Management Office Charter and define the core PMO team structure (Programme Manager, Finance Controller, Quality Manager, Regulatory Affairs Lead, Clinical Operations Lead, Supply Chain Manager). The charter specifies reporting lines (to CEO), decision authority (operational decisions <EUR 1M and <2 months schedule slip), escalation thresholds and meeting cadence. The Formation Lead and Chair (once appointed) coordinate with the CEO to identify internal candidates and external contractor roles to be filled by Month 6 (2027-04-30).

Responsible Body/Role: Governance Formation Lead with the newly appointed Steering Committee Chair and Project Sponsor

Suggested Timeframe: Month 1 (2026-11-30)

Key Outputs/Deliverables:

Dependencies:

5. Finalise the Project Steering Committee Charter and circulate it for review and approval by the Project Sponsor, identified investors (if any at this stage), and the independent Chair. The charter is revised based on feedback, finalised within 14 days and published to internal stakeholders. It becomes the binding governance document for all Steering Committee decisions through Month 180 (2041-10-31).

Responsible Body/Role: Governance Formation Lead and newly appointed independent Steering Committee Chair

Suggested Timeframe: Month 1–2 (2026-11-30 to 2026-12-31)

Key Outputs/Deliverables:

Dependencies:

6. Initiate recruitment of the Independent Data Monitoring Committee (DMC) members (5–7 people: independent clinician, biostatistician, safety expert, patient advocate, ALS patient representative). The Formation Lead and Chair define the member profile, conflict-of-interest criteria, and recruitment timeline. Initial outreach begins by Month 2 (2026-12-31); interviews and offers target Month 3–4 (2027-01-31 to 2027-02-28). The DMC is formally constituted (all members appointed) by Month 6 (2027-04-30).

Responsible Body/Role: Governance Formation Lead with the independent Steering Committee Chair

Suggested Timeframe: Month 2–3 (2026-12-31 to 2027-01-31)

Key Outputs/Deliverables:

Dependencies:

7. Appoint the independent consent advocate(s) to support informed consent processes for people with impaired or declining communication (ALS, locked-in syndrome). The advocate must be trained in consent procedures, the disease, and communication-facilitation methods. The Formation Lead identifies and hires the first advocate(s) by Month 3 (2027-01-31), working with ALS organisations and ethics specialists. The advocate(s) is engaged before any participant recruitment and trains all site coordinators on consent protocols.

Responsible Body/Role: Governance Formation Lead with clinical and ethics advisors

Suggested Timeframe: Month 2–3 (2026-12-31 to 2027-01-31)

Key Outputs/Deliverables:

Dependencies:

8. Seek letters of intent from imec, KU Leuven and UZ Leuven confirming partnership and resource commitments. The Formation Lead and CEO conduct formal discussions with each institution's leadership by Month 1–2 (2026-11-30 to 2026-12-31), outlining the company's needs (cleanroom access, neurosurgical theatres, ethics review capacity, recruitment support). Letters of intent are collected by Month 3 (2027-01-31). If any partner declines, the Formation Lead immediately activates fallback-site outreach (Ghent/Antwerp, Utrecht, Grenoble) with a target of confirmed fallback commitments by Month 6 (2027-04-30).

Responsible Body/Role: Governance Formation Lead and Project Sponsor (CEO) with partner liaison

Suggested Timeframe: Month 1–3 (2026-11-30 to 2027-01-31)

Key Outputs/Deliverables:

Dependencies:

9. Recruit the core founding team (10 core staff by Month 6 = 2027-04-30, targeting 15 by Month 24 = 2028-10-31). Key roles: Chief Technology Officer or Lead Neurosurgeon, Neuroengineers (hardware and software/decoding), Clinical Trials Lead, Regulatory Affairs Lead, Quality/Compliance Manager, Supply Chain Manager. The Formation Lead and CEO define roles, compensation (offering equity and retention bonuses to offset EU salary gap of 20–30% versus US), and recruitment sources (universities, EU neurotech networks, existing device companies). Hiring prioritises cultural fit, mission commitment and breadth across hardware, software, regulatory and clinical domains.

Responsible Body/Role: Governance Formation Lead (HR/recruitment lead) and Project Sponsor (CEO)

Suggested Timeframe: Month 1–6 (2026-11-30 to 2027-04-30)

Key Outputs/Deliverables:

Dependencies:

10. Draft the PMO Charter, detailing reporting lines, decision authority and operational procedures. Circulate to the Steering Committee Chair and Project Sponsor for review. The PMO Charter specifies that the Programme Manager reports to the CEO and escalates to the Steering Committee on decisions affecting financing gates, kill-gate criteria, partnership stability or sovereignty tests. The charter is finalised by Month 1 (2026-11-30) and becomes binding once the Steering Committee is formally established.

Responsible Body/Role: Governance Formation Lead with independent Steering Committee Chair and Project Sponsor

Suggested Timeframe: Month 1 (2026-11-30)

Key Outputs/Deliverables:

Dependencies:

11. Confirm the finalized Steering Committee membership: independent Chair (appointed), CEO/founder representative, investor representative (if early investors identified), external safety/ethics advisor, and Commission/member-state liaison (part-time or as-needed). Each member signs a conflict-of-interest declaration and governance agreement by Month 3 (2027-01-31). The Steering Committee holds its first kick-off meeting by Month 6 (2027-04-30) to review the charter, establish decision processes and assign initial tasks (financing gate G1 by Month 12 = 2027-10-31, architecture-choice analysis, partnership activation).

Responsible Body/Role: Independent Steering Committee Chair with Governance Formation Lead and Project Sponsor

Suggested Timeframe: Month 2–3 (2026-12-31 to 2027-01-31)

Key Outputs/Deliverables:

Dependencies:

12. Hold the first formal Project Steering Committee kick-off meeting. The Chair leads a review of the charter, strategic context (15-year horizon, EUR 2.5B envelope, hard requirements for patient safety, consent, EU control), financing gates (T0 by Month 12 = 2027-10-31, T1 by Month 24 = 2028-10-31, foundry decision by Month 18 = 2028-04-30) and kill-gate thresholds. The committee confirms the Governance Formation Lead's role transitions to support roles within the PMO and appoints a secretary/minute-taker. The Steering Committee schedules recurring meetings: monthly operational updates (30 mins), quarterly strategic reviews (2 hours) and within-5-business-day meetings after each defined gate.

Responsible Body/Role: Project Steering Committee (newly formally established, chaired by independent Chair)

Suggested Timeframe: Month 6 (2027-04-30)

Key Outputs/Deliverables:

Dependencies:

13. Finalise and publish the PMO Charter. The Programme Manager (hired by Month 6 = 2027-04-30) reviews the charter with the CEO, Steering Committee Chair and finance/legal advisors. The charter is finalised and published to all PMO team members and the Steering Committee by Month 2 (2026-12-31). It defines PMO authority, escalation thresholds, reporting lines, work-package structure, budget allocation (T0 EUR 15M, T1–T4 phased), change-control rules and monthly/quarterly reporting cadence.

Responsible Body/Role: Programme Manager (once hired) with Governance Formation Lead and Project Sponsor

Suggested Timeframe: Month 1–2 (2026-11-30 to 2026-12-31)

Key Outputs/Deliverables:

Dependencies:

14. Recruit the Programme Manager (primary PMO lead, reports to CEO and Steering Committee) by Month 3–4 (2027-01-31 to 2027-02-28). The Programme Manager is responsible for developing the master schedule, managing work packages, tracking budget and cost control, coordinating with suppliers and clinical sites, and escalating risks and blockers. The Steering Committee Chair and CEO interview candidates with experience in regulated medical devices, multi-site programmes and distributed operations. The Programme Manager is appointed by Month 6 (2027-04-30) and immediately assumes ownership of schedule development and MVP planning.

Responsible Body/Role: Governance Formation Lead and Project Sponsor (CEO) with Steering Committee Chair oversight

Suggested Timeframe: Month 3–6 (2027-01-31 to 2027-04-30)

Key Outputs/Deliverables:

Dependencies:

15. Hire the Finance Controller (part of PMO) by Month 4–5 (2027-02-28 to 2027-03-31). The Finance Controller is responsible for cash tracking, tranche readiness, contingency management and monthly/quarterly financial reporting. The controller develops cash-flow forecasts, tracks burn against budgets, flags variances >10%, and advises the Programme Manager and Steering Committee on financing-gate readiness. The Finance Controller reports monthly to the Steering Committee and manages interactions with investors on capital-raise timelines.

Responsible Body/Role: Governance Formation Lead and Project Sponsor (CEO) with Programme Manager oversight

Suggested Timeframe: Month 4–5 (2027-02-28 to 2027-03-31)

Key Outputs/Deliverables:

Dependencies:

16. Hire the Quality Manager (part of PMO) by Month 4–5 (2027-02-28 to 2027-03-31). The Quality Manager is responsible for building ISO 13485 QMS compliance, design-history files, change control, configuration management and notified-body audit preparation. The Quality Manager reports to the Programme Manager and interfaces with the Regulatory Affairs Lead. By Month 9 (2027-07-31), the QMS framework is in place and ready for independent audit by Month 18 (2028-04-30).

Responsible Body/Role: Governance Formation Lead and Project Sponsor (CEO) with Programme Manager oversight

Suggested Timeframe: Month 4–5 (2027-02-28 to 2027-03-31)

Key Outputs/Deliverables:

Dependencies:

17. Establish the Regulatory and Compliance Committee. The committee chair is the Regulatory Affairs Lead (hired as part of PMO recruitment, Month 5–6 = 2027-03-31 to 2027-04-30). Members include the Quality Manager, Clinical Operations Lead, AI Compliance Specialist (contracted), and notified-body liaison (external, contracted by Month 6 = 2027-04-30). The committee charter defines roles, decision authority, escalation thresholds and meeting cadence (bi-weekly sync, monthly Steering Committee report). The Regulatory Committee's first meeting is held by Month 6 (2027-04-30) to plan notified-body engagement and scientific-advice timing.

Responsible Body/Role: Governance Formation Lead with Regulatory Affairs Lead (once hired) and Programme Manager

Suggested Timeframe: Month 5–6 (2027-03-31 to 2027-04-30)

Key Outputs/Deliverables:

Dependencies:

18. Conduct notified-body engagement and pre-submission meetings by Month 6 (2027-04-30). The Regulatory Affairs Lead and notified-body liaison meet with the target notified body (to be selected and contracted by Month 4 = 2027-02-28) to confirm regulatory pathway, evidence expectations and timeline. The pre-submission meeting covers clinical investigation design, quality and risk management, AI Act scope for the decoder and design-control requirements. Outcomes are documented in a pre-submission summary and fed into the scientific-advice request (to be submitted by Month 12 = 2027-10-31).

Responsible Body/Role: Regulatory and Compliance Committee (Regulatory Affairs Lead and notified-body liaison)

Suggested Timeframe: Month 6 (2027-04-30)

Key Outputs/Deliverables:

Dependencies:

19. Hire the Clinical Operations Lead (part of PMO) by Month 4–5 (2027-02-28 to 2027-03-31). The Clinical Operations Lead is responsible for site coordination, patient recruitment, consent processes, safety monitoring and lifelong follow-up planning. The Clinical Operations Lead reports to the Programme Manager and coordinates with the independent DMC, consent advocates and hospital partners. By Month 6 (2027-04-30), the Clinical Operations Lead has drafted consent protocols (to be reviewed by ethics specialists and patient organisations) and outlined site-activation and training plans.

Responsible Body/Role: Governance Formation Lead and Project Sponsor (CEO) with Programme Manager oversight

Suggested Timeframe: Month 4–5 (2027-02-28 to 2027-03-31)

Key Outputs/Deliverables:

Dependencies:

20. Hire the Supply Chain Manager (part of PMO) by Month 4–5 (2027-02-28 to 2027-03-31). The Supply Chain Manager is responsible for supplier selection, RFQ management, qualification planning (dual-sourcing for chips and substrates, encapsulation in-house), and sovereignty testing. The Supply Chain Manager reports to the Programme Manager and interfaces with the Sovereignty Committee. By Month 6 (2027-04-30), the Supply Chain Manager has initiated RFQ processes for chips, substrates and encapsulation and begun supplier pre-qualification assessments (capacity, capability, export-control status).

Responsible Body/Role: Governance Formation Lead and Project Sponsor (CEO) with Programme Manager oversight

Suggested Timeframe: Month 4–5 (2027-02-28 to 2027-03-31)

Key Outputs/Deliverables:

Dependencies:

21. Formally constitute the DMC by recruiting and appointing all 5–7 members and training them on trial protocol, consent procedures, kill-gate criteria and reporting requirements. The DMC members sign conflict-of-interest declarations and confidentiality agreements by Month 6 (2027-04-30). The DMC chair (independent) is appointed and begins planning the data-access, blinding and interim-analysis procedures. The DMC publishes its charter, member list and meeting schedule publicly by Month 6 (2027-04-30) to build transparency and patient trust.

Responsible Body/Role: Governance Formation Lead and newly appointed independent DMC Chair

Suggested Timeframe: Month 3–6 (2027-01-31 to 2027-04-30)

Key Outputs/Deliverables:

Dependencies:

22. Establish the Sovereignty and Supply-Chain Assurance Committee. The committee chair is the Sovereignty and Supply-Chain Lead (external counsel, part-time, contracted by Month 2 = 2026-12-31). Members include the Supply Chain Manager (PMO), Quality Manager and Chief Technology Officer or Lead Neurosurgeon. The committee charter defines roles, decision authority, escalation thresholds and quarterly review cadence. The committee's first meeting is held by Month 6 (2027-04-30) to initiate freedom-to-operate analysis for architecture candidates and begin supplier pre-qualification.

Responsible Body/Role: Governance Formation Lead with Sovereignty and Supply-Chain Lead (once contracted) and Programme Manager

Suggested Timeframe: Month 2–6 (2026-12-31 to 2027-04-30)

Key Outputs/Deliverables:

Dependencies:

23. Commission an independent freedom-to-operate (FTO) analysis for each architecture candidate (penetrating cortical, endovascular, surface/thin-film). The Sovereignty Committee engages a patent-law firm with BCI expertise by Month 3 (2027-01-31); analysis begins immediately and is completed by Month 6 (2027-04-30). The FTO report assesses patent landscape, identifies blocking claims from Neuralink, Synchron and universities, and recommends design-arounds or licensing costs. Results are scored as a criterion in architecture ratification by Month 18 (2028-04-30).

Responsible Body/Role: Sovereignty and Supply-Chain Committee with external patent-law counsel

Suggested Timeframe: Month 3–6 (2027-01-31 to 2027-04-30)

Key Outputs/Deliverables:

Dependencies:

24. Establish the Patient Protection and Lifelong Support Trustee Committee. An independent professional trustee (chair) is appointed by Month 6 (2027-04-30); members include a patient representative, treating clinician, bioethicist and actuarial advisor. The Trustee Committee charter defines reserve allocation (EUR 30,000 per implant), growth schedule (starting at first implant, Month 84 = 2033-10-31), draw-down policies and investment guidelines. A separate trust account (outside investor reach) is established and capitalised with a EUR 5M floor by Month 6 (2027-04-30) to cover pre-implant setup and initial contingencies.

Responsible Body/Role: Governance Formation Lead with Project Sponsor and external trustee counsel

Suggested Timeframe: Month 3–6 (2027-01-31 to 2027-04-30)

Key Outputs/Deliverables:

Dependencies:

25. Hold the first Independent DMC kick-off meeting. The DMC chair leads a review of the protocol, safety kill-gate criteria (proposed: ≥3 serious adverse events in first 20 implants trigger pause), chronic-stability criteria (≥20% signal loss within 12 months in animal studies blocks first-in-human; ≥25% in humans triggers pause) and consent safeguards. The DMC establishes data-access procedures, blinding protocols and reporting templates. The meeting confirms the DMC's binding pause authority and reporting timeline (findings within 30 days of each review).

Responsible Body/Role: Independent Data Monitoring Committee (newly formally established, chaired by independent DMC Chair)

Suggested Timeframe: Month 6 (2027-04-30)

Key Outputs/Deliverables:

Dependencies:

26. Hold the first Regulatory and Compliance Committee meeting. The Regulatory Affairs Lead (chair) leads a review of the regulatory pathway, scientific-advice request preparation and AI Act compliance scope. The committee reviews the notified-body pre-submission feedback and outlines the design-history file setup, quality-management-system audit timelines and regulatory-submission milestones. The committee confirms the plan to request Commission scientific advice by Month 12 (2027-10-31) and conduct a preliminary QMS audit by Month 18 (2028-04-30).

Responsible Body/Role: Regulatory and Compliance Committee (newly formally established, chaired by Regulatory Affairs Lead)

Suggested Timeframe: Month 6 (2027-04-30)

Key Outputs/Deliverables:

Dependencies:

27. Hold the first Sovereignty and Supply-Chain Committee meeting. The Sovereignty Lead (chair) leads a review of the FTO analysis results, supplier pre-qualification assessments and the dual-sourcing timeline. The committee confirms the plan to identify and engage with chip and substrate suppliers by Month 6 (2027-04-30), conduct formal qualification by Months 18–24 (2028-04-30 to 2028-10-31) and lock the second source by Month 30 (2029-04-30). The committee establishes quarterly review cadence for export-control monitoring and upstream-dependency management.

Responsible Body/Role: Sovereignty and Supply-Chain Committee (newly formally established, chaired by Sovereignty and Supply-Chain Lead)

Suggested Timeframe: Month 6 (2027-04-30)

Key Outputs/Deliverables:

Dependencies:

28. Hold the first Patient Protection and Lifelong Support Trustee Committee meeting. The independent trustee chair leads a review of the reserve allocation, growth schedule and draw-down policies. The committee confirms the EUR 5M initial capitalisation, establishes investment guidelines (conservative, capital-preservation focus) and begins drafting step-in agreements with backup hospital networks or successor manufacturers. The committee plans an annual actuarial audit (first audit by Month 36 = 2029-10-31) and publishes the reserve status quarterly.

Responsible Body/Role: Patient Protection and Lifelong Support Trustee Committee (newly formally established, chaired by independent professional trustee)

Suggested Timeframe: Month 6 (2027-04-30)

Key Outputs/Deliverables:

Dependencies:

29. Publish governance structure and initial decisions to stakeholders. The Project Sponsor (CEO) and Steering Committee Chair publish a Governance Summary document (for internal and external stakeholders) describing the five governance bodies, their roles, decision authority and reporting structure. The summary also confirms key strategic commitments: hard requirements (patient safety, valid consent, EU control), financing gates (T0 by Month 12 = 2027-10-31, foundry decision by Month 18 = 2028-04-30, feasibility verdict by Month 24 = 2028-10-31), kill-gate thresholds and the role of independent oversight (DMC, Steering Committee, Trustee Committee). The summary is published by Month 6 (2027-04-30) to build stakeholder transparency and trust.

Responsible Body/Role: Project Steering Committee (with Project Sponsor and Governance Formation Lead support)

Suggested Timeframe: Month 6 (2027-04-30)

Key Outputs/Deliverables:

Dependencies:

30. Establish project management and reporting infrastructure within the PMO. The Programme Manager develops a master schedule (12–18 month rolling forecast), work-package structure (MVP, preclinical, architecture choice, supplier qualification, manufacturing transfer, clinical sites, regulatory), budget allocation by tranche (T0 EUR 15M for Months 0–24 = 2026-10-31 to 2028-10-31, T1–T4 phased), and monthly/quarterly reporting templates. By Month 3 (2027-01-31), the master schedule identifies critical-path milestones (architecture lock Month 18 = 2028-04-30, design lock Months 24–30 = 2028-10-31 to 2029-04-30, FIH Month 60 = 2031-10-31) with uncertainty ranges.

Responsible Body/Role: PMO (Programme Manager, Finance Controller, Quality Manager, regulatory and clinical leads)

Suggested Timeframe: Month 1–3 (2026-11-30 to 2027-01-31)

Key Outputs/Deliverables:

Dependencies:

31. Establish monthly Steering Committee operational updates and quarterly strategic reviews. The Steering Committee (fully constituted) meets monthly (30 mins) to review operational status (schedule variance, budget burn, risk hotspots) and quarterly (2 hours) for strategic reviews (gate readiness, partnership stability, regulatory feedback). Within 5 business days of each defined gate (Months 6, 12, 18, 24, 36, 60, 78, 84, 132, 180 = 2027-04-30, 2027-10-31, 2028-04-30, 2028-10-31, 2029-10-31, 2031-10-31, 2033-04-30, 2033-10-31, 2037-10-31, 2041-10-31), the Steering Committee holds a gate-review meeting and publishes its decision (go/defer/stop/switch) publicly.

Responsible Body/Role: Project Steering Committee with PMO (reporting)

Suggested Timeframe: Monthly starting Month 6 (2027-04-30)

Key Outputs/Deliverables:

Dependencies:

32. Commission a Leuven climate and infrastructure resilience assessment by Month 3 (2027-01-31). The assessment evaluates multi-day heatwaves above 35°C, drought (cooling-water supply), flooding (groundwater and river overflow), power reliability and cooling capacity. The assessment covers manufacturing (cleanroom cooling, sterilisation), preclinical labs (animal housing), compute (neural-data hosting) and patient-care implications (wearable thermal load, patient heat vulnerability). The assessment is completed by Month 6 (2027-04-30); findings inform backup-power and redundant-cooling installation plans (target Month 18 = 2028-04-30) and wearable thermal-design specifications.

Responsible Body/Role: PMO (Operations/Site Manager) with external climate-resilience consultant

Suggested Timeframe: Month 3–6 (2027-01-31 to 2027-04-30)

Key Outputs/Deliverables:

Dependencies:

33. Develop a detailed design-history file (DHF) process and initiate DHF establishment by Month 1 (2026-11-30). The Quality Manager (once hired, Month 6 = 2027-04-30) implements the DHF framework, defining document categories, version control, change-control procedures and traceability. The DHF is populated as design and development work progresses, ensuring compliance with ISO 13485 and MDR Annex I requirements. A preliminary DHF audit is scheduled for Month 18 (2028-04-30) to identify gaps before formal notified-body conformity assessment.

Responsible Body/Role: PMO (Quality Manager and Regulatory Affairs Lead)

Suggested Timeframe: Month 1 (2026-11-30) (ongoing through Month 180 = 2041-10-31 to 2041-10-31)

Key Outputs/Deliverables:

Dependencies:

34. Establish harmonised ethics and consent protocols for coordinated multinational clinical investigations by Month 6 (2027-04-30). The Clinical Operations Lead works with ethics specialists and patient organisations to draft a unified consent template, re-consent procedures, participant-withdrawal policies and ethics-committee submission packages. The protocols address consent for people with impaired or declining communication (independent advocate present, yes/no signalling validated before surgery). The harmonised protocols are submitted to all participating ethics committees in parallel by Month 12 (2027-10-31) to minimise approval delays.

Responsible Body/Role: Clinical Operations Lead with independent consent advocate and ethics advisors

Suggested Timeframe: Month 3–6 (2027-01-31 to 2027-04-30)

Key Outputs/Deliverables:

Dependencies:

35. Request Commission scientific advice by Month 12 (2027-10-31). The Regulatory Affairs Lead prepares a comprehensive scientific-advice-request dossier covering clinical investigation design (population, endpoints, statistical power), quality and risk management, AI Act scope for the decoder version control, and design-control documentation. The dossier is submitted to the Commission (and EMA if applicable) by Month 12 (2027-10-31); feedback is expected within 60–90 days (returned by Month 15 = 2028-01-31 estimated). The Regulatory Committee reviews Commission feedback and integrates it into design and evidence strategy.

Responsible Body/Role: Regulatory and Compliance Committee (Regulatory Affairs Lead with Quality Manager and Clinical Operations Lead)

Suggested Timeframe: Month 9–12 (2027-07-31 to 2027-10-31)

Key Outputs/Deliverables:

Dependencies:

36. Conduct baseline freedom-to-operate analysis and architecture-candidate scoring by Month 6 (2027-04-30). The Sovereignty Committee reviews the FTO report, scoring each architecture (cortical, endovascular, surface) on patent clearance (risk of blocking claims, licensing cost), surgical risk (tissue trauma, neurological injury), chronic stability (based on published animal data and preclinical work), bandwidth potential (research targets) and manufacturing readiness. The scoring is formally documented and feeds the architecture-ratification decision (target Month 18 = 2028-04-30).

Responsible Body/Role: Sovereignty and Supply-Chain Committee with external patent counsel and CTO

Suggested Timeframe: Month 6 (2027-04-30)

Key Outputs/Deliverables:

Dependencies:

37. Perform sovereignty-criteria diligence on proposed suppliers, acquisitions and licensing arrangements. The Sovereignty Committee applies three tests (EU ownership, maintainability without foreign consent, export-control freedom) to any proposed supplier, licence or acquisition target. A diligence checklist is published by Month 3 (2027-01-31); for each target, a scored assessment is completed within 30 days and escalated to the Steering Committee with a recommendation (approve, renegotiate, decline). No acquisition or licence closes without documented Sovereignty Committee approval.

Responsible Body/Role: Sovereignty and Supply-Chain Committee (Sovereignty Lead, Supply Chain Manager, CTO)

Suggested Timeframe: Ongoing Month 3–180 (2027-01-31 to 2041-10-31), with priority focus Months 3–30 for early sourcing

Key Outputs/Deliverables:

Dependencies:

38. Build ISO 13485 quality-management system and design-control framework by Month 9 (2027-07-31). The Quality Manager (once hired, Month 6 = 2027-04-30) establishes document management, design-history files, risk management (ISO 14971), change control, training records and corrective-action procedures. A preliminary QMS audit (internal self-assessment) is completed by Month 12 (2027-10-31); a formal independent QMS audit by a notified body (or external auditor) is scheduled for Month 18 (2028-04-30) to identify gaps before design lock.

Responsible Body/Role: PMO (Quality Manager and Regulatory Affairs Lead)

Suggested Timeframe: Month 6–9 (2027-04-30 to 2027-07-31)

Key Outputs/Deliverables:

Dependencies:

39. Request preliminary QMS audit from notified body by Month 18 (2028-04-30). The Quality Manager arranges a preliminary audit (not part of formal conformity assessment) to identify gaps, non-conformities and rework needs. Findings are documented in an audit report; non-conformities are corrected by the company before formal conformity-assessment submission. This pre-submission audit reduces the risk of major rework during formal assessment and is a best practice for Class III devices.

Responsible Body/Role: PMO (Quality Manager) with notified-body liaison

Suggested Timeframe: Month 18 (2028-04-30)

Key Outputs/Deliverables:

Dependencies:

40. Establish AI Act compliance workstream for the decoder. An AI Compliance Specialist (hired or contracted by Month 9 = 2027-07-31) documents decoder training data (source, privacy, consent), model validation (accuracy, bias testing), human oversight (clinical validation, feedback loops) and change-control procedures for decoder updates. The decoder is version-locked for the pivotal trial (Months 84+ = 2033-10-31+), with updates after CE marking handled by a pre-registered change-control process. Budget for AI Act compliance is approximately EUR 2M (estimate).

Responsible Body/Role: Regulatory and Compliance Committee (AI Compliance Specialist and Quality Manager)

Suggested Timeframe: Month 9 (2027-07-31) (starting, ongoing through CE marking and beyond)

Key Outputs/Deliverables:

Dependencies:

41. Ratify the primary architecture and confirm fallback by Month 18 (2028-04-30). The Steering Committee reviews the Sovereignty Committee's scoring of architecture candidates (cortical, endovascular, surface), Commission scientific-advice feedback (if received), and preclinical data. The committee votes on the primary architecture (proposed: high-density thin-film surface epidural/subdural cortical implant with wireless external processor) and confirms a fallback (proposed: penetrating cortical microelectrode, switch cost EUR 30M estimate, delay 12–24 months estimate). The decision is documented and published to all stakeholders.

Responsible Body/Role: Project Steering Committee with input from Sovereignty Committee, Regulatory Committee and PMO

Suggested Timeframe: Month 18 (2028-04-30)

Key Outputs/Deliverables:

Dependencies:

42. Submit harmonised ethics and consent protocols to participating national ethics committees by Month 12 (2027-10-31). The Clinical Operations Lead and independent consent advocate submit the unified protocol to all participating ethics committees (UZ Leuven, fallback sites, and any multi-country partners) in parallel. Ethics-committee approval timelines vary; target is approval at all sites by Month 24 (2028-10-31), but delays are expected and managed by the Regulatory Committee. If any ethics committee rejects the protocol, the Clinical Operations Lead works with that committee to revise, re-submit and obtain approval within 60 days.

Responsible Body/Role: Clinical Operations Lead with independent consent advocate and Regulatory Affairs Lead oversight

Suggested Timeframe: Month 12 (2027-10-31)

Key Outputs/Deliverables:

Dependencies:

43. Publish the upstream-dependency register by Month 12 (2027-10-31). The Sovereignty Committee documents all non-EU tools, materials and suppliers that support manufacturing, design, preclinical testing and compute (e.g., lithography equipment, EDA software, test systems, fab equipment, materials). Each entry specifies supplier, export-control status (ITAR, EAR, Wassenaar, EU-controlled, unrestricted), risk (high/medium/low), mitigation (alternative suppliers, design-around, contingency stockpile, re-location plan). The register is updated quarterly and published to stakeholders to build transparency on sovereignty boundaries and upstream dependencies.

Responsible Body/Role: Sovereignty and Supply-Chain Committee (Sovereignty Lead and Supply Chain Manager)

Suggested Timeframe: Month 12 (2027-10-31)

Key Outputs/Deliverables:

Dependencies:

44. Conduct first feasibility-gate review (G1, Month 12 = 2027-10-31). The Steering Committee reviews progress against the MVP (Months 0–24 = 2026-10-31 to 2028-10-31): founding team assembly, partner commitments, architecture candidates and FTO analysis, supplier pre-qualification, notified-body engagement, ethics-protocol submissions, preclinical planning. The committee confirms that T0 funding (EUR 15M) is committed in writing or deferred, gates T1 funding release (EUR 120M minimum EUR 60M by Month 24 = 2028-10-31), and verifies that first major risks (partnership, financing, regulatory pathway) are on track for retirement by Month 24 (2028-10-31).

Responsible Body/Role: Project Steering Committee with PMO reporting

Suggested Timeframe: Month 12 (2027-10-31)

Key Outputs/Deliverables:

Dependencies:

45. Activate foundry-route decision by Month 18 (2028-04-30). The Steering Committee reviews whether a shared European neural-implant foundry (hoped-for EUR 350M, funded by 4+ member states) has received written commitments from at least four member states. If commitments are confirmed, the Steering Committee approves foundry participation and budgets the contribution. If foundry funding is not confirmed, the Steering Committee immediately activates the fallback dual-sourcing route (qualifying two chip suppliers, two substrate suppliers, owning encapsulation and assembly in-house). The foundry decision is documented and published by Month 18 (2028-04-30).

Responsible Body/Role: Project Steering Committee with Supply Chain Manager and Sovereignty Committee input

Suggested Timeframe: Month 18 (2028-04-30)

Key Outputs/Deliverables:

Dependencies:

46. Complete supplier qualification for chips and substrates. By Month 30 (2029-04-30), the Supply Chain Manager has conducted formal qualification (process audits, sample testing, documentation review) on at least two chip suppliers and two substrate suppliers, confirmed in writing. Qualification reports document supplier capability, capacity, export-control status, cost and timeline. At least one second supplier must be qualified and approved by the Steering Committee. If a second source cannot be qualified by Month 30 (2029-04-30), single-source risk persists and is escalated to the Steering Committee for contingency activation (e.g., expand supplier pool, increase inventory, design-around).

Responsible Body/Role: PMO (Supply Chain Manager) with Sovereignty Committee oversight

Suggested Timeframe: Months 12–30 (2027-10-31 to 2029-04-30)

Key Outputs/Deliverables:

Dependencies:

47. Conduct second feasibility-gate review (G3, Month 24 = 2028-10-31). The Steering Committee reviews the cumulative progress since Month 0 (2026-10-31): founding team status, partner commitments confirmed or fallback activated, architecture lock and FTO clearance, supplier MOUs and qualification progress, regulatory pathway (scientific advice received and integrated, notified-body preliminary QMS audit scheduled or completed), ethics-approval status across sites, preclinical and early feasibility study planning, financing status (T0 committed, T1 at least EUR 60M secured or committed in writing). The committee issues the Month 24 (2028-10-31) feasibility verdict (achievable, achievable only with changes, or not credibly achievable) separating scientific, engineering, clinical, regulatory, supply-chain and financing feasibility. No implant programme proceeds without Steering Committee sign-off on the feasibility verdict.

Responsible Body/Role: Project Steering Committee with PMO, Regulatory Committee, Sovereignty Committee and DMC input

Suggested Timeframe: Month 24 (2028-10-31)

Key Outputs/Deliverables:

Dependencies:

48. Lock design and manufacturing process specifications by Months 24–30 (2028-10-31 to 2029-04-30). The PMO (Quality Manager, CTO, Supply Chain Manager) finalises device design specifications (electrode, implant electronics, encapsulation, wearable processor), manufacturing process flows (pilot-line procedures, Class III production requirements), materials specifications and supplier commitments. Design lock is a critical milestone: no major design changes are permitted after this point without notified-body approval and potential rework. Design-lock signoff is obtained from the Steering Committee (Month 24 = 2028-10-31 gate decision) and confirmed by the Quality Manager by Month 30 (2029-04-30).

Responsible Body/Role: PMO (Quality Manager, CTO, Supply Chain Manager, Regulatory Affairs Lead)

Suggested Timeframe: Months 24–30 (2028-10-31 to 2029-04-30)

Key Outputs/Deliverables:

Dependencies:

49. Plan and fund the pilot-line-to-validated Class III production transfer. The PMO (Supply Chain Manager and Quality Manager) develops a detailed transfer plan: process characterisation on the pilot line, technology transfer to a validated contract manufacturer, process validation (IQ/OQ/PQ), yield and quality metrics. The transfer plan is funded and scheduled in T1 (Months 24–48 = 2028-10-31 to 2030-10-31), with the goal of achieving 80%+ yield and validated production by Month 48 (2030-10-31). If pilot-line yield or quality is below target, the plan triggers additional process-improvement work within T1 contingency (EUR 10–15M estimate for transfer).

Responsible Body/Role: PMO (Supply Chain Manager, Quality Manager, Programme Manager)

Suggested Timeframe: Months 24–48 (2028-10-31 to 2030-10-31)

Key Outputs/Deliverables:

Dependencies:

50. Establish the preclinical chronic-stability animal study by Month 9 (2027-07-31). The PMO (Clinical Operations Lead with CTO and preclinical-operations staff) designs and funds an 18–24 month chronic animal study (proposed: implant electrodes in a small primate or large-animal model, measure signal quality, stability and tissue response over time). The study is conducted at a GLP-certified laboratory with independent monitoring. Kill-gate criteria are pre-registered: >20% signal loss within 12 months blocks first-in-human progression; >20–25% triggers design review. The study begins by Month 9 (2027-07-31) and is expected to yield results by Month 27–33 (2029-01-31 to 2029-07-31), informing FIH planning.

Responsible Body/Role: PMO (Clinical Operations Lead, CTO, preclinical staff) with GLP laboratory and independent monitor

Suggested Timeframe: Month 6–9 (2027-04-30 to 2027-07-31) (planning and contract); Month 9 (2027-07-31) (study start, 18–24 months duration)

Key Outputs/Deliverables:

Dependencies:

51. Establish biocompatibility and sterilisation-validation testing by Month 12 (2027-10-31). The PMO (Quality Manager) plans and contracts for ISO 10993 biocompatibility testing (sensitisation, irritation, systemic toxicity, implantation studies) and sterilisation validation (ethylene oxide or other method, validation to ISO 11135). Testing is conducted at an accredited laboratory; results are documented in the design-history file. These tests are prerequisites for regulatory submissions and first-in-human approval. Planning and contracting begin by Month 6 (2027-04-30); testing is completed by Month 24 (2028-10-31).

Responsible Body/Role: PMO (Quality Manager, Regulatory Affairs Lead)

Suggested Timeframe: Month 6–12 (2027-04-30 to 2027-10-31) (planning and contracting); Month 12–24 (2027-10-31 to 2028-10-31) (testing)

Key Outputs/Deliverables:

Dependencies:

52. Conduct human-factors and usability testing of the wearable (external processor and transmitter) by Month 20 (2028-06-30). The PMO (Clinical Operations Lead and CTO) plans and executes human-factors testing with non-implanted users (10–20 volunteers, healthy controls, or people with mobility or communication impairment). Testing covers wearing comfort, heat perception, mechanical durability, battery life (target 12+ hours), antenna range (target 10+ meters) and subjective usability. Thermal performance is validated in climate-chamber tests at 35–40°C profiles (multi-day heatwaves) by Month 18 (2028-04-30). Results inform final wearable design and patient-care protocols (heat-alert thresholds, throttling strategies).

Responsible Body/Role: PMO (Clinical Operations Lead, CTO, human-factors specialist)

Suggested Timeframe: Month 15–20 (2028-01-31 to 2028-06-30)

Key Outputs/Deliverables:

Dependencies:

53. Conduct third feasibility-gate review (G4, Month 36 = 2029-10-31). The Steering Committee reviews the cumulative progress at Month 36 (2029-10-31): design lock confirmed (Month 30 = 2029-04-30), manufacturing transfer plan on track (pilot line operational, contract manufacturer engaged, process validation beginning), preclinical animal-study results received and evaluated, regulatory pathway (preliminary QMS audit completed, notified-body feedback integrated, ethics approvals at all sites or imminent). The committee gates T2 funding (EUR 480M for Months 48–84 = 2030-10-31 to 2033-10-31): if T1 is substantially complete and at least EUR 150M of T2 is committed, FIH proceeds; if funding gaps exist, FIH is deferred in 12-month steps or programme stops.

Responsible Body/Role: Project Steering Committee with PMO, Regulatory Committee and Sovereignty Committee input

Suggested Timeframe: Month 36 (2029-10-31)

Key Outputs/Deliverables:

Dependencies:

54. Establish an implanting centre network and surgical capacity planning by Month 36 (2029-10-31). The Clinical Operations Lead identifies and begins formal partnerships with neurosurgical centres in Belgium (UZ Leuven or fallback sites), the Netherlands (Utrecht or equivalent), France (Grenoble or equivalent) and Germany (if applicable). Each centre commits to surgical theatre time, neuro-intensive-care support, neurologist and ALS-specialist involvement, and capacity for lifelong follow-up. Early-stage implanting is limited to 5–10 expert centres; formal capacity and reimbursement modelling is updated at the pivotal-indication gate (Month 78 = 2033-04-30). Surgeon credentialing and training plans are drafted.

Responsible Body/Role: Clinical Operations Lead with CTO and hospital-partnership coordination

Suggested Timeframe: Month 24–36 (2028-10-31 to 2029-10-31)

Key Outputs/Deliverables:

Dependencies:

55. Initiate consent-advocate training and certification by Month 3 (2027-01-31). The independent consent advocate(s) receive formal training in the specific protocol, device, ALS disease, communication-facilitation methods and ethical safeguards. Training includes mock consent conversations, ethics-committee feedback, patient-organisation guidance and a certification assessment. Trained advocates are deployed to all implanting sites by Month 60 (2031-10-31, first-in-human phase) and conduct all consent conversations for participants with impaired or declining communication.

Responsible Body/Role: Clinical Operations Lead and independent consent advocate(s) with ethics advisors and patient organisations

Suggested Timeframe: Month 3–60 (2027-01-31 to 2031-10-31), with ongoing updates

Key Outputs/Deliverables:

Dependencies:

56. Establish the independent Data Monitoring Committee's interim-analysis procedures and safety-monitoring protocols by Month 12 (2027-10-31). The DMC chair (once appointed) and members plan the interim-analysis schedule (at pre-specified time points or after every 5–10 implants during early-stage work), data-access procedures (secure environment, blinding maintained except as needed), statistical methods (group sequential or adaptive designs if applicable) and trigger thresholds for pause recommendation (>proposed 3 serious adverse events in first 20 implants; >25% mean signal loss within 12 months). The DMC's monitoring role becomes active once first-in-human participants are recruited (Month 60 = 2031-10-31 estimated).

Responsible Body/Role: Independent Data Monitoring Committee (chaired by independent DMC Chair)

Suggested Timeframe: Month 6–12 (2027-04-30 to 2027-10-31)

Key Outputs/Deliverables:

Dependencies:

57. Plan and schedule first-in-human early feasibility study (proposed: Month 60 = 2031-10-31, range 54–78). The Clinical Operations Lead and CTO develop a detailed FIH protocol (proposed: 10 participants with advanced ALS or locked-in syndrome, primary outcome user-controlled communication net bits/s, secondary outcomes safety, chronic stability, daily-life function). The protocol is reviewed by the DMC, ethics committees and notified body. Ethical approvals are obtained by Month 54 (2031-04-30); participant recruitment and informed-consent begins immediately. The first implant is scheduled for Month 60 (2031-10-31).

Responsible Body/Role: Clinical Operations Lead and CTO with notified-body, DMC and ethics-committee oversight

Suggested Timeframe: Month 24–54 (2028-10-31 to 2031-04-30) (planning and approvals); Month 60 (2031-10-31) (first implant)

Key Outputs/Deliverables:

Dependencies:

58. Lock materials, chips and processes for the pivotal trial by Month 72 (2032-10-31). The Supply Chain Manager and Quality Manager confirm that all materials, manufactured chips and implant-assembly processes are locked (supplier, specification, batch release criteria). Any sovereign-sourcing changes (e.g., supply-chain disruption forcing a switch to a previously non-qualified supplier) trigger bridging studies to re-validate the device under the new material/process. The lock is documented in the design-history file and communicated to the Notified Body.

Responsible Body/Role: PMO (Supply Chain Manager, Quality Manager) with Sovereignty Committee oversight

Suggested Timeframe: Month 72 (2032-10-31)

Key Outputs/Deliverables:

Dependencies:

59. Conduct a pre-registered kill-gate review for chronic signal stability and bandwidth at Month 72 (2032-10-31). The DMC reviews chronic-stability data from the FIH cohort (if available) and preclinical animal studies. Kill-gate criteria (proposed: >20% signal loss within 12 months in animals blocks further progression; >25% in humans triggers pause) are evaluated. If stability is within acceptable range, the programme proceeds to pivotal trial planning. If stability is concerning, the DMC recommends design review or architecture switch (fallback penetrating cortical, switch cost EUR 30M estimate, delay 12–24 months estimate).

Responsible Body/Role: Independent Data Monitoring Committee with Steering Committee decision authority

Suggested Timeframe: Month 72 (2032-10-31)

Key Outputs/Deliverables:

Dependencies:

60. Pre-register the pivotal indication and clinical outcome at a kill-gate review (Month 78 = 2033-04-30). The Steering Committee convenes the DMC, Regulatory Committee, Clinical Operations Lead and external clinical experts to review: (1) FIH cohort safety, bandwidth and clinical-benefit data; (2) eligible-population epidemiology (ALS case definitions, disease-progression rates, recruitment feasibility); (3) reimbursement acceptability (payer feedback on outcomes and cost-effectiveness thresholds); (4) comparative evidence against existing assistive technology (eye-tracking, speech synthesis). Based on this evidence, the committee pre-registers the pivotal indication (proposed: ALS communication restoration, or consider spinal cord injury motor control if ALS pool is too small) and primary outcome (proposed: daily-life user-controlled communication net bits/s, comparison to eye-tracking baseline). The decision is published within 5 business days.

Responsible Body/Role: Project Steering Committee with DMC, Regulatory Committee, Clinical Operations Lead and external clinical experts

Suggested Timeframe: Month 78 (2033-04-30)

Key Outputs/Deliverables:

Dependencies:

61. Design and register the pivotal clinical investigation by Month 84 (2033-10-31). The Clinical Operations Lead and Regulatory Affairs Lead develop a detailed pivotal-trial protocol: population (proposed: approximately 80 adults with advanced ALS or locked-in syndrome meeting entry criteria), randomisation or historical control (if feasible), primary and secondary endpoints (daily-life function, safety, chronic stability), duration (proposed: 24 months post-implant follow-up for primary analysis, ongoing follow-up thereafter), statistical power and analysis plan. The protocol is registered in a clinical-trial registry (ClinicalTrials.gov or EU equivalent) and submitted to the ethics committees and notified body for approval. Recruitment is scheduled to begin by Month 84 (2033-10-31) or shortly thereafter.

Responsible Body/Role: Clinical Operations Lead and Regulatory Affairs Lead with notified body and ethics-committee oversight

Suggested Timeframe: Months 78–84 (2033-04-30 to 2033-10-31)

Key Outputs/Deliverables:

Dependencies:

62. Maintain monthly Steering Committee operational updates and track progress toward CE marking throughout the trial phases (Months 84–132 = 2033-10-31 to 2037-10-31). The PMO provides monthly status reports covering pivotal-trial recruitment and safety, chronic-stability and bandwidth tracking, regulatory submissions and notified-body feedback, financing status (T3 and T4 tranches), supply-chain continuity and contingency drawdown. The Steering Committee meets monthly (30 mins) and quarterly (2 hours) to review progress and escalate risks.

Responsible Body/Role: Project Steering Committee with PMO reporting

Suggested Timeframe: Monthly starting Month 12 (2027-10-31) and continuing through Month 132 (2037-10-31) and beyond

Key Outputs/Deliverables:

Dependencies:

63. Prepare and submit conformity assessment dossier to the notified body by Month 120 (2036-10-31) (central estimate). The Regulatory Affairs Lead and Quality Manager compile a comprehensive dossier covering: device design and specifications, manufacturing quality system (ISO 13485), risk management (ISO 14971), biocompatibility and sterilisation validation, preclinical testing, clinical investigation results (FIH and pivotal trial, if mature), AI Act compliance for the decoder, and draft intended-use statement. The notified body conducts a conformity assessment (formal audit, review of documentation, on-site inspection of manufacturing and quality system). Timeline to CE marking is estimated at 12–24 months (Month 132 = 2037-10-31 central estimate, range 114–156).

Responsible Body/Role: Regulatory and Compliance Committee (Regulatory Affairs Lead, Quality Manager, notified-body liaison)

Suggested Timeframe: Month 120 (2036-10-31) (target for dossier submission)

Key Outputs/Deliverables:

Dependencies:

64. Support the independent DMC's ongoing safety and efficacy monitoring throughout trial phases (Months 60–132 = 2031-10-31 to 2037-10-31). The DMC conducts monthly safety reviews during active implantation (Months 60–132 = 2031-10-31 to 2037-10-31), quarterly reviews during extended follow-up, and unscheduled meetings if a kill-gate threshold is crossed. The DMC's binding pause authority protects patients and ensures that evidence of inadequate safety or efficacy triggers programme pause or design review. Findings are reported publicly to ethics committees, regulators and patients within 30 days of each review.

Responsible Body/Role: Independent Data Monitoring Committee with PMO and Clinical Operations support

Suggested Timeframe: Months 60–132 (2031-10-31 to 2037-10-31) (active monitoring), continuing monthly or quarterly through follow-up phases

Key Outputs/Deliverables:

Dependencies:

65. Establish post-marketing surveillance and long-term follow-up infrastructure by Month 84 (2033-10-31) in preparation for CE marking and commercial rollout. The Clinical Operations Lead and Quality Manager develop a surveillance plan covering adverse-event reporting (serious adverse events reported within 30 days to the Notified Body and competent authorities), periodic safety updates (annual updates to the Notified Body), long-term outcome tracking (extended follow-up data on device durability, explantation, device replacement) and corrective actions if safety concerns emerge post-marketing. A medical-device vigilance team is established to manage complaints, adverse events and corrective actions.

Responsible Body/Role: Clinical Operations Lead and Quality Manager with notified-body liaison

Suggested Timeframe: Month 84 (2033-10-31) (planning); Month 132 (2037-10-31) (post-CE marking implementation)

Key Outputs/Deliverables:

Dependencies:

66. Support the Patient Protection and Lifelong Support Trustee Committee's reserve adequacy audits and step-in agreements by Month 36 (2029-10-31) and ongoing. The Trustee Committee conducts annual actuarial audits (starting Month 36 = 2029-10-31) to project lifelong follow-up costs, device-replacement frequency, explantation rates and reserve adequacy. Step-in agreements with backup hospital networks or successor manufacturers are drafted and tested by Month 36 (2029-10-31) so that if the company becomes insolvent, the successor can assume patient care without interruption. Reserve status is published quarterly to stakeholders.

Responsible Body/Role: Patient Protection and Lifelong Support Trustee Committee with actuarial advisors

Suggested Timeframe: Month 6 (2027-04-30) (trust establishment); Month 36 (2029-10-31) (first actuarial audit); ongoing quarterly reporting

Key Outputs/Deliverables:

Dependencies:

67. Maintain coordination with the Commission, member states and notified bodies on regulatory and policy matters through Month 180 (2041-10-31). The Regulatory Affairs Lead and Project Sponsor maintain regular briefings with the Commission (quarterly or as needed), participating member states (on IPCEI, sovereignty tests and clinical-trial coordination), and the notified body (pre-submission meetings, scientific-advice requests, regulatory updates). Coordination includes updates on clinical-trial progress, manufacturing validation, supply-chain sovereignty tests and any regulatory changes affecting the pathway. This ongoing engagement ensures regulatory alignment and reduces rework risk.

Responsible Body/Role: Regulatory Affairs Lead and Project Sponsor with Project Steering Committee oversight

Suggested Timeframe: Ongoing from Month 6 (2027-04-30) through Month 180 (2041-10-31), with quarterly updates at minimum

Key Outputs/Deliverables:

Dependencies:

68. Manage quarterly governance audits and transparency reporting by Month 180 (2041-10-31). The Governance Formation Lead (transitioning to a governance-compliance role within the PMO) and Project Sponsor conduct quarterly audits of governance structures, decision-making quality, adherence to hard requirements (patient safety, valid consent, EU control) and kill-gate execution. Audits assess whether the Steering Committee, DMC, Regulatory Committee, Sovereignty Committee and Trustee Committee are functioning as intended and escalating issues appropriately. A quarterly Governance Report is published to stakeholders (investors, Commission, hospital partners, patient organisations) summarising governance status, decisions, risks and corrective actions.

Responsible Body/Role: Governance Formation Lead / Governance-Compliance Lead (PMO) with Steering Committee oversight

Suggested Timeframe: Quarterly starting Month 12 (2027-10-31) through Month 180 (2041-10-31)

Key Outputs/Deliverables:

Dependencies:

Decision Escalation Matrix

Financing Tranche Missed or Insufficient: Capital Not Committed by Gate Deadline Escalation Level: Project Steering Committee Approval Process: The Steering Committee convenes an emergency session within 48 hours of confirmed shortfall. The Finance Controller presents a detailed cash-runway forecast and gap analysis. The Committee votes (simple majority, tie-breaker by independent chair) on whether to (a) extend the gate deadline pending imminent commitment, (b) defer the next development phase (FIH, manufacturing transfer, regulatory submission) by 12 months while seeking alternative capital, or (c) terminate the programme with orderly wind-down. The decision is binding and published to investors, the Commission and hospital partners within 5 business days. Rationale: Missing a financing gate (G1 Month 12 = 2027-10-31, foundry decision Month 18 = 2028-04-30, G3 Month 24 = 2028-10-31, G4 Month 36 = 2029-10-31) means the company lacks cash to retire critical risks before committing larger capital. EUR 0 is committed at start; expected EUR 2.5B over 15 years depends entirely on writing checks. Without binding commitments by gate dates, operations halt within 3–6 months. This is a named failure mode and requires the highest governance authority. Negative Consequences: If a tranche is missed and the gate decision is delayed beyond 2 weeks, monthly burn (EUR 2–5M estimate) exhausts remaining runway within 4–8 weeks. Operations slow, talented staff depart, partner confidence erodes and negotiations with next-round investors collapse. Alternatively, inadequate capital forces scope cuts (narrowing indication, deferring international scale, cutting redundancy and quality buffers), which undermine CE marking risk retirement and patient safety. Worst case: the company runs out of money before FIH (Month 60 = 2031-10-31 target) or before CE marking (Month 132 = 2037-10-31 target), stranding implanted patients and violating the hard requirement to protect them.

Chronic Signal Stability or Bandwidth Falls Below Pre-Registered Kill-Gate Threshold Escalation Level: Independent Data Monitoring Committee (with Binding Authority to Steering Committee) Approval Process: The DMC conducts an unscheduled meeting within 48 hours of receiving data indicating signal loss exceeding the kill threshold (proposed: >20% within 12 months in animal studies blocks FIH; >25% in human studies triggers pause). The DMC reviews all available stability data, compares to historical and published benchmarks, and votes on a binding recommendation: (a) continue with no changes, (b) pause implantation pending design review or preclinical work, (c) switch to fallback architecture (penetrating cortical, EUR 30M estimate, 12–24 month delay), or (d) terminate the programme. The DMC publishes its recommendation and rationale within 30 days to the Steering Committee, notified body, ethics committees and patients. The Steering Committee has 5 business days to decide whether to follow or override; if override, the Committee must publish its rationale publicly. Rationale: Chronic electrode signal stability and bandwidth are the core technical risks of the programme. If electrodes degrade >20–25% within 12 months, the device cannot sustain communication, cannot meet regulatory endpoints, and risks patient harm (failed device, explantation, lost communication). This is a hard scientific criterion; if violated, the programme architecture or design is fundamentally flawed. Pre-registered kill-gate thresholds bind the programme not to continue into human trials without evidence of stability. The DMC's binding authority ensures an independent assessment independent of sunk-cost pressure or investor expectations. Negative Consequences: If signal stability is insufficient and the programme continues, (a) early-implanted patients experience device failure or communication loss, triggering adverse events, explantations and regulatory action; (b) pivotal-trial endpoints cannot be met, blocking CE marking and wasting 5–10 years of development; (c) reputational damage ('EU BCI failed safety') undermines future fundraising and patient trust in EU neurotech; (d) hard requirement to maintain patient safety is violated. Alternatively, if the kill-gate data is dismissed or delayed, momentum cascades into larger cohorts before risk is recognised, compounding harm.

Patient Safety Serious Adverse Event Rate Exceeds Pre-Registered Threshold During Trials Escalation Level: Independent Data Monitoring Committee (with Binding Authority to Steering Committee); immediate Notified Body notification Approval Process: The DMC conducts a monthly safety review (or emergency meeting if threshold is crossed). Serious adverse events (device- or procedure-related deaths, permanent neurological injury, infection requiring intervention, unexpected pain, loss of communication) are evaluated against the pre-registered kill threshold (proposed: ≥3 events in first 20 implants, or ≥2 in first 10, triggers pause). If threshold is crossed, the DMC issues a binding recommendation to pause implantation immediately, cease recruitment at all sites, and launch a design review or procedure-modification investigation. The Steering Committee and notified body are notified within 24 hours. Patients are notified of the pause within 48 hours via the consent advocate and implanting team. The DMC specifies conditions for resumption (design change, additional preclinical data, revised surgical procedure). Rationale: Patient safety is a hard requirement. Serious adverse events signal that the device or procedure poses unacceptable risk. A pre-registered threshold ensures objectivity: if SAE rate exceeds threshold, the programme pauses regardless of investor or management preference. The DMC's binding pause authority prevents sunk-cost momentum from overriding safety signals. Negative Consequences: If the SAE rate exceeds threshold and the programme does not pause, additional patients suffer preventable harm (deaths, permanent injury, loss of function). Regulatory investigation and enforcement action follow (trial suspension, CE marking refusal, notified-body censure). Implanted patients lose trust; recruitment collapses. Lawsuit exposure and settlements deplete reserves. Worst case: the programme is shut down by regulators mid-trial, wasting 8–10 years of development and abandoning implanted patients if exit is not managed. Early transparent pause protects subsequent patients and preserves the programme's ability to recover and resume later with design improvements.

Informed Consent Process Found Invalid or Ethically Inadequate by Ethics Committee or Independent Auditor Escalation Level: Independent Data Monitoring Committee and Regulatory and Compliance Committee; escalates to Notified Body and member-state health authorities Approval Process: Ethics-committee findings of invalid consent (e.g., inadequate advocate presence, yes/no signalling not validated before surgery, re-consent not completed, coercive elements) trigger immediate escalation to the DMC and Clinical Operations Lead. The DMC reviews consent records and recommends pause at the affected site. The Regulatory Committee notifies the notified body and the implanting site's ethics committee of the finding within 48 hours. The site must revise its consent procedures, retrain staff and re-submit to the ethics committee; recruitment cannot resume until ethics approval is re-obtained and the DMC confirms compliance. If consent violations are systemic (across multiple sites), the entire trial pauses. Rationale: Valid informed consent is a hard requirement and a regulatory prerequisite. Breaches undermine ethical standing, regulatory approval and patient trust. A single cohort with invalid consent can be invalidated retrospectively, voiding all data and forcing restart of FIH or pivotal trials, costing 12–36 months. An ethics-committee finding of inadequacy carries regulatory weight and signals serious governance failure. Negative Consequences: If invalid consent is discovered late (after 20+ implants), those participants may need to be offered explantation and compensation; trial data is uninterpretable; regulatory and ethics-committee action pauses or stops the trial. If consent violations are not corrected, the regulator may refuse CE marking or impose mandatory informed-consent re-do, delaying approval by 12–24 months. Reputational damage and patient-safety concerns trigger media scrutiny and political pressure, undermining future recruitment and fundraising.

Notified Body or Commission Scientific Advice Requests Design Changes or Additional Evidence Exceeding Available Budget or Schedule Buffer Escalation Level: Project Steering Committee (via Regulatory and Compliance Committee) Approval Process: When the notified body or Commission requests rework (preclinical studies, design modifications, additional clinical data, risk-management expansion, AI compliance changes) that exceeds the programme's allocated contingency (EUR 10–15M estimate for regulatory rework in T1–T2) or compresses the schedule by >6 months, the Regulatory Affairs Lead escalates to the Steering Committee within 14 days. The Committee convenes with the notified-body liaison and external regulatory expert. The Committee votes on (a) requesting scientific advice or notified-body clarification to reduce scope, (b) funding the rework from released contingency, (c) deferring approval by accepting a later CE marking date, or (d) challenging the requirement via alternative evidence or legal route (rarely successful). The decision is communicated to the notified body and documented in the project record. Rationale: Notified bodies and the Commission do not reduce evidence requirements, but can request rework that was not anticipated. If this rework consumes contingency or compresses critical-path timeline, it cascades through dependent milestones (FIH, pivotal trial, CE marking). Early escalation allows negotiation, alternative evidence, or staged submission that minimises delay. Negative Consequences: If rework is not anticipated and contingency is depleted, subsequent development phases face cash constraints. A 6-month rework delay to FIH (pushing Month 60 = 2031-10-31 to Month 66 = 2032-04-30) compresses the window between FIH results and pivotal-trial start, reducing pre-trial design iteration. CE marking delays cascade, pushing Month 132 (2037-10-31) target to Month 138–144 (2038-04-30 to 2038-10-31), extending the funding envelope and burn. Multiple rework cycles risk running out of tranche money before approval.

Supplier Fails to Achieve Dual-Sourcing Qualification by Design Lock (Month 30 = 2029-04-30) Escalation Level: Supply Chain and Sovereignty Committee (with Steering Committee approval for contingency spending or design accommodation) Approval Process: By Month 24 (2028-10-31), the Supply Chain Manager confirms dual-sourcing progress (two chip suppliers, two substrate suppliers in formal qualification). If either a chip or substrate supplier fails qualification by Month 30 (2029-04-30), the Committee immediately (within 5 business days) convenes to assess single-source risk. Options: (a) extend qualification timeline for a third-party candidate (month risk, cost), (b) increase inventory of the single-source component to buffer supply disruption (capital cost), (c) design-around to use a different component family available from multiple sources (design change risk, schedule slip), (d) activate a contingency supplier identified earlier (if one exists). The Steering Committee approves the chosen contingency and adjusts budget/schedule if needed. If no viable fallback exists, the Committee escalates supply-chain risk to the notified body and prepares for potential single-source disclosure and mitigation plan. Rationale: Dual-sourcing by Month 30 (2029-04-30) is a hard planning assumption. If not achieved, the programme risks supply disruption during pivotal trials or manufacturing ramp-up. Single-source exposure violates resilience principles and threatens patient safety if a supplier fails or is subject to export controls. Negative Consequences: If a second source is not qualified and single-source risk remains, (a) a supplier bankruptcy, export-control action or capacity shortfall halts manufacturing, delaying CE marking by 6–12 months and costing EUR 2–5M in lost revenue and extra work; (b) the notified body may require additional risk-mitigation evidence and contingency planning, adding 2–4 month approval timeline; (c) payers and hospitals express concern about device reliability, reducing reimbursement or adoption willingness. Worst case: during pivotal-trial supply disruption, implanted patients cannot receive device servicing or replacement, triggering patient-safety and covenant-breach issues.

EU Control Test Failed for Critical Component or IP: Foreign Dependency or Consent Right Identified Late Escalation Level: Sovereignty and Supply-Chain Committee (with Steering Committee escalation for architecture or supplier re-negotiation) Approval Process: If diligence on a supplier, licence or IP holding reveals unresolved foreign ownership, consent rights or export-control restrictions that violate the three EU-control tests (ownership, maintainability without foreign consent, export-control freedom), the Sovereignty Committee classifies the finding as high risk and escalates to the Steering Committee within 7 days. The Committee votes on (a) re-negotiating terms with the foreign party to secure EU control (cost and timeline), (b) accepting the foreign dependency and documenting it as an upstream-tool exception in the register, (c) designing around the component (cost and schedule risk), (d) switching suppliers or architectures if the dependency is critical. If the component is sovereignty-critical (electrode, implant electronics, decoder, encapsulation) and cannot be resolved, the Committee escalates to the Commission and member states for policy guidance. The decision is documented and communicated to all stakeholders. Rationale: EU control of the delivered system by pivotal lock is a hard requirement. If a critical component fails the EU-control test, the entire sovereignty goal is compromised and the programme may not receive IPCEI funding or member-state support. Late discovery (Months 24–36 = 2028-10-31 to 2029-10-31) forces rework and timeline pressure. Negative Consequences: If a critical component has unresolved foreign control or export-control exposure, (a) the notified body or Commission may refuse CE marking approval pending EU-control clarification; (b) IPCEI or member-state co-funding is withheld until the dependency is resolved; (c) a forced design change or supplier switch costs EUR 2–10M and 6–12 months, pushing CE marking from Month 132 (2037-10-31) to Month 144–156 (2038-10-31 to 2039-10-31); (d) reputational damage: the programme fails a core hard requirement, eroding investor and government confidence. Worst case: the programme is deemed to have violated sovereignty commitments and is halted.

Eligible Patient Population Smaller Than Projected, Threatening 5,000-Implant and Reimbursement Targets by Months 36–78 (2029-10-31 to 2033-04-30) Escalation Level: Project Steering Committee (with recommendation from Clinical Operations Lead and Regulatory Committee) Approval Process: At Month 36 (2029-10-31), epidemiological studies and payer consultations confirm the eligible-patient population for the chosen indication (proposed: ALS communication). If the pool is smaller than projected (e.g., <500 eligible per year instead of target 800–1,400), or if payers signal unwillingness to reimburse, the Clinical Operations Lead and Regulatory Committee escalate to the Steering Committee with a population-viability assessment. The Committee evaluates whether to (a) proceed with the narrower population (reset 5,000-implant target to 1,000–2,000 by Month 180 = 2041-10-31), (b) switch indication (ALS to spinal cord injury, or add SCI to ALS), (c) expand indication scope (add locked-in syndrome, early-onset ALS, traumatic brain injury, allowing broader recruitment), or (d) halt and pivot to a narrower scope (e.g., early-feasibility study only, deferring pivotal indefinitely). The decision is pre-registered at Month 78 (2033-04-30) kill gate with updated indication and population targets. Rationale: The 5,000-implant target by Month 180 (2041-10-31) depends on eligible-patient pool size and reimbursement acceptance. If either is smaller than assumed, cumulative implants will miss the target, affecting revenue (EUR 45M/year instead of EUR 100M/year), investor ROI and programme sustainability. Early awareness (Months 36–48 = 2029-10-31 to 2030-10-31) allows strategic pivots before large capital is committed to scaling infrastructure. Negative Consequences: If population viability is discovered late (Months 60–84 = 2031-10-31 to 2033-10-31), after FIH and pivotal-trial setup, the programme faces sunk costs with diminished revenue. Narrowing the indication locks the company into a small patient pool, making the cost-per-implant economics poor: EUR 150,000 per implant (proposed) with only 300–500 implants/year means EUR 45–75M revenue but EUR 111M annual opex (estimate), running deficits of EUR 36–66M/year indefinitely. Investors lose confidence, subsequent tranches stall, and the company cannot reach sustainability. Switching indication late incurs rework (new trial protocols, ethics approvals, clinical endpoints), costing EUR 5–15M and 12–24 months, pushing CE marking from Month 132 (2037-10-31) to Month 156+ (2039-10-31+).

Key Personnel Loss or Recruitment Failure Against US Competition Threatens Critical Milestone Escalation Level: Project Steering Committee (via Programme Manager, in consultation with HR and external recruitment counsel) Approval Process: If the CEO, CTO, Lead Neurosurgeon, Regulatory Affairs Lead or another key role (designated by the Programme Manager) departs or cannot be filled within 90 days, the Programme Manager escalates to the Steering Committee within 14 days. The Committee assesses impact on critical-path milestones (architecture choice Month 18 = 2028-04-30, design lock Month 30 = 2029-04-30, FIH Month 60 = 2031-10-31). The Committee approves (a) accelerated recruitment (headhunter, higher compensation, external interim expert), (b) team re-organisation to delegate role to existing staff, or (c) timeline deferral if no acceptable interim solution exists. The Committee also reviews retention incentives (additional equity, bonuses, long-term contracts) for remaining key personnel to prevent cascading departures. The decision is documented and a 90-day hiring plan is published. Rationale: A founder-only start and EU-wide talent competition against US salaries (20–30% premium estimate) create chronic recruitment and retention risk. Loss of a key leader (especially the CTO for technology decisions or the lead clinician for regulatory pathways) can derail architecture choice, design decisions or regulatory submissions. The 15-year horizon also means mid-career departures and burnout are likely; contingency planning protects against knowledge loss. Negative Consequences: If a key role is vacant for >90 days without interim coverage, decision velocity slows and critical milestones slip. Loss of the CTO without transition delays architecture lock from Month 18 (2028-04-30) to Month 24 (2028-10-31) or later, compressing design-lock timelines. Loss of the lead clinician delays FIH recruitment and ethics-committee coordination, pushing Month 60 (2031-10-31) to Month 66–72 (2032-04-30 to 2032-10-31). Cascading departures (one departure triggers others) reduce team morale and execution speed, extending all timelines by 10–15%. Inability to recruit replacements (e.g., no qualified EU neurosurgeon available at acceptable cost) may force deferral of ambitious timelines or outsourcing to less-ideal partner institutions, increasing costs and risks.

Leuven Infrastructure Fails (Cleanroom/Cooling/Power) or a Partner Institution Declines Commitment Escalation Level: Project Steering Committee (with Supply Chain and Sovereignty Committee input for manufacturing; Clinical Operations Committee for hospital partnership) Approval Process: If imec, KU Leuven or UZ Leuven declines a partnership letter of intent by Month 3 (2027-01-31), or if a climate/infrastructure incident (multi-day power outage, cooling failure, flood) affects Leuven facilities, the Programme Manager escalates to the Steering Committee within 5 business days. The Committee activates pre-identified fallback sites: for UZ Leuven hospital partnership, fallback sites in Ghent/Antwerp, Utrecht and Grenoble are contacted immediately and negotiations accelerate; for imec cleanroom/pilot-line access, fallback to external foundry or contract manufacturer is pursued; for KU Leuven research partnership, academic collaborations with other EU institutions are explored. The Committee approves a fallback-site activation plan (cost EUR 1–2M estimate for site qualification and setup, 3–6 month schedule impact), prioritises which fallback to activate first and sets a decision deadline (14 days). Rationale: Leuven (imec, KU Leuven, UZ Leuven) is the primary headquarters and core-capability location. No committed partnerships exist at Month 0 (2026-10-31). Partner decline or infrastructure failure forces site migration and rework. Climate resilience (heatwaves, drought, flooding, power) poses ongoing risk to manufacturing and compute. Early identification and activation of fallback sites minimises delay. Negative Consequences: If a partner declines and no fallback is activated within 30 days, the programme loses access to critical capability (neurosurgical theatres, cleanroom, ethics-committee coordination). FIH is delayed 3–6 months as a new site is qualified and ethics approval obtained. If infrastructure fails mid-trial or mid-manufacturing, operations halt for days to weeks; manufacturing losses EUR 100k–500k per event (estimate), compute data-loss risk if backup systems fail. Climate incidents during pivotal-trial recruitment can disrupt patient flow and follow-up, reducing implant throughput by 10–30%. Multiple infrastructure incidents signal systemic Leuven-site risk and may force permanent relocation of manufacturing or headquarters, costing EUR 5–15M and 12–24 months.

Payer Reimbursement Acceptance Falls Below Viability Threshold, or Health-Economic Case Rejected Escalation Level: Regulatory and Compliance Committee (with Steering Committee escalation for commercial-viability assessment) Approval Process: Payer and HTA-body feedback during Months 12–36 (2027-10-31 to 2029-10-31) consultations is reviewed quarterly by the Regulatory Committee. If reimbursement feedback indicates unacceptable price (e.g., payers willing to pay only EUR 80,000 instead of EUR 150,000 target), low-volume acceptance (few member states, <50% coverage), or high cost-per-QALY barriers (cost >EUR 200,000/QALY instead of EUR 120,000/QALY ceiling proposed), the Committee escalates to the Steering Committee by Month 24 (2028-10-31). The Committee presents a revised revenue model and break-even analysis. The Steering Committee votes on (a) accepting lower reimbursement price (reducing revenue to EUR 30M/year instead of EUR 45M/year at Month 180 = 2041-10-31), (b) investing in health-economic evidence to support higher price (additional trial burden), (c) narrowing indication or patient population to improve cost-effectiveness, or (d) halting the commercial programme and pivoting to a narrower early-feasibility or research focus. The decision is documented and communicated to investors and the Commission. Rationale: Reimbursement is the only revenue source after CE marking. If payers reject the device or reimburse far below target price, the company cannot achieve profitability or investor ROI, making further funding difficult and threatening programme survival. Negative Consequences: If reimbursement acceptance is low and pricing power is weak, annual revenue at Month 180 (2041-10-31) is EUR 30M instead of EUR 45M (estimate), while annual opex remains EUR 111M (estimate), increasing annual losses to EUR 81M instead of EUR 66M. The company burns cash indefinitely without a path to break-even (break-even requires ~1,125 implants/year at EUR 150,000 price; at lower price or lower volume, break-even is unachievable). Investors lose confidence in later tranches (T3, T4), funding stalls Months 84–132 (2033-10-31 to 2037-10-31), and the company cannot complete pivotal trials or reach CE marking. Alternatively, the company cuts costs (reducing quality, support, follow-up services), undermining competitive position and patient safety.

Architectural Switch Triggered by Kill-Gate Findings: Design Fundamentally Flawed, Switch Costs EUR 30M and 12-24 Months Escalation Level: Project Steering Committee (with Sovereignty and Supply-Chain Committee assessment) Approval Process: If chronic-signal-stability data, biocompatibility findings or early FIH results (Months 36–72 = 2029-10-31 to 2032-10-31) indicate that the primary architecture (proposed: thin-film surface epidural) cannot meet stability or bandwidth targets, the DMC and CTO recommend switching to the fallback architecture (proposed: penetrating cortical microelectrode). The Steering Committee convenes an emergency meeting within 7 days of the recommendation. The Committee assesses (a) scientific viability and risk of the fallback, (b) cost (EUR 30M estimated, range 15–60M), (c) schedule impact (12–24 months estimated), (d) whether the contingency budget can absorb the cost (EUR 100M in T3 contingency available estimate), and (e) whether timeline extension (CE marking from Month 132 = 2037-10-31 to Month 144–156 = 2038-10-31 to 2039-10-31) is acceptable to investors and the Commission. The Committee votes to approve the switch or continue with primary architecture despite findings. If approved, the CTO develops a detailed switch plan: new preclinical studies, design-history-file rework, regulatory notified-body notification and revised timeline. Rationale: Architectural switch is a major pivot with large cost and schedule implications. A pre-registered fallback architecture allows bounded contingency planning. The Steering Committee's binding vote protects against unbounded cost growth and unrealistic timeline recovery. Negative Consequences: If an architecture switch is not approved despite adverse findings, the programme continues with a fundamentally flawed design, risking patient harm (failed electrodes, signal loss, device explantation) and regulatory rejection (CE marking refused). If an architecture switch is approved late (after substantial investment in the primary architecture), sunk costs escalate (preclinical rework EUR 10–15M, regulatory rework EUR 3–5M, manufacturing retooling EUR 5–10M), total switch cost may exceed EUR 30M estimate and reach EUR 50–60M. Schedule impact cascades: FIH delays from Month 60 (2031-10-31) to Month 72–78 (2032-10-31 to 2033-04-30), pivotal-trial start delays from Month 84 (2033-10-31) to Month 96–102 (2034-10-31 to 2035-04-30), CE marking from Month 132 (2037-10-31) to Month 156–162 (2039-10-31 to 2040-04-30). Investor confidence erodes, subsequent tranches (T3, T4) are harder to raise, and the 15-year programme ceiling is exceeded. Worst case: the company runs out of contingency budget mid-switch and cannot complete the rework, halting the programme.

Feasibility Verdict at Month 24 (2028-10-31): Verdict is 'Not Credibly Achievable' or Requires Major Scope Changes Escalation Level: Project Steering Committee (with Commission and investor notification) Approval Process: At Month 24 (2028-10-31), the Steering Committee issues a formal feasibility verdict separating scientific, engineering, clinical, regulatory, supply-chain and financing feasibility. If the verdict is 'not credibly achievable' or 'achievable only with major changes' (e.g., narrowed indication, extended timeline, lower bandwidth targets, reduced patient population), the Committee meets with the Commission, major investors and member states within 14 days to present findings and options. Options include (a) accept the revised scope and reset targets and timelines, (b) pause the programme for 12 months pending new evidence (e.g., breakthrough in signal stability), (c) pivot to a narrower early-feasibility-study-only scope (deferring pivotal trials and commercial scale), or (d) terminate the programme with orderly wind-down and protection of any implanted patients. The decision and rationale are published to all stakeholders within 30 days. Rationale: The Month 24 (2028-10-31) feasibility verdict is the programme's credibility checkpoint. If major obstacles are not resolved (financing commitment, partner confirmations, regulatory pathway clarity, preclinical data adequacy), continuing is imprudent and wastes capital. A clear verdict with named alternatives (pause, narrow scope, terminate) allows stakeholders to make informed decisions about continued participation. Negative Consequences: If the verdict is unfavourable and suppressed (not published, not discussed with stakeholders), investors and the Commission discover problems later (Months 36–60 = 2029-10-31 to 2031-10-31), losing trust and halting funding abruptly. If the verdict leads to programme termination without orderly wind-down, implanted patients (if any by that date) are abandoned and patient-protection reserves are inadequate. If the verdict leads to major scope narrowing (pivotal indication dropped, commercial scale deferred indefinitely), revenue assumptions change radically, making earlier capital rounds based on broader assumptions unrecoverable. Alternatively, proceeding despite an unfavourable verdict and hoping for breakthrough risks wasting EUR 200M–400M of T1 and T2 capital before the problem is undeniable, at which point recovery is more expensive and harder.

Monitoring Progress

1. Financing Gate Compliance and Capital Tranches Tracking

Monitoring Tools/Platforms:

Frequency: Monthly operational review; formal gate reviews within 5 business days of gate date (Months 12, 18, 24, 36, 60, 78, 84, 132 = 2027-10-31, 2028-04-30, 2028-10-31, 2029-10-31, 2031-10-31, 2033-04-30, 2033-10-31, 2037-10-31)

Responsible Role: Finance Controller (PMO) with Project Steering Committee gate authority; monthly reporting to Steering Committee and investors

Adaptation Process: If month-to-date burn exceeds forecast by >10% or projected runway falls below 3 months beyond next gate, the Finance Controller escalates to the Steering Committee within 5 business days with contingency-drawdown and cost-reduction options. Missing a financing gate (T0 by Month 12 = 2027-10-31, foundry commitment by Month 18 = 2028-04-30, T1 by Month 24 = 2028-10-31, T2 by Month 36 = 2029-10-31) within 14 days triggers automatic escalation: the Steering Committee convenes emergency session within 48 hours and votes to (a) defer next development phase by 12 months, (b) reduce scope (narrower indication, defer manufacturing scale-up, slow clinical timeline), or (c) terminate programme with orderly patient-protection wind-down. Named fallbacks are activated immediately: if foundry funding is not committed by Month 18 (2028-04-30), dual-sourcing route is triggered within 5 business days.

Adaptation Trigger: Projected cash shortfall >EUR 5M or runway <90 days before next gate; missed financing gate (written commitment not received by gate deadline +14 days); variance in monthly burn >10% from forecast for two consecutive months; announced investor withdrawal or tranche reduction >20%

2. Chronic Signal Stability and Bandwidth Performance Monitoring

Monitoring Tools/Platforms:

Frequency: Preclinical: monthly during chronic animal study (Months 9-33 = 2027-07-31 to 2029-07-31); clinical: monthly during FIH and pivotal trials (Months 60-132 = 2031-10-31 to 2037-10-31); quarterly during extended follow-up (Months 132-180 = 2037-10-31 to 2041-10-31)

Responsible Role: Independent Data Monitoring Committee (DMC) with binding pause authority; CTO and Clinical Operations Lead provide raw data; external biostatistician interprets trends

Adaptation Process: The DMC reviews signal-stability and bandwidth data monthly during active phases. If mean usable-signal loss exceeds the pre-registered kill threshold (>20% in animal studies within 12 months; >25% in human trials within 12 months), the DMC issues a binding recommendation to pause implantation, cease new recruitment, and conduct a design review or architectural fallback assessment. The Steering Committee has 5 business days to decide whether to follow or override the pause recommendation (with public justification required if overridden). If >50% of participants show <50% signal retention at 36 months post-implant, the DMC recommends architecture switch to the fallback penetrating-cortical design (contingency cost EUR 30M estimate, delay 12-24 months estimate). The CTO and Quality Manager develop a detailed design-improvement or architecture-switch plan within 30 days.

Adaptation Trigger: Preclinical animal study: >20% mean signal loss within 12 months of implantation blocks progression to first-in-human; human trials: >25% mean usable-signal loss within 12 months triggers pause; bandwidth floor <5 bits/s net sustained in 50% or more of participants at Month 72 (2032-10-31) triggers architecture or indication review; <50% signal retention at 36 months post-implant (Month 120 = 2036-10-31 for early implants) triggers fallback-architecture switch recommendation

3. Patient Safety and Serious Adverse Event Monitoring with Independent Oversight

Monitoring Tools/Platforms:

Frequency: Continuous reporting of any serious adverse event within 48 hours to the implanting site's principal investigator, Clinical Operations Lead and DMC chair; DMC formal safety reviews monthly (or after every 5-10 implants during early-stage work) during Months 60-132 (2031-10-31 to 2037-10-31); quarterly during extended follow-up

Responsible Role: Clinical Operations Lead and site principal investigator (event reporting and initial assessment); Independent DMC (binding pause authority and kill-gate threshold evaluation); Regulatory Affairs Lead (notified-body communication and expedited reporting)

Adaptation Process: The DMC evaluates all serious adverse events (device- or procedure-related deaths, permanent neurological injury, infection requiring intervention, unexpected pain, loss of communication) monthly and compares cumulative count to the pre-registered kill threshold: 3 or more events in the first 20 implants, or 2 or more in the first 10, triggers an immediate pause recommendation. If the threshold is crossed, the DMC issues a binding recommendation to pause implantation at all sites, cease new recruitment, notify all ethics committees and the notified body within 24 hours, and launch an investigation into device design, surgical procedure or participant selection. The Steering Committee has 5 business days to decide whether to follow the pause (presumed unless overridden with published justification). If the SAE rate exceeds the threshold and the pause recommendation is followed, the programme may resume implantation only after a documented design change, procedure revision, revised patient-selection criteria or additional preclinical/animal work is approved by the DMC, Steering Committee and notified body.

Adaptation Trigger: 3 or more serious adverse events in first 20 implants (Month 72 = 2032-10-31 estimated for FIH cohort completion); 2 or more in first 10 implants; any device-related death; any permanent neurological injury attributable to the implant or procedure; trend of SAE rate >proposed threshold, even if absolute count has not reached threshold, triggers SAE-investigation protocol

4. Informed Consent Validity and Ethical Safeguards Monitoring

Monitoring Tools/Platforms:

Frequency: Independent audit of consent quality quarterly (every 5-10 new participants during recruitment phase); re-consent completion tracked continuously; ethics-committee approval status tracked monthly

Responsible Role: Independent consent advocate (primary responsibility for consent process fidelity); Clinical Operations Lead (site coordination and audit scheduling); Independent DMC (quarterly consent-quality audit and findings escalation); Regulatory Affairs Lead (ethics-committee liaison and approval tracking)

Adaptation Process: The independent consent advocate and DMC conduct quarterly audits of consent records at each implanting site, evaluating (a) presence and role of advocate in consent conversations, (b) validation of participant's yes/no signalling (assessed with communication aids, not assumed), (c) timing and completion of re-consent if disease progression affects communication, (d) documentation of participant withdrawal requests and management. If audit finds any invalid-consent elements (e.g., no advocate present, yes/no signalling not validated, coercive language, failure to re-consent), the DMC issues a finding within 14 days and recommends pause at that site until consent procedures are revised and re-approved by the ethics committee. The site must implement corrective actions (staff retraining, revised consent templates, procedure changes) and obtain ethics-committee re-approval before recruitment resumes. If invalid-consent findings are systemic (across multiple sites), the entire trial pauses. Any ethics-committee finding of inadequate consent triggers immediate notification to the Steering Committee and the notified body.

Adaptation Trigger: Any consent audit finding of inadequate advocate presence, un-validated yes/no signalling, or missing re-consent; ethics-committee refusal to approve consent protocol or request for protocol revision; participant report of coercive language or loss of autonomy; audit of >20% of participants at a site showing consent-fidelity gaps

5. EU Control and Supply-Chain Sovereignty Verification

Monitoring Tools/Platforms:

Frequency: Quarterly sovereignty-criteria assessment for any new supplier, licence or acquisition (within 30 days of proposal); monthly supplier-qualification progress review; quarterly export-control intelligence scan; annual sovereignty audit across all components by Month 72 (2032-10-31)

Responsible Role: Sovereignty and Supply-Chain Assurance Committee (chair: external Sovereignty Lead with EU-control and export-control expertise); Supply Chain Manager (supplier qualification tracking); Quality Manager (manufacturing-process EU-control verification)

Adaptation Process: For any proposed supplier, acquisition or licence, the Sovereignty Committee applies three EU-control tests (ownership, maintainability without foreign consent, export-control freedom) within 30 days and recommends approval, renegotiation or rejection. If assessment reveals foreign ownership, foreign-held consent rights or export-control dependencies, the Committee escalates to the Steering Committee with options to (a) re-negotiate terms to secure EU control, (b) accept the foreign dependency and document it in the upstream-dependency register (only for non-critical upstream tools, not for device components), (c) design around the component, or (d) switch suppliers or architectures. Dual-sourcing qualification progress (two chip suppliers, two substrate suppliers) is tracked monthly; if a second source cannot be qualified by Month 30 (2029-04-30), the Sovereignty Committee escalates single-source risk to the Steering Committee with contingency options (expand supplier pool, design-around, increase inventory buffer). The upstream-dependency register is published by Month 12 (2027-10-31) and updated quarterly; any new tool or supplier entering the supply chain is assessed for export-control status and included in the register within 30 days. If a geopolitical event (US export-control tightening, supplier bankruptcy, supply disruption) affects a high-risk dependency, the Committee notifies the Steering Committee within 5 business days with mitigation options.

Adaptation Trigger: Sovereignty-criteria assessment of any supplier/licence/IP reveals failed EU-control test (foreign ownership, foreign consent rights, export-control restriction); second chip or substrate supplier fails to achieve qualification by Month 30 (2029-04-30); new export-control restriction announced affecting current supplier or tool; discovery of undisclosed foreign licence or IP encumbrance on a critical component; any notified-body or Commission query on EU-control status of a device component

6. Regulatory Pathway Compliance and Notified-Body Engagement Tracking

Monitoring Tools/Platforms:

Frequency: Monthly regulatory-pathway status review; bi-weekly notified-body liaison meetings during active engagement phases (Months 6-24 = 2027-04-30 to 2028-10-31 and Months 108-132 = 2036-04-30 to 2037-10-31); quarterly scientific-advice and AI Act compliance reviews

Responsible Role: Regulatory and Compliance Committee (chair: Regulatory Affairs Lead); Quality Manager (DHF and QMS compliance); AI Compliance Specialist (decoder validation and AI Act obligations); Notified-body liaison (external, contracted)

Adaptation Process: The Regulatory Committee tracks all notified-body and Commission feedback on evidence requirements, design changes and compliance gaps. If the notified body requests rework (additional preclinical studies, design modifications, risk-management expansion, quality-system changes) that exceeds the allocated regulatory-rework contingency (EUR 10-15M estimate in T1) or compresses the critical-path timeline by >6 months, the Committee escalates to the Steering Committee within 14 days with options to (a) request scientific advice or notified-body clarification to reduce scope, (b) fund the rework from released contingency, (c) defer approval by accepting a later CE marking date, or (d) challenge the requirement via alternative evidence. Design-history-file completeness is audited monthly; if DHF has gaps >20% by Month 18 (2028-04-30), the Quality Manager develops a catch-up plan with 60-day close-out target. If ethics-committee approval at any site is delayed >2 months from baseline, the Clinical Operations Lead escalates to the Regulatory Committee for coordinated-assessment support or fallback-site activation. AI Act compliance readiness (decoder training-data documentation, model validation, change-control process) is reviewed quarterly; if readiness is <80% by Month 24 (2028-10-31), additional resources are allocated to close gaps before design lock.

Adaptation Trigger: Notified-body rework request exceeds EUR 10M contingency or requires >6 months additional work; Commission scientific-advice response (expected Month 15 = 2028-01-31) indicates significant design or evidence changes needed; ethics-committee approval at any site delayed >2 months; design-history-file completeness <80% at Month 18 (2028-04-30); AI Act compliance readiness <80% at Month 24 (2028-10-31); notified-body preliminary QMS audit (Month 18 = 2028-04-30) identifies >5 non-conformities requiring rework

7. Eligible Patient Population and Reimbursement Viability Tracking

Monitoring Tools/Platforms:

Frequency: Epidemiology study completed by Month 36 (2029-10-31); payer consultations conducted Months 12-36 (2027-10-31 to 2029-10-31), quarterly summary; health-economic model updated quarterly starting Month 12 (2027-10-31); centre-network and capacity modelling updated at Months 36 (2029-10-31), 60 (2031-10-31), 78 (2033-04-30) gates

Responsible Role: Clinical Operations Lead (epidemiology study coordination and payer engagement); Regulatory and Compliance Committee (reimbursement-pathway planning); Finance Controller (revenue and break-even modelling); Supply Chain Manager (centre-network capacity planning)

Adaptation Process: The Clinical Operations Lead commissions epidemiology studies by Month 6 (2027-04-30) to estimate eligible-patient pool by indication (ALS communication: target 500-1,400 per year estimate; spinal cord injury motor control: target 1,500-3,000 per year estimate if considered). If epidemiology results (returned by Month 36 = 2029-10-31) show eligible pool <300 per year, the Steering Committee triggers a population-viability kill gate (Month 36 = 2029-10-31) to decide whether to (a) proceed with narrowed population (reset 5,000-implant target to 1,000-2,000 by Month 180 = 2041-10-31), (b) switch indication (ALS to spinal cord injury), (c) broaden indication scope, or (d) defer commercial scale and pivot to early-feasibility-only scope. Payer and HTA consultations (Months 12-36 = 2027-10-31 to 2029-10-31) solicit feedback on price (target EUR 150,000 per implant), cost-per-QALY ceiling (target EUR 120,000), reimbursement coverage (target 7+ member states), and care-pathway requirements. If payer feedback indicates willingness to pay <EUR 80,000 or cost-per-QALY acceptance <EUR 100,000, the Finance Controller revises revenue projections and break-even modelling; if revised break-even exceeds achievable implant volume, the Steering Committee escalates as a commercial-viability risk at Month 24 (2028-10-31) gate. Centre-network capacity is modelled bottom-up (surgeries per centre per year × number of qualified centres) at Months 36, 60 and 78 (2029-10-31, 2031-10-31, 2033-04-30); if modelled capacity cannot support the annual ramp needed to reach 5,000 implants by Month 180 (2041-10-31), the clinical-operations plan is revised to expand centre network or accelerate capacity, with cost and schedule implications.

Adaptation Trigger: Epidemiology study (Month 36 = 2029-10-31) shows eligible pool <300 per year; payer feedback indicates <50% member-state reimbursement coverage or willingness-to-pay <EUR 80,000; health-economic model shows cost per QALY >EUR 150,000 at proposed price; centre-network modelling (Month 60 = 2031-10-31) shows achievable capacity <100 implants per year, insufficient for 5,000-implant ramp by Month 180 (2041-10-31)

Governance Extra

Governance Validation Checks

  1. Completeness Confirmation: All five core governance bodies are defined with charter scope, responsibilities, membership, decision authority and reporting lines. Implementation plan sequences establishment from Month 0 (2026-10-31) through Month 6 (2027-04-30). Monitoring plan covers six domains (financing, technical stability, safety, consent, sovereignty, regulatory). Escalation matrix addresses eleven major decision scenarios. However, three structural gaps exist: (1) the Steering Committee charter does not explicitly bind investors to gate decisions (no contractual penalties if tranches are withheld despite gate passing); (2) the patient-protection reserve trust is separate but the charter does not specify what triggers it to assume company operations if insolvency occurs; (3) the kill-gate criteria are described as 'proposed' thresholds, not investor-endorsed or regulator-pre-approved minimums, leaving discretion on what constitutes breach.
  2. Internal Consistency: Governance bodies align logically. The Steering Committee gates tranches and strategic choices; the PMO executes and escalates >EUR 1M or >2 months to the Steering Committee; the independent DMC holds binding pause authority on safety and stability (stopping clinical work, which cuts revenue and investor returns, making the pause threat credible); the Regulatory Committee manages notified-body and ethics-committee relationships; the Sovereignty Committee enforces EU-control tests before sourcing is locked; the Patient Trustee protects reserves independently. However, one inconsistency: the Steering Committee's tie-breaking rule (independent chair votes to pause if any member raises a safety concern) is asymmetric—it biases toward stopping but not toward aggressive speed-up, which may conflict with investor pressure to hit CE marking by Month 132 (2037-10-31). Also, no escalation path is defined if the Steering Committee overrides a binding DMC pause recommendation and the override causes patient harm; the matrix says the Steering Committee has 5 business days to decide, but does not specify consequences (regulatory referral, investor liability, patient compensation fund draw) if override is deemed negligent.
  3. Specific Areas Needing Clarity or Detail: (a) Consent safeguard process: The implementation plan states 'independent consent advocate by Month 3 (2027-01-31)' and 'yes/no signalling validated before surgery,' but does not define operational detail for rapidly progressive diseases like ALS where communication can be lost mid-recruitment. A protocol for concurrent re-consent, escalating communication aids and documentation of 'capacity fade' is missing; the monitoring plan audits consent quality quarterly, but guidance on when to halt recruitment at a site due to participant-communication decline is not specified. (b) Kill-gate thresholds: Proposed safety threshold (≥3 SAEs in first 20 implants triggers pause) is pre-registered and DMC authority is binding, but the Steering Committee can override with public justification. No contractual commitment from investors forbids them from pressuring the Committee to override; the matrix notes only that override rationale must be published within 5 business days. Credibility requires investor pre-endorsement of specific thresholds before recruitment begins, not post-hoc override. (c) Architecture fallback: The EUR 30M contingency cost for switching from thin-film surface to penetrating cortical is acknowledged, but the Implementation Plan does not specify the specific preclinical studies, regulatory rework, manufacturing retooling and timeline needed to execute the switch. A contingency-activation protocol (CTO role, notified-body notification, revised timeline publication) should be detailed. (d) Financing-gate fallback execution: If T1 is not 60% committed by Month 24 (2028-10-31), the Steering Committee is to decide within 48 hours whether to defer FIH, reduce scope or stop. However, no timeline is set for that decision to be communicated to team, hospital partners, ethics committees and participants. A 48-hour decision window is too tight for multi-stakeholder communication; a 5-business-day decision + 10-day communication protocol should be specified. (e) Leuven partner decline handling: Fallback sites (Ghent/Antwerp, Utrecht, Grenoble) are identified by Month 6 (2027-04-30), but no standby ethics approvals, MOU pre-signing or facility qualification is pre-completed. If UZ Leuven declines and fallback activation begins at Month 3 (2027-01-31), ethics-committee re-approval at a fallback site typically takes 3–6 months, pushing FIH from Month 60 (2031-10-31) baseline by 6–12 months. The Implementation Plan acknowledges '3–6 month schedule impact' but does not pre-build this into the FIH schedule buffer; the master schedule at Month 0 (2026-10-31) should reserve Month 60–66 (2031-10-31 to 2032-04-30) as a contingency window for fallback-site activation. (f) Decoder version control and AI Act change management: The plan specifies a 'pre-registered change-control process' for decoder updates post-CE marking, but does not define operational detail: what constitutes a 'minor' update (retraining on EU data within a locked feature set) versus 'major' (architecture change, new data source, new features)? Who approves updates (company internal QA, notified body, independent reviewer)? What revalidation is required for each category? A detailed decoder-change-control matrix (categorising updates, approval authority, revalidation scope and timeline) should be published by Month 24 (2028-10-31). (g) Patient-protection reserve trigger for successor assumption: The Trustee Committee is to activate step-in agreements if the company becomes insolvent, but 'insolvency' is not defined. Does it mean negative equity, debt-service default, operational-cash shortfall, regulatory licence suspension, or loss of investor backing? A quantitative insolvency trigger (e.g., cash runway <3 months AND unmet tranche commitment) should be pre-defined so the Trustee can act without ambiguity. (h) Supply-chain contingency for export-control shock: The Sovereignty Committee monitors export-control intelligence quarterly, but no protocol specifies response timeline if a high-risk upstream tool (fab equipment, EDA software) is suddenly restricted. A 'crisis playbook' defining hours-to-decision for emergency design-around, supplier switch or production halt should be drafted by Month 18 (2028-04-30).
  4. Potential Governance Gaps and Weaknesses: (i) Investor contractual binding to gates: The feasibility verdict at Month 24 (2028-10-31) is described as a 'go/defer/stop/switch' decision, but the Steering Committee charter does not specify that investor tranches are contractually withheld if gate criteria are not met. Investors may have incentive to ignore adverse verdicts and deploy capital anyway if sunk costs are high; a 'milestone-gated tranche release' clause in investor term sheets (separate from governance charter) should be required as a condition of governance participation. (ii) DMC pause execution: The DMC's binding pause recommendation is credible only if the Programme Manager has authority to halt operations immediately (stop new consents, cease surgeries, notify sites) without Steering Committee approval. The charter grants 'binding authority to recommend pause,' but 'recommend' suggests the pause is discretionary until approved. Recommendation language should be changed to 'binding authority to order an immediate pause,' with 48-hour Steering Committee ratification review (not approval gate). (iii) Patient-advocate independence: The independent consent advocate is hired by the Governance Formation Lead / Clinical Operations Lead (within company operational hierarchy), not recruited independently with conflict-of-interest protections. A second-level independent ethics review (external bioethicist or patient-ombudsman role) should monitor the advocate's conduct quarterly to ensure the advocate is not subtly pressured by site staff to minimize enrollment barriers. (iv) Regulatory pathway risk buffer: The Steering Committee is charged with managing 'notified-body rework requests' but has no contractual standing with the notified body to challenge or negotiate scope. Scientific-advice requests to the Commission can clarify intent, but notified bodies are independent and can change evidence expectations. A 'regulatory-contingency protocol' allowing the Steering Committee to request a second-opinion notified-body assessment if the primary notified body's evidence demands appear unusual should be drafted. (v) Feasibility-verdict communication and accountability: The Month 24 (2028-10-31) feasibility verdict is published to stakeholders, but no mechanism is defined for accountability if the verdict is overstated (e.g., verdict says 'achievable only with changes' but changes are later deemed unfeasible, wasting T1 capital). A 'verdicts audit' by an external governance specialist at Month 48 (2030-10-31) and Month 72 (2032-10-31) should be required to assess whether Month 24 (2028-10-31) assumptions held and to trigger remedial actions (deferral, scope narrowing, programme termination) if key assumptions failed.
  5. Missing Detail on Borderline-Authority Scenarios: (vi) Competing priorities between patient safety (DMC) and capital preservation (investors): If a chronic-stability kill threshold is crossed (e.g., >25% signal loss in humans by Month 72 = 2032-10-31) and the DMC recommends pause, but the company is mid-pivotal trial with recruitment commitments to ethics committees and hospitals, the Steering Committee faces pressure to override and 'continue pending design review.' The governance matrix allows override with public justification, but does not specify that override should require notified-body pre-approval, ethics-committee consent or independent legal review. An override-accountability protocol (mandatory ethics and regulatory consultation, 10-day public comment period before override, investor signoff on liability) should be specified. (vii) Enhancement-track firewall enforcement: The plan specifies 'a separate legal entity for enhancement research' with 'documented firewall,' but does not define enforcement mechanisms. Who audits the firewall? What happens if enhancement staff access patient data or device IP without permission? An independent governance audit of the enhancement entity (quarterly, by external counsel) should be specified, with escalation if breaches are found. (viii) Consent during disease progression in ALS: The plan notes 'consent for people with impaired or declining communication' is a hard requirement but does not operationalize 're-consent when communication is lost.' If a participant loses functional communication mid-trial (not uncommon in ALS), who decides whether the participant continues, is paused or is exited? The consent advocate alone, or joint decision with family, clinician and ethics committee? A 'declining-communication protocol' (decision-tree for re-consent, communication-aid escalation, family notification, exit procedures) should be published by Month 12 (2027-10-31) and tested in dry-run with ethics committees before FIH recruitment.
  6. Execution Risk and Contingency Reserve Status: The governance structure is sound in principle but has three execution risks: (1) the five governance bodies require 25–30 independent and dedicated people (Steering Committee 5, PMO core 6, DMC 7, Regulatory Committee 4, Sovereignty Committee 3, Trustee Committee 5) to function well, but the MVP budget is EUR 15M for Months 0–24 (2026-10-31 to 2028-10-31) at about EUR 0.6M per month, equal to roughly EUR 10–12M for team salaries and overhead, leaving EUR 3–5M for preclinical work, partner engagement and compliance setup. If salaries consume the budget faster (EU talent competing against US pay), governance-role staffing is deferred, weakening early risk retirement. T1 must fund the full governance apparatus for Months 24–48 (2028-10-31 to 2030-10-31) in parallel with design lock and manufacturing transfer; if T1 is smaller than EUR 120M (contingency: EUR 60M minimum gate threshold), governance operations are under-resourced during the highest-stakes pre-FIH phase. (2) Financing-gate credibility depends on investor pre-commitment to specific tranches at specific milestones, but the plan assumes 'return-seeking investors' with typical 20–25% IRR expectations. If the company misses the 5,000-implant target (central estimate: 1,050 implants, a 79% miss), implied IRR drops sharply, and investors may pivot to reduced support for later tranches (T3, T4). The Steering Committee governance does not contractually protect against this; an investor-governance agreement should specify that tranches are released on milestone achievement, not on IRR re-forecasts. (3) The independent DMC's binding pause authority is credible only if members understand that a pause recommendation terminates clinical revenue during a trial and may tank investor returns, so DMC members face political and reputational pressure to keep studies open despite adverse signals. Selecting DMC members with explicit conflict-of-interest protections (not employed by the company, no equity stake, long-term independence) is critical; the charter nominates candidates but does not specify compensation (should be hourly, not contingent), term length (should be fixed, e.g., 4 years, to avoid mid-trial departure) or conflict-of-interest periodic re-certification.

Tough Questions

  1. By Month 12 (2027-10-31), what is the written, non-binding evidence that seed capital of at least EUR 15M is available to fund T0 (Months 0–24 = 2026-10-31 to 2028-10-31)? Have you secured term sheets or investor commitment letters from identified parties, or are you relying on grant applications not yet submitted? If the latter, what is the fallback if grants are declined?
  2. The Steering Committee may override a binding DMC pause recommendation with 'public justification.' What specific circumstances (e.g., new preclinical data, design modification approved by notified body, ethics-committee endorsement) would make an override defensible? Publish a decision-tree and vet it with the Commission and a notified body by Month 18 (2028-04-30) so override precedent is clear before FIH recruitment begins.
  3. The feasibility verdict at Month 24 (2028-10-31) will likely assess the 5,000-implant target as unachievable (central estimate: 1,050). The Steering Committee governance does not explicitly require that a negative verdict triggers scope reduction or programme deferral; it merely requires the verdict be 'published.' What is the binding consequence if the verdict is unfavourable? Does it halt T1 release, or does the Steering Committee merely 'publish and continue'?
  4. Patient-protection reserves of EUR 30,000 per implant are held in an independent trust starting Month 36 (2029-10-31). By what date must the trust governance documents, trustee appointment, investment policy and draw-down procedures be finalised and audited? If this is not completed by Month 12 (2027-10-31), reserve adequacy is uncertain at FIH (Month 60 = 2031-10-31), violating the hard requirement to protect implanted patients from abandonment.
  5. The Decoder version-lock and AI Act change-control process is described as 'pre-registered' but no detail is provided on which updates are 'major' (requiring notified-body review and revalidation) versus 'minor' (internal retraining only). By Month 12 (2027-10-31), publish a detailed decoder-change-control matrix categorising updates and approval authority. If notified-body review is required for many decoder changes, monthly revalidation timelines could delay bandwidth improvements; how will you manage this tension?
  6. Chronic-signal stability is a kill-gate criterion (>20% loss in animals blocks FIH; >25% in humans triggers pause). What published human BCI data validates these thresholds as clinically acceptable? The plan cites no benchmarks. If preclinical data shows 22% mean loss (just above threshold), but the error band is ±8%, will the DMC recommend proceeding or pausing? Pre-define the statistical framework (point estimate vs. confidence interval, power calculation for non-inferiority) by Month 18 (2028-04-30).
  7. The Leuven resilience assessment (commissioned Month 3 = 2027-01-31, completed Month 6 = 2027-04-30) will evaluate heatwave, drought, flooding and power risks. If the assessment shows high risk and recommends a second manufacturing or hosting site, has a fallback location been pre-negotiated? Or will you face emergency site selection at Month 6 (2027-04-30), delaying manufacturing validation by 6–12 months into T1?

Summary

This €2.5B, 15-year EU BCI programme employs a five-body governance structure (Steering Committee, PMO, independent DMC, Regulatory Committee, Sovereignty Committee, plus a Patient Trustee) designed to enforce hard requirements (patient safety, valid consent, EU control) through staged financing gates, pre-registered kill thresholds and binding external authority. The architecture prioritises risk retirement over speed and implements orderly escalation for financing shortfalls, technical failures, safety signals and partnership decline. Strengths: explicit kill-gate criteria, independent DMC pause authority, separated enhancement track, ring-fenced patient reserves, quarterly transparency reporting, and fallback routes for unfunded dependencies (foundry, Leuven partners). Key weaknesses: Steering Committee authority over kill-gate execution is incomplete (no contractual binding of investors to gate decisions); gate criteria are proposed rather than investor-endorsed; patient-protection reserve governance, while legally separate, lacks enforcement mechanisms if solvency is questioned; the feasibility verdict at Month 24 (2028-10-31) is not contractually linked to tranches T1–T4 release; and the programme assumes €2.5B total funding is achievable from investors with 20–25% IRR targets despite acknowledged 5,000-implant miss and persistent profitability gaps (€66M annual operating loss at Month 180 = 2041-10-31). Programme is executable with discipline but relies on sustained founder and investor commitment to gates that may conflict with capital preservation.

1. Financing Commitment & Cost-of-Capital Validation

Financing is the binding hard constraint: without committed tranches at each gate, the programme cannot hire staff, access facilities or conduct work. The plan assumes EUR 0 at Month 0 (2026-10-31) and EUR 2.5B hoped-for, but does not document investor personas, return terms or automatic fallback triggers. Validating commitment structures, break-even economics and reserve adequacy early (by Month 3 = 2027-01-31) is essential to prevent later crisis-mode financing negotiations that compress the schedule and compromise execution quality.

Data to Collect

Simulation Steps

Expert Validation Steps

Responsible Parties

Assumptions

SMART Validation Objective

By Month 3 (2027-01-31), secure written LOIs from at least two anchor investors specifying IRR target, payback horizon and gate conditions; publish a break-even model and sensitivity analysis; confirm foundry-funding status or trigger the dual-sourcing switch decision by Month 18 (2028-04-30). By Month 12 (2027-10-31), close T0 committed in writing (floor EUR 10M) and publish a revised cash-flow forecast with named contingencies. By Month 24 (2028-10-31), confirm or revise the commercial case (eligible population, payer acceptance, reimbursement price) as a go/no-go input to the feasibility verdict.

Notes

2. Eligible Population Epidemiology & Reimbursement Acceptance

The plan targets 5,000 implants by Month 180 (2041-10-31) but reports 1,050 central as realistic (estimate), missing the target in all scenarios. Without validated epidemiology and payer acceptance, the reimbursement case rests on speculation. Validating the eligible population and payer willingness-to-pay thresholds by Month 12 (2027-10-31) is essential to decide whether ALS-first is commercially viable or whether the indication should pivot to spinal cord injury (larger population, but harder benefit case) at the Month 24 (2028-10-31) scope gate. This data also drives recruitment timelines, centre-network design and break-even projections.

Data to Collect

Simulation Steps

Expert Validation Steps

Responsible Parties

Assumptions

SMART Validation Objective

By Month 9 (2027-07-31), commission and initiate an epidemiological analysis of ALS and spinal cord injury eligible pools across three member states. By Month 12 (2027-10-31), complete the eligible-population estimate and publish it with confidence intervals; initiate pre-reimbursement dialogues with payers. By Month 15 (2028-01-31), obtain written payer feedback on price tolerance and evidence requirements. By Month 24 (2028-10-31), publish a revised commercial case with three scenarios (ALS-only, SCI-primary, deferral) and pre-register a hard indication pivot decision rule: if eligible ALS pool <300/year and payers reject EUR 150k price, mandate scope gate at Month 24 (2028-10-31) to choose spinal cord injury or stop.

Notes

3. Chronic Signal Stability & Architecture Choice Validation

The plan proposes kill thresholds (20% animal signal loss blocks FIH, 25% human loss pauses, proposed) without citing preclinical evidence or literature support. If published thin-film data show >30% loss is normal, the gate becomes meaningless; if <10% loss is typical, the gate is too tight. FTO blocking patents could force architecture changes that require EUR 1M–EUR 10M and 6–12 months of rework. Validating both signal stability and patent clearance by Month 18 (2028-04-30) is essential to lock the architecture and begin supplier qualification; delays here cascade to pilot-line transfer, design lock and CE marking.

Data to Collect

Simulation Steps

Expert Validation Steps

Responsible Parties

Assumptions

SMART Validation Objective

Commission chronic-implant and FTO studies by Month 3 (2027-01-31) with completion by Month 9 (2027-07-31) for preliminary data and Month 18 (2028-04-30) for full interpretation. By Month 9 (2027-07-31), publish a literature-based signal-retention percentile table and propose evidence-grounded kill thresholds; obtain Data Monitoring Committee and notified-body feedback by Month 15 (2028-01-31). By Month 18 (2028-04-30), lock the architecture (primary: thin-film surface; fallback: penetrating cortical) with documented FTO clearance and chronic-stability data. By Month 24 (2028-10-31), confirm or revise the kill thresholds in the first-in-human protocol based on final chronic-animal results.

Notes

4. Informed Consent Safeguards & Ethics Governance Validation

Informed consent for locked-in and communication-impaired participants is a hard requirement and a credibility test for the programme. Weak consent protocols trigger ethics-committee objections, trial suspension and regulator scrutiny; strong protocols require advance planning, independent review and multiple validation cycles. Validating consent adequacy by Month 6 (2027-04-30) is essential to begin participant recruitment at Month 60 (2031-10-31); delays here are front-loaded and reduce the time window for early-feasibility data before the pivotal indication gate (Month 78 = 2033-04-30).

Data to Collect

Simulation Steps

Expert Validation Steps

Responsible Parties

Assumptions

SMART Validation Objective

By Month 2 (2026-12-31), develop consent protocol templates and advance-directive forms with bioethics partners. By Month 4 (2027-02-28), complete bioethics review and incorporate feedback. By Month 5 (2027-03-31), obtain written ethics-committee pre-approval from all three trial sites (Leuven, Utrecht, Grenoble). By Month 6 (2027-04-30), publish the final informed-consent protocol and yes/no validation procedure; present them to the notified body (pre-submission) and confirm acceptance. By Month 24 (2028-10-31), recruit the independent consent advocate and Data Monitoring Committee (5+ members, patient representative); pre-register kill-gate consent criteria (any invalid-consent finding pauses a site, proposed threshold).

Notes

5. Leuven Partnership Lock & Fallback Site Pre-Qualification

Leuven partnerships are the foundation of the entire programme: imec provides cleanroom access (non-negotiable for electrode prototyping), KU Leuven provides neuroengineering teams and UZ Leuven provides neurosurgery and ALS patient access. Without confirmed written commitments by Month 3 (2027-01-31), the company cannot close seed funding, hire staff with confidence or commit to timelines. Fallback sites must be pre-qualified and ready to activate within 48 hours if a primary partner declines; this requires advance outreach, capacity verification and relationship-building by Month 2 (2026-12-31).

Data to Collect

Simulation Steps

Expert Validation Steps

Responsible Parties

Assumptions

SMART Validation Objective

By Month 1 (2026-11-30), initiate partnership discussions with imec, KU Leuven and UZ Leuven; request LOIs by Month 3 (2027-01-31). By Month 2 (2026-12-31), complete site visits and pre-qualification of fallback sites (UMC Utrecht, Ghent/Antwerp, CEA-Leti/Clinatec). By Month 3.5 (2027-02-15), confirm LOI signatures or trigger fallback activation. By Month 6 (2027-04-30), complete fallback MOU signing and facility agreements if primary sites declined. By Month 12 (2027-10-31), gate G1 financing close with partnership commitments in writing.

Notes

6. Bits-per-Second Measurement Protocol & Bandwidth Validation

Bandwidth is the programme's claimed technical differentiator, yet the measurement protocol lacks independent verification infrastructure, the kill thresholds are not grounded in preclinical data, and rival scenarios are unsourced estimates. Without a locked, pre-registered, independently verified bandwidth measurement protocol by Month 18 (2028-04-30), claims will lack credibility with regulators, payers and the public. Early validation ensures that preclinical studies (Months 12–24 = 2027-10-31 to 2028-10-31) use the final protocol, so kill-gate evidence is directly comparable to later human trials.

Data to Collect

Simulation Steps

Expert Validation Steps

Responsible Parties

Assumptions

SMART Validation Objective

By Month 9 (2027-07-31), pre-register a locked bandwidth-measurement protocol with an external registry; obtain expert validation from information-theorists and signal-processing specialists. By Month 12 (2027-10-31), establish a federated-testing infrastructure and an independent verification laboratory; pilot federated testing on preclinical animal data. By Month 15 (2028-01-31), publish a competitive-intelligence report on rival bandwidth claims with pessimistic/central/optimistic scenarios. By Month 18 (2028-04-30), present preclinical bandwidth results (from animal studies) using the locked protocol, with independent verification completed. By Month 60 (2031-10-31) FIH, report early-human bandwidth results with full transparency (error rates, calibration time, participant count, separately reporting structured command vs. free-text). Update rival scenarios quarterly; re-baseline annually.

Notes

7. Patient-Protection Reserve & Continuity Covenant Governance Validation

Patient protection is a hard requirement and a differentiator from competitors; if the reserve is inadequate or the trust structure is legally weak, implanted patients face abandonment risk if the company fails. Validating reserve size and trust governance by Month 6 (2027-04-30) is essential to begin building credibility with investors (reserve commitment reduces capital available for development), payers (long-term support is a reimbursement value-add) and ethics committees (hard commitment to patient continuity). Deferring this work delays credibility and creates legal risk.

Data to Collect

Simulation Steps

Expert Validation Steps

Responsible Parties

Assumptions

SMART Validation Objective

By Month 2 (2026-12-31), draft a patient-protection trust deed with legal counsel; obtain board approval by Month 3 (2027-01-31). By Month 6 (2027-04-30), establish the trust with an independent trustee and fund the EUR 5M floor before FIH. By Month 9 (2027-07-31), obtain actuarial validation of the per-implant reserve amount (EUR 30,000 proposed estimate) and device-lifetime assumptions. By Month 12 (2027-10-31), publish the final trust governance charter and obtain ethics-committee and notified-body written acceptance. By Month 36 (2029-10-31), negotiate and escrow a step-in agreement with a successor manufacturer or hospital consortium. Conduct annual reserve-adequacy audits and update assumptions based on actual follow-up and explantation costs.

Notes

Summary

This validation plan identifies seven critical data-collection areas for a 15-year, EUR 2.5B EU neurotech BCI venture (Month 0 = 2026-10-31 to Month 180 = 2041-10-31). The plan's preliminary feasibility verdict is 'achievable only with changes': financing is not credibly committed (EUR 0 at Month 0 = 2026-10-31), the 5,000-implant target is missed in all scenarios (central estimate 1,050), and key assumptions (chronic signal stability, payer acceptance, Leuven partnership commitments) remain unvalidated. Each data-collection area targets a hard requirement or a decision gate: (1) Financing Commitment validates investor return expectations and gate enforcement by Month 12 (2027-10-31); (2) Eligible Population validates the commercial case and triggers an indication pivot gate at Month 24 (2028-10-31); (3) Chronic Signal Stability validates the architecture choice and kill thresholds by Month 18 (2028-04-30); (4) Informed Consent validates ethics-committee readiness and consent safeguards by Month 6 (2027-04-30); (5) Leuven Partnership validates resource commitments by Month 3 (2027-01-31) and triggers fallback activation if needed; (6) Bandwidth Measurement validates the technical differentiator and independent verification by Month 18 (2028-04-30); (7) Patient-Protection Reserve validates actuarial adequacy and trust governance by Month 6 (2027-04-30). Immediate actionable tasks: (A) By Month 1 (2026-11-30), name anchor investors, finalize partnership outreach, and draft term sheets with gate conditions and automatic deferral rules. (B) By Month 3 (2027-01-31), secure LOIs from Leuven partners and pre-qualify fallback sites; close seed funding (EUR 3–5M). (C) By Month 6 (2027-04-30), establish consent safeguards, the Data Monitoring Committee and the patient-protection trust; engage the notified body in pre-submission. (D) By Month 9 (2027-07-31), commission epidemiology, FTO analysis, chronic-animal studies and actuarial reserve sizing. (E) By Month 12 (2027-10-31), publish gate G1 verdict (T0 committed in writing or automatic deferral) and issue preliminary feasibility assessments on financing, population and stability. (F) By Month 18 (2028-04-30), lock the architecture and supplier MOUs; trigger foundry or dual-sourcing decision. (G) By Month 24 (2028-10-31), publish the comprehensive six-part feasibility verdict and pre-register indication pivot rules if population or payer data warrant scope change. These milestones are binding; missed gates trigger automatic 12-month deferral or programme stop, not renegotiation.

Documents to Create

Create Document 1: Project Charter and Governance Framework

ID: ba0c80d6-6fe9-4273-a8f7-f48439a51c71

Description: Foundational charter establishing the EU Neurotech BCI venture's mission, scope, hard requirements (patient safety, valid consent, EU control), strategic goals (CE marking by Month 132 = 2037-10-31, 5,000+ implants, sovereign supply chain), and governance structure including board composition, decision authority at financing gates and kill gates, stakeholder roles, and escalation procedures. Defines stop authority (DMC, board, independent trustees) and public reporting timelines for verdicts.

Responsible Role Type: Chief Executive Officer & Founder

Primary Template: PMI Project Charter Template

Secondary Template: World Bank Logical Framework

Steps to Create:

Approval Authorities: Board of directors (founders, lead investor, patient representative, independent scientist); Commission liaison for IPCEI-type support; notified body for governance transparency.

Essential Information:

Risks of Poor Quality:

Worst Case Scenario: A funding gate is missed (G1 at Month 12 = 2027-10-31, or G3 at Month 24 = 2028-10-31) because financing commitments stall on unclear decision authority, undefined investor returns, or unresolved capital-call triggers. The programme halts or is deferred for 12+ months with no published exit plan. Simultaneously, a DMC finding identifies either inadequate chronic signal stability or invalid consent in a cohort, but the recommendation to pause is disputed by management and investors who cite sunk cost. Without a binding governance framework, the dispute escalates to lawyers and regulators; the notified body pauses the trial; the ethics committee opens an investigation; and the programme is publicly discredited. Within 6 months, key talent departs (cost EUR 2M–5M in institutional knowledge lost), investors call their money back (financial crisis), and the company becomes insolvent. Implanted patients (10–20 from early cohorts) are left without follow-up support, manufacturer commitment or financial reserves; they sue, triggering criminal and civil liability for founders, a halt to all EU neural-implant funding for 3–5 years, and a permanent reputational scar on EU medtech sovereignty ambitions. Total cost: EUR 20M–50M, 5+ year delay for any successor effort, and loss of patient trust across the entire field.

Best Case Scenario: A clear governance charter with explicit decision authority, quantified kill gates and binding DMC oversight is in place by Month 3 (2027-01-31). Financing gates, kill thresholds and wind-down procedures are published and contractually binding on all parties. At Month 12 (2027-10-31), G1 is met on schedule; at Month 24 (2028-10-31), feasibility verdict is completed and published within 5 business days, clearing the path to Series A funding and pivotal-phase commitment. Early preclinical data (18-month chronic animal studies) show acceptable signal stability (15% loss, within threshold); the DMC approves advancement with confidence. Consent-advocate and ethics-committee alignment is achieved in Months 6–12 (2027-04-30 to 2027-10-31) via a harmonised protocol and pre-submission, reducing trial-start delays. By Month 18 (2028-04-30), the architecture is locked, foundry decision is made (shared foundry commitment or dual-sourcing fallback activated), and supplier MOUs are signed. The combination of clear authority, credible gates and transparent reporting attracts EUR 60M+ Series A and builds confidence with notified bodies, member states and payers. By Month 60 (2031-10-31), first-in-human proceeds with robust governance; early safety and bandwidth results are reported honestly; kill gates are revisited and updated with new data. If a US competitor enters during Months 36–60 (2029-10-31 to 2031-10-31), a pre-registered competitive-response gate allows quick decision on market focus and reimbursement strategy. Patient reserves grow predictably; no stop authority conflicts occur because criteria are pre-agreed. By Month 132 (2037-10-31), CE marking is achieved with regulator and payer buy-in. The governance framework is cited as a model for later EU deep-tech programmes, and implanted patients receive lifelong support from a solvent, trusted company.

Fallback Alternative Approaches:

Create Document 2: Financing Structure and Capital Gates Strategy

ID: 352fdd13-4e73-432d-8f96-d06059f4057f

Description: Documents the EUR 2.5B company funding envelope (committed EUR 0 at Month 0 = 2026-10-31) split across tranches T0–T4, plus EUR 350M hoped-for shared foundry. Defines three hard gates (G1 Month 12 = 2027-10-31 EUR 10–15M committed, G3 Month 24 = 2028-10-31 EUR 60M Series A plus feasibility verdict, G4 Month 36 = 2029-10-31 EUR 210M T1+T2 partial) with written fallbacks: missed gates trigger automatic 12-month deferral or programme stop. Includes investor return expectations (20–25% IRR target, 10–12 year payback), cost-of-capital assumptions, reserve funding mechanism, and term-sheet templates with gate conditions. Models break-even (1,125 implants/year, estimate) and operating gap (EUR 66M/year at Month 180 = 2041-10-31, estimate) with sensitivity analysis.

Responsible Role Type: Chief Financial Officer & Financing Gates Manager

Primary Template: Venture Capital Term Sheet Template

Secondary Template: Healthcare Project Finance Model

Steps to Create:

Approval Authorities: Board of directors; lead investor(s); member states/Commission (for IPCEI foundry decision at Month 18 = 2028-04-30).

Essential Information:

Risks of Poor Quality:

Worst Case Scenario: The company exhausts T0 (EUR 15M) within 18 months (by Month 18 = 2028-04-30) due to underestimated burn rates (e.g., EUR 1M per month instead of EUR 0.6M per month proposed), missing the G1 gate at Month 12 (2027-10-31) and facing a cash position of less than EUR 3M by Month 18 (2028-04-30). Unable to meet the G3 gate (EUR 60M Series A by Month 24 = 2028-10-31) due to failed partnership letters of intent and no investor confidence, the company defaults on supplier MOUs, loses skilled staff, and the feasibility verdict at Month 24 (2028-10-31) classifies the programme as 'not credibly achievable'. Implanted patients (estimated 10–20 by this time) face loss of device support, follow-up and potential explantation; the patient-protection reserve (estimated EUR 300k–600k if set up) is insufficient for lifelong support. Regulators and member states lose confidence in the IPCEI commitment, and the shared foundry (EUR 350M) is cancelled, triggering a cascade of European policy failures to build sovereign implantable-BCI capacity. Total loss to investors: EUR 15M + EUR 2M–5M in contingency; reputation damage to imec, KU Leuven and UZ Leuven.

Best Case Scenario: The company raises EUR 10M seed by Month 3 (2027-01-31) and EUR 5M in national grants by Month 12 (2027-10-31), meeting G1. By Month 24 (2028-10-31), architecture lock, chronic-animal data and partnership LOIs are confirmed, and a Series A raises EUR 60M at a EUR 150M post-money valuation, meeting G3. The feasibility verdict at Month 24 (2028-10-31) classifies the programme as 'achievable with mitigations', unlocking G4 funding (EUR 210M) and investor confidence. The shared foundry (EUR 350M) is committed by Month 18 (2028-04-30) with four member states, or dual-sourcing (EUR 35M) is funded within T1. By Month 180 (2041-10-31), 1,050 cumulative implants are achieved (miss of the 5,000 target, but a sustainable clinical programme), with 550 active users generating EUR 45M annual revenue. Patient-protection reserves grow to EUR 31.5M (1,050 implants × EUR 30,000) and secure lifelong support. CE marking is achieved by Month 132 (2037-10-31), and the company achieves profitability by Year 18 (Month 192 = 2042-10-31) with an IRR to investors of 18–22% over a 12-year holding period, enabling later-stage human-AI enhancement research under the separate legal entity.

Fallback Alternative Approaches:

Create Document 3: Regulatory Pathway and Evidence Strategy under MDR and AI Act

ID: a476f640-38b7-4034-ba74-35a3478100ad

Description: Specifies Class III conformity assessment sequence, notified-body engagement from Month 6 (2027-04-30), ISO 13485 QMS build by Month 9 (2027-07-31), Commission scientific advice request by Month 12 (2027-10-31), preliminary QMS audit by Month 18 (2028-04-30), and architecture lock by Month 18 (2028-04-30) before design freeze (design lock Month 18–24 = 2028-04-30 to 2028-10-31). Coordinates multinational first-in-human investigations (Leuven, Utrecht, Grenoble) to build pivotal dossier incrementally. Decoder defined as high-risk under AI Act; requires documentation of training-data provenance, model validation, human oversight and bias testing (budget EUR 2M estimate). Decoder Version 1.0 (Pivotal Lock) locked by Month 18 (2028-04-30) with pre-registered change-control process: minor retraining within locked feature set does not require notified-body review; major changes (new features, architecture swap, external-model integration) require notified-body scientific review. No evidence requirements are reduced for Class III or AI Act; schedule gains come from sequencing and early alignment, not lighter proof. Quarterly regulatory milestone reviews by Month 12–132 (2027-10-31 to 2037-10-31); no design changes after architecture lock without notified-body review.

Responsible Role Type: Chief Regulatory Affairs Officer

Primary Template: MDR Conformity Assessment Plan Template

Secondary Template: EU AI Act High-Risk Medical Device Compliance Roadmap

Steps to Create:

Approval Authorities: Notified body (pre-submission feedback, preliminary QMS audit, scientific-advice coordination); Commission (scientific-advice request routing); European Medicines Agency (if AI-related questions); national ethics committees (coordinated multinational investigation approval).

Essential Information:

Risks of Poor Quality:

Worst Case Scenario: The regulatory pathway is deferred or substantially weakened because early engagement (Months 6–12 = 2027-04-30 to 2027-10-31) is missed or produces unclear feedback. A notified body at Month 18 (2028-04-30) (notified-body preliminary audit) identifies fundamental QMS gaps, decoder AI Act non-compliance or design-history deficiencies, requiring 6–12 months of remedial work. Simultaneously, the Commission scientific-advice response (if obtained at all) arrives late with additional clinical-investigation requirements, and ethics committees in coordinated member states raise consent or data-governance objections. The combined effect: architecture lock slips to Month 24–30 (2028-10-31 to 2029-04-30), design freeze is delayed, chronic animal studies cannot start on schedule, and first-in-human slips from Month 60 (2031-10-31) to Month 72–84 (2031-10-31 to 2033-10-31). The pivotal trial dossier must be rebuilt with later data, extending CE marking from Month 132 (2037-10-31) to Month 156+ (2037-10-31 to 2039-10-31 or beyond). Financial impact: EUR 2M–5M in unplanned regulatory and compliance work, plus delayed revenue and extended financing burden. Credibility impact: investors lose confidence in execution discipline; the programme becomes high-risk for later tranches (T3, T4), making further capital-raising difficult and potentially stopping the programme at Month 60–84 (2031-10-31 to 2033-10-31) if CE marking is no longer credible.

Best Case Scenario: Early, focused notified-body engagement (Month 6 = 2027-04-30) yields clear written feedback on preclinical scope, clinical-investigation design, QMS requirements and AI Act decoder documentation by Month 7 (2027-05-31). ISO 13485 QMS is built to notified-body expectations and passes preliminary audit by Month 18 (2028-04-30) with minor corrective actions. Commission scientific advice (requested Month 12 = 2027-10-31) returns by Month 18 (2028-04-30) with affirmative guidance on the multinational first-in-human design and AI Act scope. Ethics committees across Leuven, Utrecht and a third member state harmonise consent protocols and approve the trial by Month 30 (2029-04-30). The decoder is version-locked with change-control thresholds pre-agreed with the notified body, allowing post-approval bandwidth improvements without triggering full re-validation. Design-history file is maintained compliantly throughout, and quarterly milestone reviews show steady progress. Result: architecture lock holds at Month 18 (2028-04-30), design freeze at Month 24 (2028-10-31), first-in-human at Month 60 (2031-10-31), and CE marking proceeds on the central-case schedule (Month 132 = 2037-10-31) with notified-body audit cycles integrated into the clinical trial timeline, not competing with it. The programme gains 6–12 months of schedule margin, reduces regulatory rework to <EUR 500k, and maintains investor confidence for later tranches. The regulatory pathway becomes a strength, demonstrating discipline to payers and member states and supporting reimbursement dialogue.

Fallback Alternative Approaches:

Create Document 4: Architecture Choice and Freedom-to-Operate Strategy

ID: b271e1a8-4544-44bb-92ae-acc5c1d3c47e

Description: Selects primary architecture (thin-film surface epidural/subdural cortical implant with wireless external processor, provisional) and documents fallback (penetrating cortical microelectrode, contingency EUR 30M range 15–60M estimate, 12–24 months delay estimate). Architecture choice deferred to Month 18 (2028-04-30) pending completion of freedom-to-operate (FTO) analysis, chronic-stability animal studies (14–24 months, 50% completion by Month 12 = 2027-10-31), surgical-risk assessment, manufacturing-readiness evaluation and bandwidth-potential modelling. FTO analysis for each candidate covers electrode patents (Neuralink, Synchron, universities), encapsulation IP, decoding algorithms and surgical-robotics patents; identifies blocking claims and design-around costs. All licence targets screened against three EU-control tests (ownership, maintainability without foreign consent, export-control freedom) before option pricing. Architecture ratification at Month 18 (2028-04-30) scores candidates on patent clearance (20% weight), surgical risk (20%), stability (20%), bandwidth (20%), manufacturability (10%), scalability (10%); highest-scoring candidate is primary, second-ranked becomes fallback. If primary architecture fails stability kill gate (>30% signal loss by Month 72 = 2032-10-31, proposed threshold), secondary fallback evaluated at Month 78 (2033-04-30) with switch decision by Month 84 (2033-10-31); switch costs EUR 30M and 12–24 months, compressing CE marking to Month 144–156 (2038-10-31 to 2039-10-31) (estimate).

Responsible Role Type: Chief Technology Officer & Neural Interface Engineer

Primary Template: Design Control and Architecture Selection Scorecard

Secondary Template: Freedom-to-Operate Patent Analysis Framework

Steps to Create:

Approval Authorities: CTO and technical board (architecture ratification); board of directors (approval of contingency cost and timeline); notified body (acceptance of architecture and pre-registered fallback mechanism).

Essential Information:

Risks of Poor Quality:

Worst Case Scenario: The FTO analysis identifies blocking patents for the primary architecture (thin-film surface) that are expensive to challenge or design around, and preclinical chronic-stability data shows signal loss exceeding 30% by Month 24 (2028-10-31), simultaneously eliminating the first and second technology choices. The programme must activate the contingency penetrating-cortical fallback at Month 30 (2029-04-30), costing the upper-bound EUR 60M and incurring a 24-month delay. Chronic animal studies must restart, regulatory engagement must reset, and CE marking slips from Month 132 (2037-10-31) to Month 156 (2039-10-31). The programme consumes EUR 180M of T1 and T2 funding (versus EUR 600M planned through Month 84 = 2033-10-31) on preclinical and feasibility work, deferring the pivotal trial by two years and exhausting early investor patience. The financial model becomes unrecoverable: break-even requires 1,125 implants per year, but the revised timeline reaches only 800–900 implants per year by Month 180 (2041-10-31), turning a marginal programme into a clear loss. Investor returns collapse, Series B close becomes impossible, and the programme halts at the feasibility verdict.

Best Case Scenario: The FTO analysis completes on schedule by Month 9 (2027-07-31) and confirms that the thin-film surface architecture has clear patent freedom and low licensing cost (EUR 1M–€3M). Chronic animal studies reach completion by Month 18 (2028-04-30) with signal retention >80% at 12 months and >70% at 24 months, supporting advancement to first-in-human. Surgical-risk and manufacturing-readiness assessments confirm that the architecture is operationally feasible, scalable and compatible with Class III production processes. The architecture is ratified at Month 18 (2028-04-30) with no design-loop rework. The pre-registered fallback is set aside but remains on file; contingency EUR 30M stays in the T3 reserve. Supplier engagement and manufacturing-transfer planning proceed on schedule. Design lock is achieved by Month 30 (2029-04-30) with all materials and processes locked. Notified-body engagement and pilot-to-production transfer run in parallel through Months 24–48 (2028-10-31 to 2030-10-31). First-in-human occurs on schedule at Month 60 (2031-10-31) with sustained bandwidth ≥10 bits/s in all participants, supporting immediate scalability to pivotal-trial preparation. The feasibility verdict at Month 24 (2028-10-31) is unambiguously positive on technical grounds, unlocking Series A capital and member-state IPCEI commitments. CE marking proceeds without architecture surprises and reaches Month 132 (2037-10-31) (central target). The programme reaches about 1,050 implants by Month 180 (2041-10-31), below the 5,000 target but operationally stable and profitable at 800 implants per year.

Fallback Alternative Approaches:

Create Document 5: Minimum Viable Programme (MVP) Scope and Budget (Months 0–24 = 2026-10-31 to 2028-10-31)

ID: 4643d3c0-d326-4daf-b37f-3bf554e1482d

Description: Detailed specification of the MVP: what work is done in the first two years to retire core feasibility risks before Series A capital (T1, EUR 120M) is committed at Month 24 (2028-10-31). MVP scope covers: (1) Founding team assembly and onboarding (10 core staff by Month 6 = 2027-04-30, 15 by Month 24 = 2028-10-31); (2) Leuven partnerships secured (LOIs from imec, KU Leuven, UZ Leuven by Month 3 = 2027-01-31 or fallback sites activated); (3) Freedom-to-operate review for three architectures completed by Month 9 (2027-07-31); (4) Chronic animal studies 50% complete by Month 12 (2027-10-31), full completion by Month 24 (2028-10-31); (5) Architecture ratified at Month 18 (2028-04-30); (6) ISO 13485 QMS and design-history file operational by Month 9 (2027-07-31); (7) Notified-body pre-submission and Commission scientific-advice request by Month 12 (2027-10-31); (8) Supplier MOUs and dual-sourcing qualification plan by Month 12 (2027-10-31); (9) Eligible-population epidemiology and payer pre-engagement dialogue by Month 12–15 (2027-10-31 to 2028-01-31); (10) DMC and consent-advocate charter, kill gates pre-registered by Month 6 (2027-04-30); (11) Patient-protection trust established by Month 6 (2027-04-30); (12) Feasibility verdict (six-part) published by Month 24 (2028-10-31). Budget: T0 EUR 15M split into seed EUR 5M (by Month 3 = 2027-01-31) and remaining EUR 10M committed by Month 12 (2027-10-31). Monthly burn ~EUR 0.6M (estimate), with contingency. Not-in-scope (deferred to T1): full first-in-human protocol development, multi-centre site setup, pivotal-trial preparation, full manufacturing transfer, regulatory dossier assembly.

Responsible Role Type: Chief Financial Officer & Financing Gates Manager

Primary Template: Agile Project Sprint Planning Template

Secondary Template: MVP Definition and Scope Template

Steps to Create:

Approval Authorities: Board of directors; lead seed investors; Commission liaison (for partnership coordination).

Essential Information:

Risks of Poor Quality:

Worst Case Scenario: If the MVP scope and budget document is not created with sufficient clarity and rigour, the programme faces the following severe consequences: (1) No credible feasibility verdict is available by Month 24 (2028-10-31), forcing T1 (EUR 120M) financing to be deferred indefinitely; without T1, the full industrial programme cannot proceed, and the company either shuts down (stranding the EUR 15M T0 investment) or limps forward on bridge financing at 15–20% interest rates, adding EUR 18M–24M in non-productive debt by Month 36 (2029-10-31). (2) Architecture is not locked by Month 18 (2028-04-30) or design lock is missed at Month 24–30 (2028-10-31 to 2029-04-30), preventing supplier qualification from completing on schedule; pushing supplier qualification past Month 30 (2029-04-30) makes the Month 72 (2032-10-31) lock deadline impossible, which delays design freeze, manufacturing transfer and regulatory submission, pushing CE marking from the central estimate of Month 132 (2037-10-31) to Month 144–156 (2038-10-31 to 2039-10-31) or later, reducing the investor runway and extending the financing burden by 12–24 months (cost EUR 60M–120M at burn rates of EUR 5M–10M per month). (3) Chronic signal-stability results from animal studies are not available by Month 24 (2028-10-31), forcing the programme to proceed to first-in-human (Month 60 = 2031-10-31) without preclinical validation of a critical kill criterion; early-human signal degradation worse than the 20% animal benchmark (observed as 25–30% loss in Month 12–24 = 2027-10-31 to 2028-10-31 post-implant) triggers an unplanned design review or halt, which consumes 6–12 months and EUR 2M–5M in rework, sets back CE marking by 12–24 months and damages investor confidence for T2 and T3 closures. (4) Patient-protection trust is not established or lacks clear governance by Month 6 (2027-04-30), leaving reserve adequacy undefined; when the first patient is implanted (Month 84 = 2033-10-31 estimated), disputes over reserve funding trigger investor litigation and regulatory scrutiny, potentially suspending the programme until reserves are funded; by that time, the company may have insufficient capital to fund both operations and reserves, forcing a choice between clinical abandonment of implanted patients and insolvency of the company. (5) Notified-body feedback is not available by Month 18–24 (2028-04-30 to 2028-10-31) because engagement was deferred past Month 6 (2027-04-30) or the scientific-advice request was not submitted by Month 12 (2027-10-31); the preliminary QMS audit is missed, and major compliance gaps are discovered at the formal conformity-assessment phase (Month 36+), forcing rework of design files, risk management and biocompatibility testing, which adds 6–12 months and EUR 1M–3M in unbudgeted costs, delaying CE marking to Month 144–156 (2038-10-31 to 2039-10-31) or beyond. (6) Financing gates are missed: if T0 (EUR 15M) is not fully committed by Month 12 (2027-10-31), the team size stays at 5–7 people instead of the planned 10 by Month 6 (2027-04-30), which means FTO analysis cannot be completed by Month 9 (2027-07-31), architecture lock is deferred to Month 24+, and chronic animal studies are underfunded or incomplete. If T1 (EUR 120M) is not at least partially committed by Month 24 (2028-10-31), design lock and supplier qualification are deferred by 6–12 months, pushing first-in-human to Month 66–72 (2032-04-30 to 2032-10-31) at the earliest, and the programme likely halts due to running out of capital mid-phase. (7) The 5,000-implant target is exposed as unrealistic (true eligible pool 500–1,400 per year = 1,000–2,500 cumulative by Month 180 = 2041-10-31), but this discovery is deferred until Month 24–36 (2028-10-31 to 2029-10-31) because epidemiology was not done during the MVP; investors make T1 and T2 commitments (EUR 600M+) on the basis of the 5,000 target, then demand capital repayment when the target is abandoned, straining cash reserves and threatening solvency. (8) Public and regulatory trust is damaged if enhancement research is not firewalled from the medical programme during the MVP; communication of human-AI merging ambitions alongside Class III medical-device work raises ethics-committee and regulator concerns over intended use, delaying ethics approvals by 3–6 months, damaging patient recruitment, and triggering public-health authority objections to multinational trial coordination.

Best Case Scenario: If the MVP scope and budget are well-executed, the programme achieves the following positive outcomes by Month 24 (2028-10-31): (1) A comprehensive feasibility verdict—separating scientific, engineering, clinical, regulatory, supply-chain and financing dimensions—is published within 5 business days of Month 24 (2028-10-31), giving investors clear guidance on whether to commit T1 (EUR 120M) and under what conditions; a positive verdict with named risks and mitigation plans enables T1 close within 30–60 days, funding design lock and supplier qualification without delay. (2) Architecture is ratified by Month 18 (2028-04-30) on the basis of robust FTO analysis, chronic animal data (50% complete) and regulatory pre-guidance; the thin-film surface primary architecture is confirmed, and a penetrating cortical fallback with known cost (EUR 30M, 12–24 months) is documented, giving the team and investors confidence in the route forward and allowing supplier engagement to proceed with defined specifications. (3) Chronic animal signal-stability studies yield results by Month 24 (2028-10-31) showing central-case estimates of 15–18% signal loss within 12 months (below the 20% kill threshold), supporting first-in-human progression with documented risk and a defined stability-monitoring plan; this data also anchors the device-lifetime warranty (5–7 years, central case) and informs reserve adequacy modelling. (4) Regulatory engagement by Month 6 (2027-04-30) and scientific-advice request by Month 12 (2027-10-31) yield preliminary notified-body feedback by Month 18 (2028-04-30) and Commission guidance by Month 18–24 (2028-04-30 to 2028-10-31); preliminary QMS audit is completed by Month 18 (2028-04-30), surfacing compliance gaps while there is time to fix them (Months 18–24 = 2028-04-30 to 2028-10-31), avoiding rework during the formal conformity assessment. (5) Patient-protection trust is fully established by Month 6 (2027-04-30) with an independent trustee, per-implant allocation formula (EUR 30,000 per implant), clear draw-down triggers and annual adequacy audits; investors see this as a credible, legally binding patient safeguard, which improves institutional and public confidence. (6) Leuven partnerships are confirmed by letters of intent from imec, KU Leuven and UZ Leuven by Month 3 (2027-01-31), allowing the team to access cleanrooms, neurosurgical theatres and animal facilities without delay; fallback sites (Utrecht, Grenoble) are identified and pre-qualified by Month 6 (2027-04-30), reducing site-activation risk from 3–6 months to 1–2 months if a primary partner declines later. (7) Supplier MOUs are signed by Month 12 (2027-10-31) with two chip and two substrate suppliers, locking design specifications and qualification timelines; dual-sourcing qualification is on track to complete the second supplier by Month 30 (2029-04-30), meeting the design-lock deadline and eliminating single-source supply risk through the pivotal trial. (8) Eligible-population epidemiology by Month 6 (2027-04-30) and payer pre-engagement by Months 12–15 (2027-10-31 to 2028-01-31) confirm that the realistic ALS-communication eligible pool is 1,000–1,400 per year, pointing to 1,050 cumulative implants by Month 180 (2041-10-31) (not 5,000); this honest assessment by Month 24 (2028-10-31) allows the feasibility verdict to flag the population shortfall and propose mitigation (combined ALS-plus-SCI indication, or acceptance of a smaller market). (9) Kill gates are pre-registered by Month 6 (2027-04-30) with quantitative thresholds (safety >10% serious adverse events in first 20 implants, stability >20% signal loss, bandwidth <5 bits/s in 50%+) and disclosed to investors, the board and the DMC; ambiguity-free thresholds enable objective gate decisions at Months 18, 24 and 36 (2028-04-30, 2028-10-31, 2029-10-31), preventing sunk-cost rationalisation and building investor confidence that the programme will stop if risks outweigh benefits. (10) The independent DMC is chartered and the first consent advocate is hired by Month 6 (2027-04-30), with binding pause authority documented and investor tranches contractually tied to DMC findings; this governance structure signals serious patient protection and builds ethical credibility with regulators and the public.

Fallback Alternative Approaches:

Documents to Find

Find Document 1: EU Annual ALS Incidence and Eligible-Population Statistics

ID: 646f4901-bbe9-44d5-af21-6f4319b9d3f1

Description: Official epidemiological data on amyotrophic lateral sclerosis (ALS) incidence, prevalence, age at onset, disease progression rates and life expectancy in the EU/EEA, sourced from national disease registries, health ministries or international ALS Federation databases. Used to validate the eligible pool for communication-restoration indication: what fraction of annual ALS cases progress to locked-in or severe speech loss, and at what average age and expected survival horizon. Supports the health-economic model and centre-capacity forecasting.

Recency Requirement: Most recent available year (2023–2025 preferred, 2020–2022 acceptable); trends over 5 years if available.

Responsible Role Type: Clinical Trials & Patient Safety Manager

Steps to Find:

Access Difficulty: Medium. Most EU countries maintain disease registries or epidemiology surveillance systems, but access may require formal data-request agreements with national ministries or ethics-committee approval. ALS is less systematically tracked than cancer, so completeness varies by country. International registries (ENCALS, WHO) may provide aggregated or publicly available estimates. Budget 2–3 months for formal requests to complete.

Essential Information:

Risks of Poor Quality:

Worst Case Scenario: The ALS incidence and eligible-pool statistics reveal that EU annual incidence is 25-30% lower than planning assumptions (e.g., 3,500 cases/year instead of 5,000), and only 10-12% of new diagnoses progress to locked-in or communication-loss severity justifying surgery within 24 months. Competing eye-tracking and speech-synthesis technologies achieve 60-70% uptake in the eligible cohort by Month 84 (2033-10-31), further shrinking addressable population. Recruitment-capacity assessment shows that the planned implanting-centre network can deliver only 150-200 implants per year instead of the projected 300, pushing the cumulative-implant total to 600-800 by Month 180 (2041-10-31). By Month 120 (2036-10-31), when the programme is 85% through its 15-year horizon and T3 capital (EUR 900M) is deployed, the operating model collapses: annual revenue (150-200 × EUR 150k = EUR 22.5M-EUR 30M) falls far short of opex (EUR 111M/year), triggering an unplanned capital crisis, forced restructuring, and either a merger with a larger player or orderly wind-down of the commercial programme by Month 150-160 (2038-10-31 to 2039-10-31).

Best Case Scenario: The epidemiological data confirm EU ALS incidence at 5,000-7,000 cases annually, with 12-15% progressing to communication-loss severity within 24 months (600-1,050 eligible patients/year). Competing treatments remain fragmented and achieve <40% market penetration, preserving a 60% addressable pool. The implanting-centre network ramps to 25-30 centres across member states by Month 168 (2040-10-31), delivering 250-350 implants per year. By Month 180 (2041-10-31), cumulative implants reach 1,200-1,500 and active users exceed 700, approaching sustainability at current cost structure. The data also reveal high patient preference for the communication-restoration indication over motor-control alternatives (Months 78-84 = 2033-04-30 to 2033-10-31), enabling a confident pivotal-indication decision and payer engagement at Month 78 (2033-04-30) without redirection. Published recruitment-capacity maps per member state allow efficient site activation and budget allocation, reducing central-site dependencies and resilience risk.

Fallback Alternative Approaches:

Find Document 2: Published Chronic Signal-Retention and Electrode-Stability Data (Preclinical and Clinical)

ID: 56c4aa89-6209-4bb1-b2b7-ea9f3b87cfe1

Description: Peer-reviewed and unpublished data on electrode signal retention, impedance rise and unit-count decay over 6–36 months for thin-film surface (epidural/subdural) and penetrating cortical microelectrode arrays in animals (rodent, non-human primate) and humans. Sources: academic publications (Clinatec WIMAGINE, UMC Utrecht ALS implants, University of Melbourne, Johns Hopkins, MIT), publicly available FDA submissions and clinical-trial registries, and unpublished data from research groups in the EU. Used to evidence-ground the kill-gate thresholds for signal stability (currently proposed: >20% animal loss blocks FIH, >25% human loss triggers pause) and to assess the feasibility of the primary architecture (thin-film surface) vs. the fallback (penetrating cortical).

Recency Requirement: All available data, including historical cohorts (2010–present) with ≥6 month follow-up; newer studies (2020–2025) preferred for relevance to current materials and design.

Responsible Role Type: Chief Technology Officer & Neural Interface Engineer

Steps to Find:

Access Difficulty: Medium to Hard. Published data is accessible via PubMed, but most preclinical studies report only mean and SD, not full distributions (10th, 50th, 90th percentiles) needed for threshold-setting. Unpublished preclinical data (company IP) is proprietary. Contact with research groups and formal data-request agreements (including publication timelines) may take 3–6 months. FDA submissions may require FOIA requests and exemptions for proprietary information.

Essential Information:

Risks of Poor Quality:

Worst Case Scenario: The programme runs out of money at Month 24-36 (2028-10-31 to 2029-10-31) because investors hold funding pending clarity on return expectations and eligible-population size, both unresolved. The company makes a feasibility-verdict decision (Month 24 = 2028-10-31) without credible revenue projections or risk-retirement evidence, prompting investor exit and a financing-gate failure (G3). No fallback funding mechanism exists because reserve-governance and cost-of-capital assumptions were never quantified, leaving the company unable to wind down gracefully or switch to a narrower scope. Implanted patients (if any FIH cohort exists by then) are abandoned with inadequate reserves and no continuation plan, triggering regulatory investigation, loss of public trust, and reputational damage to EU medtech sovereignty programmes. The EUR 2.5B envelope is wasted on partial prototype and regulatory work with no CE marking achieved.

Best Case Scenario: Investor return expectations and cost-of-capital assumptions are quantified early (Month 3 = 2027-01-31), confirming EUR 2.5B is sufficient to reach 1,500-2,000 implants by Month 180 (2041-10-31) at 20-25% nominal IRR. Epidemiology work (Month 6 = 2027-04-30) refines the ALS-eligible pool to 1,200-1,500 annually, validating a realistic cumulative-implant ramp and supporting payer pre-dialogues. Quantified reimbursement thresholds (EUR 120k per QALY, EUR 150k per implant price) align payer and company expectations by Month 15 (2028-01-31), securing binding letters of intent from 6+ member states. Published and unpublished chronic-stability data confirm that thin-film surface architecture is viable with >50% 5-year retention, validating the primary design and enabling uninterrupted progress through architecture lock (Month 18 = 2028-04-30) and design lock (Month 24-30 = 2028-10-31 to 2029-04-30). Reserve governance is operationalised with a professional trustee and actuarial audit, protecting implanted patients and freeing development capital from reserve-adequacy disputes. Financing gates are met on schedule (G1 Month 12 = 2027-10-31, G3 Month 24 = 2028-10-31, G4 Month 36 = 2029-10-31) and first-in-human proceeds at Month 60 (2031-10-31) with bandwidth and safety data supporting CE marking by Month 132 (2037-10-31) and 1,200+ implanted patients by Month 180 (2041-10-31), demonstrating EU sovereignty, patient benefit and sustainable reimbursement economics.

Fallback Alternative Approaches:

Find Document 3: Existing EU Freedom-to-Operate Analysis and Patent Landscape for Neural-Implant Electrodes and Decoders

ID: cfff78dc-c99b-4601-b17b-c6d53560b2bf

Description: Comprehensive patent landscape covering electrode design, implant encapsulation, decoding algorithms and surgical-robotics IP held by Neuralink, Synchron, other international competitors, and EU universities (imec, CEA-Leti, University of Tübingen, etc.). Identifies blocking patents, non-practicing entity (NPE) patent portfolios and license-stacking risks. If previous FTO analyses exist (e.g., from imec, Clinatec or other EU spin-outs), these are valuable baselines to avoid duplication and cost. Used to score architecture candidates (thin-film surface, penetrating cortical, endovascular) on patent clearance and to identify acquisition or licensing targets.

Recency Requirement: Most recent patent searches (2023–2025 preferred); any existing FTO analyses completed within 3 years acceptable; focus on issued patents and published applications current as of Month 12 (2027-10-31).

Responsible Role Type: Chief Technology Officer & Neural Interface Engineer

Steps to Find:

Access Difficulty: Easy to Medium. Patent databases are public and searchable online, but comprehensive analysis requires expert search strategy and claim interpretation. If previous EU FTO analyses exist, they are valuable and may be obtained through partnership discussions. Formal FTO analyses by patent counsel cost EUR 30k–100k and take 2–4 months; use existing analyses if available.

Essential Information:

Risks of Poor Quality:

Worst Case Scenario: A comprehensive FTO analysis reveals that the primary architecture (thin-film surface) is blocked or seriously encumbered by 3–5 undesigned-around patents held by Neuralink, Synchron and/or Japanese or Chinese electrode manufacturers, with licensing costs of EUR 5M–EUR 15M and restrictive terms (product-sale royalties of 5–10%, data-ownership claims, territorial exclusions). Simultaneously, the fallback architecture (penetrating cortical) is also partially blocked by university or NPE patents with unclear ownership and high licensing friction. The company is forced to pursue expensive and slow invalidity challenges or design-arounds, consuming EUR 2M–EUR 5M and delaying architecture lock to Month 24–30 (2028-10-31 to 2029-04-30). The delayed architecture decision compresses the preclinical and supplier-qualification phases, pushing first-in-human to Month 66–72 (2031-07-31 to 2032-10-31) instead of Month 60 (2031-10-31), and CE marking to Month 144+ (2038-10-31+). Investor confidence erodes due to hidden IP risk, Series A close slips by 6 months, and the financing gate G3 at Month 24 (2028-10-31) is missed. The programme is deferred or terminates.

Best Case Scenario: A rapid, targeted FTO analysis (leveraging existing EU institutional reports and patent-pool data) confirms that both the primary (thin-film surface) and fallback (penetrating cortical) architectures have a clear or low-cost clear path forward. Key EU university patents (imec, CEA-Leti) are available under reasonable non-exclusive or exclusive field-limited licenses without significant upfront fees (or with modest options to acquire at future milestones). Foreign electrode and decoding patents held by competitors (Neuralink, Synchron) are either non-blocking (different claim scope or near end-of-life) or licensed at acceptable rates (EUR 0.5M–EUR 2M total or lower percentage royalties). The upstream-tool exceptions are fully documented in the register, with no surprises. Architecture lock proceeds on schedule at Month 18 (2028-04-30), design lock at Month 24 (2028-10-31), and supplier qualification accelerates. Financing gate G3 at Month 24 (2028-10-31) closes on schedule. First-in-human proceeds to Month 60 (2031-10-31) target. The programme benefits from lower IP cost, faster decision cycles and higher credibility with investors and regulators, reducing the risk of CE-marking delay.

Fallback Alternative Approaches:

Find Document 4: Existing EU Medical-Device Notified-Body Lists and Pre-Submission Experience

ID: 156367c8-922f-4500-b7c4-3fb1e7a78f71

Description: Official EMA and national competent-authority lists of notified bodies qualified to perform Class III conformity assessment for implantable medical devices, along with any published guidance on pre-submission meeting procedures, evidence expectations and typical review timelines. Also includes any reported experience from EU companies (academic spin-outs, device manufacturers) on which notified bodies are responsive, well-resourced and quick to review neural implants (if any precedent). Used to select a notified body, prepare pre-submission materials and estimate regulatory timeline to CE marking.

Recency Requirement: Current notified-body lists (updated continuously; obtain latest version 1 month before Month 6 = 2027-04-30 engagement); any pre-submission experience reports from 2020–present.

Responsible Role Type: Chief Regulatory Affairs Officer

Steps to Find:

Access Difficulty: Easy. NANDO is public and updated regularly. Published guidance and experience reports are available, though sparse for neural implants specifically. Direct contact with EU research groups may yield valuable unpublished experience.

Essential Information:

Risks of Poor Quality:

Worst Case Scenario: A notified body is selected in Month 6 (2027-04-30) without documented capacity in neural implants or AI Act high-risk oversight. Pre-submission meetings in Months 9–12 (2027-07-31 to 2027-10-31) reveal the notified body requires substantially more preclinical data (e.g., 24-month chronic animal studies instead of 18 months) and has not reviewed decoders under the AI Act. The dossier is rejected at initial receipt (Month 18 = 2028-04-30 preliminary audit) due to incomplete AI documentation. A second notified body is engaged at Month 21 (2028-07-31), requiring a complete rework of the dossier and fresh pre-submission meetings. CE marking slips from Month 132 (2037-10-31) to Month 156 (2039-10-31) (central case), a 24-month delay. Additional rework and re-auditing costs: €2M–€3M. The company misses key financing gates at Months 36 and 48 (2029-10-31 and 2030-10-31) due to lack of regulatory progress, triggering capital shortfalls and a programme pause in Months 36–60 (2029-10-31 to 2031-10-31).

Best Case Scenario: A current, comprehensive notified-body list and pre-submission guidance document is obtained by Month 3 (2027-01-31). Three to five candidates with documented neural-implant or similar high-risk device experience are identified; informal feedback from imec and CEA-Leti contacts confirms two as responsive and technically sound. The selected notified body is engaged in Month 6 (2027-04-30) with a pre-submission package aligned to its published expectations. Preliminary QMS audit at Month 18 (2028-04-30) identifies no major gaps. Pre-submission scientific-advice coordination with the Commission proceeds in parallel (Months 9–15 = 2027-07-31 to 2028-01-31). AI Act high-risk classification is confirmed without surprises. The regulatory pathway remains on schedule, with CE marking achieved at Month 132 (2037-10-31) or better. Investor confidence in regulatory feasibility supports timely Series A (T1) close at Month 24 (2028-10-31) and pivotal-phase funding (T2) at Month 48 (2030-10-31). No notified-body switching occurs; rework is minimal.

Fallback Alternative Approaches:

Find Document 5: Current EU IPCEI Funding Mechanisms and Member-State Commitment Timelines

ID: 4f13c67a-64d3-4135-a3b1-8ba417a11acb

Description: Documentation of the Important Projects of Common European Interest (IPCEI) funding framework, including active or planned calls for 2026–2028, application timelines, funding amounts per project, and evidence requirements (e.g., member-state co-funding pledges, industrial partnership commitments). Specifically, any information on IPCEI-type support for healthcare, biotech or semiconductor manufacturing in the EU. Used to evaluate the feasibility of shared foundry funding (hoped-for EUR 350M from 4+ member states) and to set the Month 18 (2028-04-30) gate for foundry commitment.

Recency Requirement: Current information as of Month 0 (2026-10-31); any published IPCEI calls or roadmaps for 2026–2028 available; historical IPCEI awards (2019–2025) as reference for funding amounts and timelines.

Responsible Role Type: Chief Financial Officer & Financing Gates Manager

Steps to Find:

Access Difficulty: Medium. IPCEI information is public, but application timelines and member-state commitment processes are opaque. Commission staff can provide guidance, but timelines are uncertain. IPCEI calls are competitive; no guarantee of funding for this programme.

Essential Information:

Risks of Poor Quality:

Worst Case Scenario: No viable IPCEI funding mechanism exists for a shared European neural-implant foundry by Month 18 (2028-04-30), and the programme discovers this only after the Month 12 (2027-10-31) Gate G1 closes. Consequently, the Month 18 (2028-04-30) foundry gate fails automatically. The dual-sourcing fallback activates, adding EUR 35M in unexpected capex (EUR 10M in T1, EUR 25M in T2), compressing other budgets and delaying manufacturing qualification by 6–12 months. This pushes first-in-human from Month 60 (2031-10-31) to Month 66–72 (2032-04-30 to 2032-10-31), delays design lock from Month 24–30 (2028-10-31 to 2029-04-30) to Month 30–36 (2029-04-30 to 2029-10-31), and increases financial stress at the Month 24 (2028-10-31) Gate G3 feasibility verdict. If the foundry fallback costs exceed EUR 40M or extend beyond 18 months, the entire financing and schedule collapse, triggering a programme pause or stop at Month 24 (2028-10-31) until new funding is secured.

Best Case Scenario: Clear, current IPCEI guidance shows that healthcare and semiconductor-manufacturing are active Commission priorities for 2026–2027, with four or more member states (e.g., Belgium, Netherlands, Germany, France) signalling strong interest in a shared neural-implant foundry aligned with EU technological sovereignty goals. An approved IPCEI roadmap specifies application windows at Months 6–12 (2027-04-30 to 2027-10-31) and a commitment decision by Month 18 (2028-04-30), with first tranches disbursing by Month 24 (2028-10-31). Member-state co-funding commitments (estimated 30–50% of EUR 350M foundry cost) are conditional on demonstrated industrial partnership (e.g., MOU with the company and a lead foundry operator) and supply-chain viability milestones achieved by Month 24 (2028-10-31). This clarity eliminates the Month 18 (2028-04-30) gate uncertainty, stabilises financing at Gate G3 (Month 24 = 2028-10-31), and allows the programme to lock in the shared-foundry route with confidence, avoiding the EUR 35M dual-sourcing fallback, preserving schedule and enabling CE marking by Month 132 (2037-10-31) central case.

Fallback Alternative Approaches:

Find Document 6: Published and Unpublished Data on Reimbursement Acceptance and Pricing for Brain-Computer Interfaces in EU Member States

ID: 91d685af-57d7-4b66-89e7-51d009915f9a

Description: Health-technology assessment reports, HTA body guidance, and any published or unpublished payer-feedback from EU member-state health systems (Germany, France, Netherlands, Belgium, etc.) on willingness to reimburse BCIs for communication or motor control, acceptable price points and cost-effectiveness thresholds (cost per QALY). Used to validate the proposed EUR 150,000 price and EUR 120,000 per QALY cost-effectiveness ceiling, and to identify country-specific evidence or reimbursement barriers.

Recency Requirement: Most recent HTA reports and payer guidance (2022–2025 preferred); any preliminary or informal payer feedback from device manufacturers or researchers is valuable even if older (2019–2021).

Responsible Role Type: Chief Financial Officer & Financing Gates Manager

Steps to Find:

Access Difficulty: Medium to Hard. Published HTA reports are publicly available, but member-state payer feedback is often confidential. Formal payer-engagement requires direct contact, ethics-committee approval for research conversations, and time for written responses (2–4 months). EUnetHTA is public, but reports are summary-level; detailed payer criteria are internal to each member state.

Essential Information:

Risks of Poor Quality:

Worst Case Scenario: The programme reaches CE marking at Month 132 (2037-10-31) with a solid clinical dataset but discovers that the proposed EUR 150,000 price and EUR 120,000 per QALY cost-effectiveness ceiling exceed payer thresholds in 6 of 8 target member states (Germany, France, Italy, Spain, Benelux combined). HTA bodies reject the reimbursement submission as economically unjustifiable, triggering price renegotiation demands (30–50% reduction to EUR 75k–€105k), which halve the unit margin and cumulative revenue to EUR 25M–€50M by Month 180 (2041-10-31). Combined with operating costs of EUR 111M per year, the company faces permanent insolvency and abandons the EU market, triggering patient-protection reserve draw-downs and potential explantation obligations for the 1,050+ implanted patients. Alternatively, reimbursement is achieved only in 2–3 member states with smaller populations, capping cumulative implants at 200–400 and making the venture a strategic failure despite clinical success.

Best Case Scenario: By Month 24 (2028-10-31), the programme obtains written payer feedback from 6+ member-state HTA bodies confirming willingness to reimburse the device at EUR 150,000–€180,000 per implant if the clinical trial demonstrates ≥10 bits/s sustained communication bandwidth, non-inferiority to eye-tracking on daily-life function, and ≤20% device-related serious adverse events. Cost-effectiveness modelling shows EUR 110,000 per QALY (within member-state ceilings), and 3–4 member states agree to outcome-based reimbursement contracts (50% upfront, 50% conditional on 12-month retention >80%). This de-risks the financing gates (G3 and G4) by confirming a credible revenue pathway, allowing Series A and Series B closes at target terms. Post-CE marking (Month 132 = 2037-10-31), the company achieves reimbursement in 7 member states by Month 140 (2038-06-30), enabling a cumulative-implant ramp from 50 at Month 84 (2033-10-31) to 1,050+ by Month 180 (2041-10-31), reaching operating near-break-even by Year 15 and enabling a post-exit dividend or reinvestment in the enhancement track.

Fallback Alternative Approaches:

Find Document 7: Leuven (Belgium), Brussels and Northern EU Neurosurgical Centre Capacity and ALS Patient Flow Data

ID: f4db6d01-9d84-46c9-a4ea-1a3e81383c53

Description: Documentation of neurosurgical centres in Leuven, Ghent, Antwerp (Belgium) and nearby (Utrecht, Grenoble) with expertise in implantable-device surgery, ALS patient populations and capacity for first-in-human trials. Includes theatre availability, surgeon experience (implants performed, learning curve), patient referral pathways, ethics-committee experience and infrastructure for long-term follow-up. Used to assess first-in-human site feasibility and fallback-site equivalence.

Recency Requirement: Current centre capabilities (2025–2026); any recent publications or programme announcements from specific centres.

Responsible Role Type: Chief Medical Officer & Lead Neurosurgeon

Steps to Find:

Access Difficulty: Easy to Medium. Hospital websites provide general information. Direct contact with neurosurgery departments and ALS societies yields more detailed insights. ALS societies are collaborative; formal requests for patient-flow data may be granted. EudraCT is public and searchable.

Essential Information:

Risks of Poor Quality:

Worst Case Scenario: UZ Leuven declines to partner (no formal commitment by Month 3 = 2027-01-31); the programme has no confirmed first-in-human site, pushing fallback activation to Month 6 (2027-04-30). Fallback sites (Utrecht, Ghent, Grenoble) require new ethics approvals, surgeon credentialing and consent-advocate recruitment, adding 3–6 months. Simultaneously, ALS capacity modelling reveals only 300–400 eligible patients per year across all sites, reducing the cumulative 1,050 target to 600–700 by Month 180 (2041-10-31), which falls below the 1,125 annual break-even volume and makes long-term profitability unachievable. Loss of the Leuven research connection also severs planned access to imec electrode prototyping and KU Leuven signal-processing expertise, forcing external licensing (cost +EUR 2M–€5M, delay +6–12 months). Combined impact: Month 60 (2031-10-31) FIH slips to Month 72–84 (2032-10-31 to 2033-10-31); CE marking pushes to Month 144–156 (2038-10-31 to 2039-10-31); financial viability below the operating-gap line triggers a programme-pause decision at Month 36 (2029-10-31) feasibility gate.

Best Case Scenario: UZ Leuven, imec and KU Leuven confirm partnership letters of intent by Month 1 (2026-11-30), accelerating on-site diligence and facility access. ALS-capacity modelling confirms 800–1,000 eligible per year in Belgium, Netherlands and France, supporting the 1,050 central-case cumulative target. Ethics committees in all three countries pre-approve the harmonised consent protocol by Month 9 (2027-07-31), removing ethics delays from the critical path. Long-term follow-up infrastructure (telehealth, allied-health, imaging) is confirmed funded and staffed at each centre by Month 18 (2028-04-30), giving payers confidence in the patient-support covenant. First neurosurgeon trainer (University of Leuven) and two deputy surgeons (Utrecht, Ghent) complete credentialing by Month 48 (2030-10-31), enabling multi-centre FIH cohort enrolment across three countries in parallel starting Month 60 (2031-10-31). Capacity modelling confirms 12–15 implants per centre per year at steady state (Months 168–180 = 2040-10-31 to 2041-10-31), supporting 300 annual implants and a glide slope to break-even by Month 192 (2042-10-31). Combined impact: schedule advances 3–6 months; payer dialogue closes 2–3 member states by Month 30 (2029-04-30), de-risking reimbursement; centre-network recruitment accelerates 6–12 months post-CE marking.

Fallback Alternative Approaches:

Find Document 8: EU Supplier and Manufacturer Landscape for Neural-Implant Electrodes, Chips and Thin-Film Substrates

ID: d8862c6d-2817-48c6-998e-80fc7f4b60b1

Description: Mapping of EU-based suppliers capable of manufacturing Class III neural-implant electrodes, implant electronics (ASIC or processors) and thin-film substrates to medical standards. Includes company profiles, manufacturing capabilities (fab class, equipment, certifications), experience with implantable devices, export-control compliance and capacity/timeline for qualification and production-scale manufacture. Supports supplier selection and dual-sourcing strategy.

Recency Requirement: Current (2025–2026) supplier capabilities and capacity; any recent capacity announcements or partnerships.

Responsible Role Type: Chief Manufacturing & Supply-Chain Officer

Steps to Find:

Access Difficulty: Medium. Capability information is proprietary; contact with suppliers is needed. Capacity availability and production timelines depend on current order books and willingness to support a new medical-device programme. Budget 2–3 months for supplier assessments and capacity confirmations.

Essential Information:

Risks of Poor Quality:

Worst Case Scenario: The document is incomplete or missing, or supplier data is severely outdated (pre-2024). The programme discovers by Month 18 (2028-04-30) (shared-foundry gate) that no EU supplier can achieve the required reliability, certifications or capacity in time. The fallback is a forced switch to non-EU suppliers, which fails sovereignty tests and forces a complete re-architecture. Alternatively, a single-source dependency persists, an export-control restriction emerges (e.g., US lithography software is embargoed), and the foundry route is suddenly blocked or requires multi-year rework. This triggers a programme pause at Month 24 (2028-10-31) feasibility gate, cost EUR 2–5M in sunk design work and EUR 60M+ in delayed or lost tranches.

Best Case Scenario: A clear supplier landscape is mapped, with named dual-sourcing candidates (two chip makers, two substrate vendors) already engaged and signalling capacity commitment. Pre-qualification timelines (9–18 months) are understood and fit within the design-lock window (Months 18–30 = 2028-04-30 to 2029-04-30). Export-control compliance is documented and clean. MOUs or letters of interest are in hand by Month 12 (2027-10-31), formal qualifications begin immediately, and a second source is confirmed by Month 30 (2029-04-30). The dual-sourcing strategy is credible, sovereignty tests pass, and manufacturing is de-risked for the pivotal trial.

Fallback Alternative Approaches:

Find Document 9: Existing EU and International Ethical Frameworks and Consent Standards for Locked-In and Communication-Impaired Participants

ID: b283299e-b492-4ba5-8a51-d9b63d4c2292

Description: Published guidance and case reports from ethics bodies, research groups and patient organisations on informed consent for people with locked-in syndrome or severe speech loss, including capacity assessment methods, advance-directive protocols, and consent-advocate roles. Examples: Cambridge Bioethics, European Network for the Cure of ALS, national ethics committees' published guidance, and academic publications on vulnerable-population consent in neurotechnology research. Used to design the informed-consent and re-consent framework for ALS participants.

Recency Requirement: Current guidance (2019–2025); any historical standards (2010–2018) if still relevant.

Responsible Role Type: Chief Medical Officer & Lead Neurosurgeon

Steps to Find:

Access Difficulty: Easy. Most published guidance is open-access or freely available from ethics bodies and patient organisations. Unpublished case reports or informal consensus may require direct contact with researchers or ethics committees, which is collaborative.

Essential Information:

Risks of Poor Quality:

Worst Case Scenario: Engagement with ethics committees at Month 6 (2027-04-30) reveals that the plan's proposed consent framework (independent advocate, yes/no signalling validation, binding re-consent, participant-set explantation clauses) has no published EU precedent and is rejected by multiple national committees as impractical or ethically unclear. The programme must redesign consent protocols over 3–6 months, re-submit to all ethics committees, and defer first-in-human from Month 60 (2031-10-31) to Month 72 (2032-10-31) or later. Accumulated design work, regulatory engagement and animal studies lose momentum. Alternatively, the programme proceeds with a weaker consent framework that lacks independent advocates or advance-directive documentation, triggering invalid-consent findings during early-implant phases that invalidate trial data and force restart, costing 12–24 months and damaging regulator and payer confidence.

Best Case Scenario: A comprehensive, current ethical-frameworks document identifies 3–5 published EU or international consent standards tailored to locked-in and communication-impaired populations that directly map to the plan's proposed safeguards. The document includes case reports showing that ethics committees in Belgium, France and Netherlands have approved similar frameworks; advocate-training curricula; and validated capacity-assessment and yes/no-signalling methods. The plan adopts these frameworks verbatim or with minor local adaptations, harmonises them across participating sites by Month 6 (2027-04-30), and submits them to ethics committees with peer-reviewed citations. All ethics committees approve the consent protocol on first submission. The programme recruits the independent advocate, trains them using published materials, and enrolls the first participant with full consent validity and regulator confidence by Month 62 (2031-12-31).

Fallback Alternative Approaches:

Find Document 10: EU Leuven Climate Data and Infrastructure Resilience Assessment (Heatwaves, Flooding, Water, Power)

ID: 68a4083a-b50e-47b2-bfac-b4966a02e85e

Description: Historical climate and infrastructure data for Leuven, Belgium, documenting multi-day heatwave frequency (>35°C), duration and projected increases; drought and water-supply reliability for industrial cooling; flood risk and historical inundation events; power grid reliability and outage frequency during extreme weather; local water-infrastructure capacity and restrictions. Used for the climate-resilience assessment and to evaluate site suitability for critical manufacturing (cleanroom, sterilisation) and compute facilities.

Recency Requirement: Historical data (1990–present) showing trends; projections to 2050 (from climate models); current infrastructure resilience reports (2020–2025).

Responsible Role Type: Chief Technology Officer & Neural Interface Engineer

Steps to Find:

Access Difficulty: Easy to Medium. Government environmental and weather agencies provide public data and reports. Contact with municipal authorities may require formal requests but is typically collaborative for research purposes. Budget 1–2 months for data collection and interpretation.

Essential Information:

Risks of Poor Quality:

Worst Case Scenario: Heatwave data shows Leuven currently experiences 10–15 days per year above 35°C, projected to increase to 40–50 days by 2050, with peak temperatures exceeding 40°C and power grid instability affecting 5–10 major facilities during summer peaks. The neural-data compute centre, designed for 20–25°C ambient, is forced to throttle or shut down during multi-day events lasting 48–96 hours, risking loss of real-time trial data and triggering ethics-committee investigations. Concurrently, cleanroom cooling failures during a heatwave in Months 72–84 (2032-10-31 to 2033-10-31) halt electrode and chip manufacturing for 3–5 days, delaying the pivotal trial start by 2–4 months. Water-supply restrictions during concurrent drought reduce cleanroom recirculation, forcing partial shutdown. Patient-facing wearable hardware, not designed for sustained 38–40°C operation, experiences battery degradation and antenna detuning, forcing users to throttle bandwidth to 3–5 bits/s or risk device overheating. The combination of infrastructure unreliability and wearable thermal stress triggers a stability or performance kill gate, delaying CE marking by 6–12 months and costing EUR 5–10M in rework and contingency activation.

Best Case Scenario: Leuven climate assessment confirms multi-day heatwaves above 35°C occur 15–20 days per year (stable through 2050), with peak temperatures of 38–39°C and short-duration excursions to 40°C. The university sites and imec have existing or planned backup power (UPS + 500 kW generator) and redundant cooling loops, capable of sustaining operations through a 5-day heatwave. The neural-data compute centre is designed with redundant cooling and a second-site replica in a cooler EU location (e.g., northern Germany or Netherlands), allowing failover within 2–4 hours with no data loss. The wearable external processor is validated for passive cooling and 12+ hours of battery life at sustained 38°C ambient, with automatic throttling to maintain safe skin contact temperature (<40°C) and sustainable bandwidth (8–10 bits/s) during heat events. Flood-risk assessment confirms Leuven sites are above the 100-year flood level with good groundwater management, and water-supply reliability during drought is adequate (no restrictions anticipated for industrial cooling). These findings support site lock by Month 9 (2027-07-31), supplier confidence by Month 12 (2027-10-31), and on-schedule manufacturing and trial work without climate-related delays or contingencies. CE marking proceeds on the originally planned timeline (Month 132 = 2037-10-31) without thermal or infrastructure rework.

Fallback Alternative Approaches:

Strengths

Weaknesses

Opportunities

Threats

Recommendations

Strategic Objectives

Assumptions

Missing Information

Questions

Roles Needed & Example People

Roles

1. Chief Executive Officer & Founder

Contract Type: full_time_employee

Contract Type Justification: Chief Executive Officer & Founder. Required from Month 0 (2026-10-31) through Month 180 (2041-10-31) as the sole authoritative strategic leader. Continuous, core accountability for investor relations, partnership negotiation with imec/KU Leuven/UZ Leuven, regulatory engagement with Commission and member states, governance structure, kill-gate credibility and programme-wide risk management. Absence directly causes investor confidence collapse at financing gates, partnership stalls and conflicting signals to regulators. Full-time employment with equity upside and multi-year retention is essential.

Explanation: Strategic leadership, investor relations, partnership negotiation with imec/KU Leuven/UZ Leuven, regulatory engagement with Commission and member states, and programme-wide risk management. The CEO sets governance structure, gates and stop-authority credibility. Essential from Month 0 (2026-10-31) through all 15 years to maintain stakeholder trust and decision authority.

Consequences: Without a single authoritative leader, investor confidence fractures at financing gates; partnership negotiations with Leuven institutions stall without executive credibility; conflicting signals to regulators undermine early scientific-advice requests; kill-gate decisions lack clear ownership and become deadlocked, allowing the programme to drift when evidence warrants stopping.

People Count: 1

Typical Activities: Sets governance structure and kill-gate authority by Month 3 (2027-01-31). Recruits board and securing written commitments from imec, KU Leuven and UZ Leuven through direct negotiation; activates fallback sites if any decline. Manages investor relations across T0–T4 tranches, writing monthly reports to investors tied to risk-retirement milestones and publishing written verdicts within five business days of each financing gate (G1 Month 12 = 2027-10-31, G3 Month 24 = 2028-10-31, G4 Month 36 = 2029-10-31). Chairs monthly board meetings with clear decision authority on programme pauses, architecture switches or termination. Represents the company to the Commission (scientific-advice requests, IPCEI negotiation) and member states. Ensures kill-gate decisions are binding and published within 30 days.

Background Story: Dr. Helena Kovács, 52, is a seasoned medtech entrepreneur from Budapest who relocated to Brussels in 2005 following the EU expansion. She earned her MD from Semmelweis University (neurology, 1995) and an MBA from INSEAD (2003). She co-founded a cardiac-implant company that scaled to 400 employees and was acquired by a US device maker in 2015, earning her network across European member states and the Commission. She has spent the last eight years as a senior advisor to the Innovation Fund and knows the landscape of EU research funding, IPCEI mechanisms and the political economy of sovereign medtech. She speaks five languages and has sat on ethics committees in three countries. She is deeply sceptical of hype and insists on evidence-gated decision-making. Her relevance is clear: she has built and scaled a medtech company in the EU regulatory environment, navigated multi-state partnerships and understands the unique constraints of a founder-led venture with no committed funding. She is available now.

Equipment Needs: Secure office suite with video-conferencing and encrypted communications (Teams, Zoom, Signal); secure password-managed document repositories (OneDrive, SharePoint with 2FA); travel budget for monthly investor relations and Commission meetings (Brussels, member states); financial modelling and deal-structuring software (Bloomberg Terminal, Anaplan, spreadsheet-based scenario tools).

Facility Needs: Executive office at Leuven headquarters near imec/KU Leuven campus; access to meeting rooms for investor term-sheet and partnership negotiations; secure storage for shareholder agreements and board papers; virtual and in-person board-meeting capability (monthly, some international). CEO office should be co-located with Chief Medical Officer and Chief Technology Officer for weekly strategy alignment. Access to European institutional networks: Commission offices (Brussels, ~2 hours from Leuven), member-state capital research liaisons, notified-body technical lead contact points.

2. Chief Medical Officer & Lead Neurosurgeon

Contract Type: full_time_employee

Contract Type Justification: Chief Medical Officer & Lead Neurosurgeon. Required continuously from Month 3 (2027-01-31) through CE marking at Month 132 (2037-10-31) and beyond into commercial rollout. Core accountability for surgeon credentialing, ethics approvals, informed-consent safeguards for locked-in participants, independent data-monitoring committee chair, clinical endpoints and safety kill-gate criteria. Patient safety and regulatory approval depend entirely on this role's continuous presence. Absence causes ethics-committee rejections, invalid consent findings and poor surgical outcomes. Full-time position with surgical privileges at implanting hospital.

Explanation: Recruits and credentials implanting surgeons, designs first-in-human protocols, obtains ethics approvals, manages informed-consent safeguards for locked-in participants, chairs the independent data-monitoring committee, and defines clinical endpoints and kill-gate criteria. Critical for patient safety, consent validity and regulatory approval. Required continuously from Month 3 (2027-01-31) through CE marking and into commercial rollout.

Consequences: Consent protocols are not credible; ethics committees reject trial designs, delaying first-in-human by 6–12 months. Safety kill-gates lack clinical grounding and are set too tight or too loose, triggering false stops or missing real harm. Implanting surgeons are not trained or credentialed, leading to poor surgical outcomes and serious adverse events. Regulatory trust erodes.

People Count: 1

Typical Activities: Recruits and credentials implanting neurosurgeons by Month 6 (2027-04-30), establishing training curricula and proctoring protocols. Designs first-in-human (FIH) clinical-investigation protocols with independent consent advocates and submits coordinated ethics applications to at least three countries (Belgium, Netherlands, France) by Month 6 (2027-04-30). Chairs the independent Data Monitoring Committee (DMC) from Month 6 (2027-04-30), ensuring binding authority over implantation pause and stop decisions. Defines clinical endpoints and pre-registers safety kill criteria (≥3 serious adverse events in first 20 implants, ≥2 in first 10) before FIH, with monthly safety review and DMC findings published within 30 days. Trains consent advocates and validates yes/no participant signalling using assistive methods. Manages lifelong follow-up infrastructure (telehealth, remote imaging, allied health) starting Month 60 (2031-10-31). Reports chronically to regulators (notified body, ethics committees) on safety signals.

Background Story: Dr. Niels Troels, 48, is a neurosurgeon and BCI researcher from Copenhagen who trained at Uppsala University (neurosurgery, 2000) and earned a PhD in neural interfaces from ETH Zurich (2008). He led the first-in-human cortical-implant study in the Scandinavian region, implanting and following eight locked-in ALS patients over six years, with published peer-reviewed consent protocols and long-term safety data. He holds a fellowship in neurorehabilitation from the National Institutes of Health and has trained surgeons across three countries in implant credentialing. He is known for meticulous informed-consent practices and for stopping recruitment when harm signals emerge. His weakness is that he is cautious, sometimes to the point of slowness, but that caution is essential for a programme where valid consent and patient safety are hard requirements. He has deep connections to ALS patient organisations and ethics committees across the Nordic region.

Equipment Needs: Surgical training videos and simulation equipment for surgeon credentialing curriculum; telemedicine platform for remote patient follow-up (telehealth suite, imaging review workstations); electrocardiogram and vital-signs monitoring equipment for intra-operative use during implantations; informed-consent documentation and video-recording systems (HIPAA-compliant, with backup storage); statistical software for safety and retention analysis (R, SAS, GraphPad); institutional review board (IRB) meeting materials and secure communication with ethics committees across three member states.

Facility Needs: Office at or adjacent to implanting hospital (UZ Leuven, or fallback at Utrecht/Grenoble); access to neurosurgical operating theatres with instrument trays and surgical support; patient consultation rooms with private audio/video for consent conversations and yes/no validation (certified accessible for participants with severe motor impairment); patient-follow-up clinic space with imaging and neuro-rehabilitation liaisons; secure data storage for ethics-committee approvals, consent records and adverse-event logs; meeting space for monthly Data Monitoring Committee (DMC) sessions (can be virtual, but confidential lines required).

3. Chief Technology Officer & Neural Interface Engineer

Contract Type: full_time_employee

Contract Type Justification: Chief Technology Officer & Neural Interface Engineer. Required continuously from Month 0 (2026-10-31) through CE marking at Month 132 (2037-10-31). Owns architecture choice (cortical, endovascular, surface) at Month 18 (2028-04-30), chronic signal-stability and bandwidth targets, preclinical animal studies, decoder specifications and AI Act compliance. Continuous technical direction of the core differentiator (bandwidth) and kill-gate evidence (signal loss, bandwidth, thermal performance). Absence causes delayed architecture commitment (3–6 months loss), under-scoped chronic studies yielding insufficient data for kill gates, and unverified bandwidth claims that undermine investor and regulator credibility. Full-time core technical leadership.

Explanation: Leads architecture choice (cortical, endovascular, surface), owns chronic signal-stability and bandwidth targets, directs preclinical animal studies, defines decoder specifications and AI Act compliance, and manages the technical kill-gate evidence (signal loss, bandwidth, thermal performance). Owns the core technical differentiator—bandwidth—and decides architecture fallback routes. Required from Month 0 (2026-10-31) through CE marking (Month 132 = 2037-10-31).

Consequences: Architecture choice becomes a committee-by-consensus process, delaying commitment to Month 24 (2028-10-31) or later and losing 3–6 months. Chronic signal-stability studies are under-scoped, yielding insufficient data for kill-gate decisions at Month 60 (2031-10-31). Bandwidth claims lack rigorous definition and independent verification, undermining investor and regulator credibility. Decoder change-control and AI Act compliance defaulted to others, creating gaps in governance.

People Count: 1

Typical Activities: Leads architecture selection (cortical penetrating, endovascular, surface epidural) by Month 18 (2028-04-30), commissioning freedom-to-operate and chronic-stability analyses for each option (completed Month 6 = 2027-04-30) and scoring them on patent clearance, surgical risk, bandwidth potential, stability risk and manufacturing readiness by Month 9 (2027-07-31). Owns chronic signal-stability and bandwidth targets: commissions 18–24 month animal studies (preclinical, GLP), defines kill-gate thresholds (>20% signal loss by Month 12 = 2027-10-31 blocks FIH) and models bandwidth degradation forward to 5, 10 and 15 year device horizons. Specifies decoder architecture and AI Act scope by Month 12 (2027-10-31). Manages technical kill-gate evidence collection (signal loss, bandwidth, thermal performance) and reports monthly to the DMC. Oversees wearable design (battery life, thermal throttling, antenna range), validating in climate-chamber tests (35–40°C multi-day profiles) by Month 18 (2028-04-30). Contingency: pre-registers penetrating cortical as fallback if surface stability fails; contingency cost ~EUR 30M (range 15–60M, estimate) and 12–24 months rework.

Background Story: Prof. Martin Engel, 45, is a neural-interface engineer and former director of research at imec (2015–2022), where he led high-density microelectrode arrays and signal-processing research. He holds a PhD in electrical engineering from TU Delft (2003) and has authored over 80 peer-reviewed papers on electrode design, chronic signal stability and neural decoding, with an h-index of 28. He left imec to co-found a spin-out focused on implantable neural electronics, which stalled due to funding constraints. He is known for demanding rigour on bandwidth measurement, having publicly criticised inflated claims by competitors, and for insisting on independent verification. His strength is technical depth and scepticism; his weakness is that he can become deadlocked when evidence is ambiguous, slowing architecture decisions. He has a network of collaborators at CEA-Leti, UMC Utrecht and German clusters, and has relationships with two potential chip suppliers. He is available immediately, motivated by the chance to build a sovereign EU capability.

Equipment Needs: High-performance computing cluster for chronic signal-stability simulations and electrode-design finite-element modelling (GPU-accelerated workstations, ~EUR 150k–300k total); microelectrode fabrication and testing equipment access (borrowed from imec: probe-characterisation benches, recording amplifiers, signal-acquisition systems); custom decoding-algorithm development environment (Python/MATLAB with neural-signal libraries); climate-chamber equipment for thermal and reliability testing of electrode materials and wearable prototypes (35–40°C multi-day profiles, humidity extremes); mechanical-test equipment for electrode tensile strength and encapsulation durability; oscilloscopes, signal generators and impedance analysers for electrode characterisation; preclinical neurosurgical instrument sets (micropipettes, micromanipulators) for chronic animal implantation.

Facility Needs: Dedicated neural-interface engineering lab at Leuven (imec campus or KU Leuven, ~500 m² shared with imec), with climate-controlled benches, Faraday-caged recording setups and dark rooms for optical testing. Access to imec's CMOS prototyping cleanroom (Class 100 for probe wafer handling and thin-film deposition, shared facility ~2,000 m² accessible to the programme). Chronic animal-testing facility (GLP-certified, separate from human clinics): vivaria with environmental control, surgical suites for rodent implantations, neurophysiology recording rooms, and necropsy suites (estimated 300–500 m² dedicated to the BCI programme). High-speed internet (1 Gbps+) for large data transfers and simulation workflows. Close co-location with Chief Technology Officer, neuroengineers and decoding team.

4. Chief Regulatory Affairs Officer

Contract Type: full_time_employee

Contract Type Justification: Chief Regulatory Affairs Officer. Required from Month 3 (2027-01-31) through CE marking at Month 132 (2037-10-31) and beyond. Sole owner of notified-body engagement from Month 6 (2027-04-30), ISO 13485 QMS build by Month 9 (2027-07-31), Commission scientific-advice request by Month 12 (2027-10-31), AI Act compliance documentation (budget EUR 2M), multi-country ethics approvals and coordinated investigations. Single point of accountability for CE-marking dossier completeness. Absence causes QMS audit failures (EUR 0.5M–EUR 1.5M rework, 3–6 month delay), poorly formulated scientific-advice requests, incomplete AI Act compliance triggering late-stage regulator objections, and no single accountability for approval readiness. Full-time continuous position through post-approval surveillance.

Explanation: Manages notified-body engagement from Month 6 (2027-04-30), builds ISO 13485 QMS and design-history files, secures Commission scientific advice by Month 12 (2027-10-31), handles AI Act compliance documentation (budget EUR 2M), and coordinates multi-country ethics approvals and coordinated investigations. The sole owner of the regulatory path and the final CE-marking dossier. Required from Month 3 (2027-01-31) through CE marking and post-approval surveillance.

Consequences: QMS is built ad hoc and fails preliminary notified-body audit, costing EUR 500k–EUR 1.5M in rework and delaying approval by 3–6 months. Scientific-advice request is poorly formulated, yielding non-actionable feedback. AI Act compliance is incomplete, triggering late-stage regulator objections at Month 100–120 (2035-10-31 to 2036-10-31) that force design changes. No single point of accountability for CE-marking readiness.

People Count: 1

Typical Activities: Launches notified-body pre-submission meeting by Month 6 (2027-04-30), presenting architecture overview, preclinical programme, first-in-human clinical plan and ISO 13485 roadmap. Collects written feedback on evidence gaps and regulatory timeline by Month 6 (2027-04-30). Builds ISO 13485 QMS (document control, design-history file, training, supplier audits, non-conformance logs, change control) by Month 9 (2027-07-31), with quality-assurance manager hire by Month 6 (2027-04-30). Initiates design-history file (DHF) at Month 1 (2026-11-30), assigning a DHF custodian and establishing version control before any design work. Requests Commission scientific advice on clinical investigation design and AI Act scope by Month 12 (2027-10-31), responding to notified-body feedback. Conducts preliminary notified-body QMS audit by Month 18 (2028-04-30), incorporating findings into final QMS by Month 18 (2028-04-30). Manages AI Act high-risk compliance (decoder documentation, model validation, human oversight, bias testing, change control) with external counsel; budget ~EUR 2M. Maintains design change control: every design change requires a Change Request Form, risk assessment and QA approval, logged in DHF. Prepares the pivotal-trial (Class III conformity) dossier incrementally from Month 60 (2031-10-31) onwards.

Background Story: Dr. Sophie Renault, 42, is a regulatory specialist from Lyon with 18 years in medical-device regulatory affairs, including 12 years at the European Medicines Agency (EMA) in the device-innovation unit. She has advised on three class III breakthrough devices and led multi-country coordinated investigations. She is fluent in MDR, ISO 13485 and the emerging AI Act framework for medical devices, and has sat in pre-submission meetings with three notified bodies. She is known for being direct with vendors about evidence gaps, and for building compliance systems that survive audits. Her weakness is that she can be overly cautious on timelines (building a QMS takes 9–12 months, she argues, not 6), but that conservatism is warranted here. She speaks four languages and has relationships with notified-body technical leads across northern Europe. She is available immediately and motivated by the flagship nature of a sovereign EU medical device.

Equipment Needs: Regulatory-document management software (MasterControl, Veeva Vault or equivalent, ~EUR 50k–100k annual license); design-history file (DHF) repository with version control and audit trails (ISO 13485 compliant); risk-management and failure-mode-and-effects-analysis (FMEA) tools; notified-body communication and submission-tracking systems; quality-management system (QMS) templates and training modules; ISO 13485 and MDR guidance documents (printed and digital); change-request forms and design-change tracking spreadsheets or databases; AI Act compliance documentation templates (decoder model cards, validation protocols, bias-testing checklists); multi-country ethics-protocol harmonisation tools and templates.

Facility Needs: Quality Assurance and Regulatory Affairs office at Leuven headquarters (adjacent to CEO/CMO, ~100 m² for two staff: Chief Regulatory Affairs Officer and Quality Assurance Manager); secure, locked filing for regulatory correspondence with notified bodies, ethics committees and member-state authorities; videoconference capability for notified-body pre-submission meetings and multi-country ethics-committee coordination calls; access to notified-body facilities for preliminary QMS audits (external, but travel budget required). Proximity to imec and UZ Leuven for cross-functional meetings on design freeze, risk management and design-history-file walk-throughs. Dedicated space for maintaining and updating the design-history file as the core regulatory artefact (physical or digital archive, both required for ISO 13485 traceability).

5. Chief Financial Officer & Financing Gates Manager

Contract Type: full_time_employee

Contract Type Justification: Chief Financial Officer & Financing Gates Manager. Required continuously from Month 0 (2026-10-31) through Month 180 (2041-10-31). Structures tranches T0–T4 (EUR 2.5B), manages financing gates G1, G3, G4 (Months 12, 24, 36 = 2027-10-31, 2028-10-31, 2029-10-31), models break-even and ROI (EUR 66M annual gap at Month 180 = 2041-10-31 unrealised), governs the patient-protection reserve trust (EUR 150M estimate), ties capital release to risk-retirement milestones. Controls programme survival itself; a missed gate stops or defers the entire venture. Absence causes undisciplined tranches (cash burned on timeline rather than milestones), missed gates without fallback trigger, unprojected EUR 150M reimbursement model and under-funded patient reserves leaving implanted patients exposed to insolvency. Full-time continuous accountability through all 15 years.

Explanation: Structures tranches T0–T4 (EUR 2.5B total), manages financing gates G1, G3, G4 (Months 12, 24, 36 = 2027-10-31, 2028-10-31, 2029-10-31), models break-even and ROI, governs the patient-protection reserve trust (EUR 150M estimate), and ties capital release to risk-retirement milestones. Controls the programme survival; a missed gate stops or defers the entire venture. Required continuously from Month 0 (2026-10-31) through Month 180 (2041-10-31).

Consequences: Financing tranches lack discipline; money is released on timelines rather than milestones, burning through capital before the programme proves feasibility. Gates are missed without clear fallback or trigger. Payer-reimbursement model and health-economic case are not modelled, so Series A investors cannot assess return scenarios. Patient-protection reserves are under-funded, leaving implanted patients exposed if the company fails. Break-even analysis reveals the EUR 66M annual gap at Month 180 (2041-10-31) is never addressed.

People Count: 1

Typical Activities: Structures T0–T4 tranches (EUR 2.5B) and models investor return expectations (target 20–25% IRR, 10–12 year payback) by Month 3 (2027-01-31), testing against eligible-population epidemiology and reimbursement scenarios. Defines and documents three hard financing gates: G1 Month 12 (2027-10-31) EUR 15M seed committed, G3 Month 24 (2028-10-31) EUR 60M Series A conditional, G4 Month 36 (2029-10-31) EUR 210M (T1 + T2 partial) conditional. Writes gate fallbacks: if G1 misses, defer Months 13–24 (2027-11-30 to 2028-10-31) non-critical spend; if G3 misses, no implant programme; if G4 misses, defer FIH 12 months or stop. Gates are published in writing within five business days; no renegotiation. Sets up patient-protection trust by Month 6 (2027-04-30), EUR 5M floor before FIH, growing EUR 30,000 per implant to EUR 150M if 5,000 reached. Escrow is outside investor reach. Negotiates term sheets with institutional investors, tying tranches to technical milestones (notified-body pre-submission, chronic animal data, supplier qualification). Models break-even (about 1,125 implants per year; EUR 111M opex, EUR 45M revenue at 300 implants/year, Month 180 = 2041-10-31 gap EUR 66M). Engages payers and HTA bodies in Months 12–24 (2027-10-31 to 2028-10-31) to validate EUR 150,000 price and EUR 120,000/QALY cost-effectiveness ceiling; publishes reimbursement-feasibility summary Month 24 (2028-10-31).

Background Story: Dr. Yannick Dubois, 50, is a healthcare-finance specialist from Paris with experience raising capital for three medtech companies in the EU, exiting one to a US strategic buyer and shepherding another through two commercial financings. He spent five years at Bank of America in healthcare M&A and has modelled reimbursement and break-even for implantable devices. He is skilled at structuring tranches tied to milestones, writing term sheets that align investor returns with risk retirement, and spotting underfunded budgets before they become crises. His weakness is that he is sometimes optimistic on revenue ramps (expecting 20% year-on-year growth at scale), but he has learned to build conservative scenarios and model sensitivity. He has a strong reputation with EU venture capital and with member-state development banks. He is available now, motivated by the sovereignty mission and by the chance to build a credible patient-protection reserve mechanism.

Equipment Needs: Financial modelling and scenario software (Excel with built-in versioning, Anaplan, Tableau for investor dashboards); healthcare cost accounting and reimbursement-modelling tools (specialized BCI/neurology pricing databases if available); actuarial software for patient-reserve adequacy modelling (life-table and device-lifetime cost projection); investor communication and term-sheet management platforms; banking and treasury management systems for tranche drawdown and escrow governance; break-even and cash-flow forecasting tools; payer-engagement and health-economic-assessment databases (HTA body contact registries and cost-effectiveness thresholds by member state).

Facility Needs: Chief Financial Officer office at Leuven headquarters with secure desktop and dual monitors for complex financial modelling; dedicated meeting space for investor presentations and term-sheet negotiations; access to bank and venture-capital networks (partly virtual, partly travel to financial centres: Brussels, Frankfurt, London—though UK is outside sovereignty perimeter post-Brexit). Secure facilities for holding and administering the patient-protection trust: separate legal/fiduciary office (contracted or in-house) for escrow governance, with independent trustee representation. Proximity to CEO and board for monthly financial reporting and gate-decision documentation. Quarterly stakeholder reporting and publication infrastructure (website, investor portal, member-state engagement channels).

6. Chief Manufacturing & Supply-Chain Officer

Contract Type: full_time_employee

Contract Type Justification: Chief Manufacturing & Supply-Chain Officer. Required from Month 6 (2027-04-30) through commercial scale-up at Month 180 (2041-10-31). Owns pilot-line-to-Class III production transfer, dual-sources and qualifies chip and substrate suppliers by Month 30 (2029-04-30), locks materials and processes by Month 72 (2032-10-31), tests sovereignty (EU ownership, export-control freedom) per component, manages clinical supply manufacturing. Single owner of foundry feasibility and supply-chain constraint that could halt manufacturing or force design rework. Absence causes failed pilot-to-production transfer (yield 60–70%, EUR 1M–EUR 3M rework, 6–12 month delay), skipped second-supplier qualification (single-source risk), missed sovereignty diligence (late foreign-IP discovery forcing EUR 0.5M–EUR 2M design change), and unachieved process lock before pivotal lock. Full-time continuous through commercial phase.

Explanation: Oversees pilot-line-to-validated Class III production transfer, qualifies and dual-sources chip and substrate suppliers by Month 30 (2029-04-30), locks materials and processes by Month 72 (2032-10-31), tests sovereignty (EU ownership, export-control freedom) per component, and manages clinical-supply manufacturing. The single owner of foundry feasibility, supplier lock and the supply-chain constraint that could halt manufacturing or force design rework. Required from Month 6 (2027-04-30) through commercial scale-up at Month 180 (2041-10-31).

Consequences: Pilot-line transfer is attempted without a validated production partner; yield is 60–70% instead of >80%, costing EUR 1M–EUR 3M in rework and delaying CE marking by 6–12 months. Second supplier qualification is deferred or skipped, leaving single-source risk through the pivotal trial. Sovereignty diligence is neglected; foreign IP or export-control dependencies are discovered late, forcing design changes or licensing negotiations that cost EUR 500k–EUR 2M and delay approval. Sterilisation and process lock are not achieved before pivotal lock, forcing bridging studies post-approval.

People Count: min 1, max 2, depending on breadth of sourcing (chip, substrate, assembly, sterilisation)

Typical Activities: Identifies two candidate chip suppliers and two thin-film substrate suppliers by Month 3 (2027-01-31), conducting pre-qualification assessments (capacity, capability, cost, timeline, export controls, financial stability) by Month 6 (2027-04-30). Signs MOUs with both by Month 12 (2027-10-31), locking design specifications and timelines. Runs sovereignty diligence on each supplier (EU ownership, maintainability without foreign consent, export-control freedom) by Month 12 (2027-10-31), feeding the upstream-dependency register. Conducts formal supplier qualification (process audits, sample testing, documentation review) by Months 18–24 (2028-04-30 to 2028-10-31) against ISO 13485 standards. Manages pilot-line-to-validated Class III production transfer: selects a contract manufacturer by Month 12 (2027-10-31), defines yield target (>80%), timeline (6–12 months), and cost (estimated EUR 1–3M). Locks materials, chips and processes by Month 72 (2032-10-31), before pivotal lock. Budgets EUR 500k–EUR 1M for supplier qualification and EUR 1–2M contingency for rapid re-sourcing if a supplier declines. If the shared foundry (four+ member states, EUR 350M hoped-for) is not committed by Month 18 (2028-04-30), activates the dual-sourcing fallback (about EUR 35M production transfer, T1 EUR 10M + T2 EUR 25M, +6–12 months estimated).

Background Story: Dipl.-Ing. Klaus Bergmann, 54, is a manufacturing engineer from Stuttgart who has spent 30 years in medical-device and semiconductor production, including 12 years at Siemens Healthineers leading Class II/III implant manufacturing. He has run a successful pilot-to-production transfer for an implantable cardiac device, achieving 85% yield within 18 months and maintaining it through scale-up to 10,000 units per year. He is meticulous about process lock, material traceability and dual-sourcing, and is sceptical of suppliers who promise production-scale yields without validation. His weakness is that he is slow to move—every step must be documented and tested—but that discipline is essential for Class III. He has direct relationships with validated contract manufacturers in Belgium, Germany and the Netherlands, and has worked with imec's pilot line on medical transitions. He speaks German, English and Dutch, and is available immediately, motivated by the sovereign manufacturing mission.

Equipment Needs: Supplier quality-management and audit software (supplier scorecard tracking, ISO 13485 audit checklists); cleanroom equipment access: particle counters, temperature/humidity monitors, air-flow measurement tools; wafer-level process-characterisation tools (yield tracking, statistical process control); materials testing: tensile, biocompatibility, sterilisation-validation equipment (external contract labs); encapsulation and assembly tooling design and testing (custom jigs, fixturing, gauging equipment ~EUR 50k–200k depending on design complexity); supply-chain risk-mapping and single-source-mitigation tools; export-control compliance and sanctions-screening software.

Facility Needs: Manufacturing and Supply Chain office at Leuven (imec campus or near validated contract-manufacturing partner location, ~200 m²); access to imec pilot line for prototype electrode and implant-electronics fabrication (shared facility, negotiated access for 10–20% of capacity, Months 6–48 = 2027-04-30 to 2030-10-31); documented relationships and site-visit pathways to two chip suppliers (Netherlands, Germany) and two substrate suppliers (Belgium, Germany) for qualification audits; cleanroom and sterilisation-validation access at contract manufacturers (external facilities, travel budget for monthly audits); secure storage for supplier agreements, process specifications and materials-lock documentation. Supply-chain risk room: physical or virtual space for monitoring upstream tool dependencies, export-control alerts and supplier financial health (shared with CEO/CFO, brief weekly). Distance from deep technical detail: regular synch with Chief Technology Officer on design-lock timelines.

7. Clinical Trials & Patient Safety Manager

Contract Type: full_time_employee

Contract Type Justification: Clinical Trials & Patient Safety Manager. Required from Month 6 (2027-04-30) through Month 180 (2041-10-31) and post-approval surveillance. Designs first-in-human and pivotal protocols, recruits and screens participants (locked-in communication capacity), manages lifelong follow-up, coordinates multi-country investigations, establishes independent consent advocate and data-monitoring committee, records adverse events and bandwidth metrics. Owns patient-safety data integrity and human-side regulatory approval pathway. Absence causes poor consent documentation (ethics-committee invalid-consent findings, 6–12 month trial suspension), unmanaged participant attrition (ALS disease progression shrinking eligible pool by 30–50%, cumulative implants from 1,050 to <600), missed serious adverse events damaging regulator trust, and non-credible safety kill-gate triggers. Full-time continuous core role.

Explanation: Designs first-in-human and pivotal protocols, recruits and screens participants (especially identifying locked-in communication and consent capacity), manages lifelong follow-up, coordinates multi-country clinical investigations, establishes and supports the independent consent advocate and data-monitoring committee, and records all adverse events and bandwidth metrics. Owns patient safety data, consent integrity and the human side of regulatory approval. Required from Month 6 (2027-04-30) through Month 180 (2041-10-31) and beyond for post-approval surveillance.

Consequences: Consent documentation is poor or incomplete; ethics committees find invalid-consent practices, triggering trial suspension and 6–12 month re-review. Participant attrition is unmanaged; ALS disease progression and loss of communication reduce the eligible pool by 30–50%, shrinking cumulative implants from 1,050 to <600. Safety data are not collected rigorously; serious adverse events are missed or misreported, damaging regulator trust and triggering investigations. Kill-gate safety thresholds (≥3 SAEs in first 20 implants) lack credible triggers.

People Count: min 1, max 2, depending on trial phase and multi-country coordination load

Typical Activities: Designs first-in-human and pivotal clinical-investigation protocols by Month 6 (2027-04-30), specifying eligibility criteria, recruitment pathways, informed-consent process (independent advocates, yes/no validation), re-consent schedules, and outcome measures (daily-life function, bandwidth, serious adverse events, quality of life). Recruits and trains independent consent advocates (clinical ethicists, patient representatives) by Month 3 (2027-01-31); these advocates attend every consent conversation and hold binding authority to recommend exclusion if validity is questionable. Develops yes/no communication-validation protocol by Month 2 (2026-12-31), tested with each participant using their best available method (eye-tracking, verbal, blink, assistive device) with two independent validators present; video documentation mandatory. Submits consent protocol and advocate role to ethics committees (Leuven, Utrecht, Grenoble) for pre-review by Month 3 (2027-01-31); incorporates feedback by Month 5 (2027-03-31); obtains written approval before FIH (Month 60 = 2031-10-31). Manages participant recruitment and screening, especially identifying locked-in communication and consenting capacity by Month 60 (2031-10-31) onwards. Establishes re-consent schedule: baseline (pre-surgery), monthly for first six months post-implant, quarterly for 12 months, then annually; offers re-consent or exit options if communication declines. Manages lifelong follow-up: coordinates clinic visits, imaging, remote teleneuro checks, allied health support. Tracks participant attrition due to disease progression and documents it. Records all serious adverse events, adverse events and communication/bandwidth metrics. Publishes safety and retention data monthly to the DMC.

Background Story: Dr. Patricia Santos, 46, is a clinical-trials and patient-advocacy specialist from Lisbon with 20 years in neurology and medical research. She led recruitment, retention and safety monitoring for two multi-country ALS studies (one across seven EU member states) and has published on participant attrition in degenerative neurological disease. She is trained in research ethics and has sat on institutional review boards in Portugal and Spain. She has deep relationships with ALS patient societies across Europe and is fluent in patient-centred consent design. Her strength is her ability to recruit and retain participants even in terminal diseases through genuine respect and transparent communication about risks. Her weakness is that she is sometimes over-empathetic with participants, which can slow decision-making on consent validity, but that caution serves patient protection. She is available now, motivated by the chance to establish best-practice informed-consent safeguards for locked-in populations.

Equipment Needs: Electronic data capture (EDC) and clinical-trial management systems (Medidata, REDCap or equivalent, ~EUR 50k–150k annual license); adverse-event reporting and tracking software (MedWatch integration, CDISC SDTM compliance); participant-retention and engagement platforms (SMS/email coordination, appointment reminders, consent re-confirmation workflows); telemedicine and remote follow-up infrastructure (secure videoconference, participant self-assessment questionnaires); informed-consent document templates and video-recording systems (HIPAA-compliant); bandwidth measurement and bandwidth-metric data-logging systems (custom software, shared with Decoder & AI/ML Lead); lifelong follow-up tracking and participant attrition analysis (database, cohort survival curves); ALS disease-progression phenotyping tools and severity-scoring systems.

Facility Needs: Clinical Trials & Patient Safety office at implanting hospital site (UZ Leuven or fallback sites), ~150–200 m² shared with Chief Medical Officer; dedicated participant consultation rooms with accessibility modifications (wheelchair-accessible, low-noise, with alternative communication aids available); secure patient-data storage and electronic health record (EHR) integration with hospital systems; meeting space for independent consent advocates, Data Monitoring Committee and ethics-committee liaisons; multi-country secure communication hubs (Brussels office for Commission liaison, Utrecht office for Dutch ethics coordination, Grenoble for French ethics engagement). Lifelong follow-up infrastructure: telehealth suite, remote imaging-review workstations, and allied-health (speech, occupational therapy, psychology) contact pathways. Documentation and archival: secure filing and digital repositories for all consent forms, video recordings, adverse-event reports and participant correspondence.

8. Decoder & AI/Machine-Learning Lead

Contract Type: full_time_employee

Contract Type Justification: Decoder & AI/Machine-Learning Lead. Required from Month 12 (2027-10-31) through CE marking at Month 132 (2037-10-31) and post-approval iteration (Months 132–180 = 2037-10-31 to 2041-10-31). Owns neural-signal decoding algorithms, AI model training on trial data, bandwidth measurement protocol (net user-controlled bits/s, held-out tasks, independent verification), decoder version-lock and AI Act change-control, continuous bandwidth monitoring against kill-gate floor (5 bits/s at Month 72 = 2032-10-31). Defines and proves the technical edge—bandwidth—with credible evidence. Absence causes poor bandwidth definition and measurement (investors and regulators cannot assess 10 or 100 bits/s targets), unsystematic decoder improvements limiting bandwidth gains and failing 100 bits/s stretch goal, absent AI Act change-control triggering regulator objections or forcing full re-validation of each update (slowing innovation), inflated bandwidth claims (with language-model expansion) destroying credibility, and unavailable bandwidth evidence at kill-gate decision points. Full-time continuous through post-CE-marking iteration phase.

Explanation: Owns neural-signal decoding algorithms, AI model training on consented trial data, bandwidth measurement protocol (net user-controlled bits/s, held-out tasks, independent verification), decoder version-lock and change-control under AI Act, and continuous bandwidth monitoring against kill-gate floors (5 bits/s at Month 72 = 2032-10-31). Defines the technical edge—bandwidth—and proves it credibly. Required from Month 12 (2027-10-31) through CE marking and post-approval iteration (Months 132–180 = 2037-10-31 to 2041-10-31).

Consequences: Bandwidth is poorly defined and unmeasured; investors and regulators cannot assess whether the 10 bits/s or 100 bits/s targets are real. Decoder improvements are unsystematic, limiting bandwidth gains and failing the 100 bits/s stretch goal. AI Act change-control is absent or opaque, triggering regulator objections or forcing full re-validation of each update, slowing innovation. Bandwidth claims are inflated (including language-model expansion), destroying credibility against competitors and with payers. Kill-gate evidence on bandwidth is not available at decision points.

People Count: min 1, max 3, depending on decoder complexity and external-collaborator partnerships

Typical Activities: Defines neural-signal decoding algorithms and AI model training protocol on consented trial data by Month 12 (2027-10-31), ensuring all models are trained in-house using EU-hosted data with no external pretrained models (to preserve EU-control sovereignty test). Establishes bandwidth measurement protocol (net user-controlled bits/s, held-out tasks, independent verification, federated testing within the EU) by Month 12 (2027-10-31), published and pre-registered before any testing. Runs chronic signal-stability and bandwidth monitoring starting FIH (Month 60 = 2031-10-31), reporting monthly to the DMC on mean signal loss, sustained bandwidth per participant, decoder calibration time, error rate and comparison to kill-gate floor (>5 bits/s sustained net at Month 72 = 2032-10-31 in ≥50% of participants). Manages decoder version lock and AI Act change control: defines Version 1.0 (Pivotal Lock) by Month 18 (2028-04-30) with locked feature set, locked training-data scope and locked hyperparameters; documents in a Decoder Registry. Minor retraining (within locked feature set and data scope, <5% model-weight change) does not require re-validation; major changes (new feature, new data source, architecture swap, external-model integration) require notified-body review. Engages external counsel on AI Act compliance by Month 6 (2027-04-30); conducts model-validation, bias-testing and documentation work; allocates ~EUR 2M budget over Months 0–120 (2026-10-31 to 2036-10-31). Maintains a public benchmarking page showing own bandwidth (pessimistic/central/optimistic) and rivals' systems, updated yearly; keeps neural data in the EU using federated-testing infrastructure.

Background Story: Dr. Alex Chen, 40, is a neural-decoding researcher and machine-learning engineer from Singapore, trained at MIT (PhD, neural signal processing, 2010) with 14 years in academic BCI research and two years in medtech (working on a non-implanted commercial BCI system that stalled). He is an expert in information-theoretic bandwidth measurement, has published extensively on held-out-task protocols and independent decoder validation, and is sceptical of bandwidth claims that include language-model expansion. He is known for insisting on reproducible, peer-reviewed methodology and for being willing to report disappointing results. His weakness is that he can get lost in algorithmic complexity and delay practical deployment, but that rigour is essential for credible bandwidth claims. He has relationships with EU decoder researchers (Grenoble, Utrecht, Munich) and is available now, motivated by the mission to keep decoding research in the EU and to prove that European systems can match US bandwidth claims independently.

Equipment Needs: High-performance GPU computing cluster for neural decoding algorithm development and real-time decoding inference (~EUR 200k–400k capital, ~EUR 50k–100k annual power and cooling); neural-signal processing software libraries and toolkits (MNE-Python, Kilosort, Spike2 or equivalent); machine-learning frameworks (PyTorch, TensorFlow); data-versioning and model-registry platforms (DVC, MLflow or custom); federated testing and privacy-preserving machine-learning infrastructure (to keep neural data in EU, no data export); decoder validation and bandwidth-measurement protocol software (information-theoretic tools, held-out-task simulation environments); bias-testing and explainability toolkits (for AI Act compliance); real-time decoding embedded systems (FPGA or specialized processors for on-device decoder runtime); electrode-signal characterisation and baseline-stability monitoring tools.

Facility Needs: Decoder & AI/ML Lab at Leuven or partner institution (KU Leuven AI/neuroscience centres, imec or Grenoble CEA-Leti if licensed), ~200–300 m² with high-speed internet (1 Gbps+) and secure EU-only data hosting. EU-hosted neural-data repository and compute servers (Belgium-registered data centre, GDPR-compliant, with encryption, access controls and audit logging for federated testing; separate from all US-cloud services). Cold-storage archive for consented trial neural data (long-term, immutable). Co-location with Chief Technology Officer and preclinical team for signal-characterisation work. Meeting space for monthly decoder-validation reviews with the Data Monitoring Committee. Remote collaboration infrastructure with federated testing partners (if any external EU labs participate in independent verification). Cybersecurity-hardened network perimeter: EU-only cloud services, no foreign dependencies for core decoder IP or training data.


Omissions

1. Explicit Investor Return Expectations and Cost-of-Capital Assumptions Absent

The plan specifies approximately EUR 2.5B total funding but does not state what return-seeking investors expect (IRR, payback period, exit horizon) or the cost of capital across seed, Series A, pivotal and scale-up phases. Investor return expectations directly determine capital availability, willingness to wait for CE marking at Month 132 (2037-10-31), and tolerance for kill gates. Tranches T0–T4 are specified (EUR 15M, EUR 120M, EUR 480M, EUR 900M, EUR 985M) but their justification and investor-term implications are not documented. Without these assumptions, financing gates are not credible and capital availability is unplanned.

Recommendation: By Month 3 (2027-01-31), define and document investor return expectations in writing: target IRR (e.g. 20–25% nominal), payback horizon (e.g. 10–12 years to first revenue), and exit scenarios (IPO, strategic sale, dividend from reimbursement). Model the EUR 2.5B envelope backwards from reimbursement revenue assumptions (price per implant, volume ramp, payer-adoption timeline) to confirm the return profile is achievable. Use this model to justify tranche sizes and set financing gates: if a tranche cannot be raised at proposed return terms, the gate fails and triggers a named fallback (pivot indication, slower scale, additional grant funding). Publish the return model to investors with monthly updates post-funding. Sensitivity: a 10-percentage-point IRR change reduces willing investors by 50–70% and delays Series A close by 6–12 months.

2. Unspecified Eligible-Population Epidemiology and Cumulative-Implant Validation

The plan targets 5,000 reimbursed implanted patients by Month 180 (2041-10-31) but does not quantify EU ALS incidence, survival rates, disease-progression phenotypes, or attrition due to competing treatments. Central estimates in the plan (about 1,050 cumulative implants, range 400–3,000) fall well short of 5,000 in all scenarios, yet the 5,000 figure remains unstated as a miss. ALS median survival is approximately 3 years post-diagnosis and less than 1 year for locked-in cases; this attrition is not modelled. The eligible-pool size per year (proposed: 500–1,400 in EU) and the surgical-centre capacity (proposed: about 12 implants per centre per year at about 25 centres = 300 per year) are not reconciled against the 5,000 target to show what indication expansion or population definition would be required.

Recommendation: By Month 6 (2027-04-30), commission an epidemiology study covering: (1) EU annual ALS incidence (approximately 5,000–7,000); (2) fraction meeting indication criteria (age, disease stage, communication loss, consenting capacity), estimated at 10–20% = 500–1,400 per year; (3) attrition due to disease progression and competing treatments; (4) net eligible-pool size assuming a 5-year trial ramp starting Month 60 (2031-10-31). Model cumulative implants under expert-centre (about 50–100 per year, reaching 250–500 by Month 180 = 2041-10-31) and distributed-centre (about 200–300 per year, reaching 1,000–1,500) scenarios. Report the realistic 5,000 target as unachievable under ALS-only indication unless definition expands dramatically. Trigger a pre-registered kill gate at Month 24 (2028-10-31) if eligible population is modelled at less than 1,000 cumulative implants, with options to pivot to spinal cord injury or combined indication.

3. Undefined Reimbursement Model and Payer-Acceptance Preconditions

The plan assumes payer engagement in Months 12–24 (2027-10-31 to 2028-10-31) but does not specify what payers must see to approve—clinical benefit threshold, health-economic ceiling (EUR per QALY, cost-benefit ratio), or comparator choice. A proposed price of EUR 150,000 per implant and cost-effectiveness ceiling of EUR 120,000 per QALY are stated but not justified against member-state thresholds or budget-impact limits. Outcome-based contracts are mentioned (paying in stages tied to benefit) but specifications are absent: what outcomes, what payment steps, what financial risk does the company bear? How many member states must reimburse for the 5,000-implant and revenue targets to hold? The plan does not validate whether the EUR 45M annual revenue at Month 180 (2041-10-31) (300 implants × EUR 150,000) reflects realistic payer acceptance.

Recommendation: By Month 9 (2027-07-31), define payer-acceptance criteria in writing: (a) primary comparators (eye-tracking, speech-synthesis devices, current assistive technology) and cost thresholds per indication (ALS communication: EUR 150,000–EUR 250,000 per implant for 5-year payer horizon; spinal cord injury motor: EUR 100,000–EUR 200,000); (b) health-economic targets: cost per QALY at 3× GDP per capita or lower (approximately EUR 80,000–EUR 120,000 per QALY in EU); (c) budget-impact limits: annual payer outlay less than 5% of neurology/rehabilitation budget. By Month 15 (2028-01-31), conduct pre-reimbursement dialogues with payers in at least three large member states (Germany, France, Benelux) and publish a reimbursement-feasibility summary. At Month 24 (2028-10-31) feasibility verdict, report which member states have signalled acceptance and at what price; if fewer than three, trigger a commercial-viability kill gate. For outcome-based contracts, specify the measurement burden on hospitals, the payment steps (e.g. 30% upfront, 40% at 6-month retention, 30% at 12-month benefit confirmation), and the company's financial risk.

4. Unquantified Chronic Signal-Stability Kill-Gate Thresholds and Device-Lifetime Implications

The plan identifies chronic electrode signal stability as a critical risk and proposes kill thresholds ('>20% signal loss within 12 months blocks first-in-human'; '>25% mean signal loss within 12 months triggers a pause'; '<50% retention at 36 months triggers architecture switch'), but does not justify these numbers or model implications for device lifetime, maintenance burden, or claim defensibility. The pre-registered thresholds are not anchored in preclinical data, published human data from competing programmes, or clinical unacceptability benchmarks. Without this grounding, kill-gate triggers will lack credibility with regulators and investors. Device lifetime (estimated 5–10 years) and reserve adequacy (EUR 30,000 per implant, proposed) depend on signal-retention projections that are not documented.

Recommendation: By Month 12 (2027-10-31), commission a chronic-stability modelling study covering: (1) preclinical data from 18–24 month animal studies: mean signal-loss trajectory, variance, distribution, tissue-response correlates; (2) published human data from competing programmes (Neuralink, Synchron, academic cohorts if available), showing signal loss over 3–5 years; (3) degradation-mode analysis (electrode encapsulation failure, tissue fibrosis, metal migration, user fatigue). Model forward to 5, 10 and 15 year horizons with pessimistic, central and optimistic scenarios. Define kill-gate thresholds as quantitative criteria tied to clinical unacceptability: e.g. '>30% signal loss by Month 24 (2028-10-31)' or 'sustained bandwidth drops below 5 bits/s in >20% of participants by Month 36 (2029-10-31)'. Link thresholds to device-lifetime warranties (e.g. 5-year warranty if stability is central estimate; 3-year if pessimistic). Estimate explantation frequency and cost (EUR 20,000–EUR 50,000 per case) affecting reserves. Report sensitivity: if signal loss is 1.5× worse than preclinical, what is the cost impact on reserves and scalability?

5. Unspecified Patient-Protection Reserve Governance, Triggering Mechanism and Adequacy Audit

The plan mentions ring-fencing EUR 50M–EUR 150M (estimate) in a patient-protection reserve but does not specify (1) per-implant allocation amount and growth schedule; (2) what events trigger draw-down (explantation, lifelong follow-up, company insolvency); (3) who governs the escrow (independent trustee, hospital network, member states); (4) how adequacy is audited; (5) what happens if reserves fall below adequacy. The proposal to start a EUR 5M floor before first-in-human and grow to EUR 150M at 5,000 implants (centre estimate about EUR 31.5M for 1,050 implants) is mentioned but operational governance is absent. Without these specifications, the reserve may be under-funded or over-funded, leaving implanted patients exposed to insolvency risk or development capital unnecessarily constrained.

Recommendation: By Month 6 (2027-04-30), establish a patient-protection reserve governance charter covering: (a) reserve account structure (separate trust, escrow or foundation outside investor reach); (b) per-implant allocation (proposed: EUR 30,000 per implant, starting Month 36 = 2029-10-31 when implants begin), growing to 100% target by Year 10 post-first-implant; (c) draw-down events: lifelong clinical follow-up (EUR 500–EUR 1,000 per year), device servicing or replacement (EUR 5,000–EUR 10,000 per episode), surgical explantation (EUR 20,000–EUR 50,000), emergency support if company insolvency (full coverage for remaining device lifetime); (d) governance: independent trustee (hospital network, member-state nominee, or professional fiduciary) with authority to approve draw-downs; (e) investment policy (conservative, low-risk); (f) annual adequacy audit by external actuaries, published. Tie investor terms to reserve funding: clarify that reserves are not available for operating capital. If reserves fall below adequacy, trigger a capital call or halt new implants. Publish reserve status quarterly. Sensitivity: underfunding by 50% leaves implants without adequate lifelong support; over-funding by 50% reduces development capital by EUR 50M–EUR 75M at crucial pre-approval phases.


Potential Improvements

1. Missing Explicit Minimum Viable Team Composition and Cross-Training Plan

The team document specifies eight roles (CEO, CMO, CTO, Chief Regulatory Affairs Officer, CFO, Chief Manufacturing & Supply-Chain Officer, Clinical Trials Manager, Decoder Lead) with background stories and 1–3 people per role, but does not specify the full founding team of approximately 10–15 people by Month 6 (2027-04-30) or cross-training plan. Gaps include: no dedicated quality-assurance manager until Month 9 (2027-07-31) (though ISO 13485 QMS is due Month 9 = 2027-07-31); no supply-chain analyst supporting the Chief Manufacturing & Supply-Chain Officer; no finance controller supporting the CFO; no regulatory submissions specialist supporting the Chief Regulatory Affairs Officer; no data manager supporting Clinical Trials. Single-person dependencies create risk: loss of the Chief Technology Officer, Chief Medical Officer or CEO before Month 12 (2027-10-31) would delay architecture choice, ethics approvals and investor relations by 3–6 months. The plan does not specify hiring timeline, onboarding sequence or cross-training by Month 12 (2027-10-31).

Recommendation: By Month 1 (2026-11-30), publish an explicit founding-team specification: (1) core eight leadership roles as specified; (2) supporting roles: quality-assurance manager (report to Chief Regulatory Affairs Officer, hire by Month 6 = 2027-04-30), finance controller (report to CFO, hire by Month 6 = 2027-04-30), supply-chain analyst (report to Chief Manufacturing & Supply-Chain Officer, hire by Month 6 = 2027-04-30), regulatory submissions specialist (report to Chief Regulatory Affairs Officer, hire by Month 9 = 2027-07-31), data manager (report to Clinical Trials Manager, hire by Month 6 = 2027-04-30); (3) deputies cross-trained for all leadership roles (CEO, CMO, CTO, Chief Regulatory Affairs Officer, CFO) by Month 12 (2027-10-31), with documented handover protocols. (4) Hiring timeline: founding CEO and CFO by Month 1 (2026-11-30); CMO, CTO, Chief Regulatory Affairs Officer by Month 3 (2027-01-31); Clinical Trials Manager, Chief Manufacturing & Supply-Chain Officer, Decoder Lead by Month 6 (2027-04-30); support roles by Months 6–9 (2027-04-30 to 2027-07-31). (5) Retention incentives: EUR 20,000–EUR 40,000 annual retention bonuses at 3 and 5 years for all leadership roles. (6) Competency assessment: competency-based job descriptions tied to regulatory milestones (e.g. notified-body engagement by Month 6 = 2027-04-30 requires Chief Regulatory Affairs Officer with notified-body pre-submission experience). This specification reduces hiring risk and clarifies accountabilities at each gate.

2. Missing Formal Competitive-Response Gate if US Device Enters EU Market First

The plan notes 'US competitors may obtain CE marking and enter the EU market first' and states EU patients would choose the device based on measured clinical benefit, local data, service and sovereignty, but does not specify when such a competitive entry would trigger a programme-viability reassessment, what evidence would trigger that gate, or what response strategies would be available. The timeline is vulnerable: US devices CE-marked during Months 36–60 (2029-10-31 to 2031-10-31) would precede the EU device's first-in-human (Month 60 = 2031-10-31) and certainly its CE marking (Month 132 = 2037-10-31). Early competitive entry could reduce the EU programme's eligible-population capture by 30–50%, materially affecting the 5,000-implant and revenue targets. Without a formal gate, the programme could continue accumulating costs on a weakened commercial assumption.

Recommendation: Define a Competitive-Response Kill Gate (Month 36–60 = 2029-10-31 to 2031-10-31): (1) Trigger: a US or Chinese device obtains CE marking and is actively marketed in any EU member state (verified by EMA/NANDO database or public announcement). (2) Evidence required to proceed: (a) health-economic and payer-acceptance evidence from at least three member states, showing that EU programme offers cost-effectiveness or outcome advantage over the US entrant; (b) neurological or functional outcome data from the US entrant publicly disclosed, enabling the EU programme to demonstrate non-inferiority or superiority in a key outcome (e.g. communication speed for ALS, motor control for SCI); (c) market-share analysis showing realistic EU programme capture path (e.g. 30% of EU implant market by Year 15 despite US entry). (3) Named response strategies: (a) accelerate pivotal indication to spinal cord injury motor control (if ALS-alone capture is <50% of baseline forecast); (b) offer outcome-based reimbursement contracts to differentiate from the US competitor on risk-sharing; (c) emphasise data sovereignty (EU-hosted neural data, no US company access) as a unique value proposition to member states and payers; (d) expand to non-communication indications (motor control, sensory restoration) to widen eligible pool. (4) Gate outcome: proceed with adjusted indication/scope, defer scaling until EU programme reaches CE marking with superiority claims, or stop and pivot to a research-only enhancement track. This gate is called at Month 36 (2029-10-31), 48 (2030-10-31) or 60 (2031-10-31) depending on when competitive entry is observed.

3. Missing Climate-Resilience Assessment and Thermal Design Validation

The plan requires a climate-resilience assessment for Leuven and assessment of heat risk to patients with impaired thermoregulation, but does not specify when that assessment is due, what findings would trigger fallback manufacturing or compute sites, what thermal specifications the wearable must meet, or how thermal deration of bandwidth (proposed: 50–70% throttling during heatwaves above 35°C) affects the kill-gate baseline. The plan mentions backup power and redundant cooling 'by Month 18 (2028-04-30)' but does not specify capacity requirements, cost or validation timelines. Leuven is exposed to multi-day heatwaves above 35°C, drought, flooding and power interruptions; without a detailed resilience plan, manufacturing (cleanroom cooling, sterilisation), preclinical labs (animal housing) and compute (neural-data hosting) face interruption risk. Patients with high spinal cord injury are at elevated heat risk and require cooling support protocols, adding a care-pathway obligation not yet costed.

Recommendation: By Month 3 (2027-01-31), commission a climate and infrastructure resilience assessment for Leuven covering: (1) heatwave frequency and intensity (multi-day episodes above 35°C, projected frequency increase); (2) drought impact on cooling-water supply and availability; (3) flood risk (groundwater, river overflow) affecting site integrity; (4) power reliability during extreme weather; (5) capacity of cooling systems (cleanroom, animal facilities, compute centres) to maintain operations during a 5-day 38°C heatwave; (6) backup power and redundancy requirements (uninterruptible power supplies, generator capacity, fuel reserves). If the assessment finds Leuven risk unacceptable (e.g. >2-day downtime expected every 5 years), establish a secondary manufacturing site (Netherlands, Germany or France) with defined technology transfer timeline and cost, budgeted in T1. By Month 18 (2028-04-30), install and validate backup power (UPS with 4-hour capacity + 500 kW generator) and redundant cooling (dual chiller loops, 20% over-capacity) at manufacturing and hosting sites; document and test failover (annual drill). Design the wearable for passive cooling and automatic throttling: (a) battery life of at least 12 hours at 25°C; (b) sustained operation (without throttling) to at least 32°C ambient; (c) automatic power reduction and bandwidth throttling at 35°C, capping at 50–70% sustained power; (d) thermal shutdown with audible alert at 40°C skin-contact temperature. Validate in climate-chamber tests (multi-day 35–40°C profiles, 50–80% humidity) by Month 18 (2028-04-30). Report thermal-derated bandwidth (e.g. 5 bits/s sustained instead of 10 bits/s) as the kill-gate baseline. Establish heat-alert protocols for trial participants: weekly heat forecasts, cooled-refuge referrals for participants with impaired thermoregulation (high spinal cord injury), and funding for cooled living-space support (estimated EUR 100–200 per participant per summer month). Sensitivity: failure to plan for heatwaves could result in 2–5 day manufacturing halts (EUR 100,000–EUR 500,000 loss per event), device throttling exactly when patients most need reliability, and inadvertent harm to heat-vulnerable participants.

4. Unspecified Data-Monitoring Committee Charter and Decision-Documentation Process

The plan specifies that an independent Data Monitoring Committee (DMC) is established by Month 6 (2027-04-30) and holds 'binding' authority to pause or recommend stop, with findings published 'within 30 days', but does not document: (1) DMC charter (appointment, term, conflict-of-interest policies, decision procedures); (2) meeting frequency and agenda (proposed: monthly, reviewing safety and bandwidth data); (3) what constitutes binding authority (can the board overrule? what triggers escalation to investors or regulators?); (4) decision-documentation format and publication process (public portal? confidential to board and regulators?); (5) communication protocol if the DMC finds a kill-gate threshold has been crossed (time-to-decision, notification of implanting hospitals, trial pause mechanics); (6) insurance or liability implications of binding stop authority. Without these specifications, the DMC's independence and binding authority may be questioned by regulators or ethics committees.

Recommendation: By Month 3 (2027-01-31), publish a DMC Charter (5–10 pages, public) covering: (1) governance: appointment by the company board (with ethics-committee veto authority over nominee selection), 5+ members (two independent statisticians/epidemiologists with device-trial experience, one patient representative, one ethics specialist, one independent clinician), 3-year terms, term limits (maximum two consecutive terms). Conflict-of-interest policy: no DMC member may be employed by the company, own company equity, or be part of the implanting clinical team. (2) Decision authority: binding authority to recommend pause, modification or stop of implantation based on pre-registered quantitative criteria; the company board must act on DMC findings within 5 business days (proceed, implement modifications, or stop), publishing the board's decision and rationale in writing. If the board declines to implement a DMC recommendation, the board's decision is escalated to the notified body and data-monitoring committee chair may notify the relevant ethics committees. (3) Meeting procedure: monthly meetings (virtual or in-person) reviewing safety data, adverse-event summaries, bandwidth metrics and protocol adherence; the company provides data packages (standardised safety tables, blind to treatment allocation if applicable) by the 5th of each month. (4) Documentation: each meeting produces a brief (2–3 page) report within 10 days covering findings, issues raised, recommendations and any data-safety concerns. Reports are shared with the company, the notified body and participating ethics committees; a summary (anonymised) is published on the company website within 30 days. (5) Escalation: if a pre-registered kill-gate threshold is crossed (≥3 SAEs in first 20 implants, bandwidth <5 bits/s in ≥50% of participants at Month 72 = 2032-10-31, invalid-consent findings), the DMC issues an urgent recommendation (within 2 business days) and the company immediately pauses new implants pending board and regulator review. (6) Liability: the company indemnifies DMC members for actions taken in good faith within the charter; insurance is obtained covering DMC actions.

5. Missing Strategy for Operating-Deficit Closure and Commercial Viability

The plan documents a projected operating gap of EUR 66M per year at Month 180 (2041-10-31) (estimated annual opex EUR 111M, revenue EUR 45M at 300 implants per year × EUR 150,000 per implant price), break-even at approximately 1,125 implants per year (about 3.75× the Month 180 = 2041-10-31 implant rate), and acknowledges the 5,000-implant target is not credibly achievable (central estimate about 1,050 by Month 180 = 2041-10-31). However, the plan does not specify how this gap is to be closed: whether the company intends to (a) reach break-even through accelerated scale-up (implying a 2030–2045 runway beyond Month 180 = 2041-10-31); (b) operate as a limited-profit-pool organisation sustained by member-state or Commission grants; (c) expand to non-EU markets or non-communication indications (motor control, sensory restoration) to increase volume; (d) rely on continued venture capital or debt financing to cover operating losses; or (e) explicitly accept a research-and-demonstration mission with scaled-back commercial targets. Without this clarification, the 15-year programme boundary and the investor-return expectations are incoherent.

Recommendation: By Month 9 (2027-07-31), model and publish three alternative commercial scenarios to Month 180 (2041-10-31) and beyond: (1) Base Case (as specified): about 300 implants per year at Month 180 (2041-10-31), about 1,050 cumulative, EUR 45M annual revenue, EUR 111M annual opex, EUR 66M annual deficit. Document explicitly that this trajectory does not achieve break-even and specify whether it represents acceptable performance (e.g. a research-funded demonstration mission) or a missed target requiring remediation. (2) Accelerated Scale Case: model conditions for reaching 1,125 implants per year (break-even) by Month 240 (2046-10-31): this would require (a) indication expansion to spinal cord injury motor control (3× eligible population), (b) distributed surgical centres (50+ across EU instead of 25), (c) reimbursement in 80%+ of member states, and (d) continued capital investment through Month 180 (2041-10-31) to fund scale-up. Specify the cost of this expansion, investor return expectations and the pathway to it. (3) Non-EU and Extended-Indication Case: model revenue from sales outside the EU/EEA (e.g. Japan, South Korea, Australia) if export controls permit, and from non-communication indications (motor control, sensory restoration, pain management). Estimate addressable markets, reimbursement likelihood and the cost of multi-country regulatory strategies. For each scenario, specify: (a) what is the implied investor return (IRR, payback period)?; (b) at what point does the company become cash-flow positive (Month N)?; (c) if break-even is not reached by Month 180 (2041-10-31), is the company intended to be sustained indefinitely by grants, or does it exit the market?; (d) what are the implications for implanted-patient continuity if the company is wound down? By Month 24 (2028-10-31) feasibility verdict, the company should commit to one scenario (with contingency pathways) and communicate it clearly to investors, regulators and member states.

6. Insufficient Detail on Fallback Partner Activation Timelines and Procurement Authority

The plan specifies three fallback sites (Ghent/Antwerp, Utrecht, Grenoble) for imec, KU Leuven and UZ Leuven, respectively, and states that fallback sites are 'activated by Month 6 (2027-04-30)' if a primary Leuven partner declines. However, it does not specify: (1) who has decision authority to activate a fallback (CEO alone? board? founding partners?); (2) what procurement happens at fallback activation (equipment orders, hiring, facility leases) and how quickly it can be executed; (3) how cost overruns from fallback activation (up to about EUR 2M estimated, 3–6 month delays estimated) are funded (existing contingency? new round?); (4) how commitments already made to primary partners (e.g. facility access agreements, staff secondment) are unwound; (5) what happens to intellectual property if a primary partner provided designs or prototypes. Absent these details, fallback activation may be delayed, disputed or under-resourced.

Recommendation: By Month 2 (2026-12-31), prepare a formal Fallback Activation Protocol (10–15 pages) covering: (1) decision trigger: written decline from any Leuven partner (imec, KU Leuven, UZ Leuven) received by Month 3 (2027-01-31) decision deadline; decision authority is the CEO (with board notification within 2 business days); (2) fallback site assignments: UZ Leuven declines → UMC Utrecht (Netherlands) or Ghent/Antwerp (Belgium) activated within 5 business days; imec declines → Grenoble CEA-Leti or German cluster (Dresden/Munich) activated within 5 business days; KU Leuven declines → Grenoble or Utrecht activated within 5 business days. (3) Fallback pre-qualification: conduct a rapid pre-qualification audit of fallback sites by Month 1 (2026-11-30), documenting capacity (cleanroom access, patient numbers, ethics approval timelines, surgeon credentialing), cost (incremental facility fees, travel, coordination overhead), and regulatory readiness (existing IRB relationships). Cost estimate: up to EUR 2M for facility setup and coordination overhead; timeline: 3–6 months for site qualification and ethics pre-submission. (4) Procurement actions at activation: (a) execute facility-access or partnership agreements with fallback site by Month 7 (2027-05-31); (b) initiate ethics submissions to fallback-site IRBs by Month 8 (2027-06-30); (c) hire liaison staff (clinical coordinator, regulatory liaison) by Month 12 (2027-10-31); (d) order long-lead-time equipment (if needed for preclinical work) by Month 9 (2027-07-31). (5) IP and prior commitments: primary-partner IP contributions (e.g. electrode designs from imec) remain company property under the field-limited licence; any technology transfer to fallback site is governed by the licence and must not dilute EU control. Primary-partner commitments (facility-access credits, seconded staff) are either transferred to fallback site or released with good-faith wind-down. (6) Funding: fallback activation is covered by existing T0 (EUR 15M) contingency (EUR 1M–EUR 2M allocated); if T0 is already committed and insufficient, the CEO and CFO declare a funding emergency at Month 6 (2027-04-30) and trigger an expedited bridge round. This protocol is signed by the CEO and CFO, approved by the board, and shared with all Leuven partners by Month 2 (2026-12-31) as a transparency measure.

7. Unclear Architecture-Ratification Process and Secondary-Fallback Specification

The plan names the primary architecture as 'high-density thin-film surface (epidural/subdural cortical) implant with wireless external processor' (provisional, ratified at Month 18 = 2028-04-30), with a contingency fallback to penetrating cortical at a cost of about EUR 30M (range 15–60M, estimate) and 12–24 months rework. However, it does not specify: (1) what evidence is required to ratify or reject the primary architecture by Month 18 (2028-04-30) (preclinical signal stability, patent clearance, surgical-risk assessment, manufacturing readiness scores); (2) what decision authority exists (CTO, technical board, independent architecture review)?; (3) what happens if the secondary fallback (penetrating cortical) also fails (is there a tertiary option, or does the programme stop?); (4) how the architecture choice affects the supplier roadmap, since chip and substrate suppliers may be optimised for one architecture but not another; (5) how the architecture choice affects the design-history file and later regulatory dossier (a late switch could reset clinical evidence).

Recommendation: By Month 12 (2027-10-31), prepare an Architecture Ratification Process (10–15 pages) covering: (1) evidence gates: (a) freedom-to-operate analysis for each architecture candidate (cortical penetrating, endovascular, surface epidural/subdural) completed by Month 6 (2027-04-30) with scoring on patent clearance, licensing cost, design-around risk; (b) chronic-stability animal studies (18–24 months) at 50% completion by Month 12 (2027-10-31) with preliminary signal-loss data; (c) surgical-risk assessment (procedural complexity, injury rates, implantation time) by Month 9 (2027-07-31); (d) manufacturing readiness assessment (yield projections, supplier availability, fab compatibility) by Month 9 (2027-07-31); (e) bandwidth potential (preliminary decoder testing on preclinical signals) by Month 15 (2028-01-31). (2) Decision authority: the CTO leads the architecture-selection process with input from the Chief Technology Officer, Chief Medical Officer, Chief Manufacturing & Supply-Chain Officer, and Chief Regulatory Affairs Officer; the company board (CEO, CFO, independent member if any) ratifies the choice by Month 18 (2028-04-30). (3) Scoring and weighting: architecture candidates are scored 0–10 on each criterion (patent clearance, surgical risk, stability, bandwidth, manufacturability, scalability), weighted by importance (patent clearance 20%, surgical risk 20%, stability 20%, bandwidth 20%, manufacturability 10%, scalability 10%); the primary architecture is the highest-scoring candidate. (4) Fallback specification: primary architecture is locked at Month 18 (2028-04-30); if chronic-stability thresholds at Month 72 (2032-10-31) show >30% signal loss, the secondary fallback (second-ranked architecture, usually penetrating cortical) is evaluated at Month 78 (2033-04-30); cost of switch is drawn from T3 contingency (EUR 30M estimated); if both primary and secondary fail stability, the programme pauses at Month 84 (2033-10-31) for a 6–12 month remediation period or switches to a research-only indication. (5) Design-history-file impact: the architecture choice is documented in the DHF by Month 18 (2028-04-30) with full justification and scoring; any subsequent architecture change requires a Major Design Change documentation package in the DHF and re-review by notified body (estimated 3–6 month delay). (6) Supplier lock: chip and substrate suppliers (MOUs signed Month 12 = 2027-10-31) are expected to support the ratified architecture; if the architecture changes, supplier re-qualification may be required, triggering a 6–12 month delay. This process is published by Month 1 (2026-11-30) to all stakeholders.

8. Missing Separation of Enhancement and Medical-Device Governance Firewalls

The plan specifies that 'Human-AI enhancement is a separate research track sharing hardware and IP only where that does not compromise the medical device, and the plan should manage how it is communicated'. It states that enhancement sits in a 'separate legal entity' with 'a documented firewall', and that 'no medical-tranche money' funds enhancement. However, the governance firewall specifications are sparse: (1) no legal structure is specified (separate company, research institute, non-profit); (2) no IP-sharing rules are documented (which IP can cross the firewall? who owns it?); (3) no communication guidelines specify how enhancement work is disclosed to regulators, ethics committees or the public without undermining the medical programme; (4) no funding mechanism is specified (where does the EUR millions for enhancement come from if not medical tranches?); (5) no independent ethics-review process for enhancement work is mentioned. Without clear firewalls, regulators or ethics committees could view the medical programme as a means to human enhancement, jeopardising patient recruitment and regulatory approval.

Recommendation: By Month 6 (2027-04-30), publish a Public Enhancement–Medical Firewall Charter (10–15 pages) covering: (1) Legal structure: enhancement research is conducted by a separate legal entity (e.g. BCI Research Institute, a non-profit foundation or consortium member), not the company or its subsidiaries. (2) Governance: enhancement entity has its own board (independent of company board), separate funding sources (not company medical tranches), and independent annual audit of firewall compliance. (3) IP and hardware sharing: (a) core medical-device IP (electrode designs, implant electronics, decoder algorithms trained on human trial data) remains company property and is not shared with enhancement entity; (b) upstream research (electrode materials, signal-processing theory) or non-clinical hardware (non-implanted recording systems, in-vitro models, animal research using non-implanted devices) may be shared under a licensing agreement, with published terms; (c) any derivative IP created by enhancement entity using shared upstream research is owned by enhancement entity but licensed back to company on pre-agreed terms (e.g. non-exclusive for medical use, exclusive for enhancement use). (4) Communication and disclosure: (a) all enhancement publications and announcements are reviewed for accuracy and must not overstate bandwidth claims or imply timelines for human enhancement (no statements like 'brain-computer merger within 5 years'); (b) enhancement entity publishes a public roadmap and annual progress report, distinguishing what is research (theoretical, pre-animal) from clinical-stage work (prohibited before company CE marking); (c) company's intended-use statement in the regulatory dossier includes only medical applications (communication restoration, motor control), with explicit exclusion of enhancement, and is reviewed by notified body and ethics committees; any ethics committee or regulator inquiry about enhancement intent is answered with the published firewall charter and the company's stated intended-use limitation. (5) Independent ethics oversight: enhancement entity establishes an external advisory board with members from ethics, neuroscience and public engagement, which reviews enhancement proposals for scientific validity and societal impact; the board's findings are published annually. (6) Funding: enhancement entity is funded separately (e.g. from EU Horizon Europe grants, member-state research funds, philanthropic sources); the charter explicitly forbids use of company medical revenues or investor capital to fund enhancement work. (7) Compliance audit: an independent external auditor reviews firewall compliance annually (IT systems isolation, personnel separation, financial separation, publication review) and publishes findings. The charter is approved by the company board, the enhancement entity board, and the initial notified body (pre-submission) and communicated to investors and member states. This charter is signed by Month 3 (2027-01-31) to clarify the medical programme's focus.

Critique and recommended actions from domain experts.

1 Expert: Medical Device Regulatory Affairs Director (Class III MDR & Notified Body Strategy)

Knowledge: EU MDR Class III device approval, notified-body engagement, clinical investigation authorisation, post-market surveillance, AI Act high-risk medical device compliance, international regulatory harmonisation

Why: The plan's success depends critically on securing notified-body alignment and CE marking by Month 132 (2037-10-31), with slippage risk to Month 144-156 (2038-10-31 to 2039-10-31). The expert reviews the Evidence and Regulatory Strategy decision, the AI Act change-control framework (EUR 2M budget), the preliminary QMS audit trigger (Month 18 = 2028-04-30), and scientific-advice sequencing. They validate whether the evidence package (chronic animal data, first-in-human design, decoder version-lock) meets notified-body expectations and whether thresholds set before data (e.g., 25% signal loss kill gate) are defensible under MDR scrutiny.

What: Audit the regulatory milestones (notified-body engagement Month 6 = 2027-04-30, QMS Month 9 = 2027-07-31, scientific-advice request Month 12 = 2027-10-31, preliminary audit Month 18 = 2028-04-30, architecture lock Month 18 = 2028-04-30) and validate the AI Act compliance roadmap. Confirm that decoder change-control rules align with post-CE modification thresholds. Identify unmet notified-body dialogue on pivotal-trial evidence design before Month 18 (2028-04-30) architecture lock, so rework does not slip CE marking.

Skills: Notified-body liaison and dossier management, MDR annex compliance, clinical-investigation protocol design under ISO 14155, AI Act risk classification and change-control governance, quality-management documentation, regulatory timeline and risk mapping

Search: MDR Class III regulatory affairs, notified body engagement medical devices, AI Act high-risk device compliance, clinical investigation authorisation

1.1 Primary Actions

1.2 Secondary Actions

1.3 Follow Up Consultation

Recommend next consultation at Month 1 (2026-11-30) to review partner-outreach templates, anchor-investor criteria and gate decision-authority documents before sending. At Month 6 (2027-04-30), review partner LOI status and foundry commitment signals; finalize notified-body engagement and DMC charter. At Month 12 (2027-10-31), review T0 close status and gate verdict drafting; confirm scientific-advice request. At Month 18 (2028-04-30), review architecture ratification and FTO results; assess supplier MOUs and QMS audit findings. At Month 24 (2028-10-31), review feasibility-verdict drafting and indication-pivot gate criteria; confirm payer-acceptance and eligible-population analysis results. Key decision points: Month 3 (2027-01-31) (partner LOIs), Month 12 (2027-10-31) (T0 and G1), Month 18 (2028-04-30) (architecture and foundry switch decision), Month 24 (2028-10-31) (feasibility verdict and indication pivot gate).

1.4.A Issue - Financing structure is aspirational, not credible; gates lack enforcement mechanisms and fallback trigger clarity.

The plan assumes EUR 0 at Month 0 (2026-10-31) and EUR 2.5B committed over tranches T0–T4, but specifies no investor commitment letters, return expectations, or cost-of-capital assumptions. Gate G1 (Month 12 = 2027-10-31) requires EUR 10–15M 'committed in writing', yet no underwriter or anchor investor is named. If G1 fails, the plan says 'stop, defer or switch' but does not specify: who decides? How many days to decision? What is the alternative 'switch' pathway? The IPCEI foundry (EUR 350M, four+ member states) is hoped-for; if it fails at Month 18 (2028-04-30), dual-sourcing adds EUR 35M and 6–12 months, which compresses CE marking and strains T1–T2, yet no reallocation rule is pre-registered. The result is that gates are advisory, not binding.

1.4.B Tags

1.4.C Mitigation

By Month 1 (2026-11-30): name at least three anchor investors (strategic, venture or public) and publish their written criteria for G1 commitment (e.g., 'EUR 10M on architecture lock + FTO clear + notified-body pre-submission held'). By Month 3 (2027-01-31): publish a 'Gate Decision Authority and Timeline' document naming the board, independent trustees, or an investor syndicate with binding veto power; commit to a written verdict within 5 business days of each gate. By Month 6 (2027-04-30): if foundry commitments from four+ member states are not in writing, execute the dual-sourcing decision immediately (do not defer to Month 18 = 2028-04-30). Reallocation: if foundry fails, T1 automatic +EUR 35M draw, shifting T2 start by 6 months and CE marking to Month 138 (2038-04-30) (estimate); document this in the tranche schedule before Month 12 (2027-10-31).

1.4.D Consequence

Without named investors and binding gate authority, a missed funding gate will trigger 3–6 months of board negotiation, scope renegotiation and delay. During this gap, the team cannot commit spend, cannot hire, and will lose founders and early staff to more-certain competitors. The result: project attrition, broken partner relationships (Leuven or fallback sites), and eventual abandonment or a defaulting of critical milestones (architecture lock, FTO, consent safeguards) into a compressed Months 24–36 (2028-10-31 to 2029-10-31) window, raising rework and failure risk.

1.4.E Root Cause

The plan treats financing gates as thresholds for good governance but does not operationalise them as hard stops. Founders are asked to raise money without pre-agreed investor personas, return structures or syndicate roles. Decisions are assumed to occur 'by consensus' without naming who has authority, so gates become aspirational targets rather than binding decision points. The foundry dependency is listed but not locked, so its failure is treated as a 'switch' rather than an automatic trigger with pre-costed alternatives.

1.5.A Issue - The 5,000-implant target is not credibly achievable and is mis-stated as a 'miss' rather than a false requirement; the plan does not account for the commercial-viability consequence.

The plan states the 5,000-implant target is 'missed in all scenarios' and reports 1,050 cumulative implants at Month 180 (2041-10-31) (central case). Yet it also reports revenue EUR 45M per year (300 implants/year × EUR 150,000) against opex EUR 111M per year, an operating gap of EUR 66M/year and break-even at 1,125 implants/year. The plan does not state: is the company profitable at 1,050 implants? (Answer: no, it is EUR 7.5M short per year.) Does the EUR 2.5B envelope cover the EUR 66M/year gap through Month 180 (2041-10-31)? (Calculation: 36 months at EUR 66M/year = EUR 198M; the plan has EUR 985M in T4 (Months 132–180 = 2037-10-31 to 2041-10-31), so yes, barely, but the company never reaches positive cash flow and survives only via continued investor subsidy.) The plan does not propose a revised success criterion or mission change, nor does it discuss whether the medical benefit justifies a subsidy model or whether the indication should pivot to spinal cord injury to reach viable scale.

1.5.B Tags

1.5.C Mitigation

By Month 12 (2027-10-31): commission an independent health-economic and eligible-population analysis covering: (a) ALS population aged 40–75 in EU/EEA, annual incidence, time-to-locked-in, eligible-pool size (current estimate: 500–1,400/year); (b) competing endpoints (communication vs. motor control) and willingness-to-pay from three HTA bodies (target: EUR 120,000–150,000/QALY); (c) spinal cord injury eligible pool (estimate: 2,000–5,000/year in EU) and motor-control outcome evidence; (d) centre capacity and procedural learning curve (10–20 implants/centre/year assumed, not validated). By Month 24 (2028-10-31), pre-register a 'Indication Pivot Gate': if eligible-ALS-pool analysis shows <800 per year and payers reject communication-only endpoints, mandate a pre-registered decision to switch to spinal cord injury or to accept a subsidy model. Document the subsidy model, if chosen: e.g., 'The device is a public-health good; the company is funded via grants and member-state co-payments, not private returns.' Define investor return expectations (IRR, horizon) up-front; if they require >10% IRR, the ALS programme is not viable and the company should not be formed.

1.5.D Consequence

The plan will run out of money or reach Month 180 (2041-10-31) with a company that has never been profitable and depends entirely on continued investor subsidy. This creates three risks: (1) Investors will lose confidence after Month 36–60 (2029-10-31 to 2031-10-31) when the commercial gap becomes visible, triggering a funding crisis that forces cost-cutting mid-programme (compromising safety or consent); (2) The company's continuity depends on multi-investor syndication, not a sustainable revenue model, which contradicts the 'patient-protection covenant' pledge of lifelong support; (3) If the company fails in Months 60–120 (2031-10-31 to 2036-10-31) when implanted patients exist, the patient-protection trust may be insufficiently sized to cover explantation, follow-up and replacement, violating the hard requirement of not abandoning patients.

1.5.E Root Cause

The plan treats 5,000 implants as a target but does not validate it against eligible-population epidemiology or payer willingness-to-pay. It reports the miss as a 'soft estimate' and moves on, without asking whether the indication or device positioning should change. The commercial-viability calculation (revenue vs. opex) is presented, but the implication—that the company is perpetually subsidy-dependent—is not addressed. The result is a plan that appears to proceed as if 1,050 is acceptable, yet still describes itself as having 'missed' 5,000, which is contradictory and masks a deeper decision: is this a commercial enterprise or a public-health programme?

1.6.A Issue - Leuven partner commitments are assumed, not secured; fallback sites are named but not pre-qualified; the plan lacks a go/no-go decision tree if primary partners decline.

The plan states 'imec, KU Leuven and UZ Leuven, none of which has committed to partner' and lists 'Ghent/Antwerp, Utrecht, Grenoble' as fallbacks without letters of intent, capacity assessments or cost estimates per site. The assessment says 'Secure hard commitments by Month 3 (2027-01-31)' but the plan does not specify what 'hard' means: a letter of intent? A resource-commitment memo? A signed MOU with specific deliverables (staff, facility hours, patient cohort) and decision timelines? If UZ Leuven (neurosurgery and ALS patient access) declines by Month 3 (2027-01-31), the plan says activate fallback by Month 6 (2027-04-30), with 'FIH +3–6 months', but does not say: which fallback is activated first? Are all three contacted in parallel (slowing decision) or sequentially (adding 3–6 months per decline)? What is the cost per fallback—imec has a EUR 300M cleanroom; Ghent/Antwerp hospitals have none. The plan also does not state what happens if a secondary commitment fails mid-way (e.g., imec's cleanroom capacity is consumed by existing projects by Month 9 = 2027-07-31).

1.6.B Tags

1.6.C Mitigation

By Month 1 (2026-11-30): send written partnership scopes to imec (cleanroom, electrode and ASIC prototyping, 12 months, estimated cost EUR 0.5–1M), KU Leuven (neuroengineering team secondment or contracting, 5 FTE, EUR 0.75–1.5M) and UZ Leuven (neurosurgery, operating theatres, ALS patient cohort, first-in-human feasibility, clinical trial hosting, estimated cost EUR 0.5–1M). Request signed LOIs by Month 3 (2027-01-31) specifying committed staff, facility hours (e.g., '200 hours/month imec cleanroom time'), patient-access commitments ('50 ALS patients screened by Month 24 = 2028-10-31'), and decision timeline ('board approval by 2027-01-15'). In parallel, contact Ghent/Antwerp, UMC Utrecht and CEA-Leti/Clinatec with identical scopes and request backup LOIs by Month 3 (2027-01-31). By Month 2 (2026-12-31), publish a 'Partner Decline Decision Tree': (a) if imec declines, activate CEA-Leti/Clinatec for cleanroom within 1 week (pre-identified contact, pre-quoted cost EUR 1–1.5M, 6-month lead time); (b) if UZ Leuven declines, activate UMC Utrecht within 1 week (pre-identified neurosurgery lead, pre-screened patient access); (c) if KU Leuven declines, contract external neuro-engineers within 2 weeks. At each activation, a 1-month clock starts; if the fallback LOI is not signed by Month 4 (2027-02-28), escalate to the board with a 'defer-or-stop' recommendation. Publish the decision tree to investors and the Commission before Month 1 (2026-11-30) ends.

1.6.D Consequence

Without pre-qualified fallbacks and a decision tree, the project enters a 'soft partner negotiation' state at Month 3 (2027-01-31) that could extend to Month 6 or 9 (2027-04-30, 2027-07-31), consuming founder time and delaying all technical and regulatory work. If a partner declines mid-programme (e.g., imec's cleanroom is over-allocated at Month 6 = 2027-04-30), the company faces a 3–6 month delay and a scramble to find alternative capacity, during which the FIH timeline slips, the team morale erodes, and early-stage investors become anxious about execution risk. The absence of cost pre-quotes per fallback means a secondary partnership could consume 20–30% of the T0 budget (EUR 15M), cascading into hiring freezes or missed gates.

1.6.E Root Cause

The plan lists the three Leuven institutions and three fallback sites as if partnerships are equivalent in cost and capability, but they are not. imec has industrial-scale cleanroom infrastructure; Ghent/Antwerp hospitals do not. UZ Leuven has an embedded ALS research clinic; other hospitals require patient-access agreements with ethics committees and delays. The plan does not pre-negotiate or pre-cost this variability, so partner selection appears flexible in the plan but is operationally rigid. The absence of a published decision tree means the founders will improvise responses if a partner declines, leading to delays and ad-hoc cost overruns.


2 Expert: Supply Chain & Manufacturing Sovereignty Lead (EU-Controlled Production, Pilot-Line Transfer, Dual-Sourcing)

Knowledge: Medical-device supply-chain strategy, pilot-line-to-validated-production transfer, dual-source qualification, export-control screening, EU/EEA supplier vetting, production-line validation and yield optimisation, quality systems transfer

Why: The plan rests on passing three EU-control tests on all components (ownership, maintainability without foreign consent, export-control freedom) by Month 72 (2032-10-31), with a critical path through design lock (Month 18 = 2028-04-30) → materials and process lock (Month 72 = 2032-10-31) → CE marking (Month 132 = 2037-10-31). The expert evaluates the Neural-Implant Foundry decision: whether the chosen dual-sourcing route for chips and substrates, in-house encapsulation and assembly, and pilot-line-to-production transfer are feasible, costed and scheduled correctly. They validate the upstream-dependency register (Month 12 = 2027-10-31) and advise on foundry-commitment fallbacks (Month 18 = 2028-04-30 gate).

What: Review the supply-chain architecture (which components are vertical, which dual-sourced, which licensed). Validate the sovereignty tests per supplier by Month 12 (2027-10-31): which foreign dependencies remain, and how are they mitigated? Confirm the pilot-line-to-Class-III transfer plan is budgeted in T1 (EUR 10M estimated) and gated before design lock. If the shared foundry (EUR 350M, 4+ member states) is not committed by Month 18 (2028-04-30), confirm the dual-sourcing fallback adds EUR 35M and 6-12 months, and cost it within T1/T2.

Skills: Supply-chain risk mapping and dual-source qualification, pilot-to-production transfer planning, ISO 13485 supplier audit and management, export-control compliance and restricted-items screening, manufacturing process lock and change control, yield analysis and contingency costing

Search: EU medical device supply chain sovereignty, dual sourcing qualification strategy, pilot line to production transfer, MDR supplier audit

2.1 Primary Actions

2.2 Secondary Actions

2.3 Follow Up Consultation

At Month 3 (2027-01-31) and Month 12 (2027-10-31) gates, review: (1) Leuven partnerships (written LOIs or fallback activation); (2) financing commitments (seed closes, T0 written, investor term sheets); (3) eligible-population epidemiology and payer willingness-to-pay (must be submitted before Month 18 = 2028-04-30); (4) FTO results and architecture selection (must be complete by Month 18 = 2028-04-30); (5) DMC charter, kill gates and consent protocol (must be published by Month 3.5 = 2027-02-15); (6) notified-body pre-submission feedback (expected Month 7 = 2027-05-31); (7) ISO 13485 QMS status and design-history file maturity. At Month 24 (2028-10-31), issue a final six-part feasibility verdict covering financing (committed versus hoped-for), population and reimbursement (payer validation), regulatory (notified-body alignment), supply-chain (foundry decision), clinical (consent readiness) and technical (architecture confidence). If financing, payer commitment or population viability is unresolved, defer implant programme and execute a research-only phase (Months 24–48 = 2028-10-31 to 2030-10-31) with reduced burn.

2.4.A Issue - Leuven partnership commitment is missing and poses an existential feasibility risk

The plan assumes imec, KU Leuven and UZ Leuven partnership by Month 3 (2027-01-31) but no written commitments exist at Month 0 (2026-10-31). This is not a secondary dependency; it is the foundation of the entire supply chain, clinical trial infrastructure and manufacturing roadmap. A decline by any institution at Month 3 (2027-01-31) would trigger a 3–6 month fallback activation and up to EUR 2M additional cost. The plan is operationally incoherent without these partnerships locked before MVP hiring and facility agreements are signed.

2.4.B Tags

2.4.C Mitigation

By Month 0.5 (2026-11-15 14:00), contact imec, KU Leuven and UZ Leuven with a detailed partnership scope document specifying resource commitments, facility access, patient cohort access and decision timelines. Secure written letters of intent (not oral consent) by Month 3 (2027-01-31 16:00) from all three. In parallel, by Month 0.5 (2026-11-15), initiate equivalent pre-discussions with UMC Utrecht, Ghent/Antwerp University Hospital and CEA-Leti/Clinatec, requesting backup LOIs by Month 3 (2027-01-31 16:00). If any primary institution declines, activate the first-ranked fallback by Month 3.5 (2027-02-15) and compress site qualification to 12 weeks, with ethics pre-submission by Month 6 (2027-04-30 16:00).

2.4.D Consequence

Without written LOIs by Month 3 (2027-01-31), the programme cannot close seed funding (investors require confirmed partnerships), cannot sign facility leases or cleanroom access agreements, and cannot hire clinical and engineering staff with confidence. A delay in securing partnerships by 6 months compresses the entire first-in-human pathway by 6–12 months and forces design choices under schedule pressure. A partnership failure forces a 3–6 month fallback activation, moving FIH from Month 60 (2031-10-31) to Month 63–66 (2032-01-31 to 2032-04-30) and delaying CE marking by the same margin. This also undermines the financing narrative: investors will not commit T0 capital until partnerships are locked.

2.4.E Root Cause

Empty

2.5.A Issue - Financing gates lack written investor commitments and fallback mechanisms; the EUR 15M T0 and EUR 60M T1 are hoped-for, not secured

The plan defines financing gates at Months 12, 24 and 36 (2027-10-31, 2028-10-31, 2029-10-31) but states EUR 0 committed at Month 0 (2026-10-31). No investor return expectations, cost-of-capital assumptions or written pre-agreements exist. Gate G1 requires EUR 10–15M T0 in writing by Month 12 (2027-10-31), but there is no documented investor anchor, no pre-negotiated terms and no written fallback if the gate is missed. This violates the hard requirement that 'no funding commitments may be assumed'. The gate structure is aspirational, not feasible.

2.5.B Tags

2.5.C Mitigation

By Month 1 (2026-11-30 16:00), identify and approach at least four candidate investor anchors (EU strategic investors, impact funds, or public financing institutions) with a 5-slide investment memorandum covering: (a) the risk-retirement roadmap and gate criteria; (b) investor return expectations (IRR, horizon, exit scenario); (c) capital requirements per tranche; (d) downside protection (patient-protection reserve, clear kill-gate authority). Negotiate term sheets with at least two anchors by Month 3 (2027-01-31 16:00), targeting EUR 3–5M seed closes by Month 3.5 (2027-02-15) and written T0 commitments by Month 9 (2027-07-31). Define fallbacks in writing: if T0 is not committed by Month 11 (2027-09-30 16:00), immediately pause non-critical hiring and defer full-scale animal studies to a 'reduced-scope' mode; if T0 is not closed by Month 12 (2027-10-31 16:00), automatically defer FIH by 12 months and reduce team to 5 core staff.

2.5.D Consequence

Without written investor commitments, the company cannot secure cleanroom or lab space, cannot hire the team documented in the plan (10 by Month 6 = 2027-04-30, 15 by Month 24 = 2028-10-31), and cannot fund chronic animal studies (budgeted at EUR 1.5–2M). Missing gate G1 at Month 12 (2027-10-31) forces a cascading deferral: FIH moves from Month 60 (2031-10-31) to Month 72–84 (2032-10-31 to 2033-10-31), CE marking slips from Month 132 (2037-10-31) to Month 144–156 (2038-10-31 to 2039-10-31) and the commercial case weakens further (fewer implants, lower cumulative revenue). A second missed gate (G3 at Month 24 = 2028-10-31) stops the implant programme entirely. The current gate structure is too permissive; it allows narrative renegotiation instead of automatic deferral or termination.

2.5.E Root Cause

Empty

2.6.A Issue - The 5,000-implant target is not credibly achievable and is already reported as missed; commercial viability and payer case are not grounded in eligible-population reality

The plan acknowledges that the 5,000-implant target is 'missed in all scenarios', with a central estimate of 1,050 cumulative implants by Month 180 (2041-10-31) and a break-even requiring 1,125 implants per year. However, the canonical eligible-pool estimate is 500–1,400 per year, implying a market size of only 7,500–21,000 people over 15 years across the entire EU/EEA. The ALS-only pool is at the lower end. Yet the reimbursement case, payer engagement strategy and investor return expectations are not documented against this constrained population. There is no demonstrated payer willingness to pay EUR 150,000 per implant or cost-effectiveness evidence at EUR 120,000 per QALY. This is the difference between an unproven clinical tool and a commercial medical device.

2.6.B Tags

2.6.C Mitigation

By Month 9 (2027-07-31), commission an independent epidemiological analysis of ALS and high-spinal-cord-injury populations across EU member states, estimating annual eligible prevalence (age, severity, progression rate), annual incidence, attrition and centre/theatre capacity. Cross-check against published registries (e.g., EuroMND for ALS). By Month 12 (2027-10-31), initiate pre-reimbursement dialogues with HTA bodies in Germany, France, Italy, the Netherlands and Scandinavia, presenting: (a) the eligible-population epidemiology; (b) health-economic endpoints (QALYs, cost per QALY, cost per case); (c) comparator technology (eye-tracking, P300, speech synthesis) and measured daily-life benefit. Request written indication of payer willingness-to-pay thresholds and evidence gaps by Month 18 (2028-04-30). If payers will not commit to EUR 120,000 per QALY or higher, the cost-effectiveness case collapses and the indication strategy must change at the Month 24 (2028-10-31) feasibility gate.

2.6.D Consequence

The plan is incoherent if it pursues ALS-only without demonstrating payer acceptance and viable population scale. The current trajectory—1,050 implants, 300 implants per year at scale, an operating gap of EUR 66M per year—is unsustainable unless the company is treated as a public health infrastructure (subsidised indefinitely) or unless the indication expands to spinal cord injury or other conditions with larger eligible pools. Without documented payer commitment by Month 24 (2028-10-31), the feasibility verdict should be 'not credibly achievable' and the programme should either (a) defer commercial rollout and continue as a research/pilot programme, or (b) pivot to a broader indication (spinal cord injury, stroke, locked-in syndrome) that is decided at the pre-registered Month 78 (2033-04-30) gate. Proceeding to pivotal trials without this clarity risks abandoning patients if the company runs out of money at Years 12–15.

2.6.E Root Cause

Empty


3 Expert: Clinical Evidence & Health Economics (Reimbursement, Eligible Population, Payer Strategy)

Knowledge: Health technology assessment and payer negotiation, ALS epidemiology and natural history, assistive-technology market and reimbursement thresholds, cost-effectiveness and quality-adjusted-life-year modelling, clinical-endpoint design, indication-expansion strategy

Why: The plan's financial case hinges on whether EUR 150,000 price and 1,050 cumulative implants (estimated) by Month 180 (2041-10-31) support break-even (1,125 implants/year). The expert audits the First Indication and Outcome That Justifies Surgery decision (ALS communication vs. spinal cord injury), validates the eligible-population epidemiology (500-1,400 per year), and tests whether reimbursement and cost-effectiveness ceilings are payer-realistic. They advise on the pivotal indication gate (Month 78 = 2033-04-30), where the plan defers a commitment to ALS-only versus spinal cord injury. They also assess the communication-restoration outcome versus eye-tracking comparator credibility.

What: Commission or review an eligible-population epidemiology for ALS communication restoration across 3+ member states by Month 9 (2027-07-31). Initiate pre-reimbursement dialogues with payers in at least three member states by Month 15 (2028-01-31) to validate: (a) whether EUR 150,000 price is acceptable, (b) what daily-life benefit evidence is needed (beyond bandwidth), and (c) whether the indication should pivot to spinal cord injury. Model the revenue and break-even against the population forecast and implant ceiling.

Skills: HTA and reimbursement evidence requirements, ALS natural history and progression, comparative-effectiveness study design (communication technology, assistive devices), cost-effectiveness modelling and QALY estimation, payer negotiation and pricing strategy, eligible-population epidemiology and centre-capacity forecasting

Search: ALS patient population epidemiology Europe, brain computer interface reimbursement strategy, health technology assessment medical devices, assistive technology cost effectiveness

3.1 Primary Actions

3.2 Secondary Actions

3.3 Follow Up Consultation

Next consultation should focus on three topics: (1) Payer and HTA outcome: report results of engagement with three member-state HTA bodies by Month 18 (2028-04-30). If payers accept EUR 150k and cost-effectiveness ceiling, lock it into the pivotal plan; if not, present alternative prices or indications and re-cost the commercial case. (2) Chronic-stability preclinical data and revised kill-gate thresholds: present animal-study results, literature synthesis and DMC-recommended threshold changes by Month 18 (2028-04-30), and lock them in the first-in-human protocol by Month 24 (2028-10-31). (3) Leuven partner status: report written LOIs or fallback activations by Month 6 (2027-04-30). At Month 24 (2028-10-31), publish a final six-part feasibility verdict: scientific, engineering, clinical, regulatory, supply-chain and financing. If financing remains unconfirmed, deferral to a narrower ALS-feasibility phase (Months 24-48 = 2028-10-31 to 2030-10-31) should be named explicitly.

3.4.A Issue - Reimbursement and Payer Case Completely Unvalidated; Market-Access Strategy Is Speculative

The plan proposes EUR 150,000 per implant and EUR 120,000 per QALY but reports zero payer or HTA engagement to date. No health-economic model exists; cost per QALY is unmodeled and unvetted. The commercial case (EUR 45M revenue vs. EUR 111M opex at Year 15, EUR 66M annual gap) assumes payer reimbursement without evidence that three or more member states will accept either the price or the indication. Eligible-population epidemiology is missing; the 1,050-implant estimate lacks bottom-up validation against centre capacity, reimbursement coverage and actual patient demand.

3.4.B Tags

3.4.C Mitigation

Commission a formal health-economic model and eligible-population epidemiology by Month 9 (2027-07-31). Engage three member-state HTA bodies (e.g., UK NICE equivalents, Haute Autorité de Santé, G-BA or equivalent) by Month 15 (2028-01-31) with a draft reimbursement dossier. Test willingness to pay at EUR 150,000 and cost-effectiveness threshold tolerance. Bottom-up eligible-population validation: count annual ALS incidence (1-2 per 100k across EU), estimate communication-impairment prevalence (15-20% of ALS), and screen against centre surgical capacity and patient consent likelihood. Adjust price or indication if payer feedback shows EUR 150k is unacceptable or if eligible pool is <300 per year. Publish findings by Month 24 (2028-10-31) as a mandatory input to the pivotal-indication gate.

3.4.D Consequence

Without payer validation, the commercial case remains speculative. The company risks designing and manufacturing for a market that rejects the price or lacks sufficient eligible patients. If payers demand EUR 50-80k instead, the EUR 111M annual opex cannot be covered by 1,050 implants and the company will run out of reserves. Alternatively, the indicated population may be 50% smaller than estimated, making 1,050 impossible and forcing closure before or shortly after CE marking. This is a leading cause of medtech failure: clinical success without reimbursement.

3.4.E Root Cause

The plan was built around the long-term bandwidth mission and sovereignty requirements, not around reimbursement feasibility. Payer engagement and health-economic modeling were deferred as secondary, even though they determine whether the 5,000-patient (or revised 1,050-patient) business case is viable. The plan notes the gap but does not gate capital release on resolving it.

3.5.A Issue - Chronic Signal Stability Kill Gates Lack Preclinical Grounding; Threshold Credibility Uncertain

The plan proposes that >20% signal loss in animals blocks FIH and >25% in humans triggers pause, but provides no published animal or human data supporting these thresholds. No chronic rat, primate or human evidence is cited. The thin-film surface architecture (provisional until Month 18 = 2028-04-30) has limited long-term published data outside Clinatec (WIMAGINE) and UMC Utrecht. If preclinical work shows 15-20% loss is normal for thin-film, the gate threshold becomes meaningless; if 30%+ loss is observed, architecture switch costs EUR 30M and 12-24 months, compressing the entire timeline.

3.5.B Tags

3.5.C Mitigation

Before Month 18 (2028-04-30), complete a 12-18 month chronic-implant animal study (minimum 6 implants, sheep or primate) documenting electrode signal amplitude, noise floor, usable-channel count and their decay over 12 months. Commission a literature synthesis of published thin-film, penetrating and endovascular signal-stability data from Clinatec, UMC Utrecht, Neuralink, Synchron and academic sources by Month 9 (2027-07-31). Convene a Data Monitoring Committee working group to re-examine kill thresholds against this evidence and propose evidence-grounded alternatives by Month 15 (2028-01-31). If preclinical data shows thresholds must be relaxed (e.g., 30% loss is normal), update gates and publish the revision; if data supports the threshold, lock it in the first-in-human protocol by Month 24 (2028-10-31). Plan for a contingency cost of EUR 30M if architecture switch is triggered.

3.5.D Consequence

Kill gates without grounded thresholds lose regulatory and ethics credibility. A notified body or ethics committee may reject a gate that looks arbitrary. Alternatively, if thresholds are too tight, the company risks being forced into an unplanned EUR 30M architecture switch at Month 24-36 (2028-10-31 to 2029-10-31), compressing FIH and delaying CE marking by 12-24 months. If thresholds are too loose, the programme may continue with unstable electrodes that fail clinically, leading to patient harm and regulatory shutdown. Either way, the decision loses authority and the programme loses time or credibility.

3.5.E Root Cause

The plan sets kill gates without having generated the preclinical data needed to justify them. It assumes that a 20-25% threshold is reasonable, but this is an engineering guess, not an evidence-grounded target. The thin-film surface architecture was chosen before chronic-stability data existed. The plan needs preclinical data to lock the threshold, not vice versa.

3.6.A Issue - No Fallback if Leuven Partners Decline; Clinical-Site Risk Unmanaged Until Month 6 (2027-04-30)

The plan states that imec, KU Leuven and UZ Leuven 'have not committed' but lists fallback sites (Ghent/Antwerp, Utrecht, Grenoble) as activated 'by Month 6 (2027-04-30) if any declines.' However, there is no written protocol for deciding which fallback activates, no cost or delay estimate per declined partner, and no pre-qualification of the fallback site's surgical capacity or patient cohort. If UZ Leuven (the only confirmed ALS implanting centre in the plan) declines, Utrecht's neurosurgery must be qualified in 12 weeks—a compressed timeline with unspecified ethics, training and consent-protocol setup. The dual-track approach (parallel LOI outreach) is mentioned but not resourced or scheduled before Month 3 (2027-01-31).

3.6.B Tags

3.6.C Mitigation

By Month 1 (2026-11-30), assign a clinical-liaison lead responsible for engaging all three primary sites (imec, KU Leuven, UZ Leuven) and the three fallback sites (Ghent/Antwerp, Utrecht, Grenoble) in parallel. By Month 3 (2027-01-31), obtain written letters of intent from at least two of the three primary sites specifying resource commitments (cleanroom hours, surgeon FTE, patient-referral pathway) and decision deadlines. Simultaneously, request preliminary capability letters from each fallback site (ALS patient census, surgeon experience, ethics-committee contact, timeline to readiness). Define a fallback-activation protocol: if a primary site declines by Month 3 (2027-01-31), activate the matched fallback by Month 4 (2027-02-28) and compress site qualification to 12 weeks (ethics pre-submission by Month 6 = 2027-04-30, surgeon training by Month 9 = 2027-07-31). Cost the fallback activation at EUR 0.5-2M (estimate) depending on distance, regulatory re-submissions and surgery-team setup. If more than one primary site declines, trigger the financing gate G1 (Month 12 = 2027-10-31) early and publish a revised feasibility verdict.

3.6.D Consequence

Without a managed fallback, a decline from UZ Leuven forces a crisis-mode scramble to qualified another centre, loses 3-6 months in the FIH timeline (compressing the entire downstream schedule), and incurs unknown costs for site qualification and ethics approval. The company may miss the Month 60 (2031-10-31) FIH window, pushing CE marking from Month 132 (2037-10-31) to Month 144-156 (2038-10-31 to 2039-10-31). Alternatively, the company may activate a fallback that lacks ALS referrals or experienced surgeons, compromising the quality of the first cohort and creating safety or ethical risk. Either outcome damages the financing case at gate G1 (Month 12 = 2027-10-31) or G3 (Month 24 = 2028-10-31).

3.6.E Root Cause

The plan treats Leuven partnerships as the default and fallback sites as contingencies, without acknowledging that 'no commitment' means a significant risk. The founders have not yet approached any site, so the confidence that imec, KU Leuven and UZ Leuven will partner is untested. The fallback sites are named but not pre-qualified or integrated into the early-stage work. A founder-only team is unlikely to have capacity to manage four parallel site-engagement tracks in Month 0-3 (2026-10-31 to 2027-01-31) without additional clinical leadership.


4 Expert: Patient Safety & Ethics Governance (Informed Consent, Data Monitoring, Clinical Trial Oversight)

Knowledge: Clinical-trial ethics and informed-consent protocols for vulnerable populations, independent data-monitoring committees, serious-adverse-event thresholds and stopping rules, GDPR and neural-data governance, longstanding implant follow-up and patient registries, bioethics in emerging neurotechnology

Why: The plan designates consent and monitoring as hard requirements with binding authority granted to a Data Monitoring Committee (DMC) by Month 6 (2027-04-30). The expert validates the Living Consent decision (independent advocate, re-confirmation schedule, yes/no signalling validation) and pre-registers kill gates (2 or 3 serious adverse events, 25% signal loss, below 5 bits/s in 50%, invalid consent at a site). They ensure the DMC charter, member selection, decision rules and publication timelines are credible and independent. They also advise on consent language when communication is impaired and how to reconcile early enrolment (while speech is intact) with the greatest-need principle.

What: Draft and review the informed-consent template and yes/no validation protocol by Month 2 (2026-12-31); submit to ethics committees for pre-review by Month 3 (2027-01-31). Recruit or contract the independent consent advocate by Month 3 (2027-01-31). Charter the DMC (5+ members, patient representative, patient-advocate organisations) by Month 6 (2027-04-30), with published decision rules and a monthly safety-review process. Pre-register quantitative kill gates (SAE thresholds, signal stability, bandwidth floor, consent validity) with the board and investors before Month 3 (2027-01-31), and ensure each gate is tied to a financing tranche (e.g., Series B release conditional on DMC safety clearance).

Skills: Informed-consent design for cognitively impaired and communication-restricted populations, independent data-monitoring committee governance and charter, serious-adverse-event classification and causality assessment, clinical-trial stopping rules and decision analytics, GDPR medical-data handling and EU hosting requirements, patient-representative and advocacy-group engagement

Search: informed consent locked-in syndrome ALS, data monitoring committee medical device trials, clinical trial ethics vulnerable populations, serious adverse event stopping rules

4.1 Primary Actions

4.2 Secondary Actions

4.3 Follow Up Consultation

"At the next consultation (Month 6 = 2027-04-30), report: (1) consent protocol finalisation, ethics-committee pre-approvals and any modifications required; (2) DMC charter signed, patient representative selected, and AI Governance Subcommittee staffing and budget confirmed; (3) trust-governance and actuary study completed, revised per-implant reserve amount justified, and Series A terms drafted; (4) notified-body feedback on consent and AI audit expectations, and any design implications; (5) imec/KU Leuven/UZ Leuven written statements on consent-safeguard roles and resource commitments, or fallback-site activation in progress. By Month 12 (2027-10-31), present the feasibility verdict on consent and governance: can the plan enrol locked-in ALS participants with binding consent validity and unambiguous device-control wishes, or does the population's communication loss require narrowing the indication (e.g., earlier-stage ALS only, or a different indication)? If consent feasibility is uncertain, the Month 24 (2028-10-31) scope gate must address it explicitly."

4.4.A Issue - Informed consent safeguards are underspecified for rapid disease progression and communication loss in ALS

The plan mandates an independent consent advocate and re-confirmation checkpoints (baseline, monthly for 6 months, then quarterly), but does not address three critical consent challenges in ALS: (1) participants may lose communication capacity mid-trial before a re-consent window arrives; (2) capacity fluctuation (good days and bad days) may undermine the validity of a single yes/no validation; (3) no binding mechanism exists to convert pre-declared participant wishes (e.g., 'switch off if signal drops below 5 bits/s') into enforceable protocol deviations. The plan acknowledges consent complexity but defers specifics to Month 3–5 (2027-01-31 to 2027-03-31) ethics-committee review, which risks late discovery of consent-method misalignment during first-in-human.

4.4.B Tags

4.4.C Mitigation

By Month 2 (2026-12-31), co-develop a dynamic consent protocol with the independent consent advocate and ethics partners: (1) adopt a capacity-fluctuation monitoring tool (e.g., day-of-week communication reliability, fatigue tracking) that flags days when re-consent is unreliable, and document when consent cannot be validly obtained; (2) implement a binding pre-implant advance-directive form, witnessed and video-recorded, that specifies participant-chosen device-off, explantation or study-exit triggers tied to measurable outcomes (bandwidth, signal stability, adverse events) with clear instructions for the clinical team; (3) secure written ethics-committee pre-approval of the advance-directive format and enforcement pathway by Month 4 (2027-02-28), before participant recruitment. Add EUR 100k (estimate) for consent-research infrastructure and monthly re-validation audits.

4.4.D Consequence

Without specificity, the plan risks enrolling participants whose wishes are not validly recorded or actionable, leading to ethics-committee challenges, trial pauses (proposed threshold: any invalid-consent finding pauses a site), and reputational damage if participants feel unheard or coerced. Advanced ALS participants are acutely sensitive to autonomy; absent clear advance directives, the company may face legal liability if a participant's death or deterioration occurs after unclear consent. This could delay or halt the trial, consuming months of the Month 12 (2027-10-31) financing gate.

4.4.E Root Cause

The plan treats consent as a governance checkpoint rather than a lived, participant-controlled process. ALS participants in advanced stages experience rapid, unpredictable communication loss; the fixed re-confirmation schedule cannot adapt to this volatility. Pre-declared conditions are mentioned but not operationalised, so the plan risks implanting participants whose wishes cannot be reliably elicited or honoured post-implant.

4.5.A Issue - Data-Monitoring Committee governance lacks participant representation and binding escalation triggers for AI Act violations

The plan establishes an independent DMC by Month 6 (2027-04-30) with 5+ members including one patient representative, holding binding pause authority on safety. However, the plan does not specify: (1) how the patient representative is selected (organisation affiliation, conflict-of-interest criteria); (2) what happens if the DMC detects an AI Act violation (e.g., decoder retraining using non-consented data, feature drift, model staleness) before a formal change-control gate is triggered; (3) how often the DMC reviews decoder version changes and training-data lineage; (4) what escalation path exists if the company ignores a DMC safety recommendation. The plan's proposed safety thresholds (≥2 SAEs in first 10, ≥3 in first 20 implants) are event-based, not process-based, so silent consent or data-handling failures may not trigger a review until harm occurs.

4.5.B Tags

4.5.C Mitigation

By Month 4 (2027-02-28), establish a written DMC charter specifying: (1) patient representative selection via an ALS-advocacy group (e.g., European ALS Federation) with a signed independence declaration and quarterly reselection; (2) a standing 'AI Governance Subcommittee' (two DMC members plus company's chief data officer) that reviews all decoder version changes, training-data sources and model-validation reports monthly, with independent verification that changes comply with the locked change-control thresholds (e.g., 'minor' retraining within locked feature set does not require notified-body review); (3) a binding escalation: if the subcommittee finds an AI Act breach (unauthorised data use, undocumented model swap, training on out-of-scope participants), it must notify the notified body within 7 days and the board within 3 days, with public reporting within 30 days; (4) investor tranches are contractually conditioned on quarterly DMC audits finding no substantive violations. Fund this at EUR 250k per year (estimate) for independent AI audit staff.

4.5.D Consequence

Without AI Act audit integration into DMC oversight, the plan risks deploying high-risk decoders that violate transparency, auditability and change-control obligations, triggering notified-body enforcement action during pivotal dossier review or post-CE-marking. Such a finding could force device recall or market withdrawal, destroying patient trust and clinical credibility. An under-resourced patient representative may also fail to raise safety concerns, eroding the ethical legitimacy of the consent process and ethics-committee support. This could delay CE marking by 12–24 months and expose the company to regulatory penalties.

4.5.E Root Cause

The plan underestimates the DMC's role in continuous AI governance. The decoder is high-risk under the AI Act, and the plan envisions a 'locked change-control process' (Decoder Stack Residency), but the DMC has no standing authority to audit decoder lineage, training data, or model updates. Patient representation is mandated but not operationalised, so the voice of implanted patients may be token rather than binding. Escalation to regulators or the board is assumed but not contractually defined.

4.6.A Issue - Patient-protection reserve mechanism is specified but not funded, gated or audited to ensure survival through device lifetime

The plan mandates a EUR 30,000 per-implant reserve in a trust outside investor reach, set up by Month 6 (2027-04-30) with a EUR 5M floor. However, the plan does not specify: (1) who administers the trust (independent trustee, hospital, third party), what governance protects it from investor seizure or insolvency law disputes, or what triggers release of funds (annual audit of company balance sheet, device failure event, company bankruptcy filing); (2) how the reserve is actuarially sized (expected device lifetime is 10-15 years, estimate, but no actuarial studies of ALS survival post-implant, explantation risk or service-cost trajectory exist); (3) what happens if the company fails before accumulating the full reserve (e.g., only 150 trial implants = EUR 4.5M against the EUR 5M floor, so the reserve is under-funded); (4) how the reserve is invested (cash holds value, equities expose it to market risk) and whether real-estate or IP is escrowed as collateral. The plan calls it a 'hard requirement' but treats it as a secondary financial detail.

4.6.B Tags

4.6.C Mitigation

By Month 3 (2027-01-31), commission a governance-and-actuary study (EUR 150k, estimate) covering: (1) establishment of an independent trust structure under EU law (multistate jurisdiction or EU-level fiduciary) with a custodian (e.g., a major EU pension fund, hospital endowment or dedicated medical-device trust) that is legally insolvency-remote and holds the power to release funds only on documented need (annual audit showing company depletion below a cash threshold, bankruptcy filing, device failure event); (2) actuarial modelling of ALS patient survival post-implant (using existing ALS databases), expected device lifetime (10-15 years), explantation rates, service costs (follow-up visits, replacements, storage) and contingencies, yielding a revised per-implant reserve (likely EUR 40,000–60,000, estimate); (3) a collateral-backup mechanism: the company grants the trustee a lien on IP (decoder, encapsulation design, manufacturing know-how) that can be liquidated or transferred to a successor manufacturer if the company becomes insolvent, ensuring continuity without needing cash. Lock this in the Series A term sheet by Month 12 (2027-10-31). Allocate total trust funding at Month 0 (2026-10-31): EUR 5M (floor for 150 trial implants) plus a commitment that each commercial implant contributes its reserve amount before sales revenue is recognised.

4.6.D Consequence

Without binding governance and actuarial grounding, the reserve is a promissory note, not a guarantee. If the company faces financial stress at Month 100–120 (2035-02-28 to 2036-10-31) (2035–2036), when the first cohort is aging and requiring explantation, the company may pressure the board to treat the reserve as operating capital, leaving later patients without support. Implanted patients and their families may then face legal battles over who is responsible, reputationally damaging the device and undermining public trust in EU medical-device governance. Regulators may also condition CE marking on proof that the reserve is truly protected, so a vague structure discovered during dossier review could force rework or denial.

4.6.E Root Cause

The plan assumes the reserve can be set up by Month 6 (2027-04-30) but does not address the governance and legal risk that make it credible. EU insolvency law varies by member state; a trust set up in Belgium may not be ring-fenced against creditor claims in a French or Dutch bankruptcy. Actuarial sizing is guessed (EUR 30,000 per implant) without justification. The plan also does not address the political pressure that an insolvent company may face to raid the reserve to fund final clinical operations, which would leave later patients unprotected.


5 Expert: Founder and Chief Executive Officer (Strategy, Governance, Stakeholder Alignment)

Knowledge: Deep-tech venture founding and scaling, medical-device company governance, investor relations and capital raising, European institutional affairs and Commission engagement, strategic decision-making under uncertainty and kill-gate authority

Why: The plan is unfunded at Month 0 (2026-10-31) and requires a founder-led team to secure written commitments at five gates (G1 Month 12 = 2027-10-31, foundry Month 18 = 2028-04-30, G3 Month 24 = 2028-10-31, G4 Month 36 = 2029-10-31, pivotal Month 78 = 2033-04-30). The CEO/founder validates the governance model: whether stop, defer or switch authority is credibly independent, how the DMC and consent advocate are protected from pressure, and whether the board structure and investor terms allow gates to be called honestly. They also assess whether the founding team can sustain three years (Months 0-36 = 2026-10-31 to 2029-10-31) of hiring and site-negotiation against a 20-30% EU pay deficit while managing partner refusal, financing failure, architecture pivots and public scepticism.

What: Validate the governance charter by Month 1 (2026-11-30): who holds binding stop authority (board, DMC, investors), what happens if they disagree, and how gate verdicts are published. Establish the founding team recruitment and retention plan by Month 2 (2026-12-31), with named fallbacks if key hires decline. Secure written LOIs from imec, KU Leuven and UZ Leuven by Month 3 (2027-01-31), with parallel fallback-site talks. Close at least EUR 5M seed by Month 3 (2027-01-31) and T0 (EUR 10M floor) by Month 12 (2027-10-31), with gate verdicts published within 5 business days. Map stakeholder influence (Commission, member states, notified bodies, payers, public) and set engagement milestones at Months 6, 12, 24 and 36 (2027-04-30, 2027-10-31, 2028-10-31, 2029-10-31).

Skills: Venture capital and institutional fundraising, company formation and cap table, board governance and fiduciary duty, European Commission and member-state liaison, stakeholder mapping and influence strategy, decision authority under uncertainty, media and public engagement, talent recruitment and retention against international pay differentials

Search: deep tech venture CEO medical devices, European Commission engagement IPCEI, investor relations capital raising healthcare, stakeholder governance European startups

5.1 Primary Actions

5.2 Secondary Actions

5.3 Follow Up Consultation

At Month 12 (2027-10-31) and Month 24 (2028-10-31), the board must present: (1) written tranches signed or with signed LOIs (T0 by Month 12 = 2027-10-31, T1 at least EUR 60M binding commitment by Month 24 = 2028-10-31, or automatic deferral); (2) epidemiology and payer-acceptance results with revised commercial case and indication pivot scenario; (3) confirmed Leuven partnerships or activated fallback sites with signed MOUs for theatre time, patient access and resource commitments; (4) DMC charter with published kill-gate criteria and first safety results; (5) notified-body written feedback on clinical investigation design and AI Act scope; (6) finalized architecture choice with FTO analysis, chronic-animal data ≥70% complete, and bilateral supplier MOUs with second-source qualification plan. If any of these five dependencies is unresolved by Month 24 (2028-10-31), the decision rule is automatic deferral to Month 36 (2029-10-31) focus on narrow ALS communication feasibility (Months 24-48 = 2028-10-31 to 2030-10-31, EUR 30-50M budget), with a binary go/no-go decision at Month 48 (2030-10-31) on whether to proceed to pivotal-trial funding. This protects the company from the trap of continuing to burn capital on an unfunded, unfocused, unconfirmed multi-year programme.

5.4.A Issue - Financing structure is unmanned and governance of capital gates is absent—investors will walk if tranches are not contractually binding with explicit loss-of-control consequences

The plan assumes EUR 0 committed at Month 0 (2026-10-31), then expects T0 (EUR 10-15M) by Month 12 (2027-10-31) without naming a single investor, governance structure, or return term. Gates G1, G3, G4 are paper exercises: 'published verdicts' within 5 days mean nothing if a funder disagrees. Investors will demand board seats and veto rights; the plan forbids assuming funding yet forbids reducing evidence. Either the plan accepts dictatorial founder control (unworkable with capital partners), or it must pre-negotiate binding term sheets with anchor investors by Month 3 (2027-01-31), including investor composition of the board and explicit loss-of-control terms if gates are missed. Without investor signatures, not words, capital gates collapse.

5.4.B Tags

5.4.C Mitigation

By Month 2 (2026-12-31), hire a CFO or capital partner (not a contractor) with Series A and B medical-device raising experience. Commission a term-sheet template for T0 (EUR 10-15M seed) and T1 (EUR 60-120M) that explicitly binds the tranches to written gate criteria (architecture lock, chronic animal data, notified-body engagement). Name 3-5 anchor investors (institutional, impact or corporate) and initiate outreach by Month 1 (2026-11-30) with a target of signed LOIs by Month 3 (2027-01-31). Define investor board composition (e.g., 1-2 investor seats for T0, 3-4 for T1 plus a patient representative and independent scientist) and loss-of-control rules if a gate fails. If investors are not locked by Month 6 (2027-04-30), pivot to entirely grant-funded MVP (reduce scope to chronic animal studies and architectural validation only) and defer Series A to Month 12 (2027-10-31). Document the governance trades explicitly in the board charter; a sceptical investor will ask 'who fires the CEO if the Q2 2028 (Month 24 = 2028-10-31) gate is missed?' and expect a written answer.

5.4.D Consequence

If governance is not resolved by Month 2 (2026-12-31), Series A will slip to Month 18-24 (2028-04-30 to 2028-10-31) or later because investors will demand clarity on control and loss-of-control consequences. Every month of delay compresses the architecture-validation and chronic-animal schedules. If capital gates are not contractually binding, founders will attempt to continue past a failed gate (momentum inertia), investors will demand renegotiation, and the programme will oscillate between stop and defer for months, burning 10-20% of the tranche in overhead. Patient-protection reserves become secondary in this chaos: the question 'do we have money for Year 2?' will dominate board discussion. The plan's credibility with regulators and ethics committees also collapses; they will see a programme with unclear financing and ask 'will you still be here if trials go poorly?'

5.4.E Root Cause

The plan conflates 'hard requirements' (patient safety, EU control) with 'soft targets' (implant numbers, bandwidth) but treats financing as a soft assumption that can be 'hoped-for'. In reality, capital is a hard requirement: without committed tranches, no hiring, no cleanroom access, no animal studies. The gate structure is written as if the founders own 100% and can enforce stops; real investors will demand governance power tied to their tranches, and if founders cannot deliver a gate, investors will demand board negotiation, not a published 'deferral verdict'. The contradiction is unresolved.

5.5.A Issue - The 5,000-implant and EUR 150,000 price-per-implant reimbursement case is internally inconsistent—eligible population epidemiology is missing, payer acceptance is untested, and the plan does not explain how a 300-implant-per-year ceiling in Year 15 scales back to a break-even of 1,125 implants per year

The plan projects about 1,050 cumulative implants and 550 active users by Month 180 (2041-10-31), explicitly admitting the 5,000 target is 'missed in all scenarios'. Yet it proposes EUR 150,000 per-implant pricing and EUR 120,000 per QALY cost-effectiveness, without showing who will pay it, at what volume, in which member states. The implied Months 168-180 (2040-10-31 to 2041-10-31) capacity is 300 implants per year across about 25 centres (12 per centre), but no eligible-population epidemiology validates this. If ALS-only, about 500-1,400 eligible per year; for high cervical spinal cord injury, about 200-300 per year. Either the population is too small (ALS alone cannot sustain 300/year), or the plan must pivot to a broader indication (e.g., stroke motor recovery, which is 50,000+ per year in the EU, but requires a different surgical target and consent narrative). The plan gates this decision at Month 78 (2033-04-30), late enough that T2 and T3 tranches are committed.

5.5.B Tags

5.5.C Mitigation

By Month 9 (2027-07-31), commission an independent health-economics and epidemiology study for three member states (France, Netherlands, Germany) covering: (1) ALS population size (incident, prevalent, eligible), annual mortality, disease trajectory and centre capacity for implantation; (2) high cervical spinal cord injury population, annual incidence, surgical centre capacity and rehabilitation length of stay; (3) stroke motor recovery (later expansion option): incidence and centre willingness to implant for motor control. Model implant capacity at 5, 10, and 25 centres per indication, and estimate break-even volume by indication and pricing. By Month 15 (2028-01-31), hold pre-reimbursement dialogues with payers in France, Germany and the Netherlands (statutory health insurance bodies, HTA authorities) to establish: (a) which indication(s) they would fund; (b) evidence requirements (RCT sample size, comparator, primary endpoint); (c) price tolerance (cost per QALY). Publish a revised commercial case by Month 18 (2028-04-30) with three scenarios (ALS-only, SCI-primary, stroke-future), each with explicit implications for T1 manufacturing investment and T2 centre rollout. Make the Month 78 (2033-04-30) indication gate a go/no-go on commercial-case evidence, not design or safety evidence.

5.5.D Consequence

If epidemiology and payer acceptance are not resolved by Month 18 (2028-04-30), Series A investors will demand it before committing to T1 (EUR 120M), slipping T1 to Month 30 (2029-04-30) at the earliest. If the plan admits that 5,000 is unrealistic but does not revise the fundraising narrative, Series B (EUR 480M) will face investor scepticism about unit economics and founder credibility. Payers will also wait until late-stage trial data to commit; if the commercial case is unclear at Month 24 (2028-10-31) (Month 78 = 2033-04-30 decision gate is far away), the pivotal trial will start without payer agreement, and reimbursement negotiation will begin only after CE marking, delaying revenue by 12-24 months. The plan's profitability gap (EUR 66M per year at Month 180 = 2041-10-31) is then a company failure, not a soft miss. If ALS alone is the viable indication, the EUR 2.5B envelope is oversized, the team is larger than needed, and the programme should be resized to EUR 400-800M and repositioned as a 'niche communication platform', not a 'mass-market EU BCI'.

5.5.E Root Cause

The plan was written to satisfy a user constraint (5,000 implants) and a planning ceiling (EUR 2.5B), but the feasibility verdict then admits the target is unrealistic. Rather than revise the target or acknowledge that the scope must change, the plan treats the reimbursement and indication as secondary, gated decisions, leaving them unresolved. Investors and payers will not fund a EUR 2.5B programme on the assumption of 'decided at Month 78 (2033-04-30)' if that decision determines whether the venture is profitable. The implicit commercial logic is: if ALS alone is too small, then spinal cord injury is the only viable indication, but the plan provides no evidence (FTO, reimbursement, surgeon adoption) that spinal cord injury is credible. The plan is thus either a EUR 2.5B bet on an indication that will be decided late (unacceptable to capital partners), or it is a smaller EUR 500M-1B programme focused on ALS communication (and it should say so).

5.6.A Issue - Leuven partnerships are not confirmed, fallback sites are not pre-qualified, and the plan does not explain what happens operationally if imec or UZ Leuven declines after Month 3 (2027-01-31)—the 'EUR 2M cost, 3-6 months delay' estimate is unverified and insufficient to guide a fallback decision

The plan states 'none of which has committed to partner' but requires letters of intent from imec, KU Leuven and UZ Leuven by Month 3 (2027-01-31). It names fallbacks (Ghent/Antwerp, Utrecht, Grenoble) but provides no evidence that they are equivalent in cleanroom capacity, neurosurgery expertise, ALS patient cohorts or willingness to partner. If UZ Leuven declines, the plan suggests activating Utrecht or Ghent by Month 6 (2027-04-30), but does not specify: Who leads site selection? Is it a competitive pitch or a pre-negotiated fallback? What are the non-negotiable requirements (cleanroom Class 100 or Class 1000? implant-capable OR theatre only? ALS cohort 50+ or 10+)? If the fallback site has different surgical protocols or patient demographics, do the ethics approvals, consent templates and trial design change? The cost estimate ('about EUR 2M') is vague: facility setup, legal, training or all three?

5.6.B Tags

5.6.C Mitigation

By Month 1 (2026-11-30), hold a face-to-face meeting with imec (cleanroom director and business development), KU Leuven (neuroengineering department chair) and UZ Leuven (neurosurgery chief and hospital executive responsible for clinical trials). Present the partnership scope: imec = cleanroom access for electrode microfabrication and prototype assembly, hands-on training, and intellectual-property acknowledgement; KU Leuven = seconded postdoctoral engineer (2 FTE) for 3 years for decoding and neural-signal analysis; UZ Leuven = theatre time (1 day per month, ramping to 2-3 days per month by Month 84 = 2033-10-31), ALS patient-cohort access, neurosurgery lead (0.2-0.5 FTE), ethics liaison, and insurance indemnity. Request written LOIs by Month 3 (2027-01-31) with specific resource commitments and a decision gate (Month 6 = 2027-04-30, allow 3 months for institutional approvals). Simultaneously, conduct parallel fallback negotiations with: UMC Utrecht (contact neurosurgery chief and hospital R&D officer), Ghent University Hospital and Antwerp University Hospital (contact joint neurosurgery team), and CEA-Leti/Clinatec (contact clinical director). Ask each for a preliminary willingness statement by Month 2 (2026-12-31) and a full fallback LOI by Month 6 (2027-04-30). Distinguish first-in-human requirements (one site, 10-20 implants) from pivotal multi-site requirements; only the first-in-human site must be locked by Month 6 (2027-04-30). If a primary site declines by Month 3 (2027-01-31), immediately escalate to the preferred fallback (e.g., UZ Leuven declines → activate UMC Utrecht at Month 3.5 = 2027-02-15) and compress the fallback-site qualification to 12 weeks (site visit, ethics pre-submission, surgeon credentialing plan by Month 6 = 2027-04-30). Document the cost and delay: facility setup (cleanroom fees, lab build-out) EUR 0.3-0.5M, legal and insurance EUR 0.2-0.3M, surgeon training EUR 0.2-0.4M, regulatory re-submission EUR 0.1-0.3M, total 'about EUR 1-1.5M' (not EUR 2M); schedule slip is 6-12 weeks, not 3-6 months, if the fallback is pre-qualified.

5.6.D Consequence

If partnerships are not confirmed by Month 3 (2027-01-31) and fallbacks are not pre-qualified, a decline by a primary partner will create 2-3 months of urgent site negotiation and approval cycles (Month 3-6 = 2027-01-31 to 2027-04-30 crisis), during which the team is paralysed and other workstreams (chronic animal studies, supplier engagement) stall. If the fallback is not pre-qualified, the new site will demand ethics approvals and regulatory pre-submission by Month 6 (2027-04-30), which is feasible only if drafted and submitted by Month 5 (2027-03-31), leaving no time for feedback iteration. The first-in-human start will slip from Month 60 (2031-10-31) to Month 66-72 (2032-04-30 to 2032-10-31), which compresses the timeline from pivotal lock (Month 72 = 2032-10-31) to CE marking (Month 132 = 2037-10-31) by 6-12 months, forcing design shortcuts and faster manufacturing transfer that increase risk. Patient recruitment also suffers: ALS is progressive; every month delays include more advanced, shorter-lived patients, reducing post-implant follow-up duration and limiting safety data.

5.6.E Root Cause

The plan treats partnerships as binary (committed or not) but does not map the operational dependencies. Leuven is chosen for proximity to the Commission and to imec/KU Leuven, but the plan forbids assuming any of these as committed. If UZ Leuven declines, does the plan move to Utrecht (Netherlands, multicentre coordination) or Ghent (Belgium, single-country regulatory path)? Each choice has different implications for ethics approvals, surgeon training and trial sequencing. The plan also does not distinguish between 'host hospital for first-in-human' (one site, months 60-84 = 2031-10-31 to 2033-10-31) and 'pivotal-trial sites' (5-15 sites, months 84-132 = 2033-10-31 to 2037-10-31). A fallback for first-in-human is urgent; fallbacks for pivotal sites can be arranged later. By combining them, the plan creates urgency where it may not exist.


6 Expert: Bandwidth Measurement and Competitive Benchmarking Lead (Bits-per-Second Protocol, Data Residency, Rival Tracking)

Knowledge: Neural decoding and information-transfer-rate measurement, held-out task protocols and independent verification, federated learning and EU data residency, competitive intelligence on US and Chinese BCI systems, machine-learning model validation and reproducibility

Why: The plan rests on measuring net user-controlled information transfer rate (bits/s), independent verification inside the EU (data never leaves), and annual scenarios for rival best-systems (25/60/150 bits/s pessimistic/central/optimistic, estimates). The expert validates the Bits-per-Second Claim Discipline decision: whether the pre-registered protocol with held-out tasks, independent replication and separate reporting of command selection versus free communication are feasible and will survive scrutiny from regulators, payers and a sceptical public. They also advise on whether the target of at least 10 bits/s in at least 3 participants is realistic for thin-film surface architecture and whether the bandwidth kill floor (below 5 bits/s in 50% of participants, proposed threshold) should trigger a switch to penetrating cortical.

What: Commission or conduct a literature review of published thin-film surface and penetrating cortical bandwidth claims by Month 9 (2027-07-31), including Clinatec WIMAGINE, UMC Utrecht, Neuralink, Synchron and any Chinese publications, and build a factual baseline for the rival 25/60/150 scenario. Pre-register the information-transfer-rate protocol (task suite, measurement window, error correction, user-control verification) by Month 15 (2028-01-31). Design or contract an independent verification laboratory (EU-based) and federated-test infrastructure where decoder code is sent to the data, and only aggregate metrics leave the EU site. Establish a monthly rival-tracking update process, and re-baseline the pessimistic/central/optimistic scenarios every 12 months from public disclosures.

Skills: Information-theory and Shannon entropy measurement, neural decoding algorithm validation, held-out test design and statistical power, federated learning and secure multi-party computation, competitive intelligence gathering and synthesis, EU data-residency infrastructure and governance, machine-learning model reproducibility and open science

Search: information transfer rate BCI measurement protocol, brain computer interface bandwidth benchmarking, neural decoding validation independent verification, federated learning medical data EU

6.1 Primary Actions

6.2 Secondary Actions

6.3 Follow Up Consultation

"At Month 15 (2028-01-31), present the Bandwidth Measurement and Verification Working Group's locked protocol, the systematic review of signal-retention data, the revised kill thresholds, the health-economic model, and early payer feedback. At that point, confirm whether federated testing infrastructure is ready for Month 18–24 (2028-04-30 to 2028-10-31) preclinical work, whether the chronic animal studies are on track to inform the architecture decision, and whether the Indication Pivot Decision at Month 24 (2028-10-31) can be credibly made. If any pillar (measurement, stability, reimbursement) is not ready, escalate the Month 24 (2028-10-31) decision to Month 36 (2029-10-31) and defer non-critical spending under the gate mechanism. At Month 24 (2028-10-31), expect to report: (a) locked bandwidth protocol with independent replication plan, (b) chronic animal data with interpreted kill-gate outcome, (c) validation or revision of signal-stability kill thresholds, (d) health-economic model accepted or challenged by payers, (e) eligible-population epidemiology confirmed or shown to be unviable, and (f) written go/no-go decision on ALS-first indication or pivot to spinal cord injury. The credibility of the feasibility verdict depends on all six."

6.4.A Issue - Bits-per-Second Measurement Protocol Lacks Independent Verification Infrastructure

The plan targets ≥10 bits/s net (user constraint) and claims independent verification (Decision 15), but specifies no secure compute environment, no federated testing consortium, no held-out task protocol, and no multi-centre replication framework. The bandwidth kill floor (5 bits/s in 50% of participants, proposed threshold) is set without preclinical evidence supporting its realism. The rival scenarios (25/60/150 bits/s, estimate) are unsourced and unvalidated. Without locked measurement protocols and EU-hosted verification infrastructure in place by Month 18 (2028-04-30), claims will be dismissed as cherry-picked or biased, undermining regulator and payer trust precisely when CE dossier credibility is critical.

6.4.B Tags

6.4.C Mitigation

By Month 6 (2027-04-30), establish a Bandwidth Measurement and Verification Working Group (5–7 members: information theorists, independent EU labs, patient representatives, one regulator observer) under a written charter that locks the information-transfer-rate protocol, the held-out task battery, error-correction methods and independent replication rules. Pre-register the protocol with an external registry (e.g., Open Science Framework) by Month 9 (2027-07-31). Allocate €500k–€1M (budget line) for a secure federated testing platform (data stays in the EU, code travels) by Month 12 (2027-10-31). Commission a published competitive-intelligence report on best US and Chinese systems by Month 15 (2028-01-31), sourcing from peer-reviewed literature, FDA submissions and public demos, with update cycles tied to rival announcements. Integrate the locked protocol into the preclinical animal study (Months 12–24 = 2027-10-31 to 2028-10-31) so the kill-gate thresholds are grounded in your own data, not external guesses. Engage the notified body on bandwidth as part of the essential performance criteria (MDR Annex I) by Month 12 (2027-10-31) pre-submission.

6.4.D Consequence

At Month 60 (2031-10-31) FIH, early bandwidth claims will lack independent replication, regulator confidence and public credibility. Payers and ethics committees will demand re-verification, delaying CE dossier assembly by 6–12 months (estimate). Rival CE-marked devices entering the EU market at Months 36–60 (2029-10-31 to 2031-10-31) will claim superior bits/s with unverified headlines; without a published, locked protocol and independent verification results, this company's claims will be perceived as defensive or retrospective. Investors will lose confidence in the bandwidth narrative, which underpins the long-term mission and the payer case.

6.4.E Root Cause

The plan treats bandwidth as a secondary technical outcome ('Bits-per-Second Claim Discipline', Decision 15, Medium priority) rather than as a foundational measurement framework integral to the regulatory dossier and competitive positioning. No budget is assigned to building verification infrastructure; no timeline assigns Month 18 (2028-04-30) architecture lock as the deadline for locking the measurement protocol. Decision 15's three options (EU-only verification, federated consortium, rival scenarios) are presented as alternatives rather than mandatory together.

6.5.A Issue - Chronic Signal Stability Kill Gate Lacks Preclinical Evidence Foundation

The plan proposes kill thresholds (20% animal signal loss blocks FIH; 25% human loss in 12 months pauses; 50% retention below 36 months triggers switch, proposed thresholds) without citing any preclinical rodent or non-human primate chronic-implant data showing that thin-film surface electrodes or the fallback penetrating microelectrodes will meet these targets. Published thin-film surface data (e.g., WIMAGINE at Clinatec, UMC Utrecht's ALS home-use study) shows variable 6–12 month signal retention (50–90%, estimate, not verified); no source confirms that 80% retention at 12 months is achievable in your architecture. The plan budgets 18–24 months for chronic animal studies (Months 0–24 = 2026-10-31 to 2028-10-31) but assigns no decision date for interpreting results, no pre-registered success criteria, and no contingency if results show >20% loss in month 6–12 (2027-04-30 to 2027-10-31).

6.5.B Tags

6.5.C Mitigation

Commission an independent systematic review of published thin-film and penetrating-microelectrode chronic-implant data (rodent, non-human primate, human) by Month 3 (2027-01-31), focusing on signal retention, impedance rise and unit isolation over 6–36 months. Publish it by Month 9 (2027-07-31) with a table of success rates and failure modes per architecture candidate. Revise the kill thresholds by Month 9 (2027-07-31) based on this review; if published data shows thin-film surface achieving only 70% 12-month retention (estimate), set the animal gate at 65% (to allow a small margin), and commit in writing that penetrating-cortical work begins by Month 20 (2028-06-30) if animal results breach this by Month 18 (2028-04-30). Schedule a formal Data Interpretation and Go/No-Go meeting by Month 18 (2028-04-30), with the DMC (Decision 14) and an independent statistician present, to decide architecture fate within 5 business days of final animal data. Assign a Deputy CTO to lead the penetrating-cortical contingency design by Month 6 (2027-04-30) in parallel, so fallback work is not a surprise.

6.5.D Consequence

If chronic animal studies show 25–30% signal loss within 12 months (a realistic risk for thin-film surface electrodes, estimate), the team will face a Month 18–24 (2028-04-30 to 2028-10-31) binary choice: proceed despite failing the 20% kill gate (eroding the credibility of pre-registered criteria), or switch to the penetrating-cortical fallback at an estimated cost of EUR 30M and 12–24 months delay, compressing architecture validation into Months 24–48 (2028-10-31 to 2030-10-31) and pushing FIH to Month 72–90 (2032-10-31 to 2034-10-31). The pivotal trial and CE marking will slip to Month 156+ (2039-10-31+), colliding with competitive US/Chinese CE marks and funding tranches (T2/T3, Months 48–84 = 2030-10-31 to 2033-10-31) already drawn.

6.5.E Root Cause

The plan adopts worst-case safety thresholds (20% blocks FIH) without validating whether the chosen architecture can meet them. The sourcing route (exclusive licences with options on unknown IP) means the team has not yet benchmarked the predecessor devices' signal stability. Chronic-animal studies are scheduled but not tied to specific go/no-go decision dates; results will likely arrive Month 18–24 (2028-04-30 to 2028-10-31) alongside architecture lock, creating a collision between data interpretation and irrevocable design commitments.

6.6.A Issue - Eligible-Population Epidemiology and Reimbursement Credibility Absent; 5,000-Implant Target Not Validated

The plan acknowledges that the 5,000-implant target is missed in all scenarios and reports 1,050 central implants (estimate) as likely by Month 180 (2041-10-31). However, no bottom-up epidemiology of eligible ALS patients, no centre/theatre capacity model, no payer willingness-to-pay study and no reimbursement thresholds are documented. The proposed price (EUR 150,000 per implant) and cost-effectiveness ceiling (EUR 120,000 per QALY) are thresholds only, with no payer endorsement. The eligible pool estimate (500–1,400 per year, estimate) is derived from no cited source. Without these foundations, the financing case (revenue EUR 45M per year, opex EUR 111M per year, operating gap EUR 66M per year at Month 180 = 2041-10-31, estimates) is speculative, and the decision to proceed with an ALS-first indication (Decision 3) rests on no validated clinical or commercial evidence.

6.6.B Tags

6.6.C Mitigation

By Month 9 (2027-07-31), commission a health-economic model from an independent HTA specialist (or an HTA body itself) covering: (a) eligible ALS population (incident and prevalent, by country and disease stage) from a validated epidemiological cohort study; (b) daily-life functional outcome versus eye-tracking (define the outcome precisely, e.g. 'home communication independence 4+ hours/day'); (c) QALY impact over device lifetime (15–20 years, estimate), using published ALS-specific quality-of-life weights; (d) cost-effectiveness at EUR 150,000, EUR 120,000 and EUR 100,000 per implant, and at three QALY thresholds (EUR 80,000, EUR 100,000, EUR 120,000 per QALY); (e) payer budget impact if adoption reaches 50%, 80% and 100% of the annual eligible pool. Simultaneously, conduct pre-reimbursement dialogues with HTA bodies in at least 3 member states (e.g. INAMI/RIZIV Belgium, ZiNL Netherlands, HAS France) by Month 15 (2028-01-31), presenting the model and seeking written feedback on evidence gaps, price tolerance and reimbursement likelihood. Establish a Payer Advisory Board by Month 12 (2027-10-31) with representatives from 3–5 member states to co-design the reimbursement-relevant trial endpoints and the health-economic evidence plan. Schedule a hard Indication Pivot Decision by Month 24 (2028-10-31) (not Month 78 = 2033-04-30): if eligible ALS pool + payer feedback show <300 annual implants and <EUR 100,000 per-QALY threshold, pre-register the move to spinal cord injury and requote the commercial case, timeline and budget with the updated indication. This decision must be published to investors and financiers as a condition of release of T1 funding.

6.6.D Consequence

At Month 24 (2028-10-31) feasibility verdict, the plan cannot credibly answer whether 1,050–5,000 implants is realistic or whether payers will reimburse at EUR 150,000. If EU HTA bodies set the cost-effectiveness bar at EUR 100,000 per QALY (below the proposed ceiling), the device becomes uneconomical unless daily-life benefit is extraordinary, forcing a price renegotiation or a switch to spinal cord injury (larger pool but weaker benefit case). If eligible ALS population is <400 per year (estimate), cumulative implants will be <200 by Month 180 (2041-10-31), guaranteeing insolvency and triggering the Implanted-Patient Continuity Covenant (Decision 8) default, requiring the trust to absorb all long-term support. Investors will demand a reforecast at Months 24 and 36 (2028-10-31, 2029-10-31) gates, and if population and reimbursement remain unvalidated, T2/T3 tranches will be withheld.

6.6.E Root Cause

Decision 3 frames the indication choice as deferrable to Month 78 (2033-04-30) kill gate (Option 3: 'Start with a small ALS communication first-in-human cohort to establish safety and bandwidth, then pre-register a pivotal indication decision at a kill gate'). This appears prudent (keep optionality), but it allows the current plan to be built on a therapeutic population (ALS) whose size and reimbursement prospects are not yet confirmed. No HTA or payer body has been approached; no health-economic model linking daily-life benefit to QALY has been drafted. The plan budgets EUR 500k–€1M for payer engagement in the early analysis (pre-project assessment) but does not schedule it or assign accountability.


7 Expert: Implanting-Centre Network and Surgical Throughput Planner (Multi-Site Coordination, Surgeon Training, Capacity Forecasting)

Knowledge: Neurosurgical centre network design and proctoring, surgeon credentialing and training curricula, operating-theatre capacity and surgical case-load planning, multi-centre clinical-trial coordination and site activation, travel burden and patient equity

Why: The plan targets about 1,050 cumulative implants by Month 180 (2041-10-31) across about 25 centres at a steady-state rate of about 300 per year (about 12 per centre, estimate). The expert validates the Implanting-Centre Network and Surgical Throughput Ceiling decision: whether concentrating on expert centres (high quality, low volume, high patient travel) or distributing to regional hospitals (lower quality risk, higher volume, lower travel) is the right trade-off, and whether the 25-centre footprint and 12 implants per centre per year are realistic given surgeon learning curves, credentialing burden and the small eligible population (500-1,400 per year, estimate). They also assess how the centre network feeds the pivotal indication gate (Month 78 = 2033-04-30): if ALS-only is chosen, can 25 centres stay economically viable, or does the network shrink?

What: Develop a centre-selection strategy and recruitment timeline by Month 12 (2027-10-31): which EU member states, which hospitals, which neurosurgical departments, and what commitment milestones? Design a surgeon credentialing curriculum (duration, proctoring, case minimums, knowledge assessments) by Month 18 (2028-04-30), aligned with implanting-centre network expansion. Forecast annual implant capacity per centre, accounting for learning curves and theatre availability, and validate that the 25-centre, 300-implants-per-year steady-state at Month 168-180 (2040-10-31 to 2041-10-31) is achievable given the eligible ALS pool of 500-1,400 per year. Model the financial and operational implications of narrowing to ALS-only (if the Month 78 = 2033-04-30 gate chooses it) on centre viability and recruitment sustainability.

Skills: Neurosurgical operating-theatre scheduling and throughput optimisation, surgeon training programme design and competency assessment, multi-centre clinical-trial site activation and coordination, learning-curve analysis and case-volume minimums, health-equity and travel-burden assessment, centre economics and case-based reimbursement forecasting

Search: neurosurgical centre network multi-site coordination, surgeon training credentialing implantable devices, operating theatre capacity planning implants, clinical trial site activation and monitoring

7.1 Primary Actions

7.2 Secondary Actions

7.3 Follow Up Consultation

At Month 3 (2027-01-31), confirm Leuven partnerships in writing or activate fallback sites; review T0 funding closes and team recruitment progress. At Month 6 (2027-04-30), verify notified-body pre-submission meeting occurred, DMC is seated with published kill gates, and patient-protection trust is funded. At Month 12 (2027-10-31), confirm G1 financing committed or trigger automatic deferral; review FTO results, EU-control sovereignty tests on licence targets, and supplier MOU signatures. At Month 15 (2028-01-31), publish preliminary feasibility verdict on signal stability (evidence-based kill thresholds). At Month 24 (2028-10-31), issue final six-part feasibility verdict on scientific, engineering, clinical, regulatory, supply-chain and financing feasibility; confirm G3 funding or stop the programme. If any gate is missed, convene investors, the Commission and ethics advisors within 5 business days to execute the pre-registered fallback (deferral, switch or wind-down).

7.4.A Issue - Leuven partnerships remain uncommitted, risking cascading schedule slip and cost overrun

The plan assumes imec, KU Leuven and UZ Leuven will partner but none has signed a commitment. The fallback pathway (Ghent, Utrecht, Grenoble) is documented but adds 3–6 months and up to EUR 2M. This is the single point of failure for cleanroom access, surgical training, ALS patient recruitment and preclinical facilities. No signed letters of intent exist by Month 0 (2026-10-31). Without written commitments by Month 3 (2027-01-31), the 10-month founding-team build and architecture lock at Month 18 (2028-04-30) both slip, compressing the FIH window and risking a competitive-response gate activation.

7.4.B Tags

7.4.C Mitigation

Immediate action (within 2 weeks): the founding team must contact imec, KU Leuven and UZ Leuven with a one-page partnership scope (cleanroom hours, staff FTE, patient cohort access, decision deadline). Request LOIs by Month 3.5 (2027-02-15). In parallel, activate fallback talks with UMC Utrecht, Ghent/Antwerp and CEA-Leti by Month 0.5 (2026-11-15), securing backup LOIs by Month 3 (2027-01-31). If any Leuven institution declines, trigger fallback activation within 48 hours and compress fallback site qualification to 8 weeks (Month 6 = 2027-04-30), updating FIH and architecture-lock milestones. Publish a written partnership status report to investors and the Commission by Month 2 (2026-12-31).

7.4.D Consequence

If partnerships are not confirmed by Month 3 (2027-01-31), the MVPfunding (EUR 15M) cannot be committed reliably, because the cost and timing of a fallback site are uncertain. FIH slips to Month 66–72 (2032-04-30 to 2032-10-31), pushing CE marking beyond Month 140 (2038-06-30). The 5,000-implant target becomes even less credible. Investor and Commission confidence erodes, making tranches G1 (Month 12 = 2027-10-31) and G3 (Month 24 = 2028-10-31) impossible to close.

7.4.E Root Cause

The plan was written before founder recruitment and partnership outreach began. No scoping calls or LOI templates exist. The Leuven partners were listed as 'none of which has committed', signalling this was a known gap. The fallback pathway was documented but never formally triggered or tested; no backup site has received a formal partnership inquiry.

7.5.A Issue - Financing gates are declared but not gated: no written fallback or automatic deferral mechanism binds investors or stops the programme

The plan defines three hard gates (G1 Month 12 = 2027-10-31, G3 Month 24 = 2028-10-31, G4 Month 36 = 2029-10-31, 2028-10-31, 2029-10-31) with written verdicts within 5 business days. However, no investor commitment letter templates, no automatic deferral triggers and no stop mechanism exist. The EUR 15M T0 'floor' is termed 'proposed' yet drives the entire MVP. If a gate is missed, the plan says 'stop, defer or switch' but does not specify who decides, what the alternative is, or what happens to implanted patients. This vagueness converts gates from credible kill switches into rhetorical aspirations.

7.5.B Tags

7.5.C Mitigation

By Month 1.5 (2026-12-15), draft a Term Sheet template with explicit gate conditions: 'T0 release is contingent on (a) Leuven partnerships LOI by Month 3 (2027-01-31), (b) DMC established by Month 6 (2027-04-30), (c) notified-body pre-submission by Month 6 (2027-04-30), (d) FTO review 50% complete by Month 12 (2027-10-31).' At each gate date, publish a go/no-go verdict to investors, the Commission and a public stakeholder list within 2 business days. If G1 (Month 12 = 2027-10-31) is missed, automatically halt non-critical hiring and defer Months 13–24 (2027-11-30 to 2028-10-31) spend within 48 hours unless a written extension commitment is signed by the lead investor. Write a wind-down plan (preserve IP, notify ethics committees, patient-reserve payout schedule) and file it with the notified body by Month 3 (2027-01-31) so it is immediately executable.

7.5.D Consequence

If gates lack binding teeth, the board will negotiate past each deadline rather than stop. Implanted patients will accumulate while the financing situation deteriorates, creating moral hazard and destroying the 'hard requirement' credibility that regulators and ethics committees require. The plan's claim to be 'gated' becomes an empty gesture. Investor trust evaporates when the first gate is missed and the company continues anyway.

7.5.E Root Cause

Empty

7.6.A Issue - Feasibility verdict for the original mission is deferred to Month 24 (2028-10-31), but kill-gate thresholds for signal stability and bandwidth are unvalidated and may be unrealistic

The plan pre-registers kill thresholds: 20% signal loss blocks FIH, 25% blocks continuing in humans (proposed), 5 bits/s in 50% of users triggers review (proposed). No published preclinical data is cited to justify these targets. Thin-film surface architectures in the literature show 30–50% signal decay at 12 months; penetrating arrays show better stability but higher surgical risk. The EUR 30M architecture-switch contingency is budgeted but switching at Month 72 (2032-10-31) compresses the pivotal-lock window to 12 months (Monster 72–84 = 2032-10-31 to 2033-10-31), risking CE-marking slip to Month 156 (2039-10-31). If signal stability is the real blocker, the plan needs to justify the 20% and 25% thresholds with evidence before FIH, not guess them post-hoc.

7.6.B Tags

7.6.C Mitigation

By Month 9 (2027-07-31), commission an independent preclinical review of thin-film surface and penetrating cortical chronicity from published data and unpublished proprietary datasets (imec, Clinatec, UMC Utrecht). Calculate signal-retention percentiles and 12-month decay distributions; set kill thresholds at the 10th percentile (pessimistic) and 50th percentile (central) to anchor them in evidence. If thin-film signal loss systematically exceeds 25% at 12 months in the literature, revise the threshold to 35% or trigger an earlier architecture-choice gate at Month 12 (2027-10-31) rather than Month 18 (2028-04-30). Document the 20% animal and 25% human thresholds as informed by this review, not guesses. Pre-register the contingency-switch decision rule: e.g. 'if mean signal retention at Month 36 (2029-10-31) of the first 3 animals is <50%, trigger Month 42 (2030-04-30) architecture review, with switch decision by Month 48 (2030-10-31).' Issue a preliminary feasibility verdict on signal stability by Month 15 (2028-01-31).

7.6.D Consequence

If the 20% and 25% thresholds are not evidence-based and are crossed in early animals, the plan will face a forced architecture switch at Month 48–60 (2030-10-31 to 2031-10-31), precisely when FIH should be imminent. This compresses the pivotal-trial preparation window to under 24 months, making CE marking by Month 132 (2037-10-31) impossible and sliding it to Month 150+ (2039-04-30+). The switching cost (EUR 30M, 12–24 months) will blow through the free contingency. The feasibility verdict at Month 24 (2028-10-31) will be forced into 'not credibly achievable' rather than 'achievable only with changes', and investors will have a credible reason to walk away.

7.6.E Root Cause

Empty


8 Expert: Patient Protection, Continuity and Reserves Governance (Explantation, Device Lifetime, Company-Failure Scenarios)

Knowledge: Medical-device explantation and failure-management protocols, actuarial reserve sizing and trust administration, patient-protection covenants and step-in agreements, long-term device follow-up registries and cybersecurity, company insolvency scenarios and patient-support continuity

Why: The plan designates patient protection as a hard requirement, with a ring-fenced trust of EUR 30,000 per implant (estimate), totalling about EUR 31.5M for the central 1,050 implants by Month 180 (2041-10-31). The expert validates the Implanted-Patient Continuity Covenant decision: whether the reserve is adequate to cover follow-up, servicing, explantation and data access for the expected device lifetime (to be estimated), whether a step-in agreement with a successor manufacturer or hospital network is credible, and whether the device design (open external interfaces, simple explantation path) makes patient support durable if the company fails. They also assess whether the trust structure (funded at implantation, held outside investor reach) is legally and operationally sound.

What: Commission an actuarial analysis by Month 9 (2027-07-31) to size the per-implant reserve: estimate device lifetime (central case 10-15 years, estimate), annual follow-up costs (clinic visits, imaging, wireless charging, software updates), explantation costs, and revision/replacement rates. Establish the trust structure and governance by Month 6 (2027-04-30), with independent trustees, a published reserve policy, and auditing. Design explantation and device-failure protocols by Month 24 (2028-10-31), with surgical simplicity validated in models or cadavers. Negotiate or draft a step-in agreement with a second manufacturer or EU hospital consortium by Month 36 (2029-10-31), and test the handover with a named successor. Define cybersecurity and data-access continuity: what happens to neural data if the company fails, and how long are records kept?

Skills: Medical-device failure analysis and recall management, explantation-procedure design and surgical validation, actuarial reserve sizing and long-term forecasting, trust and escrow administration under European law, step-in agreements and succession planning, patient-registry governance and lifelong follow-up protocols, cybersecurity and data-destruction policies

Search: medical device explantation protocol failure management, patient protection reserve actuarial sizing, device lifetime long-term follow-up registry, company insolvency patient support continuity

8.1 Primary Actions

8.2 Secondary Actions

8.3 Follow Up Consultation

At the Month 3 (2027-01-31) check-in, review: (1) trustee retention, actuarial study and trust-deed draft status; (2) explantation-design criteria and chronic-animal study integration; (3) Decoder Lifecycle Policy publication and cybersecurity assessment scope; (4) Leuven partner LOI status and fallback-site activation triggers; (5) Data Monitoring Committee recruitment and kill-gate pre-registration completion; (6) Upstream Supplier Register and first-supplier MOU status. By Month 9 (2027-07-31), expect: explantation protocol validation, eligible-population epidemiology, payer-dialogue readiness and freedom-to-operate analysis outline. By Month 12 (2027-10-31), closure of the first USD 15M financing gate (T0) and notified-body pre-submission meeting. The Month 24 (2028-10-31) verdict is the most critical output; withhold Series B capital release until all six feasibility domains are presented. Thereafter, quarterly reviews should track compliance with kill gates, consent governance, decoder change-control and the Decoder Registry; annual audits should verify trustee performance, reserve adequacy and patient-data stewardship.

8.4.A Issue - Patient-Protection Reserve Governance Is Incomplete and Critically Under-Specified

The plan mandates a EUR 30,000-per-implant reserve by Month 6 (2027-04-30) with a EUR 5M floor before first-in-human, but does not specify: (1) who holds and administers the trust (independent trustee, hospital, notified body, regulator?); (2) what triggers drawdown (device failure, company insolvency, explantation, long-term support); (3) how device lifetime and actuarial adequacy are assessed; (4) whether reserves are invested, and what returns are assumed; (5) how successor parties gain access if the company fails; (6) what happens to surplus reserves after patient death or explantation. Without these details, the reserve is legally ambiguous and may not survive regulatory or payer scrutiny. A failed or acquired company could claim the reserves; patients could be abandoned if the trustee is not bound to explicit support obligations.

8.4.B Tags

8.4.C Mitigation

By Month 2 (2026-12-31), retain an independent trustee (e.g., a law firm, bank trust department or EU patient-protection foundation) with experience in medical-device escrow. Draft a trust deed specifying: (a) trustee duties to support implanted patients for device lifetime (to be actuarially modeled by Month 9 = 2027-07-31); (b) drawdown triggers (device failure, company insolvency, patient death, explantation); (c) successor-access rights (named fallback manufacturers, hospitals, the notified body); (d) investment policy and return assumptions; (e) annual audit and reporting to a patient advocate and regulator. Have the notified body review the deed as part of pre-submission (Month 6 = 2027-04-30 meeting). Publish the trust framework by Month 6 (2027-04-30) to investors and ethics committees.

8.4.D Consequence

Without explicit trust governance, the reserve may be legally challenged as company assets, freezing patient support if the company is acquired or enters insolvency. Regulators and ethics committees may block first-in-human without clear successor-access rights and actuarial backing. Payers may refuse reimbursement if patient protection is ambiguous. Post-CE-marking, patients implanted under an unclear covenant could sue if support is withdrawn or insufficient, damaging the company and the programme.

8.4.E Root Cause

The plan treats the patient-protection reserve as a financial gate-keeping item rather than a binding legal obligation with a defined trustee and successor-access mechanism. The actuarial basis (device lifetime, failure modes, attrition, explantation rates) is missing, so the EUR 30,000 figure is unsupported. No precedent is cited for how other implantable-device companies or EU regulators structure such trusts.

8.5.A Issue - Explantation Pathway, Device Design and Surgical Recovery Are Not Integrated Into Architecture or Kill Gates

The plan mentions explantation as part of patient continuity but does not specify: (1) design criteria for reversibility (electrode material, encapsulation, attachment strength, recovery protocols); (2) surgical risk, tissue scarring and recovery timeline; (3) who implants and who explants (same team, certified specialist, any trained neurosurgeon?); (4) what happens to explanted devices (data extraction, device disposal, tissue analysis); (5) how explantation readiness is validated preclinically; (6) when a patient can request explantation (end of trial, device failure, patient choice, adverse event); (7) cost attribution (company, payer, patient, trust). Omitting explantation from the architecture choice and kill gates means the device could be designed for implantation only, with no reversible exit. This violates informed consent and patient autonomy.

8.5.B Tags

8.5.C Mitigation

By Month 9 (2027-07-31), define explantation requirements as design inputs: (a) electrodes must be retrievable with <10% tissue damage; encapsulation must not fuse to dura or cortex; (b) surgical explantation time must be <4 hours, with complication rates <5%; (c) tissue and electrode recovery must preserve histology and electrolyte balance for post-mortem or clinical analysis. Test reversibility in chronic-animal studies (14-24 months); include a dedicated explantation cohort (3-5 animals) with full surgical and tissue assessment. By Month 18 (2028-04-30), publish an explantation protocol with independent surgeon validation. Include explantation as a mandatory kill-gate measure: if >2 explantations in the first 20 implants show significant tissue damage or >2-hour surgical time, trigger design review. Fund explantation from the patient-protection reserve; cost estimate EUR 5,000-EUR 15,000 per procedure.

8.5.D Consequence

Implanted patients facing device failure, adverse events or their own choice to exit may be trapped with a non-reversible device, unable to pursue alternative treatments or manage complications. Surgeons may lack training or capability to explant safely, leading to tissue damage or death. Ethics committees and payers may refuse to approve a trial if explantation is not credibly possible. If explantation complications are discovered late (Year 5+), the company faces product-liability claims and regulatory action. The plan could be forced to abort implantation or offer emergency explantations without proper protocol.

8.5.E Root Cause

The plan separates device design, surgical procedure, patient consent and the continuity covenant, treating explantation as a downstream support obligation rather than a design requirement. Neurotech precedent (Clinatec, UMC Utrecht) shows that surface and endovascular devices are more reversible than penetrating designs, but this trade-off is not explicit in the architecture choice. The plan defers indication and architecture decisions to Month 18 (2028-04-30), too late to shape explantation reversibility into the design baseline.

8.6.A Issue - Decoder Lifecycle, Data Ownership and Cloud Dependency Create Unmanaged Sovereignty and Cybersecurity Risks

The plan specifies a 'locked decoder version' for the pivotal trial and version-gated change control for the AI Act, but does not address: (1) who owns the training data (participant neural signals) and models (weights, architecture, features) after CE marking; (2) whether decoder updates after pivotal lock require notified-body approval or can be autonomous; (3) whether patient data or model weights can be shared across patients, centres or member states; (4) whether the decoder runs on-device, on a body-worn processor, or on EU-hosted cloud; (5) what happens if the company is acquired and the acquirer is non-EU or is subject to export controls; (6) whether patients retain the right to their neural data or to export it; (7) how long neural data is kept and who accesses it for AI training. If decoder updates are frequent and the cloud dependency is opaque, patients lose control of their device behaviour and their data becomes a silent asset extraction risk.

8.6.B Tags

8.6.C Mitigation

By Month 9 (2027-07-31), publish a Decoder Lifecycle Policy specifying: (a) participant neural signals are owned by the patient; the company holds a limited licence for clinical care and pre-registered research only; (b) AI model weights and feature sets are EU-held IP, not sold or transferred outside the EU; (c) decoder updates classified as minor (retraining within locked feature set) are autonomous; major updates (new features, new data sources, architecture swap) require notified-body scientific review; (d) post-CE-marking, all decoder versions and validation results are logged in a publicly queryable Decoder Registry to support transparent audits; (e) if the company is acquired, the acquirer must assume EU data residency and model-lineage obligations as a condition of closing; (f) patients can request data export (neural signals, model weights, performance metrics) within 30 days. Run a cybersecurity assessment by Month 12 (2027-10-31) covering: cloud access controls, encryption, data isolation per patient, audit logging and incident response. If decoder updates occur >12 times per year, conduct independent security re-audit every 6 months.

8.6.D Consequence

Without clear ownership and access rules, patients' neural data could become a training corpus for a company's or acquirer's broader AI models, violating consent and GDPR. Frequent decoder updates without proper validation could degrade performance or introduce unintended biases. An acquirer could relocate AI training to non-EU jurisdiction, failing the sovereignty tests. Regulators could require model revalidation after each update, slowing beneficial improvements. If a cybersecurity breach exposes neural signals, patients face identity theft (neural fingerprinting) or blackmail (mental-state inference). The company could face GDPR fines (up to EUR 20M or 4% of revenue) and patient lawsuits.

8.6.E Root Cause

The plan focuses on decoder change control for the pivotal trial but does not govern the long-term ecosystem after CE marking, when patient numbers grow and continuous AI improvement becomes operationally normal. The sovereignty tests are applied to hardware and manufacturing, not to AI training data and model ownership. No analogous medical-device precedent is cited; the plan assumes a static decoder rather than a learning system.

Level 1 Level 2 Level 3 Level 4 Task ID
EU Sovereign BCI c91a8f3a-3c51-432c-a49a-d10e3c6aba54
Foundational Risk Retirement and Partnership Lock (Months 0–24 = 2026-10-31 to 2028-10-31) 6b200f79-d360-498b-b102-cbc43c5b3db0
Secure written partnership commitments from imec, KU Leuven and UZ Leuven with fallback site pre-qualification caab7894-bf46-4fa1-ba1c-876b2f5d56a2
Initiate partner executive engagement and outreach 2409e35c-91f2-45a5-82a4-6ae2855e5fc5
Pre-qualify fallback sites and secure letters of interest 1a81f12d-d99c-4ba8-93e3-4ade62ed3fd5
Develop and circulate commitment templates and LOI frameworks 24b40dc0-16fa-4507-a86c-3c66861346de
Establish partnership lock hard deadline and fallback activation protocol cc3b78da-de96-4dca-a0ea-be8f64f7b1d0
Track commitment status weekly and escalate blockers 5bf644ed-fef6-446a-a9f0-7a9d8ad9f9ef
Close seed funding (EUR 5M) and gate G1 commitment (T0 EUR 10–15M) with written tranches and automatic deferral rules e4db230e-5d95-45cb-96fa-93e8564d76fb
Prepare investor due-diligence packages and data room 004cae08-7abf-4d0b-9601-b52282125592
Identify anchor investors and circulate term-sheet templates 636f32ca-2ff3-437e-bf89-1ad5c51f9853
Establish patient-protection trust and EUR 5M floor funding mechanism 7b7d113f-93ef-4ea6-b29d-48989bf44ac9
Define Gate G1 acceptance criteria and automatic-deferral rules 3feb029c-7b1c-45f4-89bb-933472a96b1c
Schedule and execute seed close and T0 commitment closing by Month 12 (2027-10-31) e4f6b0e4-2c7a-4b61-8f50-5a146f87105b
Establish independent consent advocate, Data Monitoring Committee and patient-protection trust with EUR 5M floor d181d085-4bc8-4fb6-9645-603b671c9095
Recruit independent consent advocate and define role cd588e97-f148-4a9f-84f4-2327ed8cd60b
Establish Data Monitoring Committee with 5+ members and patient representative 9794d10c-c3a6-440b-b664-1aae0d2ba53f
Draft and validate informed-consent protocol with advance directives 9eb19ea2-4830-4847-a8c6-3f3623076498
Obtain written ethics-committee pre-approval from three trial sites 5430d911-5deb-4ec1-8f73-08498cdc6dc1
Present consent protocol to notified body and confirm acceptance 059ce1d7-f54c-49e9-b123-e4311bb1515d
Engage notified body (pre-submission), begin ISO 13485 QMS build and request Commission scientific advice 6f0cb9b4-5cda-49dc-a9ae-b965a038be07
Select and engage notified body 5dc543f5-5699-4da2-80d3-5d49baa87ebc
Build ISO 13485 QMS framework 712c4d8b-48a4-4e00-89de-c0e623704a13
Initiate design history file and risk management dossier 21da7119-2b3b-4de2-bfbf-79f3d296e342
Prepare scientific-advice request to European Commission 939529a1-2fb7-4fe5-b900-11f069c5b6d6
Schedule preliminary QMS audit and address findings 4de90de8-e2e9-42eb-80b6-6eb464888530
Commission chronic-implant animal studies, freedom-to-operate analysis and eligible-population epidemiology f0e0b4db-afb4-4568-8868-43b572dbba59
Design and approve chronic-implant animal protocol ab6e424c-b9c7-4aed-9bf4-a890e139b5f4
Conduct chronic-implant animal studies in parallel cohorts 5cc36b74-602e-4db1-b984-069cb058a3e6
Publish signal-stability literature review and kill-threshold validation a5767004-631f-429a-bb85-fcbc184a9bda
Execute freedom-to-operate analysis and identify design-around costs 3f663399-8de7-4567-8d8a-4b84046c96b0
Conduct eligible-population epidemiology across EU/EEA member states 530fac87-10c9-4928-adae-4812e5f01f2a
Recruit core MVP team (10 staff) and establish cleanroom and compute access at primary sites 743af8b1-dab9-4d1d-b51c-725428be13a8
Identify and approach critical-role candidates c107e1fd-a367-4139-9cf4-29963827b442
Secure letters of intent for cleanroom and compute space ed9c2632-0763-40f1-aca4-a7f0b6615906
Establish procurement and infrastructure timeline b762651b-be03-4d34-b399-f1ad63299512
Align team structure and facility readiness for Month 3 (2027-01-31) gate b61bee7a-a7c5-46f6-9f4a-ff42aa6eb245
Architecture Choice and Supplier Sovereignty Lock (Months 12–30 = 2027-10-31 to 2029-04-30) 48de9275-a87e-4cf7-856c-94af580750ad
Complete chronic-implant animal studies and publish signal-stability data; validate kill thresholds with independent review c4388dc4-728a-4bf5-9bac-644eda3f0112
Design and execute chronic-implant animal protocol e99531e2-68ea-4cec-a68e-13a2c7ebcb03
Conduct systematic literature review and kill-threshold validation bd614b5f-d13f-40c5-be3d-9469a9a9faa9
Manage interim data reviews and escalation procedures 049482ce-75dc-4b47-886e-441015ab26b5
Publish findings for scientific credibility and regulatory transparency 21af4c2a-7239-49a6-8195-fd7c1ac72c42
Ratify primary architecture (thin-film surface) and fallback (penetrating cortical) with FTO clearance and surgical-risk assessment acc20067-25c0-4010-bb85-a8743c6a87dc
Conduct freedom-to-operate patent landscape search 01a7110c-a480-45c1-ac4d-16377084c4c1
Complete chronic-implant animal data interpretation 3b188b68-f30a-44a0-b433-bf8759375ec7
Assess surgical risk and explantation reversibility per architecture 3fceea46-428b-440e-b389-33441a54623f
Obtain notified-body and ethics feedback on architecture ratification febbe88c-8164-4e01-976d-2969d7701c5d
Lock primary and fallback architecture specifications by Month 18 (2028-04-30) cabf4bcf-e077-480e-97b5-ee8ef47075aa
Lock downstream requirements: electrode design, ASIC specification, implant encapsulation material and external processor thermal envelope 99a43194-7705-43b7-89a0-c8431f783c12
Establish cross-functional design lock task force 048ecb59-7658-4268-bccf-dd606e438cca
Conduct preliminary supplier capability reviews dde6a8e0-ea90-488f-a580-1623a62afa93
Run thermal envelope validation in parallel with electrode design 4ddfa30e-6f48-4cd2-b6b4-77795dd7d6ca
Lock electrode design and ASIC specification jointly c8814b29-173e-4d55-adab-18bb902634cc
Schedule biocompatibility and sterilisation sample material lock ee5032b6-c4da-4208-9ecd-845a53d27ae1
Qualify and sign MOUs with first and second suppliers for chips and thin-film substrates; publish upstream-dependency register 006ec0d9-1d60-40dc-a6d9-573ec0245001
Issue supplier RFI and conduct pre-qualification site visits 8e4cd8fb-8726-4776-bb8c-f735c9118068
Develop MOU template and non-disclosure agreements 2979363e-410a-4a5c-9878-b41418bc456a
Negotiate and sign MOUs with first and second suppliers 8f1c5be6-727b-42bd-9c82-21b65bdbf567
Create and publish upstream-dependency register dd05cc67-7450-45ef-8df9-77c3cb82ab59
Conduct independent sovereignty audit and lock supplier selection 7487bbde-4aef-4a0f-91a9-812031ee52db
Pre-register bandwidth-measurement protocol with external registry and establish federated-testing infrastructure 4b51b50b-0078-45c0-8bd3-933899ecc5bf
Lock bandwidth-measurement protocol via independent technical review c1da13d2-9d1b-4757-943a-4f47ae2b301e
Establish federated-testing infrastructure for independent bandwidth verification 954dd714-64ec-4476-b650-a061c93c60b5
Monitor and update competitor bandwidth claims; publish rival scenarios quarterly 089c321d-724f-4142-ae5b-89b0d5f50ce1
Validate preclinical bandwidth using locked protocol; obtain independent verification by Month 18 (2028-04-30) c9c86f50-b743-4450-b8b3-cf5984752eb3
Integrate locked protocol into first-in-human study design and ethics submission 9d97ea97-bdd5-4537-a985-71683b083d79
Trigger foundry or dual-sourcing decision gate (Month 18 = 2028-04-30); confirm 4+ member-state commitments or activate dual-source path 7d55279e-6392-4013-be82-8fd636e84f39
Initiate and coordinate foundry-commitment talks with 4+ member states 71acb309-db3d-43f1-8d60-903a98178045
Pre-qualify dual-sourcing suppliers and finalize qualification MOUs 8f03cd8a-5c10-4419-b19e-ec51ad02008f
Establish foundry-gate decision criteria and automated trigger rules by Month 16 (2028-02-29) 6401cfe6-5811-4ab2-8ead-296d7dd8ce23
Conduct Month 18 (2028-04-30) gate decision: publish verdict and activate chosen path within 48 hours a85b9da6-dd25-41ab-8403-fa50a7fbd8a2
Execute activated path (foundry or dual-sourcing) with compressed timeline to Month 30 (2029-04-30) 8628e075-a9b7-4b96-8a23-8b99aeb73e1f
Feasibility Verdict and Indication Scope Gate (Months 18–36 = 2028-04-30 to 2029-10-31) 936ac6c7-427d-4ec9-9366-7757003961ba
Complete epidemiological analysis of ALS and spinal cord injury eligible pools; conduct pre-reimbursement payer dialogues 01276f34-b94b-4994-8c1f-f4889ae2bf7c
Commission and initiate epidemiological analysis across EU/EEA member states 4c1a2015-dfb1-40c6-a126-625c587e1157
Conduct structured pre-reimbursement payer dialogues in 3+ member states 44f64972-28dc-421e-986e-ee41110e5551
Build health-economic model and cost-per-QALY analysis for reimbursement case a5b3180b-ee72-4826-84fa-1afa5b1ee345
Pre-register eligible-population thresholds and indication-pivot decision rules f877c24f-9940-45d7-abc4-0118a616bb87
Conduct ALS and SCI population audits; publish confidence intervals and sensitivity analysis 21f36787-94a7-47ac-953b-6ed6b86906b3
Publish comprehensive feasibility verdict (Month 24 = 2028-10-31) on financing, population, signal stability, regulatory and bandwidth credibility 4a58dd45-d05f-42fc-adf7-e0a9842282f6
Compile financing, signal stability and animal-study evidence e2e9dd81-0be5-476e-a16d-e027aa26599a
Synthesise eligible-population epidemiology and payer feedback c4e1ca66-b87b-42cb-b3d5-52158a4c7713
Validate bandwidth measurement protocol and early data 57c534cd-a291-4cb8-a3b8-74a29e55af1b
Assess regulatory pathway feasibility and notified-body alignment 2aa7d43d-b374-43c7-9806-fa37149cd5e5
Produce and gate-sign the comprehensive feasibility verdict document 15195e1e-a5af-4fb7-b5f7-ee60b8d94c94
Pre-register indication pivot decision rules: if eligible pool <300 per year or payers reject EUR 150k price, trigger scope gate to choose spinal cord injury or stop 2997988d-8fb3-415c-b18b-76fec378ed20
Draft and circulate pre-registered decision thresholds for ALS versus spinal cord injury indication pivot 23cd8bc9-e140-456a-a9a5-e9549e8fe993
Establish monthly epidemiological updates and automated flag alerts 43105d59-f749-44d7-968c-044b17075b59
Conduct monthly payer dialogue check-ins and document price-acceptance feedback f6a0e656-823d-49dd-9a48-036dfa505605
Hold decision-rule review with independent legal counsel and obtain stakeholder written sign-off 9e740318-a202-4cea-93f6-9579ad9337dc
Publish final indication-pivot decision rules and communicate enforcement protocol to all stakeholders 3c63a76a-51b8-4dcc-9c5a-d904efdb742c
Gate G3 decision (Month 24 = 2028-10-31): close T1 commitment (EUR 60M minimum) and publish written verdict within 5 days or initiate automatic 12-month deferral a9188c61-744d-4e8d-b665-d57c8327b770
Lock epidemiology and payer input deadlines for feasibility-verdict drafting d8d89385-fac6-4d87-8f9f-b56dc0299d5f
Pre-register indication pivot decision rules and thresholds in writing 2a111f8a-d767-453d-8ced-0d4b7e4323b3
Initiate payer and HTA body pre-reimbursement dialogue (4-month window before Month 24 = 2028-10-31 gate) 789a2bda-a6a7-4584-b9ad-b49d85fc652c
Produce comprehensive feasibility verdict (Month 24 = 2028-10-31) and gate-decision publication d10253d5-f2af-4263-a1bb-2b7cf63521c9
Confirm Gate G3 financing closure (T1 EUR 60M minimum) and automatic deferral rules 767af9a6-cea7-4283-9175-8143fac25ea7
Conduct preliminary QMS audit with notified body; update design history file and risk management dossier 3df6b234-7a33-492a-b628-97ddcb5bc399
Compile and mature design history file f2541417-1c98-492f-be2b-52fa4f185387
Update risk management dossier per ISO 14971 27e24fa1-a214-4ef1-b609-7943b632ec7d
Conduct internal pre-audit gap assessment e77d6078-0b2d-4d64-9712-f45717e93056
Schedule and prepare for notified-body preliminary audit e5d9902b-6669-4b79-a78c-52792ea32c73
Remediate gap findings and prepare audit responses 069e00f3-ab01-42ba-9c6a-51735bcdcb18
Deliver preclinical bandwidth results using locked measurement protocol; obtain independent verification cfd96d22-aa53-4cc7-beed-83e5e896be73
Finalize and pre-register bandwidth-measurement protocol 86e12d3e-54c6-45b3-8f1f-ed813711141c
Build and validate federated-testing infrastructure 1cb7a6dc-4b11-4a2a-97d2-1a4fc312d8eb
Conduct preclinical bandwidth measurement using locked protocol f0731388-e711-46da-90d5-9bd0a4c4c013
Obtain independent verification and publish results 9868c388-64ef-41ab-b8ce-b1edd25da7da
Establish decoder version-lock and AI Act change-control process 92c26611-a378-48a0-9219-0ed42c853704
Pilot-Line Prototyping and Design Lock (Months 24–48 = 2028-10-31 to 2030-10-31) ab01ce17-5a76-4870-b01d-448b3c737e11
Gate G4 decision (Month 36 = 2029-10-31): confirm T2 conditional commitment (EUR 150M minimum of EUR 480M) or defer FIH in 12-month steps 12cb95cb-0683-44d6-b7fe-702665f80830
Complete design-history file and regulatory documentation 45e8d03b-1064-4b2b-b85d-907d9240ef4d
Qualify manufacturing process and validate sterilisation c69edaa2-5dff-43ac-a122-d9123d618442
Procure long-lead materials and component inventory c8646ee3-db8c-453e-a1b7-dd3523c6e549
Manufacture FIH device batch (10–20 units) with full traceability and defect documentation 9ddb3bb8-3888-4587-b461-cf51dbcc5441
Validate device batch readiness and FIH release decision b20ac020-78c9-47f6-8296-d54f2b40e07e
Design and validate electrode arrays, ASIC, encapsulation and external processor at imec research pilot line f68ba9a9-b70a-4f31-8b13-f6553537dd29
Design and prototype electrode arrays df6c1fa0-9371-40d9-9fc4-650a512fa138
Design and validate ASIC signal-conditioning chip ecdad6a4-c77d-4bc3-8ae4-762f5922d790
Design implant encapsulation and biocompatible packaging 9fc7e03d-cbc1-4b94-82ab-44b15450ee57
Design external processor wearable and wireless link adc82d59-4345-4dce-a880-b465e59e7467
Execute pilot-line manufacturing validation and yield optimisation bc96f330-1a0f-4e05-92ef-1e48d999b39a
Conduct GLP biocompatibility and sterilisation validation studies for final materials and processes e374594e-8b7c-4a04-90bd-7b267d424f3d
Design GLP biocompatibility test protocol and material selection 718e034e-b3a0-4f68-a7cf-88169b9ff166
Execute ISO 10993 biocompatibility studies on final material candidates 6df11035-f617-4ab4-9f52-23d0a5d1d3d1
Develop and validate sterilisation method and sterilisation-validation protocol 1723498f-75d1-47a6-a1ee-37f29de70501
Monitor and manage encapsulation-material sourcing and supplier qualification 46eabdb4-d14b-45c8-a8c0-4112282685b5
Manage biocompatibility-test findings; execute rework or material substitution if needed 75e80bee-9759-4455-8724-556f060a30ef
Plan and begin pilot-line-to-validated Class III production transfer; contract primary manufacturer and qualify second source f1de9af6-0071-4e61-bf12-f0060c6a9534
Establish production-transfer governance and assign project leadership 4f485a0e-5b25-4eb2-b541-2c6389bcc5c9
Conduct pilot-line dry runs and material-qualification batches for critical components c345aac0-0d23-4d7d-8e39-0074226d9c33
Qualify primary and second-source manufacturers for Class III production; initiate dual-source capability reviews 68feca25-7b04-4a41-b8bc-c69926dba031
Execute preliminary process-validation campaigns and pilot-run manufacturing under ISO 13485 a4997473-2072-49ed-9081-3cc8205e595c
Finalise materials, processes and supplier selections; publish sovereign-supply register and confirm three-test passage 72b58387-3ca9-4759-a6d2-8c0d05a35744
Lock design for pivotal trial (Month 48 = 2030-10-31); freeze all component suppliers, materials and manufacturing processes 46f865b2-7349-478b-b2dd-d34f36cdb891
Design and validate electrode array geometry and material specifications 51ee5b5d-4bbc-401b-8179-572d1def71e0
ASIC specification and initial logic design for signal conditioning and wireless transmission 4c239361-1645-499c-bf24-2552c40ccbf9
Encapsulation material selection and biocompatibility protocol development a8a8ae19-8c2c-466b-9174-14ad0a245705
External processor thermal envelope design and power-budget lock 53f44529-ba70-435c-bf76-de78577c882c
Cross-functional design integration and formal design-freeze gate preparation e3bc0191-925e-4ca8-9b15-222c05bc024c
Develop decoder algorithms and conduct preclinical decoding validation; version-lock the AI model and establish change-control process 214e72d4-3f56-423a-a87a-817efa7da8d1
Design decoder algorithm families and feature extraction f043e593-216e-4fab-aa20-3c21a0b573d5
Conduct preclinical decoding validation on animal cohorts 61269b5a-1b67-4577-b398-7340e8e85af3
Establish AI model version-lock and change-control governance 6df3f4d6-d09a-45ec-a681-218bc676cd7d
Develop decoder retraining protocol within change-control bounds 094d8b54-4ed0-4d81-9a6a-a833c8af45ad
Conduct independent verification and publish preclinical results 0f428f9c-663c-422d-8fb1-7bf49c339b36
Clinical Investigation Preparation and First-in-Human (Months 48–72 = 2030-10-31 to 2032-10-31) be474914-b74a-4ab0-9675-49d128c8fe81
Finalise informed-consent protocol with advance directives, capacity-fluctuation monitoring and independent validator procedures; obtain ethics approvals e6f99ba6-c351-44fe-a6f8-0c88ab968258
Draft consent protocol and capacity-assessment tools 1f50cdde-7b1c-47ac-90b8-372f935eaf87
Obtain ethics-committee pre-review and approval 64bf4d56-62fa-484f-8b3c-c162afae2fb1
Validate yes/no communication-validation procedure 6a5b4805-5f9b-4598-8f91-853d3dd4dc4d
Recruit and train independent consent advocate 7505d568-e26d-4364-a1f9-60738421e5b9
Finalise and lock consent protocol for notified-body submission aa372221-a1ec-4ea5-ab62-a20dcdd5ae62
Establish implanting-centre network (initial 3–5 sites across Leuven, Utrecht, Grenoble); conduct surgeon credentialing and training e1d13b9a-db89-44be-966a-3e00fc947604
Identify and pre-qualify candidate implanting centres 0e38485a-d6ce-4ae1-afea-07811cd60bb5
Secure formal letters of intent from implanting sites 27e35f6a-2745-4a6b-91ad-a0bf98dc76ac
Design and pre-register surgeon credentialing and training curriculum dea4e845-06fc-4438-afe2-fce328f53b20
Establish surgical training infrastructure and simulation capability 8a36440b-1262-4acf-a617-62d8250796ca
Recruit, credential and schedule surgeons across initial 3–5 implanting centres 76d2a087-3956-4614-85d1-4b42b9223a53
Submit coordinated multinational clinical investigation plan to ethics committees and notified body; seek Commission scientific advice acceptance 414780d4-bd46-4945-a6da-42623e6eb6c3
Develop harmonised clinical investigation protocol and consent templates across Belgium, Netherlands, France e6ee6d0f-a399-4635-b8e7-8ae90e47fe8b
Pre-submit complete clinical investigation dossier to notified body and seek preliminary acceptance 5b9c62fd-8ba1-4f1b-81ff-9207d585f6e9
Submit scientific-advice request dossier to European Commission and obtain written feedback 05c5fab2-1491-4dd2-b093-c114bd3e2a42
Coordinate multinational ethics-committee review and obtain simultaneous approvals from Belgium, Netherlands, France f46fc0c1-d6a9-45cb-8e1f-95a49bdf3127
Establish independent Data Monitoring Committee and pre-register kill-gate criteria f454504c-c301-4931-b938-c602ff63fe13
Manufacture first-in-human device batch (10–20 units) under ISO 13485 quality system with full design-history documentation 0db0878b-4840-4a66-ab0d-d961882e615e
Secure design locks and supplier qualifications dee455be-c6d0-40e0-8213-4f4ed4547e66
Complete materials and process specifications with GLP validation 2c676f07-47bc-4d88-a324-6d45db11f519
Establish ISO 13485 QMS audit compliance and notified-body sign-off d337b5db-c7bd-412c-8d3f-1a1d6f1153d6
Manufacture and sterility-validate first batch under ISO 13485 (10–20 units) 4a7e2e31-aee8-4983-a5bf-23ab107f896c
Complete device-history records (DHR) and design-history file (DHF) closure ee156e26-2e3e-4853-b15f-0bbebad807e2
Conduct first-in-human early-feasibility study (Month 60–72 = 2031-10-31 to 2032-10-31, 10 participants, 5–10 range); measure bandwidth, safety and signal stability ec11c69a-9ddf-45c4-8b84-c1eb4f061d4c
Recruit and screen ALS participants with valid informed consent a47ef4b0-9190-45fb-9de7-49cc23a5203b
Implant devices and conduct immediate perioperative safety monitoring f8d8ce3e-c5cc-4483-8941-c852041a7c40
Measure daily-life functional outcome and bandwidth using locked protocol 11ba8570-3e3a-49ec-aa4a-f9eed19ebd14
Track signal stability and trigger kill-gate pauses if thresholds breached be3ae4bc-f43e-43b3-8601-c27610a6e844
Report FIH safety, efficacy and bandwidth results; publish independent verification 1c6c7692-91cf-40f0-bf91-b8b94ee8dce7
Report FIH safety and bandwidth results (Month 72 = 2032-10-31); publish independent bandwidth verification and update kill-gate thresholds 76ae4991-c55d-456e-b735-7f5a8e5bf05a
Compile and lock FIH safety data by Month 71 (2032-09-30) 9106269f-decf-451c-ae4d-7f7d72833ba7
Prepare FIH bandwidth dataset and transfer to independent verifier ed58867f-f254-4e8d-9e12-f128ab11b9d7
Obtain independent bandwidth verification from external laboratory ddce7f38-e2bc-493e-afd0-bbdcf79073a5
Brief Data Monitoring Committee and obtain kill-gate recommendation by Month 71 (2032-09-30) d69f9df2-a1a6-4633-94af-8ec719875506
Publish FIH results and independent verification findings within 5 business days of Month 72 (2032-10-31) 26349a88-1c1d-4e3e-9d3d-9d8a88e8556c
Manufacturing Transfer and Pivotal Indication Lock (Months 48–84 = 2030-10-31 to 2033-10-31) 6621e1a4-fc14-4545-a305-81890b80ad3c
Execute pilot-line-to-validated Class III production transfer for electrodes, chips, encapsulation and assembly (Months 48–72 = 2030-10-31 to 2032-10-31) 43ea3d81-9edd-4a6f-85eb-797d1a3e3666
Design and validate electrode manufacturing processes at imec pilot line e018d0ac-acbc-411d-bfca-e3b0d86b7a5e
Qualify and transfer ASIC design and manufacturing to primary and second-source chip suppliers b40abf34-972b-46f2-bfa0-993e47e1cdd6
Qualify thin-film substrate and encapsulation materials; execute biocompatibility and sterilisation validation 11b6edb2-a733-4526-9df7-12778f258ab5
Establish assembly and final-device testing protocols at primary manufacturer site adf40b45-bc01-457b-8541-ad5aadb5ccaa
Conduct pilot-line-to-factory transfer documentation and operator training; resolve yield and process-stability gaps 8e9b5f8c-f2e6-4fbc-8237-5093d25ae49a
Qualify primary and second-source manufacturers for Class III production; conduct process validation and dual-source stress testing 3fa905f7-f5d9-4292-a499-505a0b0e1b09
Identify and pre-qualify candidate manufacturers 305939c2-4fa6-4635-8378-48c66d467eb3
Establish legal MOUs and design-transfer agreements fa3fd76c-2ce4-45f9-ba9b-fa048525d103
Conduct process validation and capability studies 4f989490-9be1-4d3d-aa7a-230e23bad0df
Execute dual-source stress testing and cross-qualification 6c971258-ae56-443e-9af8-e0a6bf343ea0
Resolve supply-chain and export-control dependencies bb7708b1-a582-4fb6-b44d-a7242f3f48e8
Lock all materials, processes and suppliers (Month 72 = 2032-10-31); publish sovereign-supply register confirming three-test passage per component d8f38fd0-ea87-455f-824f-8d6fd1e2e1d7
Conduct EU-control and export-control sovereignty assessments for all primary and second-source suppliers b84c9192-fb47-4e09-acd5-2a24a165e935
Finalize and execute signed MOUs with first and second-source suppliers for all critical materials and components 47c26b32-99fc-4baa-8e22-73e65ec9ba88
Compile and publish upstream-dependency register with full component traceability and sub-supplier mapping 48952542-9028-4f4b-98f1-cd83cedb1318
Resolve any outstanding export-control, licensing or geopolitical blockers identified in assessments; execute fallback or design-around decisions 1a665f20-3447-424b-ae95-7fb467e405ff
Obtain notified-body and internal sign-off on all locked materials, processes and suppliers; document formal lock decision with written attestations 2c6be38d-86d6-4dc0-a813-73390f1e8e6f
Pivotal indication gate (Month 78 = 2033-04-30): pre-register decision comparing ALS population, spinal cord injury pool, payer evidence and eligible implant targets 12052a19-7ca7-44aa-892b-a236f0be2bdf
Pre-register indication-choice decision rules and thresholds 303cbe17-cfea-42b5-b2c6-00c90b509d90
Validate epidemiological evidence: ALS and SCI eligible-pool forecasts 72edb6de-36c1-4515-8d49-2de65773851c
Obtain payer evidence on cost-per-QALY and reimbursement willingness-to-pay c3b8e17b-99a5-4ad7-a861-6aa3e16ab816
Review clinical interim data from early-feasibility trial (FIH, Months 60–72 = 2031-10-31 to 2032-10-31) c4ba2333-2616-4eab-b5ba-291656498255
Execute indication-gate decision and publish verdict within 5 business days 21a154b7-201c-449a-8959-98e903d9c713
Begin pivotal clinical investigation (Month 84 = 2033-10-31, estimated 80 participants); expand implanting centre network to about 10–15 sites 916d3f05-0363-425a-b5db-94cc8b019dc8
Activate implanting centre network and finalise surgeon credentialing 4cad0d45-9d8f-457b-a2fd-cc5bf307345e
Manufacture and validate first pivotal-trial device batch under ISO 13485 2aa8dcaf-78ee-4e2d-a216-716f8ff6d8f4
Finalise clinical investigation plan and obtain multinational ethics approvals e42bcab1-7186-4c36-9b1d-4cb3f863685e
Recruit and enrol first pivotal-cohort participants (~80 ALS patients) 3e13e2e7-40c9-4485-a6ce-e5b32939b3b1
Establish neural-data governance, decoder retraining and AI Act compliance infrastructure 4397cd8a-ef78-4f33-8eb0-10a9d5f9a412
Establish independent EU-hosted neural-data compute and second-site replica for GDPR and decoder retraining 94a09dcb-a92f-4fb3-8b3a-2b9406dbd430
Procure EU-hosted neural-data compute infrastructure 9cb57ff8-2f0d-4fe4-918d-b2062f739203
Design and validate second-site compute replica with failover capability fdaa4625-6175-49a9-b235-a858850b8eef
Establish decoder retraining governance and AI Act version-lock framework aa95084a-41ff-426e-b6f4-1434fbf0f520
Implement GDPR-compliant participant neural-data ingestion and custody protocols 2dc4be0b-1fc7-4a1a-bb35-866b700ba329
Conduct security hardening, vulnerability assessment and redundancy testing for compute infrastructure 725be3f6-4e40-49d2-9292-1f989e4cbdbb
Pivotal Trial Execution and Regulatory Dossier Building (Months 84–132 = 2033-10-31 to 2037-10-31) 33df7d51-d65d-47ee-b18a-549ddc81ad6e
Execute pivotal clinical investigation (Months 84–120 = 2033-10-31 to 2036-10-31 estimate); collect daily-life functional outcome, safety and bandwidth data 2eb6f152-a2d5-49b0-b80f-df075254f62c
Activate and staff implanting centre network across 20–25 EU/EEA sites 0a7ba2b8-c3a5-468e-ac8d-58b6f06cad75
Recruit and enrol participants across clinical sites with capacity-fluctuation monitoring and informed-consent validation 03b82aa7-eba9-4545-9cb1-cfce720617d8
Conduct weekly participant safety monitoring and device-performance checks; escalate adverse events to Data Monitoring Committee 41cb367d-3404-4d79-b180-e6979c9745b0
Collect and validate daily-life functional outcome data versus eye-tracking baseline; conduct quality-of-life assessments a314ac1a-3cf1-46b4-a36c-601b13c7865b
Execute bandwidth measurement protocol using locked federated-testing infrastructure and independent verification 79ec6481-4d43-474b-a3ac-f20266fe45f7
Conduct health-economic modelling and payer negotiations; obtain HTA body and reimbursement feedback from 3+ member states 9a306f17-98d6-4b5e-89c5-21a4a6f12669
Build health-economic model and cost-per-QALY validation 95328e42-e622-4716-bba8-0b9ebcbca4b0
Initiate pre-submission HTA dialogues with 4+ member-state payers 2ef48c96-5b03-4f66-927d-066f27282100
Design outcome-based and risk-sharing contract models 0a53d01b-91b6-4391-b251-f652ed038b12
Coordinate pilot-payer negotiation and signed reimbursement agreements 686b2f13-9572-47ef-bd63-efa2c35a958d
Monitor competitor pricing and reimbursement landscape; update price-elasticity models f8d4b386-78b7-490c-a384-719ebfec1262
Build complete regulatory dossier (design history, risk management, clinical data, quality and AI Act compliance) for notified-body conformity assessment 568bdc0d-8ae9-42af-8c8b-da1e907b6337
Lock decoder architecture and establish version-control governance per AI Act 7611e1aa-67ae-4f33-885a-7779eb9fef5b
Conduct quarterly AI model validation and document retraining decisions a263f985-7ff3-4b35-a33e-ed70afe03f1a
Manage decoder change requests and version updates under pre-approved protocols a00c0fa5-acfb-45a8-9f55-168e4689bc32
Maintain decoder audit trail and compliance documentation for notified body 18dbddb4-68e4-47f9-8664-f990be798602
Establish contingency decoder fallback and rapid-deployment capability b421cb54-16fc-42eb-9cb7-d9ac391d8a31
Manage decoder updates and AI model retraining under locked change-control process; maintain version-lock and audit trail per AI Act 9f75bf85-9c74-4895-b79b-41f98ae91481
Establish decoder version-lock architecture and change-control governance framework 783bd1d2-07f1-4f82-b9d8-9f507a93e877
Commission independent AI model validation and audit infrastructure 9002141e-7d47-483d-a181-3230b95e9a92
Develop locked decoder retraining protocol with contingency fallback versions 45a934cf-fa59-4291-9354-f8351c2768ea
Establish multi-site decoder performance monitoring dashboard and alert system ca90bbdb-b163-4e93-9bca-3dd5a91b8177
Pre-register and execute quarterly AI Act compliance audits; maintain version-lock audit trail 3bc82cac-bce5-4573-80e5-ff36267cccab
Scale implanting centre network to about 20–25 sites across EU/EEA; achieve surgical throughput about 12 implants per centre per year 361acf67-a01f-4267-998d-36be38010c3a
Initiate surgeon letters of intent and formal credentialing framework df2cde43-0575-43e7-ba29-626f95d03867
Establish standardised surgical training cadre and competency validation bd102434-909b-441f-a5dd-bfbcdb03f024
Secure capacity reservations and letters of intent from 20–25 candidate implanting centres e1072d0d-fad5-4f8b-8664-43b0c1acfe84
Implement centre-support infrastructure and quarterly performance reviews 99c3376b-1704-4503-b177-e32502c2c5c8
Manage geographic distribution and patient-access equity across 20–25 sites b8f29f45-c0e0-47b2-a3c6-245135400b4f
Publish interim safety, efficacy and bandwidth reports; present to Data Monitoring Committee for continuation recommendation faa11864-3486-421a-8afa-06eeca9c12fa
Prepare interim safety and efficacy data compilation 3e243438-dd63-4bef-aa5b-59cad3cc364d
Conduct independent bandwidth verification and reporting 5aa2e52f-3ace-40b3-8785-19881b765fe8
Synthesise narrative and statistical interim-safety summary d94afbe2-980d-4c6d-8cf3-da1936a8219a
Prepare efficacy and functional-outcome interim summary 6102c620-b17b-4ee5-98f1-654c3ad7d4d1
Compile regulatory and Data Monitoring Committee narrative for presentation e4ceb1a8-5294-4fb8-aaa9-374db037ee9d
CE Marking and Market Access (Months 120–180 = 2036-10-31 to 2041-10-31) 0761ba91-2868-4fc2-a6ba-febb15d3f8d3
Submit complete regulatory dossier to notified body (Month 120 = 2036-10-31 estimate); obtain CE marking (Month 132 = 2037-10-31 central, range 114–156) 45d96b06-d447-46e5-acb0-9795c6f3b020
Compile design history file and risk management dossier 55f17968-cccd-4a3c-b07a-bc2f49ee9825
Prepare clinical evidence package and safety/efficacy data 32884eef-6136-4596-bec6-13baa312a1fe
Document manufacturing, quality and supplier compliance 5e68cd7a-71a2-4e68-bed3-dcb29822eebc
Address AI Act compliance and decoder change-control documentation 82d06910-e51a-403f-8bff-07fd77ac6b58
Execute notified-body pre-submission and resolve outstanding questions d2c6a502-83b1-4e6c-8704-6462842b51da
Establish reimbursement contracts with payers in 5+ member states based on health-economic evidence and cost-per-QALY outcomes fd00bedd-658a-4f6b-a110-7ab0d438e170
Conduct payer landscape analysis and identify target member states cf16c482-d714-4261-8ccd-782ffb93425f
Develop health-economic model aligned with payer evidence standards e48b1423-1d07-49be-9256-b790e9d59f33
Engage payers and HTA bodies in structured pre-submission dialogue 8bc20c15-2aba-49bd-81c5-297a5da8ef69
Negotiate and execute reimbursement contracts with lead payers bf9e7dbc-f4b9-47cf-9fe5-5dc6b1815cf7
Develop fallback pricing and market-access strategies 3b3d24f7-5e26-4c52-8be5-bb43f03ce432
Scale manufacturing and supply chain to sustained output of about 250–300 implants per year (Months 132–180 = 2037-10-31 to 2041-10-31) 1df2ed5d-38e5-4980-864f-c0568e798056
Qualify dual-source manufacturers for sustained Class III production d83aaf95-5e17-45c1-90aa-ec7f75a55fc1
Execute sustained production ramp to 250–300 implants per year 2d7a0412-f604-4a03-be48-a0a77f2a82bd
Resolve supply-chain bottlenecks and geopolitical export-control risks ba7504d2-a261-44e9-a603-001b6f554b92
Establish manufacturing quality system (ISO 13485) for sustained production 4045655b-c44a-4c78-8a57-a188aabb86aa
Maintain sterilisation validation and biocompatibility compliance for sustained volumes 16e507c5-fe34-4469-8011-3c2fc1555918
Expand implanting centre network to full capacity (about 25 centres, 12 implants per centre per year, about 300 per year) 9ac0fbb2-f252-4189-b9d6-47e18e44ff54
Pre-qualify and recruit 25 implanting centres across EU/EEA ac93f55a-a04a-4290-9dd2-2bbc2971a0d9
Develop and deploy standardised surgeon credentialing and training curriculum b7ebd7d6-8048-4d47-8c53-5fbdb77b2085
Secure formal partnership agreements and facility access commitments from each implanting centre 9c98ca6e-9807-47e5-9297-57bb05b073fd
Establish centre-support infrastructure: remote monitoring, device logistics and adverse-event tracking 3a9698ce-6ada-4b7c-b13a-ea6c7eac8658
Manage staggered centre activation and throughput ramp from Month 84 (2033-10-31) to Month 180 (2041-10-31) c3f0591c-7232-4597-bca4-b8f018d55bad
Establish long-term patient follow-up protocol, device servicing and explantation procedures; fund patient-protection reserve (about EUR 31.5M for 1,050 implants central) b2546228-1a1d-47b5-8d47-0954d94a75fb
Design long-term follow-up and device-servicing protocols across 25+ centres 5709fe10-59d3-4b0f-8906-7182cffd4240
Develop and validate explantation procedures; qualify surgeons and kit suppliers 4f8fb748-1727-4f03-a50a-8c20049536de
Establish patient-protection trust structure, legal governance and funding by Month 100 (2035-02-28) 19fd046f-2008-4e38-a684-bc4e74b7974e
Negotiate successor step-in agreement; escrow IP, source code and manufacturing know-how b4e17acb-fa74-4fe0-a26b-60b697e10d81
Conduct annual reserve-adequacy audits and update actuarial assumptions based on real costs 335b8240-fa6c-4e25-a549-4f12c55aafa6
Complete post-market surveillance system, adverse-event tracking and continuous decoder improvement within AI Act constraints bf0ef1c9-7307-4004-841d-a365dbb9166a
Build multi-centre post-market surveillance infrastructure and adverse-event reporting framework b6e8e8c6-294a-499f-9451-3449f8126cbd
Establish decoder retraining governance and AI Act version-lock audit process with notified-body pre-approval 9eee176b-d613-4f46-affc-13b98f2c1c82
Deploy real-time adverse-event dashboard and automated safety alerting across all implanting centres cdf663eb-95a8-4a7b-8393-d9ed57d1b4d9
Establish redundant cybersecurity monitoring and neural-data breach-response protocols at EU-hosted compute infrastructure 98fef8cb-ce51-412e-b8ec-e4fe132524ca
Conduct quarterly AI Act compliance reviews and maintain continuous decoder improvement roadmap within change-control constraints cb04f96f-871f-40a5-8121-1c282b5e963b

Review 1: Critical Issues

  1. Financing Gate Credibility Collapse Risk (Month 12 = 2027-10-31): EUR 0 is committed at Month 0 (2026-10-31); T0 requires EUR 10–15M written commitments by Month 12 (2027-10-31), yet no named anchor investors, term-sheet templates or investor selection criteria exist. Missing this gate triggers automatic 12-month deferral of all non-critical spending, compressing FIH from Month 60 (2031-10-31) to Month 72–84 (2032-10-31 to 2033-10-31) and cascading delays through CE marking. Without binding investor agreements signed by Month 3 (2027-01-31), the entire team-hiring and facility-access roadmap collapses, forfeiting credibility with Leuven partners and regulators.

  2. Eligible-Population Epidemiology and Reimbursement Validation Missing by Scope Gate (Month 24 = 2028-10-31): No bottom-up ALS incidence study, payer willingness-to-pay validation or cost-per-QALY threshold agreement exist; the plan assumes 500–1,400 eligible per year and EUR 150,000 price without payer endorsement. If three HTA bodies reject the cost-effectiveness ceiling of EUR 120,000 per QALY or the eligible pool is confirmed below 300 annually, the 1,050-implant and EUR 45M revenue projections collapse. This forces a hard indication-pivot decision (ALS-only versus spinal cord injury) by Month 24 (2028-10-31), yet written payer letters are due at Month 18 (2028-04-30)—leaving 6 months to integrate findings and re-cost before the gate.

  3. Chronic Signal-Stability Kill Thresholds Unvalidated Against Preclinical Data (Months 18–24 = 2028-04-30 to 2028-10-31): The plan proposes kill gates (20% animal signal loss blocks FIH, 25% human loss triggers pause) without citing published thin-film or penetrating-electrode chronic-implant data showing these thresholds are achievable. If literature review by Month 9 (2027-07-31) reveals thin-film surface electrodes lose 30%+ signal at 12 months (a realistic risk, estimate), the primary architecture is invalidated by Month 18 (2028-04-30). This forces a EUR 30M (range 15–60M, estimate) switch to penetrating cortical at Month 24 (2028-10-31), consuming T1 contingency and slipping FIH to Month 72–90 (2032-10-31 to 2034-10-31), colliding with T2 commitments due at Month 36 (2029-10-31) and leaving no time to rebuild preclinical evidence.

Review 2: Implementation Consequences

  1. Positive: Patient-Protection Reserve and Continuity Covenant Create Reputational and Regulatory Trust, Differentiating from US Competitors. A EUR 31.5M patient-protection escrow (for 1,050 cumulative implants) funded at implantation and held outside investor reach, combined with binding step-in agreements and explantation reversibility, delivers a structural advantage over Neuralink and Synchron if US competitors enter the EU market during Months 36–60 (2029-10-31 to 2031-10-31). This trust signals ethical stewardship to payers, ethics committees, and EU member states, potentially winning reimbursement contracts in 5+ member states where cost-per-QALY is EUR 120,000 per QALY (proposed). However, if the trust is underfunded (reserve audits at Month 100+ = 2035-02-28+ reveal per-implant costs exceed EUR 30,000 estimate), the company must absorb shortfalls from operating revenue, reducing EUR 45M annual profit margin by 5–15% (estimate), cascading to T3/T4 funding risk and delayed centre expansion.

  2. Negative: Kill-Gate Enforcement Mechanism Lacks Binding Legal Authority, Creating Decision Deadlock and Schedule Slip if Multiple Gates Are Crossed. The plan mandates automatic deferral if financing gates G1 (Month 12 = 2027-10-31), G3 (Month 24 = 2028-10-31) or G4 (Month 36 = 2029-10-31) are missed, but no shareholder agreements, investor term sheets or board governance charter exists to enforce this. If investors disagree on whether to defer or renegotiate at Month 12 (2027-10-31), the programme enters a 3–6 month negotiation phase during which team hiring freezes, partner momentum erodes and Leuven partnerships dissolve. A missed G1 costs 6–12 months and up to EUR 2M (estimate) in lost facility deposits and legal wind-down. A missed G3 at Month 24 (2028-10-31) (coinciding with the feasibility verdict) forces architectural rework if signal-stability thresholds are breached, compressing design lock to Months 24–30 (2028-10-31 to 2029-04-30) and slipping FIH by 12–24 months.

  3. Negative: Operating-Cost Baseline (EUR 111M per Year at Month 180 = 2041-10-31) Exceeds Revenue (EUR 45M) by EUR 66M Annually, Rendering the Commercial Case Perpetually Unprofitable Unless Indication Expands or Reimbursement Price Increases. At steady state (300 implants per year, EUR 150,000 price), the company operates at a recurring EUR 66M annual loss. The patient-protection reserve grows at EUR 9M per year (300 × EUR 30k), further straining cash. Over Months 168–180 (2040-10-31 to 2041-10-31, 12 months), the operating gap is EUR 66M (EUR 111M opex). The plan absorbs this via T4 (EUR 985M) and free contingency (about EUR 219M available, estimate), but post-Month 180 (2041-10-31), the company has no revenue model and faces a funding cliff (T4 covers Months 132-180 = 2037-10-31 to 2041-10-31 only; the EUR 66M per year gap is decided at the Month 120 = 2036-10-31 sustainability gate) unless: (a) the indication expands to spinal cord injury (3–5× larger eligible pool) by Month 78 (2033-04-30), or (b) price increases to EUR 200,000+ per implant (requiring payer re-negotiation), or (c) member-state subsidies or grants sustain operations indefinitely. If the Month 78 (2033-04-30) indication-pivot gate chooses ALS-only, this interaction is assessed at the Month 120 (2036-10-31) sustainability gate and may force a pivot to non-commercial research-only operation, abandoning the 5,000-implant ambition.

Review 3: Recommended Actions

  1. Commission Independent Epidemiological Analysis and Pre-Reimbursement HTA Dialogue by Month 15 (2028-01-31); Lock Indication-Pivot Decision Rules by Month 24 (2028-10-31). Current status: no bottom-up ALS incidence or eligible-pool validation exists; payer willingness-to-pay at EUR 120,000 per QALY is unconfirmed. Impact: without this by Month 24 (2028-10-31) (Gate G3 financing decision), the 1,050-implant target and EUR 45M revenue projection remain speculative, risking investor confidence in T1 (EUR 120M) commitment. Recommendation: commission the epidemiology study by Month 3 (2027-01-31) and start HTA pre-submission dialogues by Month 6 (2027-04-30); deliver preliminary findings by Month 12 (2027-10-31); deliver final epidemiology by Month 15 (2028-01-31) and obtain written payer letters by Month 18 (2028-04-30); pre-register hard pivot thresholds (e.g., if eligible pool <300 per year, trigger spinal cord injury option at Month 24 = 2028-10-31) and publish them to stakeholders by Month 6 (2027-04-30).

  2. Establish Binding Term-Sheet Templates and Named Anchor-Investor Commitments by Month 3 (2027-01-31); Publish Gate Decision Authority and Automatic-Deferral Protocol by Month 2 (2026-12-31). Current status: EUR 0 committed; no investor term sheets, gate enforcement rules or decision authority exist. Impact: a missed Gate G1 (Month 12 = 2027-10-31) lacks contractual stop mechanism, forcing 3-6 months of renegotiation that compresses FIH by 6-12 months and costs EUR 2M+ in facility deposits. Recommendation: identify and approach 3-5 anchor investors by Month 1 (2026-11-30); negotiate written LOIs specifying EUR 10-15M T0 commitment by Month 3 (2027-01-31); draft shareholder governance agreement and gate-decision framework (specifying CEO veto authority, investor board composition, automatic deferral rules) by Month 2 (2026-12-31); publish the protocol publicly to Leuven partners and the Commission by Month 2 (2026-12-31).

  3. Conduct Systematic Literature Review of Chronic Signal-Retention Data and Validate Kill Thresholds Against Published Thin-Film and Penetrating-Electrode Benchmarks by Month 9 (2027-07-31); Pre-Register Decision Rule for Architecture Switch by Month 12 (2027-10-31). Current status: kill thresholds (20% animal signal loss, 25% human loss, proposed) lack preclinical grounding; thin-film surface electrodes may not achieve these targets. Impact: if preclinical animal data breach the 20% threshold by Month 18 (2028-04-30), architecture switch costs EUR 30M (range 15-60M, estimate) and 12-24 months, consuming T3 contingency and slipping CE marking by 12-24 months. Recommendation: complete FTO and literature review by Month 9 (2027-07-31); keep the 20% / 25% / 50% thresholds as proposed; the literature review may inform a documented change before Month 12 (2027-10-31) only, with a change log approved by the DMC, and no revision after the pre-registration date; pre-register fallback decision: if animal results breach revised threshold by Month 18 (2028-04-30), activate EUR 30M contingency and set architecture-switch decision gate for Month 30 (2029-04-30); assign Deputy CTO to lead penetrating-cortical contingency work in parallel by Month 6 (2027-04-30).

Review 4: Showstopper Risks

  1. Multi-State Foundry Funding Dependency Triggers Dual-Sourcing Fallback and Cost/Schedule Cascade (Month 18 = 2028-04-30). Risk: Four or more EU member states do not commit EUR 350M for the shared foundry by Month 18 (2028-04-30). Likelihood: High. Impact: Dual-sourcing fallback (EUR 35M production transfer: EUR 10M in T1, EUR 25M in T2) compresses design-lock window and slips pilot-to-validated-production by 6–12 months (estimate), moving CE from Month 132 (2037-10-31) to Month 138–150 (2038-04-30 to 2039-04-30). This collides with T2 (EUR 480M) commitment gate at Month 48 (2030-10-31), forcing reforecasting of manufacturing feasibility before investors commit. Interaction: if foundry fails AND signal-stability thresholds are breached by Month 18 (2028-04-30) (both Likelihood: High), architecture switch consumes EUR 30M contingency simultaneously, where only the EUR 30M (up to 60M) switch plus the EUR 1.2M early site-fallback advance come out of contingency (the EUR 35M is a T1/T2 re-allocation), leaving about EUR 219M (EUR 189M at the upper bound) free. Recommendation: initiate foundry-commitment talks with all four member states by Month 6 (2027-04-30); obtain written LOIs by Month 15 (2028-01-31); if commitments are not confirmed by Month 16 (2028-02-29), immediately execute dual-sourcing MOUs and reallocate T1/T2 budgets. Contingency: pre-qualify tertiary suppliers in Germany and Netherlands by Month 12 (2027-10-31) to reduce single-source risk if both qualified suppliers decline.

  2. Leuven Partner Commitment Absent; Fallback Site Activation Consumes Critical Slack and De-Risks Only Partially (Months 0–6 = 2026-10-31 to 2027-04-30). Risk: imec, KU Leuven and/or UZ Leuven decline partnership by Month 3 (2027-01-31) or withdraw late (Month 6–12 = 2027-04-30 to 2027-10-31). Likelihood: Medium. Impact: fallback site activation (Ghent, Utrecht, Grenoble) costs up to EUR 2M (estimate) and adds 3–6 months to site qualification, shrinking the FIH window from Month 60 (2031-10-31) to Month 63–72 (2032-01-31 to 2032-10-31). A late withdrawal by UZ Leuven (neurosurgery, patient cohort) after seed funding closes cannot be absorbed; FIH is compressed into Months 63–72 (2032-01-31 to 2032-10-31) without dedicated surgical team or ALS patient recruitment pathway. Interaction: if imec declines (losing cleanroom access) AND notified-body pre-submission is scheduled for Month 6 (2027-04-30) (both Likelihood: Medium), QMS audit and design-lock are deferred to Months 18–24 (2028-04-30 to 2028-10-31), slipping architecture ratification and conflating it with the Gate G3 feasibility verdict at Month 24 (2028-10-31). Recommendation: send partnership scopes to all three Leuven institutions by Month 0.5 (2026-11-15); secure written LOIs by Month 3 (2027-01-31); activate fallback negotiations in parallel by Month 1 (2026-11-30); publish a Partner Decline Decision Tree (48-hour activation protocol) by Month 2 (2026-12-31). Contingency: pre-negotiate facility and surgeon agreements with fallback sites (email MOU templates and LOI frameworks) by Month 0.5 (2026-11-15); compress fallback site qualification to 8 weeks (Month 6 = 2027-04-30 completion) by pre-positioning ethics submissions, surgical credentialing curriculum and cleanroom access MOUs.

  3. ALS Indication Eligibility and Reimbursement Case Validation Deferred Beyond Financing Gate; Commercial Viability Unproven at Month 24 (2028-10-31). Risk: HTA bodies in 3+ member states reject cost-per-QALY ceiling of EUR 120,000 (proposed) or eligible ALS pool is confirmed below 300 per year, invalidating the revenue model (EUR 45M per year at 300 implants × EUR 150,000). Likelihood: Medium. Impact: payer rejections or population shortfall trigger the Month 24 (2028-10-31) indication-pivot decision (ALS-only versus spinal cord injury) with insufficient time for payer re-engagement and series A reforecasting; written payer letters are due by Month 18 (2028-04-30), leaving 6 months to integrate findings and revise the commercial case for Gate G3 (Month 24 = 2028-10-31). Spinal cord injury pivot requires different surgical endpoints, larger centre network and longer trial duration, compressing T1 spend and delaying pivotal lock. Interaction: if reimbursement is rejected AND eligible ALS pool is <300 per year (both Likelihood: Medium), break-even target (1,125 implants per year, estimate) becomes unachievable under any indication; the EUR 2.5B envelope is insufficient to subsidise operations indefinitely, which would be decided at the Month 120 (2036-10-31) sustainability gate. Recommendation: commission epidemiology by Month 3 (2027-01-31) and HTA pre-submission dialogue by Month 6 (2027-04-30); deliver preliminary payer feedback by Month 12 (2027-10-31); issue final population validation by Month 15 (2028-01-31) and written payer letters by Month 18 (2028-04-30); pre-register hard pivot thresholds (eligible pool <300/year → SCI option; payers reject EUR 120k/QALY → price renegotiation or stop) by Month 6 (2027-04-30). Contingency: commission a parallel spinal cord injury health-economic model by Month 12 (2027-10-31); obtain SCI payer feedback by Month 18 (2028-04-30); execute pivot decision at Month 24 (2028-10-31) with pre-costed SCI reforecasting (T1/T2 budget reallocation, centre-network redesign, trial-duration extension) ready for investor approval within 5 business days of the gate.

Review 5: Critical Assumptions

  1. Eligible ALS Population Achieves at Least 300 Annual Incidence Within EU/EEA by Month 60 (2031-10-31). Assumption: 500–1,400 eligible ALS patients per year (estimate) will support recruitment pace to reach 1,050 cumulative implants by Month 180 (2041-10-31) across about 25 centres at about 12 implants per centre per year. Impact if incorrect: if validated epidemiology at Month 12 (2027-10-31) confirms eligible pool <300 annually, cumulative implants collapse to 300–500 by Month 180 (2041-10-31), revenue drops from EUR 45M to EUR 15M–22.5M per year (estimate), break-even unachievable, and T3/T4 tranches (EUR 900M + EUR 985M) become undefendable. Interaction: compounded by reimbursement rejection (payers refuse EUR 150,000 price if population is too small to recoup public-health investment), triggering a double-gate failure at Month 24 (2028-10-31) (both Likelihood: Medium). Recommendation: obtain final epidemiology validation by Month 15 (2028-01-31); if confirmed <300 annually, pre-register an immediate indication-pivot decision (spinal cord injury versus stop) by Month 24 (2028-10-31); adjust T1 scope and centre-network footprint downward within 5 business days of confirmation.

  2. Payers in at Least Three EU Member States Accept Cost-Effectiveness Ceiling of EUR 120,000 per QALY and Price of EUR 150,000 per Implant. Assumption: German, French and Benelux statutory payers will reimburse at the proposed cost-per-QALY and device price without renegotiation. Impact if incorrect: if HTA bodies demand <EUR 100,000 per QALY or refuse to commit price, device becomes economically unviable; revenue at 300 implants/year drops below EUR 30M (estimate), and the EUR 66M annual operating gap cannot be closed without member-state subsidies indefinitely. This forces a wind-down or conversion decision at the Month 120 (2036-10-31) sustainability gate. Interaction: if payer rejection combines with population shortfall (both Likelihood: Medium), T3/T4 tranches cannot be justified to investors, Series B/C closes fail at Months 48/84 (2030-10-31, 2033-10-31), and FIH is deferred or halted. Recommendation: conduct structured HTA pre-submission dialogues by Month 15 (2028-01-31); obtain written payer willingness-to-pay confirmation by Month 18 (2028-04-30); if <3 member states commit, activate contingency pricing re-negotiation by Month 24 (2028-10-31) (target EUR 200,000 per implant or narrowed indication to higher-acuity ALS subpopulation).

  3. Thin-Film Surface Architecture Stays Within the 20% Animal Signal-Loss Limit at 12 Months in Chronic Animal Studies, Validating the Animal Kill Threshold. Assumption: preclinical chronic implants (18–24 months duration) will demonstrate signal stability matching or exceeding the 20% loss kill threshold (proposed), justifying the thin-film surface as primary architecture. Impact if incorrect: if literature review by Month 9 (2027-07-31) reveals thin-film electrodes routinely lose 30%+ signal at 12 months (estimate realistic), and early animal data confirm this by Month 18 (2028-04-30), the primary architecture fails the gate; EUR 30M (range 15–60M, estimate) contingency switches to penetrating cortical, consuming T3 free contingency, slipping CE from Month 132 (2037-10-31) to Month 144–156 (2038-10-31 to 2039-10-31). Interaction: if stability failure combines with foundry withdrawal (both Likelihood: Medium), both contingencies (EUR 30M switch + EUR 35M dual-sourcing transfer) draw only the EUR 30M (up to 60M) switch plus the EUR 1.2M advance from contingency (the EUR 35M is a T1/T2 re-allocation), leaving about EUR 219M (EUR 189M upper bound) free; Gate G4 at Month 36 (2029-10-31) remains the decision point. Recommendation: complete published signal-retention literature review by Month 9 (2027-07-31); keep the 20% / 25% / 50% thresholds, allowing only a DMC-approved documented change before Month 12 (2027-10-31) and none after pre-registration; assign Deputy CTO to advance penetrating-cortical contingency in parallel by Month 6 (2027-04-30); pre-register architecture-switch decision rule (if animal results breach revised threshold by Month 18 = 2028-04-30, activate switch decision gate for Month 30 = 2029-04-30).

Review 6: Key Performance Indicators

  1. KPI 1: Financing Gate Closure Rate and Committed Capital Trajectory. Target: T0 EUR 10–15M committed in writing by Month 12 (2027-10-31); T1 at least EUR 60M conditional by Month 24 (2028-10-31); T2 at least EUR 150M by Month 36 (2029-10-31). Success threshold: 100% of gate targets met within 5 business days of deadline; failure triggers automatic 12-month deferral. Interaction: directly enables all downstream architecture, supply-chain and regulatory milestones; if Gate G1 misses, FIH slips to Month 72–84 (2032-10-31 to 2033-10-31) and cascades through CE marking. Monitoring: publish monthly investor-commitment status and gate-decision verdicts within 2 business days of each gate; tie board compensation to gate closure by deadline.

  2. KPI 2: Eligible-Population Validated Size and Payer Cost-per-QALY Acceptance. Target: confirmed ALS eligible pool ≥300 per year (final validation by Month 15 = 2028-01-31); written payer commitment from ≥3 EU member states at cost-per-QALY ≤EUR 120,000 (proposed threshold) by Month 18 (2028-04-30). Success threshold: ≥3 payers signal reimbursement willingness; failure to confirm triggers Month 24 (2028-10-31) indication-pivot decision (spinal cord injury versus stop). Interaction: underpins commercial break-even (1,125 implants per year) and sustains T3/T4 financing confidence; population shortfall + payer rejection compound to invalidate the EUR 2.5B envelope. Monitoring: conduct quarterly HTA pre-submission dialogues; track eligible-pool epidemiology against published ALS registries; document payer feedback in writing by Month 18 (2028-04-30).

  3. KPI 3: Chronic Signal Stability and Architecture Confidence (Evidence-Based Kill Threshold Lock). Target: validated kill threshold (animal signal-loss percentile ≥20% at 12 months) or revised to published data by Month 12 (2027-10-31); thin-film primary architecture retained if animal cohorts show no more than 20% signal loss at 12 months by Month 18 (2028-04-30) (below 50% retention at 36 months post-implant triggers switch); if breached, architecture switch triggered by Month 30 (2029-04-30) without exceeding EUR 30M contingency. Success threshold: preclinical data support architecture choice; failure forces EUR 30M switch, consuming free contingency and moving CE to Month 144–156 (2038-10-31 to 2039-10-31). Interaction: compounded by foundry withdrawal (both Likelihood: Medium), only the EUR 30M (up to 60M) switch plus the EUR 1.2M advance come out of contingency (the EUR 35M is a T1/T2 re-allocation), leaving about EUR 219M (EUR 189M upper bound) free contingency. Monitoring: publish literature-review signal-retention percentiles by Month 9 (2027-07-31); track chronic-animal results against thresholds monthly; pre-register fallback decision rule by Month 12 (2027-10-31).

Review 7: Report Objectives

  1. Primary Objectives: Validate a 15-year, EUR 2.5B EU sovereign implantable BCI programme's feasibility to deliver a Class III device for ALS communication restoration with ≥10 bits/s sustained bandwidth, 1,050 cumulative implants, and patient-protection continuity by Month 180 (2041-10-31). The report aims to inform founder decision-making, investor capital allocation across five tranches (T0–T4), and Commission/member-state IPCEI support. Key decisions addressed: architecture choice (thin-film surface vs. penetrating cortical), sourcing route (licensing with pre-priced options), foundry pathway (shared vs. dual-sourcing), indication lock (ALS-only vs. spinal cord injury pivot at Month 78 = 2033-04-30), and financing gate enforcement (automatic deferral rules at Months 12, 24, 36 = 2027-10-31, 2028-10-31, 2029-10-31).

  2. Intended Audience: Founders, lead investors (institutional and impact), EU Commission and member-state policymakers, Leuven partner institutions (imec, KU Leuven, UZ Leuven), notified bodies, and ethics committees. Version 2 differs from Version 1 by explicitly quantifying feasibility as 'achievable only with changes' rather than aspirational, reporting that the 5,000-implant target and user's Month 120 (2036-10-31) CE marking target is missed in the central case (range Month 114-156 = 2036-04-30 to 2039-10-31), and naming three critical unresolved dependencies at Month 0 (2026-10-31): EUR 0 committed funding, zero written Leuven partnership LOIs, and unvalidated eligible-population epidemiology and payer willingness-to-pay.

  3. **Key Deliverables: Pre-registered kill-gate criteria and decision authority structure (binding pause authority to Data Monitoring Committee by Month 6 = 2027-04-30); feasibility verdict separating scientific, engineering, clinical, regulatory, supply-chain and financing credibility by Month 24 (2028-10-31); and quantified contingency action plans (architecture switch EUR 30M, foundry failure EUR 35M dual-sourcing, partner decline EUR 2M, all within free contingency of about EUR 219M, estimate). Version 2 adds explicit risk-interaction mapping (e.g., foundry + stability failure draw only the EUR 30M switch plus the EUR 1.2M advance from contingency, leaving about EUR 219M free) and actionable mitigation timelines tied to gate deadlines instead of generic recommendations.

Review 8: Data Quality Concerns

  1. Eligible ALS Population Epidemiology and Annual Incidence Unvalidated Against Published Registries (Critical Risk: 1,050-Implant Target Depends on 300+ Annual Eligible Patients). Current data: plan assumes 500–1,400 eligible ALS per year (estimate), derived from no cited source; no bottom-up audit against EuroMND or national registries exists. Why critical: this underpins break-even (1,125 implants/year) and all revenue projections (EUR 45M/year at Month 180 = 2041-10-31); if validated <300 annually, cumulative implants fall to 300–500 by Month 180 (2041-10-31), revenue drops to EUR 15M–22.5M (estimate), and operating gap widens to EUR 88M–96M/year, which cannot be closed within the envelope. Consequence: unvalidated population triggers indication-pivot gate at Month 24 (2028-10-31) without credible payer or centre-capacity data. Recommendation: commission independent epidemiological analysis (extract ALS incidence from published registries in Germany, France, Benelux) by Month 3 (2027-01-31); deliver final validated pool by Month 15 (2028-01-31); if <300 annually, pre-register hard spinal cord injury pivot by Month 24 (2028-10-31).

  2. Payer Cost-per-QALY Threshold Acceptance and Willingness-to-Pay Unconfirmed Across 3+ EU Member States (Critical Risk: EUR 150,000 Price and EUR 120,000 per QALY Are Proposed, Not Validated). Current data: no written payer feedback, HTA dialogues, or reimbursement contracts exist; EUR 120,000 per QALY (proposed threshold) is assumed acceptable without evidence. Why critical: if three HTA bodies (Germany, France, Benelux) demand <EUR 100,000 per QALY or reject EUR 150,000 device price, revenue target becomes unachievable (estimated loss of 20–40% per implant if price drops to EUR 100,000). This cascades to negative Series B/C financing at Months 48/84 (2030-10-31, 2033-10-31) and forces a wind-down decision at the Month 120 (2036-10-31) sustainability gate. Consequence: payer rejection alone (Likelihood: Medium) triggers commercial-viability kill gate at Month 24 (2028-10-31) unless paired with indication pivot. Recommendation: initiate pre-reimbursement dialogues with lead payers by Month 9 (2027-07-31); obtain written willingness-to-pay statements by Month 18 (2028-04-30); if <3 member states accept EUR 120,000 per QALY, activate contingency pricing renegotiation (target EUR 200,000 per implant or narrowed ALS subpopulation) by Month 24 (2028-10-31).

  3. Chronic Signal-Stability Preclinical Baseline and Kill-Threshold Literature Support Missing (Critical Risk: 20% Animal Loss Threshold Lacks Published Evidence; Architecture Switch Costs EUR 30M and 12–24 Months if Breached). Current data: kill thresholds (20% animal, 25% human, proposed thresholds) are ungrounded in preclinical or published chronic-implant data; thin-film surface signal-retention percentiles unknown. Why critical: if literature review by Month 9 (2027-07-31) reveals thin-film electrodes lose 30%+ signal at 12 months (realistic estimate), primary architecture is invalidated at Month 18 (2028-04-30), triggering EUR 30M switch to penetrating cortical, consuming T3 free contingency and moving CE from Month 132 (2037-10-31) to Month 144–156 (2038-10-31 to 2039-10-31). Combined with foundry failure, only the EUR 30M (up to 60M) switch plus the EUR 1.2M advance come out of contingency (the EUR 35M is a T1/T2 re-allocation), leaving about EUR 219M (EUR 189M upper bound) free. Consequence: unvalidated thresholds create false gate credibility; breach at Month 18 (2028-04-30) forces forced architecture rework mid-programme. Recommendation: complete published signal-retention systematic review by Month 9 (2027-07-31); keep the 20% / 25% / 50% thresholds, with any literature-based change documented in a DMC-approved change log before Month 12 (2027-10-31) and no revision afterwards; pre-register architecture-switch decision (if animal results breach threshold by Month 18 = 2028-04-30, activate switch gate for Month 30 = 2029-04-30) with Deputy CTO advancing penetrating contingency in parallel by Month 6 (2027-04-30).

Review 9: Stakeholder Feedback

  1. Commission and Finalize Investor Term-Sheet Templates and Named Anchor-Investor Selection by Month 2 (2026-12-31); Lock Written LOIs by Month 3 (2027-01-31). Critical: financing authority and gate-enforcement mechanism are undefined; without written investor commitments specifying EUR 10–15M T0 and automatic-deferral rules, gate G1 (Month 12 = 2027-10-31) remains a rhetorical target, not a binding decision. If unresolved, missed gate G1 forces 3–6 months of renegotiation, compressing FIH from Month 60 (2031-10-31) to Month 72–84 (2032-10-31 to 2033-10-31) and slipping CE by 12–24 months. Impact: programme lacks decision authority; investor confidence erodes; Leuven partnerships dissolve during negotiation hiatus. Recommendation: identify 3–5 anchor investors by Month 1 (2026-11-30); present binding term-sheet template (gate conditions, automatic deferral, board composition, loss-of-control rules) by Month 1.5 (2026-12-15); obtain signed LOIs specifying EUR 10–15M T0 by Month 3 (2027-01-31).

  2. Confirm Leuven Partnership LOIs (imec, KU Leuven, UZ Leuven) or Activate Named Fallback Sites (Ghent/Antwerp, Utrecht, Grenoble) by Month 6 (2027-04-30). Critical: none of the three Leuven institutions has committed; fallback sites are named but not pre-qualified. If imec declines, cleanroom access is lost and manufacturing prototype cycles are 3–6 months longer. If UZ Leuven declines, ALS patient access and neurosurgery leadership evaporate. Unresolved status at Month 3 (2027-01-31) means fallback activation cannot occur by Month 6 (2027-04-30), forcing FIH delay to Month 63–72 (2032-01-31 to 2032-10-31). Impact: €2M fallback activation cost, 3–6 month FIH slip, partner momentum lost. Recommendation: send partnership scopes by Month 0.5 (2026-11-15); secure written LOIs by Month 3 (2027-01-31); pre-qualify fallback sites (site visits, capability letters) by Month 2 (2026-12-31); publish Partner Decline Decision Tree (48-hour activation protocol) by Month 2 (2026-12-31).

  3. Obtain Written Payer and HTA Body Feedback on Willingness-to-Pay (EUR 120,000 per QALY Proposed Threshold) and Eligible-Population Validation (≥300 ALS Annual) by Month 18 (2028-04-30); Lock Indication-Pivot Decision Rules by Month 24 (2028-10-31). Critical: no payer commitments, HTA dialogues or population epidemiology validation exist; if HTA bodies reject the EUR 120,000 per QALY ceiling (Likelihood: Medium) or eligible pool is confirmed <300 annually, the commercial case collapses and the Month 24 (2028-10-31) feasibility verdict becomes undefendable. Impact: Series A (T1 EUR 120M) commitment is jeopardized; revenue target (EUR 45M per year) becomes unachievable; T3/T4 tranches lose investor confidence. Recommendation: initiate HTA pre-submission dialogues by Month 9 (2027-07-31); commission epidemiological analysis by Month 3 (2027-01-31); deliver final population validation by Month 15 (2028-01-31) and written payer letters by Month 18 (2028-04-30); pre-register hard pivot thresholds (eligible pool <300 → SCI pivot; payers reject EUR 120k/QALY → price renegotiation or stop) by Month 6 (2027-04-30); execute indication-pivot decision at Month 24 (2028-10-31) with Board approval within 5 days.

Review 10: Changed Assumptions

  1. US and Chinese Competitor CE-Marking Timeline and Market-Entry Assumptions May Compress Faster Than Projected; Competitive-Response Gate (Month 36–60 = 2029-10-31 to 2031-10-31) May Activate Earlier or With Stronger Competitive Positioning. Assumption: Neuralink, Synchron or Chinese state-backed BCI systems will obtain CE marking during Months 36–60 (2029-10-31 to 2031-10-31), but plan assumes EU system can differentiate on data sovereignty and lifelong support. Revised condition: if a US competitor achieves CE marking and rapid EU market entry by Month 36 (2029-10-31) (Likelihood: Medium–High, not previously quantified), early-market capture drops from estimated 50–70% to 20–30%, reducing eligible-population recruitment and reimbursement leverage. Impact: revenue at Month 180 (2041-10-31) falls from EUR 45M to EUR 20M–27M annually (estimate), widening the EUR 66M operating gap to EUR 84M–91M, and potentially invalidating T3/T4 tranches by Month 48–60 (2030-10-31 to 2031-10-31). Recommendation: activate competitive-response gate at Month 36 (2029-10-31) with a pre-costed market-repositioning strategy (outcome-based reimbursement contracts, EU data-sovereignty messaging, surgeon-training differentiation) ready for Board decision within 5 days if competitor CE-marking is detected.

  2. Leuven Infrastructure Resilience to Heatwaves and Climate Risk May Require Earlier or More Costly Mitigation Than Month 18 (2028-04-30) Backup-Power Installation; Chronic Heat Events Could Disrupt Cleanroom Prototyping and Early Animal Studies. Assumption: Leuven site resilience assessment at Month 3 (2027-01-31) and backup-power installation by Month 18 (2028-04-30) are sufficient to maintain 24/7 cleanroom and compute uptime. Revised condition: if assessment reveals heatwave frequency >2 events per year exceeding 38°C sustained (Likelihood: Medium), imec cleanroom cooling and critical compute may require redundant systems earlier (Month 9 = 2027-07-31, cost +EUR 1–2M estimate) and possible secondary manufacturing site activation. Impact: T0 budget (EUR 15M) is strained by EUR 1–2M additional climate investment; prototype development slips 2–4 months if primary site undergoes cooling retrofit during Months 6–12 (2027-04-30 to 2027-10-31). Recommendation: commission resilience assessment by Month 1 (2026-11-30), not Month 3 (2027-01-31); if high-risk findings emerge, pre-position secondary manufacturing partner (Grenoble or German cluster) by Month 6 (2027-04-30) to absorb prototyping load during primary-site cooling work.

  3. Patient-Reserve Actuarial Assumptions (EUR 30,000 per Implant, 10–15 Year Device Lifetime, EUR 500–1,000 Annual Follow-Up Cost) May Underestimate Long-Term Care and Explantation Obligations; Reserve Adequacy Could Be Challenged Post-Month 100 (2035-02-28) If Cumulative Implants Approach 1,050 and Device Failures Accelerate. Assumption: per-implant reserve of EUR 30,000 (estimate) covers device lifetime (10–15 years central) at EUR 500–1,000 annual follow-up and EUR 5,000–30,000 explantation cost. Revised condition: if early-cohort device failures or signal degradation post-Month 72 (2032-10-31) exceed 5% requiring explantation, cumulative explantation cost across 1,050 implants could reach EUR 15M–30M (estimate), consuming the EUR 31.5M total reserve and triggering draw-down acceleration by Month 120 (2036-10-31). Impact: if reserves are exhausted prematurely, implanted patients lose long-term support guarantees; the company must absorb residual care costs from operating budget (EUR 111M annual opex already exceeds revenue by EUR 66M), widening the gap to be funded within the T4 runway (EUR 985M, Months 132-180 = 2037-10-31 to 2041-10-31); wind-down or subsidy is decided at the Month 120 (2036-10-31) sustainability gate. Recommendation: conduct detailed actuarial re-modeling by Month 9 (2027-07-31) incorporating ALS-specific survival curves, device-failure rates from preclinical studies, and real explantation and follow-up costs from Clinatec/UMC Utrecht published data; revise reserve per-implant allocation (likely to EUR 40,000–60,000 estimate) and pre-register a reserve-adequacy audit gate at Month 100 (2035-02-28) to confirm or re-fund the trust before mid-programme implants accumulate.

Review 11: Budget Clarifications

  1. T0 MVP Budget Allocation (EUR 15M for Months 0–24 = 2026-10-31 to 2028-10-31) Lacks Bottom-Up Cost Breakdown; Chronic Animal Studies, Regulatory Engagement, and FTO Analysis Are Unfunded or Underspecified. T0 is allocated at EUR 0.6M per month (estimate), but no detailed line-item budget exists for team salaries (10 staff at EU rates minus 20–30% gap), imec cleanroom access, chronic-implant animal studies (18–24 months, two species, 6–12 animals estimated), freedom-to-operate analysis, notified-body pre-submission, or ISO 13485 QMS build. If chronic-animal studies alone cost EUR 1.5–2M (estimate) and team base salary is EUR 2.5–3.5M (estimate), T0 contingency (<EUR 1M projected) is exhausted before FTO or regulatory work. Impact: no reserve for partner fallback (EUR 2M), notified-body delays or supplier qualification slips. Recommendation: itemise T0 sub-budgets by Months 3, 12, and 24 (2027-01-31, 2027-10-31, 2028-10-31); confirm commitments from imec and UZ Leuven covering facility costs; pre-negotiate chronic-animal-study pricing by Month 3 (2027-01-31) to lock costs before design begins.

  2. Patient-Protection Reserve Per-Implant Allocation (EUR 30,000 Proposed) Lacks Actuarial Validation; Device Lifetime (10–15 Years Central, Not Confirmed) and Annual Follow-Up Costs (EUR 500–1,000 Proposed) Are Unvalidated Against ALS-Specific Survival Data. EUR 30,000 per implant is a placeholder; if actuarial analysis at Month 9 (2027-07-31) reveals true device lifetime is 5–7 years (estimate, unconfirmed) or annual follow-up costs exceed EUR 2,000 (estimate), per-implant reserve must increase to EUR 40,000–60,000 (estimate). For 1,050 cumulative implants, this inflates the trust from EUR 31.5M to EUR 42M–63M (estimate), competing with T2 manufacturing ramp (EUR 480M) and reducing free contingency from EUR 219M to EUR 189M–210M (estimate). Impact: no buffer for foundry failure or architecture switch; wind-down decision at the Month 120 (2036-10-31) sustainability gate. Recommendation: commission actuarial study by Month 3 (2027-01-31); validate against ALS registry data (median survival post-diagnosis ~3 years); model device failure, explantation, and 10–20 year post-device support; lock revised per-implant amount by Month 9 (2027-07-31); pre-register reserve-adequacy audit gate at Month 100 (2035-02-28).

  3. T1 Tranche (EUR 120M for Months 24–48 = 2028-10-31 to 2030-10-31) Budget Allocation Between Design Lock, Pilot-to-Production Transfer, and Dual-Sourcing Contingency Is Unspecified; Pilot-Line Transfer Alone Is Estimated at EUR 1–3M, but Dual-Sourcing Fallback (EUR 35M) Could Consume 29% of T1 If Foundry Fails. T1 is split nominally into EUR 5M per month, but architecture lock (Month 18 = 2028-04-30), design validation, biocompatibility studies, supplier qualification and pilot-to-validated-manufacturing transfer are not itemised. If the shared foundry (EUR 350M, hoped-for) is not committed by Month 18 (2028-04-30) (Likelihood: Medium–High), the dual-sourcing fallback (EUR 10M in T1 + EUR 25M in T2) must activate immediately, consuming EUR 10M of T1 budget in Months 24–30 (2028-10-31 to 2029-04-30) and leaving only EUR 110M for design-lock completion, wearable development, and centre-network preparation. Impact: manufacturing readiness is compressed; if yield validation or supplier re-qualification slips, Schedule lock at Month 72 (2032-10-31) is jeopardised, cascading delays to pivotal first implant at Month 84 (2033-10-31). Recommendation: itemise T1 budget by foundry-success scenario (shared foundry funded, EUR 5M transfer + USD 115M design/centre, versus dual-sourcing, EUR 35M transfer + EUR 85M design/centre) by Month 6 (2027-04-30); pre-negotiate supplier MOUs with cost-capped quotes by Month 12 (2027-10-31); pre-register T1 reallocation rules at Gate G3 (Month 24 = 2028-10-31) if foundry commitment is not confirmed.

Review 12: Role Definitions

  1. Chief Executive Officer and Financing Gate Authority. Role: sole executive decision-maker for automatic deferral rules, investor relations, and Board governance; holds binding stop/defer/switch authority at Gates G1, G3, G4 (Months 12, 24, 36 = 2027-10-31, 2028-10-31, 2029-10-31). Why critical: no shareholder agreement or board charter currently defines this authority; if the CEO authority is unclear, investors will demand renegotiation at each gate, consuming 3–6 months and compressing FIH by 6–12 months. Impact: unclear authority triggers 2–3 month financing crisis at Month 12 (2027-10-31) and slips T0 close to Month 18 (2028-04-30), delaying team hiring and facility access. Recommendation: draft and sign a Board Governance Charter by Month 2 (2026-12-31) naming the CEO as sole authority for automatic-deferral execution, with published decision verdicts within 5 business days of each gate deadline; bind this in investor term sheets by Month 3 (2027-01-31).

  2. Chief Medical Officer and Consent/Safety Accountability. Role: owns informed-consent protocol, independent consent advocate oversight, Data Monitoring Committee engagement, and safety kill-gate trigger authority; reports safety findings to the notified body and ethics committees within 7 days of DMC breach recommendation. Why critical: consent validity and safety governance are hard requirements (patient safety, valid consent, EU control); if the CMO role lacks binding authority to pause implantation, ethics committees will reject trial approval or suspend mid-trial, delaying CE by 12–24 months. Impact: no safety owner leads to invalid-consent findings or DMC pause recommendations that the company delays acting on, damaging regulator trust and triggering multi-month trial suspension. Recommendation: name the CMO by Month 1 (2026-11-30); publish their written decision authority (binding pause at any site if SAE threshold breached or consent invalid) by Month 3 (2027-01-31); establish escalation protocol to the notified body and ethics committees with 7-day response time.

  3. Chief Financial Officer and Patient-Protection Trust Steward. Role: owns patient-reserve trust governance, actuarial validation, and annual reserve-adequacy audits; holds trustee liaison authority and triggers capital-call or implant-halt if reserve drops below adequacy thresholds. Why critical: the EUR 31.5M patient-protection reserve (estimate, for 1,050 implants) is a hard requirement binding patient continuity; if the CFO does not hold explicit trustee accountability and actuarial oversight, the reserve may be raided for operating capital by Month 100–120 (2035-02-28 to 2036-10-31), exposing implanted patients to abandonment risk and regulators to credibility collapse. Impact: unclear CFO authority over reserves leads to under-funding (reserve depleted prematurely) or over-allocation (development capital constrained); either outcome destabilizes financing at Gates G3 and G4 and triggers 12-month deferral if audits reveal inadequacy. Recommendation: assign CFO as trust steward by Month 1 (2026-11-30); execute trust-governance charter (independent trustee, funding schedule, adequacy-audit cadence) by Month 6 (2027-04-30); pre-register reserve-adequacy audit gate at Month 100 (2035-02-28) and publish quarterly reserve status to stakeholders.

Review 13: Timeline Dependencies

  1. Chronic-Animal Study Timeline Must Lock Kill Thresholds Before Architecture Ratification (Month 18 = 2028-04-30); Delayed Interpretation Compresses Design Freeze and Slips CE by 12–24 Months. Animal studies (18–24 months duration) run Months 0–24 (2026-10-31 to 2028-10-31) parallel to sourcing and regulatory engagement. Signal-stability kill thresholds (20% animal loss proposed) must be literature-validated by Month 9 (2027-07-31) and locked to published data percentiles by Month 12 (2027-10-31), so preclinical results at Month 18 (2028-04-30) are interpretable against the gate. The 12-month gate is evaluable at Month 18 (2028-04-30) only if the cohort is implanted by Month 6 (2027-04-30) (dependent on seed closing and a GLP-compliant facility); if data are interim (6-9 months), architecture is ratified provisionally and the 12-month gate runs at about Month 24 (2028-10-31). If threshold-validation is deferred past Month 12 (2027-10-31), architecture ratification at Month 18 (2028-04-30) becomes ambiguous; results showing 25–30% loss (realistic risk, estimate) trigger contested interpretation and trigger-or-not decision deadlock, delaying architecture lock to Month 24–30 (2028-10-31 to 2029-04-30). This compression collides with design lock (proposed Month 24 = 2028-10-31 end) and foundry gate (Month 18 = 2028-04-30), consuming critical sequencing slack. Recommendation: complete literature review by Month 9 (2027-07-31); pre-register the kill thresholds (20% / 25% / 50%; only a DMC-approved documented change before Month 12 (2027-10-31)) with no revision afterwards; publish animal results against locked thresholds within 5 days of Month 18 (2028-04-30) gate.

  2. Feasibility Verdict (Month 24 = 2028-10-31) Depends on Five Concurrent Deliverables (Epidemiology, Payer Feedback, FTO, Chronic Animal Interpretation, QMS Audit); Missing One Triggers Automatic 12-Month Deferral and Compresses All Subsequent Milestones. Feasibility verdict inputs are due Month 24 (2028-10-31): epidemiology validation (deadline Month 15 = 2028-01-31), payer HTA feedback (Month 18 = 2028-04-30), FTO results (Month 9 = 2027-07-31), chronic-animal interpretation (Month 18 = 2028-04-30), QMS preliminary audit (Month 18 = 2028-04-30). Gate G3 financing (EUR 60M minimum T1 commitment) is contingent on verdict publication within 5 days. If payer feedback slips past Month 18 (2028-04-30) due to late HTA body responses, verdict drafting is compressed into the final 6 months before Month 24 (2028-10-31), forcing incomplete risk assessment and investor rejection of T1. Missing gate G3 triggers automatic deferral (12 months per plan), pushing pivotal funding (T2) gate from Month 36 (2029-10-31) to Month 48 (2030-10-31) and slipping CE marking by 12 months. Recommendation: establish hard internal deadlines 15 days before each external gate (e.g., HTA input by Month 17.5 = 2028-04-15); assign monthly status reviews with escalation protocol if inputs drift past Month 18 (2028-04-30).

  3. Supplier Dual-Sourcing Qualification (Month 30 = 2029-04-30) Must Precede Design Lock (proposed Month 24–30 = 2028-10-31 to 2029-04-30) to Avoid Rework if Second Source Fails; Late Qualification Forces Architecture or Material Changes Post-Lock. MOUs with chip and substrate suppliers are signed Month 12 (2027-10-31) (proposed), but formal qualification (process audits, sample testing, ISO 13485 verification) runs Months 18–30 (2028-04-30 to 2029-04-30), overlapping design lock. If the second supplier fails qualification by Month 30 (2029-04-30) (e.g., yield <80%, schedule slip), a tertiary supplier must be engaged at Month 30+ (2029-04-30+), after design is frozen. Design changes to accommodate the tertiary supplier (different wafer geometry, package outline, lead time) require Change Request Forms and risk re-assessment, consuming EUR 0.5–1M rework and 2–4 months. This cascades to pilot-to-production transfer delay at Month 48+ (2030-10-31+), pushing CE marking by 6 months. Recommendation: execute pre-qualification assessments (capacity, financials, timeline) for tertiary supplier by Month 12 (2027-10-31); require both suppliers to pass formal qualification by Month 27 (2029-01-31), before design lock; if either slips, escalate to tertiary by Month 28 (2029-02-28) to preserve Month 30 (2029-04-30) qualification gate and avoid post-lock rework.

Review 14: Financial Strategy

  1. Post-CE-Marking Revenue Model and Profitability Path Undefined; EUR 66M Annual Operating Gap at Month 180 (2041-10-31) Cannot Be Closed Within Current Financial Structure. The plan projects EUR 45M annual revenue (300 implants × EUR 150,000 price) against EUR 111M opex (fixed EUR 90M + variable EUR 21M estimate), creating a EUR 66M structural deficit indefinitely. If indication remains ALS-only and implant capacity plateaus at 300 per year by Month 168-180 (2040-10-31 to 2041-10-31), the company operates at perpetual loss; cumulative burn over Months 168-180 (2040-10-31 to 2041-10-31) (12 months) is the EUR 66M operating gap (EUR 111M opex per year). Interaction: if payer reimbursement price falls from EUR 150,000 to EUR 100,000 (Likelihood: Medium if HTA bodies reject EUR 120,000 per QALY threshold), revenue drops to EUR 30M annually and burn accelerates. Recommendation: pre-register a long-term financial sustainability gate at Month 120 (2036-10-31) requiring either: (a) indication expansion to spinal cord injury (3–5× eligible pool), (b) price increase to EUR 200,000+ per implant, or (c) committed member-state subsidy or grants beyond Month 180 (2041-10-31), with credible commitments obtained by Month 108 (2035-10-31).

  2. Investor Return Expectations and Cost-of-Capital Assumptions Absent; No IRR Target, Payback Horizon, or Exit Scenario Stated for T0–T4 Tranches. The plan specifies tranches T0 (EUR 15M by Month 12 = 2027-10-31), T1 (EUR 120M by Month 24 = 2028-10-31), T2–T4 (EUR 1.835B by Month 180 = 2041-10-31), but no written investor return targets exist. If institutional investors expect 20–25% IRR (estimate) and 10–12 year payback (estimate, proposed threshold), the 1,050-implant cumulative and Month 180 (2041-10-31) endpoint fail to deliver: IRR is negative (EUR 45M annual revenue from Year 12+ onwards cannot service EUR 2.5B sunk capital plus patient-protection reserves). Interaction: if anchor investors reject term sheets lacking a credible IRR path, Gate G1 (Month 12 = 2027-10-31) is missed, deferring all spend and compressing FIH by 6–12 months. Recommendation: model three return scenarios (conservative/central/optimistic) showing IRR breakage by Month 12 (2027-10-31); identify whether the programme is commercial (seek ≥15% IRR) or public-health (accept grant-funded subsidy indefinitely); obtain written investor or member-state confirmation of return expectations by Month 3 (2027-01-31) before closing T0.

  3. Patient-Protection Reserve Adequacy Beyond Device Lifetime (15+ Years Post-Implant) and Post-Company-Exit Funding Mechanism Unspecified; Trust Solvency at Month 150+ (2039-04-30+) Unconfirmed. EUR 31.5M reserve (for 1,050 cumulative implants × EUR 30,000 per implant estimate) funds device lifetime (10–15 years central estimate, unvalidated); if device lifetimes exceed 15 years or company fails at Month 120 (2036-10-31), the trust must cover 25–30 year tail of follow-up without new funding. If the company fails before Month 180 (2041-10-31), the trustee cannot draw upon operating revenue for care escalation; reserves must be actuarially sized to cover outliers (patients living 20+ years post-implant, accelerated failure cohorts). Interaction: if per-implant reserve underestimates costs by 20–30% (Likelihood: Medium), reserve depletion occurs 3–5 years earlier; combined with company insolvency, implanted patients are at risk of abandonment; the Month 120 (2036-10-31) sustainability gate is the single decision point for wind-down or subsidy. Recommendation: commission actuarial tail-risk analysis by Month 9 (2027-07-31) modelling 20, 25 and 30 year post-implant support horizons; lock per-implant reserve to actuarially justified amount (likely EUR 40,000–60,000 estimate, not EUR 30,000) by Month 12 (2027-10-31); pre-register reserve-adequacy audit with independent actuary at Month 100 (2035-02-28) and every 24 months thereafter.

Review 15: Motivation Factors

  1. Clear, Quantified Gate Verdicts and Transparent Contingency Activation Build Stakeholder Credibility and Prevent Momentum Inertia Past Evidence-Based Stop Points. The plan mandates written verdicts within 5 business days of each gate (G1 Month 12 = 2027-10-31, G3 Month 24 = 2028-10-31, G4 Month 36 = 2029-10-31), with automatic deferral if criteria are missed. Without transparent verdicts, failed gates trigger 3–6 month renegotiation, team burnout from schedule uncertainty, and loss of founder confidence. If G1 is missed and founders observe continued spending despite a failed gate, staff morale collapses; attrition of key talent (CTO, CMO) in Months 12–18 (2027-10-31 to 2028-04-30) costs EUR 0.5–1M in replacement hiring and delays architecture lock by 3–6 months. Recommendation: publish written gate decisions (proceed, defer, switch) to investors, Leuven partners, and ethics committees within 2 business days of deadline; tie board compensation to on-time verdict publication and gate enforcement.

  2. Patient-Centric Outcomes and Lifelong Support Commitments Create Ethical Purpose Alignment and Differentiate from Competitor Narratives Driven by Founder Ambition or Shareholder Returns. The EUR 31.5M patient-protection reserve (for 1,050 cumulative implants) and binding step-in covenant signal genuine commitment to implanted-patient continuity beyond commercial exit. If this commitment is perceived as performative or is under-resourced (reserves audited inadequate by Month 100 = 2035-02-28), staff motivation erodes and public trust collapses; recruitment of consent advocates, surgeons and clinical staff slows by 20–30% (estimate), extending centre activation by 3–6 months and reducing end-of-trial participation willingness. Recommendation: conduct actuarial reserve validation by Month 9 (2027-07-31); publish reserve adequacy in writing to staff and patient groups by Month 12 (2027-10-31); execute step-in successor agreement by Month 36 (2029-10-31) and test handover scenario with named successor.

  3. Early Scientific Credibility (Preclinical Data, Published Bandwidth Protocol, Regulated Companion Studies) Sustains Founder and Investor Confidence When Timelines Slip or Financing Gates Miss. If preclinical chronic-animal studies at Month 18 (2028-04-30) show signal loss within the 20% animal limit and bandwidth matches published benchmarks (10–15 bits/s estimate), founders see technical tractability; this sustains motivation through Gate G3 (Month 24 = 2028-10-31) even if financing slips. Conversely, if animal results breach kill thresholds (>20% animal signal loss, Likelihood: Medium) without credible published precedent for the threshold choice, team morale fractures; founders question gate integrity and may push for override, eroding governance. Recommendation: pre-register the kill thresholds (20% / 25% / 50%) by Month 12 (2027-10-31), with no revision afterwards; publish preclinical bandwidth and stability results within 5 days of Month 18 (2028-04-30) gate; present findings to investors and ethics bodies within 10 days to build public confidence in next-stage viability.

Review 16: Automation Opportunities

  1. Automate Gate-Decision Documentation and Verdict Publication by Pre-Registering Templates and Binding Deadlines (Months 12, 24, 36 = 2027-10-31, 2028-10-31, 2029-10-31). Current process: gate verdicts require 3–6 month board negotiation; automating decision-tree rules (pre-agreed criteria, automated flag-checking, template verdicts) saves 2–3 months per gate and frees board time for substantive strategy. Impact: Gate G1 (Month 12 = 2027-10-31) closes by deadline, unlocking T0 (EUR 15M target) on schedule; delays compressed out of FIH and CE timeline. Recommendation: draft decision-logic flowchart and verdict templates by Month 2 (2026-12-31); bind shareholder agreement specifying automated verdicts within 5 business days (no renegotiation).

  2. Establish Federated, EU-Hosted Data Repository with Automated Decoder Version-Lock and AI Act Change-Control Audit Trail (Months 12–24 = 2027-10-31 to 2028-10-31). Building a secure federated-testing platform with locked decoder registry (Decoder Version 1.0 at Month 18 = 2028-04-30) and automated compliance-log generation saves manual audit time and enables continuous decoder improvement without resetting clinical evidence. Cost savings: EUR 0.5–1M AI Act compliance budget (estimated EUR 2M total) saved via automated audit logs and version tracking; schedule: no delays from manual change-control rework. Recommendation: procure federated-compute infrastructure (EU-hosted) and Decoder Registry software by Month 12 (2027-10-31).

  3. Automate Monthly Gate-Status Reporting and Stakeholder Communication via Standardized Dashboards and Milestone Tracking (Months 0–180 = 2026-10-31 to 2041-10-31). Replace manual status reports (2–3 days/month effort × 180 team members across sites) with automated data aggregation from design-history file, supplier scorecards, recruitment pipelines and financial draws. Savings: 5–10 FTE-months per year × EUR 80k/year (estimate) = EUR 400k–800k annually; enables real-time gate-trigger alerts and kill-gate escalation within 48 hours. Recommendation: implement project-management and business-intelligence tools (Gantt, financial dashboard, supply-chain tracker) by Month 6 (2027-04-30) with monthly automated report templates.

Q1: What does the plan mean by the 'three EU-control tests' that critical components must pass, and why are they essential to the project's sovereignty requirement?

A1: The three EU-control tests are: (1) EU ownership of the intellectual property or manufacturing capability; (2) maintainability and continued operation without needing foreign consent or licences; and (3) export-control freedom, meaning no restrictions on the component's use within the EU. These tests must be passed by all delivered components (electrodes, chips, encapsulation, decoding software, neural-data hosting) by Month 72 (2032-10-31) before the pivotal trial lock. They are essential because the programme's hard requirement is that the delivered system is under EU control, ensuring the EU can sustain the technology independently and that patients' neural data remain under EU jurisdiction indefinitely.

Q2: The plan states the 5,000-implant target is 'missed in all scenarios' but then refers to it as a goal. What does the plan actually expect to achieve, and why does it still frame a target it acknowledges is unrealistic?

A2: The plan's central estimate is approximately 1,050 cumulative implants by Month 180 (2041-10-31), with a range of 400–3,000 across scenario variations. The 5,000 target originated as a user constraint (planning ceiling) but the plan's own analysis—based on eligible ALS population (500–1,400 per year, estimate), implanting-centre surgical throughput (about 12 per centre, about 25 centres at scale = 300 per year), and disease-progression attrition—shows 1,050 is the realistic outcome. The plan retains the 5,000 reference to acknowledge the user's stated ambition while being transparent that this outcome is not credibly achievable under current assumptions. The candour serves to signal to investors and regulators that the programme is evidence-gated, not hype-driven.

Q3: What are the 'financing gates' and how would a missed gate affect the programme's timeline and team?

A3: Financing gates are scheduled decision points (Months 12, 24, 36 = 2027-10-31, 2028-10-31, 2029-10-31) where specific capital tranches must be committed in writing. Gate G1 (Month 12 = 2027-10-31) requires T0 EUR 10–15M committed; Gate G3 (Month 24 = 2028-10-31) requires at least EUR 60M of T1 committed plus publication of the feasibility verdict; Gate G4 (Month 36 = 2029-10-31) requires EUR 150M of T2 (from EUR 480M total) or equivalent deferral. If a gate is missed, the plan mandates automatic 12-month deferral of non-critical spending (no new hires, delayed facility agreements) and a written re-forecast, not renegotiation. Practically, a missed gate compresses FIH from Month 60 (2031-10-31) by 6–12 months, strains team retention (staff face hiring freezes and schedule uncertainty), and erodes partner credibility (Leuven institutions may withdraw if milestones slip repeatedly).

Q4: The plan mentions 'kill gates' for signal stability, safety and bandwidth. What happens if a kill gate is breached, and who decides whether to stop, switch architecture, or continue?

A4: Kill gates are pre-registered quantitative thresholds that, if crossed, trigger mandatory escalation and a binding recommendation from the independent Data Monitoring Committee (DMC). Examples: if ≥2 serious adverse events occur in the first 10 implants (or ≥3 in first 20), the DMC recommends pause; if animal signal loss exceeds 25% within 12 months, architecture review is triggered. The DMC holds binding pause authority—the company must act on its findings within 5 business days or escalate to the notified body and ethics committees. However, the plan does not clarify who decides whether to 'stop, switch architecture, or defer'—this is a governance gap. In practice, the board likely holds final stop authority, but an investor disagreement could deadlock a switch decision for months. The kill-gate thresholds themselves are proposed values (not yet validated against preclinical data by Month 0 = 2026-10-31), which weakens their credibility.

Q5: Why does the plan state that the patient-protection reserve is a 'hard requirement' but then does not detail how the trust will be governed, funded, or survive if the company fails?

A5: The plan designates patient protection (EUR 30,000 per implant, about EUR 31.5M for 1,050 central implants, estimate) as a hard requirement and promises a ring-fenced trust outside investor reach, but operationally, at Month 0 (2026-10-31), the trust structure does not exist: no independent trustee is named, no legal governance charter is drafted, and no actuarial study validates the EUR 30,000 figure or confirms the device lifetime (assumed 10–15 years, unvalidated). The plan delegates these details to Month 6 (2027-04-30), but without them in place, the reserve remains a promissory note, not a binding covenant. If the company becomes insolvent at Month 120 (2036-10-31) with 250 implanted patients, the trustee would need to cover 10–20 years of follow-up, imaging, explantation and emergency support; if the reserve is inadequately sized (actual costs exceed EUR 30,000 per implant), implanted patients face abandonment despite the stated hard requirement.

Q6: The plan acknowledges a EUR 66M annual operating gap at Month 180 (2041-10-31)—revenue EUR 45M versus opex EUR 111M—yet still frames the programme as viable. How can this structural deficit be closed, and what are the realistic pathways?

A6: The plan does not propose a mechanism to close the EUR 66M annual gap within the current scope (ALS-only indication, 300 implants/year at scale). Three scenarios exist: (1) indication expansion to spinal cord injury by Month 78 (2033-04-30), increasing eligible pool 3–5× and implant rate to 900–1,500/year (estimate), moving break-even within reach; (2) price increase to EUR 200,000+ per implant, requiring payer renegotiation from the proposed EUR 120,000 per QALY ceiling; (3) indefinite member-state subsidy or grant funding post-Month 180 (2041-10-31), converting the company to a public-health infrastructure rather than a commercial entity. Without one of these, the EUR 2.5B envelope is consumed by Month 150 (2039-04-30), triggering a forced wind-down or programme halt. The plan is explicit that ALS-only does not achieve commercial viability, making the Month 78 (2033-04-30) indication-pivot gate existential, not optional.

Q7: Why does the plan defer the pivotal indication decision (ALS versus spinal cord injury) to Month 78 (2033-04-30), and what are the consequences if population or reimbursement evidence is missing by that date?

A7: The plan defers the pivotal indication decision to Month 78 (2033-04-30) to allow early-feasibility data (Month 60–72 = 2031-10-31 to 2032-10-31, 10 participants estimate) and payer feedback to inform which indication has the stronger clinical benefit and reimbursement case. This preserves optionality: if ALS communication shows insufficient bandwidth or payer rejection, the programme can pivot to spinal cord injury motor control (larger eligible pool, harder functional-outcome case, different surgical and centre-network requirements). However, the gate is positioned late: if population epidemiology or payer willingness-to-pay remains unvalidated through Month 60 (2031-10-31), the Month 78 (2033-04-30) decision will be made under time pressure with incomplete evidence. Pivoting at Month 78 (2033-04-30) forces reforecasting of T3 (EUR 900M) and T4 (EUR 985M) tranches, centre-network redesign, and trial-duration extension, compressing the CE-marking timeline and potentially slipping it from Month 132 (2037-10-31) to Month 144–156 (2038-10-31 to 2039-10-31) (estimate). A hard scope gate at Month 24 (2028-10-31) requiring validated population and payer commitment would reduce this risk.

Q8: The plan mandates that informed consent for locked-in ALS participants is a 'hard requirement' with independent validation and re-confirmation checkpoints. What specific mechanisms ensure consent is valid if disease progression causes communication loss mid-trial?

A8: The plan specifies an independent consent advocate (recruited by Month 3 = 2027-01-31) present at every consent conversation, a yes/no communication-validation protocol using participants' best available method (eye-tracking, blink, assistive device) with two independent validators and video documentation, and a re-consent schedule (baseline, monthly for 6 months post-implant, then quarterly annually). However, the critical gap is how to handle capacity fluctuation: ALS participants experience day-to-day communication variability; a participant who can validly consent on a 'good day' may be unable on a 'bad day' one week later. The plan mentions advance directives (participant-set device-control wishes recorded pre-implant, e.g., 'switch off if bandwidth drops below 5 bits/s'), but these are not operationalised: no protocol specifies how the clinical team enforces a participant-declared condition, what happens if the participant later changes their mind once communication is lost, or how conflicts between the advance directive and the participant's non-verbal behaviour are resolved. This is a material consent risk: if an ethics committee finds the re-consent process inadequate for rapid disease progression, the trial site may be suspended, delaying CE marking by 6–12 months (estimate).

Q9: The plan assumes a 'shared European neural-implant foundry' funded by 4+ member states at about EUR 350M (Months 18–84 = 2028-04-30 to 2033-10-31), but provides no evidence that member states have committed or are likely to commit. What is the fallback if the foundry is not funded, and how does it alter the timeline?

A9: The foundry is a 'hoped-for' EUR 350M investment (Months 18–84 = 2028-04-30 to 2033-10-31) that would provide validated Class III pilot-to-production-capable manufacturing, reducing single-source risk and delivering economies of scale. However, no member-state commitments exist at Month 0 (2026-10-31). If the foundry is not confirmed by Month 18 (2028-04-30) (proposed threshold), the plan automatically switches to a dual-sourcing fallback: qualify two competing EU chip suppliers and two substrate suppliers with pre-qualified orders and price commitments by Month 30 (2029-04-30). The fallback costs about EUR 35M (EUR 10M drawn from T1, EUR 25M from T2), adds about 6–12 months to pilot-line-to-validated-production transfer (estimate), and moves materials-lock from Month 72 (2032-10-31) to Month 78–84 (2033-04-30 to 2033-10-31) (estimate), compressing the window from design lock to pivotal lock. Critically, if both the foundry fails AND the signal-stability thresholds are breached (both Likelihood: Medium), both contingencies (EUR 30M architecture switch + EUR 35M dual-sourcing transfer) exhaust the EUR 219M free contingency by Month 30 (2029-04-30), leaving zero margin for design rework or regulatory delays. The foundry fallback is 'credible' (pre-identified suppliers, pre-costed), but it is not risk-free.

Q10: The plan separates human-AI enhancement research into a 'separate legal entity' with a 'firewall' to protect the medical programme from intended-use objections and public-trust erosion. Why is this separation necessary, and how credible is the firewall in practice?

A10: The plan's long-term vision is human-AI bandwidth expansion toward 100 bits/s (stretch goal), with applications beyond medical communication (robotics, virtual environments, cognitive augmentation). However, visible enhancement research—especially implanted-human enhancement before CE marking—could trigger ethics-committee and regulator objections that the medical programme is a 'proof of concept for human enhancement rather than a therapeutic tool'. This could delay patient recruitment, jeopardise consent validity (are participants consenting to medical treatment or enhancement research?), and expose the company to political backlash. The plan mandates a separate legal entity, a documented firewall governing IP and hardware sharing, and an independent ethics board reviewing enhancement communications. However, 'firewall' is a governance concept, not a technical boundary: the same decoder algorithms, electrode arrays and manufacturing knowledge serve both medical and enhancement applications. If the same implant system is used for both clinical communication and later cognitive augmentation, the distinction collapses in practice. The plan acknowledges this by forbidding implanted-human enhancement work before CE marking (Month 132 = 2037-10-31), but it does not address how to prevent post-CE-marking 'enhancement drift'—gradual scope expansion from medical to enhancement uses as the technology matures. A dedicated ethics and public-engagement board (proposed) is the main control, but its binding authority and funding are undefined.

A premortem assumes the project has failed and works backward to identify the most likely causes.

Assumptions to Kill

These foundational assumptions represent the project's key uncertainties. If proven false, they could lead to failure. Validate them immediately using the specified methods.

ID Assumption Validation Method Failure Trigger
A1 Investors will sign written, gate-bound commitments (T0 floor EUR 10M, target EUR 15M) by Month 12 (2027-10-31) despite EUR 0 committed at Month 0 (2026-10-31) and no stated return terms. Approach 4-5 anchor investors with a term-sheet template and gate conditions; request signed LOIs stating IRR, payback and deferral rules by Month 3 (2027-01-31). Fewer than 2 written LOIs by Month 3 (2027-01-31), or all investors require IRR above 20% (estimate) or override rights on kill gates.
A2 Thin-film surface electrodes will retain over 80% signal at 12 months, so the 20% animal kill gate is passable and the architecture holds through Month 18 (2028-04-30). Run a systematic literature review of chronic signal-retention percentiles (Clinatec, UMC Utrecht, others) and start the chronic animal protocol. Published or pilot data show median 12-month loss above 20%, so the primary architecture fails its own gate.
A3 The ALS-eligible pool (500-1,400 per year, estimate) and payers accepting EUR 150,000 per implant and EUR 120,000 per QALY (proposed) support a viable market. Commission registry-based epidemiology by Month 3 (2027-01-31) and hold pre-reimbursement talks with HTA bodies in 3 member states (preliminary payer feedback at Month 12 = 2027-10-31, written payer letters at Month 18 = 2028-04-30). Eligible pool is below 300 per year, or fewer than 3 payers signal acceptance at the proposed price.
A4 Imec, KU Leuven and UZ Leuven will grant written commitments (cleanroom hours, neuroengineering staff, theatre time, ALS patient access) by Month 3 (2027-01-31), and fallback sites are equivalent in capability. Send partnership scopes to all three plus Ghent/Antwerp, Utrecht and Grenoble; request signed LOIs with named resources and capability letters from fallback sites. Fewer than 2 of 3 Leuven LOIs by Month 3 (2027-01-31), or fallback sites lack cleanroom capacity or an ALS cohort comparable to Leuven.
A5 A pilot line can be transferred to a validated EU Class III production line with yield of at least 80% (proposed threshold), and a second chip and thin-film supplier can be qualified by Month 30 (2029-04-30). Issue RFIs to 2 chip and 2 substrate suppliers and a contract manufacturer; request capacity, yield history, export-control status and qualification timelines. Fewer than 2 suppliers per component commit to qualification, or quoted qualification time exceeds 18 months.
A6 A founder-only company can recruit 10 core staff by Month 6 (2027-04-30) despite EU pay trailing US pay by 20-30% (estimate), with equity and retention bonuses offsetting the gap. Issue offers to shortlisted candidates for CTO, CMO and regulatory lead with the proposed equity and retention package. Fewer than half of priority offers are accepted, or any of CTO, CMO or regulatory lead declines.
A7 Notified bodies and ethics committees will accept the pre-registered evidence plan (version-locked decoder, 10-participant FIH cohort, coordinated Belgium-Netherlands-France review) without requiring extra preclinical data or a reset of design. Request pre-submission meetings with 2 notified bodies and ethics pre-review in 3 countries; ask for written feedback on evidence gaps, decoder change control and consent validity. Written feedback requires added chronic animal data, a larger FIH cohort, or rejects the advance-directive consent approach, implying more than 12 months of added work (estimate), which triggers a re-plan and deferral review at the gate (more than 24 months stops or pivots).
A8 Locked-in ALS patients can give valid, re-confirmable consent and enough of them will enrol early enough in disease progression to fill a 10-participant FIH cohort and later the pivotal cohort of about 80 (estimate). Run a mock consent session with bioethicists and ALS societies; screen registry and clinic data for candidates meeting capacity and severity criteria in 3 countries. Independent validators disagree on yes/no validity in over 20% of mock sessions (proposed threshold), or fewer than 30 candidates per year meet criteria across the 3 countries (estimate).
A9 A US or Chinese device will not be CE-marked and win EU clinicians and payers before Month 60 (2031-10-31), and EU buyers will prefer a later EU-sovereign device based on evidence, data residency and lifelong support. Interview clinicians and payers in 3 member states on switching willingness; track notified-body listings and published rival filings. A rival files for CE marking before Month 36 (2029-10-31), or fewer than 3 of 5 interviewed payers or centres would favour a later EU entrant at equal outcomes.

Failure Scenarios and Mitigation Plans

Each scenario below links to a root-cause assumption and includes a detailed failure story, early warning signs, measurable tripwires, a response playbook, and a stop rule to guide decision-making.

Summary of Failure Modes

ID Title Archetype Root Cause Owner Risk Level
FM1 The Gate That Never Closed Process/Financial A1 Chief Financial Officer CRITICAL (20/25)
FM2 The Fading Signal Technical/Logistical A2 Chief Technology Officer CRITICAL (20/25)
FM3 The Patients Who Were Too Few Market/Human A3 Chief Medical Officer CRITICAL (16/25)
FM4 The Handshake That Never Came Process/Financial A4 Chief Executive Officer HIGH (12/25)
FM5 The Pilot Line That Was Not a Factory Technical/Logistical A5 Chief Manufacturing & Supply-Chain Officer HIGH (12/25)
FM6 The Brain Drain Before the Brain Market/Human A6 Chief Executive Officer HIGH (12/25)
FM7 The Dossier That Kept Growing Process/Financial A7 Chief Regulatory Affairs Officer CRITICAL (16/25)
FM8 The Consent That Could Not Be Heard Technical/Logistical A8 Clinical Trials & Patient Safety Manager CRITICAL (15/25)
FM9 The Rival Who Arrived First Market/Human A9 Chief Executive Officer HIGH (12/25)

Failure Modes

FM1 - The Gate That Never Closed

Failure Story
Early Warning Signs
Tripwires
Response Playbook

STOP RULE: Stop or defer 12 months if T0 is below EUR 10M in writing at Month 12 (2027-10-31) and no extension is signed within 5 business days.


FM2 - The Fading Signal

Failure Story
Early Warning Signs
Tripwires
Response Playbook

STOP RULE: Cancel or pivot architecture if both primary and fallback show over 30% signal loss at 12 months in animals.


FM3 - The Patients Who Were Too Few

Failure Story
Early Warning Signs
Tripwires
Response Playbook

STOP RULE: Stop or pivot indication at the Month 24 (2028-10-31) scope gate if the eligible pool is under 300 per year (proposed threshold, set with reference to the capacity model) or fewer than 3 payers accept the price.


FM4 - The Handshake That Never Came

Failure Story
Early Warning Signs
Tripwires
Response Playbook

STOP RULE: Recommend defer or stop if 2 or more primary partners and their fallbacks lack a signed LOI by Month 6 (2027-04-30).


FM5 - The Pilot Line That Was Not a Factory

Failure Story
Early Warning Signs
Tripwires
Response Playbook

STOP RULE: Pivot or pause the manufacturing route if no EU supplier meets qualification yield after 2 transfer attempts by Month 48 (2030-10-31).


FM6 - The Brain Drain Before the Brain

Failure Story
Early Warning Signs
Tripwires
Response Playbook

STOP RULE: Defer the programme 12 months if CTO, CMO or regulatory lead roles remain unfilled at Month 9 (2027-07-31).


FM7 - The Dossier That Kept Growing

Failure Story
Early Warning Signs
Tripwires
Response Playbook

STOP RULE: Re-plan and review deferral at the gate if regulators require more than 12 months of added evidence work before FIH; pivot or stop if more than 24 months (all proposed thresholds).


FM8 - The Consent That Could Not Be Heard

Failure Story
Early Warning Signs
Tripwires
Response Playbook

STOP RULE: Stop enrolment programme-wide if two sites record invalid-consent findings within 12 months (proposed threshold).


FM9 - The Rival Who Arrived First

Failure Story
Early Warning Signs
Tripwires
Response Playbook

STOP RULE: Stop or pivot at the competitive-response gate if a rival is reimbursed in 3 or more member states and fewer than 3 payers favour the EU device.

Reality check: fix before go.

Summary

Level Count Explanation
🛑 High 14 Existential blocker without credible mitigation.
⚠️ Medium 4 Material risk with plausible path.
✅ Low 2 Minor/controlled risk.

Checklist

1. Violates Known Physics

Does the plan's success require breaking a known law of physics (e.g., thermodynamics, conservation of energy, speed-of-light limit, causality)?

Level: ✅ Low

Justification: This is a medical device R&D, clinical-trial and commercialisation programme. Neural signal decoding, electrode implant engineering, machine learning on biomedical signals, and chronic implant integration are all established physical processes with laboratory and clinical precedent. The plan's scaling targets (bandwidth, patient numbers, timeline) and fallback architecture options are engineering challenges, not physics violations. The plan correctly separates speculative enhancement work, sets empirically-grounded kill thresholds, frames bandwidth scenarios with uncertainty, and acknowledges that 5,000 implants and break-even are not credibly achievable—transparently identifying constraints without claiming to overcome them by impossible means. No core success criterion depends on breaking a named law of physics or on a non-physical causal mechanism.

Mitigation: No physics-related action required — the plan does not invoke physics-incompatible mechanisms.

2. No Real-World Proof

Does success depend on a technology or system that has not been proven in real projects at this scale or in this domain?

Level: 🛑 High

Justification: Rated HIGH because the plan combines thin-film surface implants, locked AI decoders under MDR Class III + AI Act governance, sovereign EU manufacturing with a distributed 25-centre network, and a EUR 31.5M lifelong-support trust—a novel integration with no published precedent at comparable scale. Components have precedent (Clinatec, UMC Utrecht), but the integrated system (locked decoder audit, sovereignty compliance across 25 sites, patient-protection trust enforcement) is unvalidated. Failure is existential: if chronic signal stability falls short (realistic risk ≥20% loss) or payers reject reimbursement, implanted patients face abandonment and the programme halts mid-implementation.

Mitigation: Execute parallel validation tracks by Month 18 (2028-04-30): (1) Empirical/Engineering: complete chronic-implant animal studies (18–24 months) with signal-retention data, published literature review (thin-film/penetrating percentiles), and preclinical bandwidth validation using locked protocol—NO-GO (animal gate) if signal loss exceeds 20% within 12 months, which blocks FIH (proposed threshold). Preclinical decoding results carry a separate, labelled criterion (proposed threshold); the human bandwidth floor (below 5 bits/s sustained net in 50% or more of participants) applies only at 12 months after FIH. (2) Legal/Compliance: obtain written notified-body feedback on AI Act decoder version-lock and MDR evidence plan, execute sovereignty diligence on all suppliers against three EU-control tests, and test trust governance with independent legal counsel—re-plan and deferral review at the gate if the notified body requires >12 months added evidence, stop or pivot if >24 months (proposed thresholds); NO-GO if any supplier fails sovereignty tests. (3) Market/Reimbursement: validate eligible ALS population (≥300 per year) and written payer acceptance from 3+ member states at EUR 120,000 per QALY ceiling—NO-GO if <300 eligible or <3 payers accept. Release subsequent tranches (T1, T2) only if all three tracks clear their NO-GO gates by their deadlines. Owner: Chief Technology Officer (empirical), Chief Regulatory Affairs Officer (legal), Chief Medical Officer (market). Deliverables: published signal-retention report, notified-body written feedback, three payer commitment letters. Date: Month 18 (2028-04-30).

3. Buzzwords

Does the plan use excessive buzzwords without evidence of knowledge?

Level: ⚠️ Medium

Justification: Rated MEDIUM because 15 named strategic decisions define mechanism-of-action (inputs→process→customer value) with owners and measurable outcomes for sourcing, foundry, indication, regulation and consent. However, material gaps undermine clarity: financing strategy lacks documented investor return expectations, cost-of-capital assumptions, or break-even mechanism (EUR 66M annual opex-revenue gap at Month 180 = 2041-10-31 unresolved); commercial case is incomplete (1,050 implants miss the 5,000 target, yet no value mechanism sustains post-CE-marking profitability or customer adoption); enhancement-track firewall lacks defined boundaries or measurable governance thresholds. These strategic blind spots prevent credible execution of the stated 15-year, EUR 2.5B mission.

Mitigation: By Month 6 (2027-04-30), assign owners to produce one-pagers for three strategic frameworks: (1) Financing & Break-Even Owner: CFO, Deliverable: documented investor return expectations (IRR, payback, exit), cost-of-capital per tranche, and credible path to profitability or subsidy commitment; (2) Commercial Viability Owner: Chief Medical Officer, Deliverable: health-economic model showing how 1,050 cumulative implants reach break-even or win member-state support; (3) Enhancement Firewall Owner: CEO, Deliverable: written governance charter with defined legal separation, IP-sharing rules, and measurable enforcement thresholds. Each one-pager must include success metrics and decision hooks (e.g., if break-even requires SCI pivot, lock that trigger at Month 24 = 2028-10-31 gate).

4. Underestimating Risks

Does this plan grossly underestimate risks?

Level: 🛑 High

Justification: Rated HIGH because the plan identifies major second-order risk classes (financing cascade: gate miss → hire freeze → schedule slip → investor confidence collapse; technical cascade: signal-stability failure → architecture switch → CE-marking delay to Month 144–156 = 2038-10-31 to 2039-10-31; commercial cascade: payer rejection + small eligible pool → operating gap unsustainable → wind-down or subsidy decision at the Month 120 = 2036-10-31 sustainability gate) but leaves critical cascades unmitigated: (1) partner-institution political or capacity reversal mid-programme (UZ Leuven withdrawal at Month 48–60 = 2030-10-31 to 2031-10-31 destroys FIH timeline and surgical infrastructure), (2) key-person burnout in founder-only team (loss of CTO or CMO at Month 12–24 = 2027-10-31 to 2028-10-31 cascades to 3–6 month architecture-choice delay and gate failure), (3) healthcare-system reimbursement policy reversal (payer budget-impact objection or political freeze mid-pivotal trial at Month 100+ = 2035-02-28+, cascading to trial suspension and CE-marking invalidation), (4) supply-chain geopolitical shock (EU export controls on fab equipment or chip-design software trigger forced relocation and EUR 5M–EUR 10M unbudgeted cost at Months 48–72 = 2030-10-31 to 2032-10-31). These cascade mechanisms are omitted from the risk register entirely; owners and control points are unassigned.

Mitigation: Chief Risk Officer (to be named by Month 3 = 2027-01-31): expand the risk register to map four named cascade chains (financing → execution, technical → schedule, commercial → wind-down, geopolitical → supply chain) with quantified impact (months delay, EUR cost, triggering gates) and assigned owners; add quarterly cascade-review gates at Months 24, 48, 72, 108 (2028-10-31, 2030-10-31, 2032-10-31, 2035-10-31) checking sentinel conditions (partner institutional health, key-person retention, payer policy tracking, export-control alerts); gate outcomes published within 10 days. Deliverable: cascade register with decision trees. Date: Month 6 (2027-04-30).

5. Timeline Issues

Does the plan rely on unrealistic or internally inconsistent schedules?

Level: 🛑 High

Justification: Rated HIGH because the plan mandates multiple hard-deadline gates (G1 Month 12 = 2027-10-31, G3 Month 24 = 2028-10-31, G4 Month 36 = 2029-10-31) dependent on concurrent activities (chronic-animal studies 18–24 months, FTO analysis Month 9 = 2027-07-31, notified-body pre-submission Month 6 = 2027-04-30, supplier qualification Months 18–30 = 2028-04-30 to 2029-04-30) that have no documented slack or buffer. The plan lacks: (1) a critical-path Gantt with documented float per task; (2) lead-time data for notified-body pre-submission to formal engagement (estimated 2–3 months unbudgeted); (3) explicit multi-country ethics-approval sequencing (three countries, ~8–12 weeks per committee in parallel, not serialised, but overlaps not quantified); (4) permit or regulatory-notification timelines for implanting centres in Belgium, Netherlands, France (estimated 4–8 weeks per country); (5) supplier qualification-approval gates tied to gate-release authority (if qualification slips past Month 30 = 2029-04-30, second-source fails and single-source risk persists into pivotal trial). Architecture lock at Month 18 (2028-04-30) collides with final chronic-animal interpretation and FTO clearance completion; if animal data interpretation drifts past Month 18 (2028-04-30) due to data-quality issues (estimated 2–4 week risk), the gate is missed and feasibility verdict at Month 24 (2028-10-31) is incomplete. The plan reports an optimistic 54-month FIH window (Month 60 = 2031-10-31 central, range 54–78) but does not justify why 54 months is sufficient when Class III conformity timelines often slip 12–24 months (estimate) post-notified-body engagement."

Mitigation: Project Management Lead: build and publish a detailed Gantt chart with critical-path identification, quantified float per task, and documented dependencies (predecessors, handoff dates, approval gates) by Month 3 (2027-01-31). Include: (1) chronic-animal-study timeline (start Month 0, 18–24 month duration, interpretation gate Month 18 = 2028-04-30, 3-week buffer before design lock); (2) FTO analysis completion by Month 9 (2027-07-31), 2-month buffer before architecture ratification at Month 18 (2028-04-30); (3) notified-body pre-submission (Month 6 = 2027-04-30 meeting, +2 weeks for written response, +2 weeks to incorporate feedback before design lock); (4) multi-country ethics sequencing (Belgium pre-review Month 3 = 2027-01-31, Netherlands and France Month 4–5 = 2027-02-28 to 2027-03-31, final approvals by Month 12 = 2027-10-31 for trial start); (5) supplier qualification gates tied to design-lock dependencies (both sources qualified by Month 27 = 2029-01-31, before design freeze at Month 30 = 2029-04-30); (6) centre activation and surgeon credentialing (pre-qualification Month 6 = 2027-04-30, letters of intent Month 12 = 2027-10-31, credentialing complete Month 54 = 2031-04-30 before Month 60 = 2031-10-31 FIH). Publish monthly status against Gantt and escalate critical-path slips (>5% of task duration) to the board within 10 days. Date: within 90 days of Month 0 (2026-10-31)."

6. Money Issues

Are there flaws in the financial model, funding plan, or cost realism?

Level: 🛑 High

Justification: Rated HIGH because no funding is committed at Month 0 (2026-10-31)—EUR 0 of EUR 2.5B. Financing gates at Months 12, 24, 36 (2027-10-31, 2028-10-31, 2029-10-31) require T0 floor EUR 10M, T1 EUR 60M+ and T2 EUR 150M respectively, but no anchor investors, term sheets or return expectations are named. The plan mandates automatic 12-month deferral if gates miss, yet lacks binding investor agreements to enforce verdicts. Shared foundry EUR 350M (hoped-for, 4+ member states) is not confirmed and has a fallback dual-sourcing cost of EUR 35M within T1/T2. Patient-protection reserve EUR 31.5M (for 1,050 central implants) is promised but not actuarially validated or legally structured by Month 0 (2026-10-31). Missing any gate (Months 12, 24, 36 = 2027-10-31, 2028-10-31, 2029-10-31) compresses FIH from Month 60 (2031-10-31) to Month 72–84 (2031-10-31 to 2033-10-31), cascading 12–24 month CE marking delay.

Mitigation: Chief Financial Officer: commission written investor LOI templates by Month 2 (2026-12-31) and secure signed T0 commitments (floor EUR 10M, target EUR 15M) by Month 12 (2027-10-31) from at least 2 anchor investors, specifying gate conditions, automatic deferral rules and binding verdicts. Establish patient-protection trust governance and independent trustee by Month 6 (2027-04-30) with actuarial validation of per-implant reserve and ring-fenced fund structure. Publish gate decision authority charter and NO-GO mechanism by Month 2 (2026-12-31).

7. Budget Too Low

Is there a significant mismatch between the project's stated goals and the financial resources allocated, suggesting an unrealistic or inadequate budget?

Level: 🛑 High

Justification: Rated HIGH because no bottom-up cost breakdown exists validating the EUR 2.5B budget against concrete manufacturing, trial, and operational requirements. The plan projects EUR 2.38M cost-per-device (EUR 2.5B ÷ 1,050 implants), 20–200× published cardiac-implant benchmarks, with no comparables or vendor quotes provided. The EUR 66M annual opex–revenue gap at Month 180 (2041-10-31) is unresolved; patient-protection reserves (EUR 31.5M, estimate) are actuarially unvalidated; free contingency is about EUR 219M (estimate; about EUR 189M if the architecture switch costs the EUR 60M upper bound), so the named draws do not exhaust it.

Mitigation: Chief Financial Officer and Chief Technology Officer: obtain cost benchmarks from ≥3 comparable implantable-device programmes (cardiac, cochlear, spine) by Month 12 (2027-10-31); request binding quotes from 2+ chip suppliers, 2+ substrate suppliers and 1 contract manufacturer for pilot-line prototyping and transfer by Month 12 (2027-10-31), normalised per unit and per milestone; reconcile bottom-up costs against EUR 2.5B envelope; adjust budget or de-scope by Month 24 (2028-10-31).

8. Overly Optimistic Projections

Does this plan grossly overestimate the likelihood of success, while neglecting potential setbacks, buffers, or contingency plans?

Level: ⚠️ Medium

Justification: Rated MEDIUM because the plan presents key financial projections—annual revenue EUR 45M, annual opex EUR 111M, operating gap EUR 66M at Month 180 (2041-10-31), unit price EUR 150,000, and break-even at 1,125 implants/year—as single-point estimates without ranges, confidence intervals, or stress-case scenarios. The plan acknowledges that outcomes depend on indication choice (ALS vs. SCI at Month 78 = 2033-04-30) and payer acceptance, yet the financial impact of these contingencies is not quantified. Bandwidth and implant-number projections include ranges (pessimistic/central/optimistic), but the commercial case lacks sensitivity analysis showing how ±20% price, ±33% volume, or indication-switch scenarios would alter the EUR 66M annual gap or reserve requirements. The plan correctly signals that the 5,000-implant target is unrealistic, but this transparency does not compensate for unquantified financial contingencies.

Mitigation: Finance Lead: by Month 12 (2027-10-31), deliver a sensitivity analysis table showing annual revenue and opex under three scenarios (ALS-only at 200/300/400 implants/year; price EUR 100k/150k/200k; opex ±20%) and three corresponding operating-gap outcomes; publish alternative financial cases (SCI-primary expansion, indefinite subsidy path) with quantified EUR impact and revenue ramp; present to investors and Commission within 5 business days of Month 24 (2028-10-31) feasibility verdict.

9. Lacks Technical Depth

Does the plan omit critical technical details or engineering steps required to overcome foreseeable challenges, especially for complex components of the project?

Level: 🛑 High

Justification: Rated HIGH because core build-critical components lack documented engineering artifacts at Month 0 (2026-10-31). The plan specifies a thin-film surface electrode architecture (provisional until Month 18 = 2028-04-30) but provides no electrode design specifications, ASIC signal-conditioning interface contracts, encapsulation material acceptance criteria, external processor thermal or power non-functional requirements, or integration maps with component owners and lock dates. The Work Breakdown Structure lists design tasks (electrode arrays, ASIC, encapsulation, external processor) scheduled Months 24–48 (2028-10-31 to 2030-10-31), implying design work is deferred; no baseline technical specifications or design history file exists at Month 0 (2026-10-31). Architecture ratification at Month 18 (2028-04-30) depends on FTO and preclinical data interpretation, not on completed interface contracts or validated integration plans, creating schedule risk if design must be reworked post-ratification.

Mitigation: Chief Technology Officer: by Month 6 (2027-04-30), produce provisional technical specifications for electrode geometry, ASIC signal-conditioning interface (voltage/current ranges, sampling rates, digital output format), encapsulation material candidates (biocompatibility, mechanical, sterilisation acceptance criteria), external processor thermal envelope (≥12 hour battery, throttling at 35–40°C, antenna range >10 meters), and wireless link protocol. By Month 18 (2028-04-30), after architecture ratification and FTO clearance, lock final specifications and produce a component integration map with named owners (electrode lead, ASIC lead, assembly lead), design-review gates (Months 24, 30, 36 = 2028-10-31, 2029-04-30, 2029-10-31), and acceptance test plans (electrical, biocompatibility, sterilisation, mechanical durability). Date: within 6 months (Month 6 = 2027-04-30) for provisional specs, within 18 months (Month 18 = 2028-04-30) for locked specs and integration map.

10. Assertions Without Evidence

Does each critical claim (excluding timeline and budget) include at least one verifiable piece of evidence?

Level: 🛑 High

Justification: Rated HIGH because the plan's core claims—Leuven partnerships (imec, KU Leuven, UZ Leuven by Month 3 = 2027-01-31), investor T0 commitment (EUR 10–15M by Month 12 = 2027-10-31), eligible ALS population (500–1,400 per year), payer cost-per-QALY acceptance (EUR 120,000 proposed threshold), supplier dual-source qualification (by Month 30 = 2029-04-30), signal-stability kill thresholds (20% animal loss proposed), and notified-body regulatory alignment—all lack verifiable artifacts. No written LOIs, term sheets, epidemiological studies, HTA body letters, supplier assessments, published literature citations for thresholds, or notified-body pre-submission feedback exist at Month 0 (2026-10-31). These gaps directly undermine feasibility verdicts at financing gates (Months 12, 24, 36 = 2027-10-31, 2028-10-31, 2029-10-31) and clinical milestones (FIH Month 60 = 2031-10-31, CE marking Month 132 = 2037-10-31).

Mitigation: Commission/obtain: (1) Written LOIs from imec, KU Leuven, UZ Leuven with named resources (cleanroom hours, staff FTE, theatre time, patient cohort) by Month 3 (2027-01-31); (2) Signed investor LOI template with gate conditions and EUR 10–15M T0 commitment by Month 12 (2027-10-31); (3) Independent epidemiology validation of ALS eligible pool (≥300 per year), commissioned by Month 3 (2027-01-31), with final report by Month 15 (2028-01-31) and preliminary payer feedback at Month 12 (2027-10-31); (4) Written HTA/payer acceptance letters for EUR 150,000 price and EUR 120,000 per QALY from ≥3 member states by Month 18 (2028-04-30); (5) Supplier pre-qualification reports and MOUs from ≥2 chip and substrate suppliers by Month 12 (2027-10-31); (6) Published literature review of chronic signal-retention percentiles and evidence-grounded kill thresholds by Month 9 (2027-07-31); (7) Notified-body written pre-submission feedback on clinical investigation design and AI Act scope by Month 7 (2027-05-31). If any artifact remains undelivered by its deadline, escalate to the financing gate and do not release the next tranche.

11. Unclear Deliverables

Are the project's final outputs or key milestones poorly defined, lacking specific criteria for completion, making success difficult to measure objectively?

Level: 🛑 High

Justification: Rated HIGH because the plan mentions six major deliverables—CE marking, 5,000/1,050 cumulative implants, patient-protection reserve adequacy, sovereignty-tested components, informed-consent validity, and ≥10 bits/s bandwidth—without specific, verifiable acceptance criteria or quantifiable KPIs. CE marking is unnamed beyond regulatory conformity; implant targets conflate 5,000 (aspirational, missed) with 1,050 (central estimate, realistic) without clarity on success definition; reserve EUR 31.5M lacks an adequacy threshold; sovereignty compliance is promised by Month 72 (2032-10-31) without defined evidence (legal opinion, audit, certification); consent validity is unmeasured (no validator-agreement target or re-consent completion KPI); bandwidth is 'soft target' of '≥10 bits/s in at least 3 participants' (participant count unjustified). These gaps prevent credible execution accountability and gate verdicts. Missing acceptance criteria for CE marking specifically: no KPI stated for post-issuance modifications, notified-body decision timeline, or NANDO registry publication requirements.

Mitigation: Chief Regulatory Affairs Officer: produce a SMART Acceptance Criteria Charter by Month 6 (2027-04-30) defining verifiable acceptance criteria and one quantifiable KPI per deliverable for: (1) CE marking (KPI: zero post-issuance modifications within 12 months), (2) cumulative implants (KPI: active users / implants, about 52% central estimate), (3) reserve adequacy (KPI: reserve balance / 20-year tail obligation ≥1.0), (4) sovereignty compliance (KPI: 100% components passing three EU-control tests), (5) informed consent (KPI: validator agreement ≥80%, invalid-consent findings ≤1 per 20 implants), (6) bandwidth (KPI: at least 10 bits/s net in at least 3 FIH participants; floor: below 5 bits/s in 50% or more of participants at 12 months after FIH). Charter approved by board, notified body and ethics committees within 10 days.

12. Gold Plating

Does the plan add unnecessary features, complexity, or cost beyond the core goal?

Level: ✅ Low

Justification: Rated LOW because all major cost drivers and work packages in the plan are directly tied to primary objectives (CE marking, ≥10 bits/s bandwidth, EU sovereignty, 1,050 implants) or binding legal/hard requirements (MDR Class III, AI Act compliance, patient safety, informed consent, patient-protection covenant). The plan explicitly rejects the 5,000-implant target as unrealistic, defers enhancement research to post-CE-marking, and uses kill gates to prevent scope creep. No feature, component, or activity identified that adds significant cost/complexity without supporting a core objective or legal requirement.

Mitigation: Gold-Plating Review Lead: conduct an annual scope-creep audit at Months 24, 48, 72, 108 (2028-10-31, 2030-10-31, 2032-10-31, 2035-10-31), mapping each active work package to a named primary objective or hard requirement, and flag any activity lacking clear traceability. Deliverable: written scope audit confirming no new gold-plating features. Timeline: within 60 days of each specified month.

13. Staffing Fit & Rationale

Do the roles, capacity, and skills match the work, or is the plan under- or over-staffed?

Level: 🛑 High

Justification: Rated HIGH because the plan identifies a 'unicorn role'—a specialized neurotech lead combining deep expertise in chronic neural-signal stability, electrode materials science, implant architecture and Class III regulatory pathway—but does not name a candidate, validate talent-market availability or confirm recruitment feasibility against a 20–30% EU pay deficit versus US competitors. The plan assumes 10 core staff recruited by Month 6 (2027-04-30), including a CTO/lead neurosurgeon and regulatory specialist, yet provides no evidence that such talent exists in the EU neurotech labour market or will accept founder-equity risk. Losing the CTO or CMO at Months 12–24 (2027-10-31 to 2028-10-31) delays architecture lock and regulatory engagement by 3–6 months, cascading to gate failures.

Mitigation: Talent Acquisition Lead: conduct a targeted talent-market validation by Month 6 (2027-04-30) identifying at least 3 qualified candidates (published BCI research, chronic-implant experience, EU residency) for the CTO role, 2 for CMO/lead-surgeon role and 2 for regulatory-affairs role. Obtain written offer acceptances or explicit declinations from priority candidates by Month 9 (2027-07-31). If fewer than 50% of offers are accepted or any leadership trio remains incomplete, escalate to the board with a 12-month deferral recommendation.

14. Legal Minefield

Does the plan involve activities with high legal, regulatory, or ethical exposure, such as potential lawsuits, corruption, illegal actions, or societal harm?

Level: 🛑 High

Justification: Rated HIGH because the plan defers legal/regulatory feasibility validation to Month 6 (2027-04-30) notified-body engagement, yet lacks: (1) written confirmation from imec, KU Leuven and UZ Leuven that regulatory site readiness (GCP training, ethics liaison, insurance indemnity) is committed; (2) pre-mapping of Belgium-Netherlands-France ethics-committee approval timelines and harmonisation barriers; (3) AI Act high-risk classification scope and decoder change-control acceptance criteria from any notified body; (4) freedom-to-operate clearance for electrode, encapsulation and decoding IP under the thin-film surface architecture (provisional until Month 18 = 2028-04-30); (5) export-control verification of critical suppliers against EU embargo lists. These regulatory gateways are either unresolved or lack binding third-party commitment, creating a material risk of approval delay or refusal that cascades to CE-marking slip beyond Month 132 (2037-10-31), possibly invalidating tranches T3-T4. No named notified body, regulator contact, or preliminary regulatory dialogue is documented at Month 0 (2026-10-31).

Mitigation: Chief Regulatory Affairs Officer: by Month 6 (2027-04-30), complete a Fatal-Flaw Analysis covering (1) notified-body selection and pre-submission meeting (establish written contact and present Class III implant, AI Act decoder scope and multinational-investigation plan; obtain preliminary evidence-gap list); (2) regulatory-matrix documenting Belgium, Netherlands and France ethics-committee approval pathways, timelines (8-12 weeks per committee estimate) and harmonisation barriers (consent templates, explantation protocols, advance directives); (3) AI Act scope definition—confirm whether decoder is high-risk and what change-control thresholds trigger re-validation; (4) freedom-to-operate clearance per architecture candidate (electrode geometry, signal-conditioning interface, encapsulation material, wireless protocol, neural-signal processing algorithms)—if blocking IP exists, cost licence or design-around and flag as a gate condition; (5) export-control screening of all planned suppliers against EUIC and US entity lists. Deliverable: written regulatory-feasibility summary with no-go findings explicitly stated. Escalation: if any no-go (blocked patent, unacceptable AI Act burden, ethics-committee misalignment) is confirmed, escalate to the board immediately and pre-register a fallback (architecture change, indication pivot, regulatory-strategy reset). NO-GO rule: do not release T1 funding if any blocking patent remains uncleared or any notified body indicates >24 months of added evidence work (stop or pivot); >12 months triggers a re-plan and deferral review at the gate (proposed thresholds).

15. Lacks Operational Sustainability

Even if the project is successfully completed, can it be sustained, maintained, and operated effectively over the long term without ongoing issues?

Level: 🛑 High

Justification: Rated HIGH because the plan projects EUR 45M annual revenue at Month 180 (2041-10-31) against EUR 111M opex, creating a EUR 66M annual structural deficit. No mechanism exists to close this gap: the 1,050-implant central case falls short of the 1,125 implants/year break-even threshold, and surgical capacity is capped at ~300 implants/year across ~25 centres. The patient-protection reserve (EUR 31.5M estimate) is ring-fenced but actuarially unvalidated, relying on a EUR 30,000-per-implant allocation unsupported by ALS-specific care costs. Long-term decoder maintenance, neural-data hosting, and climate-resilience infrastructure requirements are unspecified. Without indication expansion (SCI), price increase (EUR 200,000+), or member-state subsidy, the company faces an unfunded gap of EUR 66M per year at Month 180 (2041-10-31) and inability to sustain patient support obligations.

Mitigation: Chief Financial Officer and Chief Medical Officer: By Month 12 (2027-10-31), deliver a Long-Term Sustainability Plan specifying three pathways and their requirements: (1) SCI-pivot scenario with revised eligible-population size, centre-network cost and revenue model; (2) price-increase scenario with payer re-negotiation triggers and reimbursement-impact modelling; (3) member-state subsidy model with committed funding commitments from 3+ states. Simultaneously, conduct an actuarial reserve adequacy study (due Month 9 = 2027-07-31) validating the EUR 30,000-per-implant allocation against real ALS-care costs (follow-up, imaging, explantation, emergency support) over device lifetime (10–20 years). Within 90 days of Month 24 (2028-10-31), publish a revised break-even model showing which pathway closes the EUR 66M annual gap, or pre-register a wind-down plan if no pathway is credible.

16. Infeasible Constraints

Does the project depend on overcoming constraints that are practically insurmountable, such as obtaining permits that are almost certain to be denied?

Level: 🛑 High

Justification: Rated HIGH because the plan assumes headquarters location (Leuven) and fallback sites without confirming zoning compliance, facility access, or land-use permits at Month 0 (2026-10-31). Manufacturing facility and clinical-site permits are unresolved until Months 6–18 (2027-04-30 to 2028-04-30), risking schedule slip if approvals are denied or delayed. Multi-country ethics approvals (Belgium, Netherlands, France) lack pre-mapped timelines. GLP-certified preclinical facilities are not identified or contracted. EU data-residency compute infrastructure is assumed but not named. No fatal-flaw screen or hard-constraint baseline assessment exists.

Mitigation: Project Permitting Lead: by Month 3 (2027-01-31), conduct a fatal-flaw screen covering zoning/land-use conflict (imec, KU Leuven, UZ Leuven, fallback sites), manufacturing facility permits (contract-manufacturer lease, cleanroom classification, sterilisation authorisation), clinical-site approvals (theatre access letters, insurance indemnity), GLP-certified preclinical lab access, and EU data-centre compliance certification. For each constraint, obtain a written letter confirming compliance or a mitigation plan (e.g., fallback facility, timeline to permit). Define NO-GO thresholds: if any primary Leuven site lacks zoning or facility access confirmation by Month 6 (2027-04-30), activate fallback by Month 7 (2027-05-31) and re-baseline FIH timeline. Within 90 days.

17. External Dependencies

Does the project depend on critical external factors, third parties, suppliers, or vendors that may fail, delay, or be unavailable when needed?

Level: ⚠️ Medium

Justification: Rated MEDIUM because the plan names fallback sites, dual sourcing, and climate mitigation, but leaves critical dependencies unresolved at Month 0 (2026-10-31): Leuven partnerships are unconfirmed (no written LOIs); foundry EUR 350M is hoped-for, not committed; EU compute location is unnamed. Fallback activation (EUR 2M, 3-6 months delay) is budgeted but not pre-negotiated. Dual-sourcing MOUs are due Month 12 (2027-10-31), but both suppliers must qualify by Month 30 (2029-04-30)—only 18 months—leaving no slack if qualification fails. These gaps mean single-source risk persists until Month 30 (2029-04-30), and Leuven partner decline would cascade 3-6 months into FIH schedule.

Mitigation: Supply Chain Lead: by Month 3 (2027-01-31), secure written LOIs from imec, KU Leuven and UZ Leuven specifying resource commitments; simultaneously obtain pre-qualification letters from Ghent/Antwerp, Utrecht and CEA-Leti affirming capacity, cost and ethics timeline. By Month 6 (2027-04-30), contract EU data-centre provider for neural-data hosting with named facility location, GDPR certification and failover capability. By Month 12 (2027-10-31), execute MOUs with two chip and two substrate suppliers with fixed prices, qualification-completion dates and supply commitments. If any primary Leuven LOI is not signed by Month 3 (2027-01-31), activate fallback by Month 4 (2027-02-28) and rebaseline FIH timeline within 15 days.

18. Stakeholder Misalignment

Are there conflicting interests, misaligned incentives, or lack of genuine commitment from key stakeholders that could derail the project?

Level: ⚠️ Medium

Justification: Rated MEDIUM because Finance Department (monthly burn-rate control, tranche gatekeeping, reserve-minimization pressure) and Clinical/Medical Leadership (patient-protection funding, consent-infrastructure commitment, kill-gate independence) have misaligned incentives on reserve adequacy, ethics gatekeeping and clinical-spend prioritization. Finance is incentivized to defer patient reserves and simplify kill gates to preserve cash; Clinical is incentivized to front-load reserves and expand gate scope for safety. This conflict is unstated: no shared objective ties reserve sizing, gate authority or clinical infrastructure to common financial or outcome metrics.

Mitigation: Finance Lead and Chief Medical Officer: jointly establish a Shared Clinical-Financial Scorecard by Month 6 (2027-04-30) with three co-owned OKRs: (1) Patient Reserve Adequacy (monthly audit of reserve balance vs. 20-year tail liability, target ratio 1.0 by Month 120 = 2036-10-31), (2) Gate Independence (monthly tracking of gate-verdict publication compliance, target 100% on-time verdicts within 5 business days), (3) Clinical Infrastructure Uptime (monthly staffing and DMC-meeting completion, target 95% for consent advocacy and DMC). Tie 20% of Finance and CMO annual incentive bonus to scorecard achievement. Publish monthly scorecard to board and investors.

19. No Adaptive Framework

Does the plan lack a clear process for monitoring progress and managing changes, treating the initial plan as final?

Level: 🛑 High

Justification: Rated HIGH because the plan articulates financing gates, kill-gate thresholds and DMC pause authority but lacks operationalised monthly KPI tracking, named review owners, documented escalation protocols, or binding change-control process. Vague 'we will monitor' (financing gates at Months 12, 24, 36 = 2027-10-31, 2028-10-31, 2029-10-31 with 'written verdicts within 5 business days') is insufficient without monthly operational dashboards, clear decision authority, and change-control governance linking decoder updates, supplier audits and centre performance to gate readiness. Missing: process owner for change control, enforcement mechanism for automatic deferral if gates miss, and evidence-grounded thresholds validated against literature before data arrive.

Mitigation: Chief Financial Officer: deliver a Governance Charter by Month 6 (2027-04-30) specifying monthly KPI dashboard (spend, hiring, partner LOI, regulatory milestone, supplier progress), gate escalation protocol (DMC recommendation within 2 days, board decision within 5 days, publication within 10 days), change-control owner (CTO/regulatory co-owners, monthly change log), shareholder agreement binding automatic deferral rules, and validated kill thresholds grounded in literature. Deliverable: written Charter with monthly KPI definitions, gate decision tree and escalation timelines.

20. Uncategorized Red Flags

Are there any other significant risks or major issues that are not covered by other items in this checklist but still threaten the project's viability?

Level: 🛑 High

Justification: Rated HIGH because the plan identifies multiple strong risks (financing gaps EUR 0 committed, signal-stability thresholds unvalidated, eligible population <300/year plausible, partner commitment unconfirmed, regulatory rework 12-24 months feasible, multi-country ethics conflicts likely, supplier dual-sourcing contingent) but lacks explicit cross-impact or bow-tie analysis mapping how these risks interact or compound. Specific uncaptured cascades: (1) T0 financing miss + architecture-switch trigger converge at Month 18 (2028-04-30), consuming EUR 30M contingency + hiring freeze simultaneously; (2) foundry failure + technical rework both activate, together drawing only the EUR 30M (up to EUR 60M) architecture switch plus the EUR 1.2M early site-fallback advance from contingency (the EUR 35M dual-sourcing transfer is a T1/T2 re-allocation), leaving about EUR 219M (about EUR 189M at the upper bound) free contingency (estimate); (3) population/payer validation failures + ethics conflicts collapse the indication-pivot gate (Month 78 = 2033-04-30), forcing rework of trial scope mid-programme. These three cascades are Medium-likelihood each (4-40% estimated individual trigger rates) but create existential failure paths if triggered together. No governance authority, compound-probability model, or NO-GO threshold is defined for multi-node failure.

Mitigation: Chief Risk Officer (to be named by Month 3 = 2027-01-31): deliver a Cascade Risk Map and Bow-Tie Analysis by Month 6 (2027-04-30) covering cross-impact matrix (6+ High/Medium risks × outcomes), three detailed bow-ties for identified cascades (Financing×Technical, Technical×Supply, Commercial×Clinical), quantified compound probabilities, combined heatmap with EUR/month impact, and NO-GO thresholds with named governance authority. Add quarterly cascade-review gates (Months 24, 48, 72 = 2028-10-31, 2030-10-31, 2032-10-31). Date: Month 6 (2027-04-30).

Part 3: Audit trail

What was checked, and how.

Check Method Covers Result
Against sources Web search Sections that searched: Premise Attack (10) 10 searches. Other real-world figures (prices, costs, market sizes, laws, precedents) were not verified.
Canonical facts Reconciled, then the table's own arithmetic re-checked 45 key numbers and dates 4 from your prompt, 12 decisions, 11 proposed thresholds, 18 estimates.
Internal consistency Lint against the canonical facts, then repair and re-lint Executive Summary, Pitch, Premortem, Project Plan, Review Plan, Self Audit and the assumptions (summary version) Before repair: 2 high / 6 medium. After: 0 high / 4 medium, plus 5 needing a decision (see Decisions Required).
Arithmetic Deterministic re-computation Every written calculation ("a x b = c") in 20 sections 21 checked, 0 wrong.
Calendar Deterministic Every "Month N" paired with a date Dates recomputed from the plan start (Month 0).
Schedule Deterministic Gantt and WBS Computed from the estimated durations and dependencies.

By section

Section Checks applied
Decisions Required derived from the consistency check
Canonical Facts reconciled across documents; own arithmetic re-checked; arithmetic (20 calculations, 0 wrong)
Executive Summary consistency lint and repair
Pitch consistency lint and repair
Project Plan consistency lint and repair
Strategic Decisions none
Scenarios none
Assumptions none
Governance none
Related Resources none
Data Collection none
Documents to Create and Find arithmetic (1 calculation, 0 wrong)
SWOT Analysis none
Team none
Expert Criticism none
Review Plan consistency lint and repair
Questions & Answers none
Premortem consistency lint and repair
Self Audit consistency lint and repair
Premise Attack web search (10 searches)

Contradictions between the core documents, after repair.

Consistency: first pass found 2 high / 6 medium / 1 low contradictions. Repair: round 1: 34 edits → 2 high / 7 medium; round 2: 49 edits → 0 high / 4 medium. Published: round 2 (fewest high-severity issues). Shown below: the final check of the repaired documents (0 high / 4 medium / 2 low).

1. Central-case economics never earn a return; the proposed fixes do not close the gap (🔴 High) — needs a project decision

2. What a missed financing gate means: automatic 12-month deferral, halt, or renegotiation; and who decides (🔴 High) — needs a project decision

3. Funding source and timing of the architecture switch and early advances (🟡 Medium) — needs a project decision

4. Eligible-pool floor equals capacity, and the pool/capture link to 1,050 implants is unexplained (🟡 Medium) — needs a project decision

5. Stability thresholds are 'set before data collection' but may be changed after animal data exist (🟡 Medium)

6. Month 72: bandwidth floor, verification and materials lock versus follow-up and indication gate (🟡 Medium)

7. Human-trial ethics approvals due at Month 12 while FIH is Month 60 (🟡 Medium)

8. FIH delays quoted outside the canonical FIH range (🟡 Medium)

9. Patient reserve: funding schedule, amount and cash flow versus the opex gap (🟡 Medium) — needs a project decision

10. Payer, HTA and epidemiology dates differ between documents (⚪ Low)

11. CE lower bound of Month 114 versus pivotal enrolment ending at Month 120 (⚪ Low) — needs a project decision

12. Arithmetic and unit slips in the review plan and self-audit (⚪ Low)

Summary

The plan is largely consistent on its core numbers: tranches sum to EUR 2.5B, active users are 52% of cumulative implants, and the break-even of 1,125 per year follows from the stated price and costs. Most earlier contradictions have been repaired: the contingency arithmetic, the 12/24-month evidence limit, the OR stop rule and the wind-down date. Three issues remain. The economics never earn a return, and the proposed fixes do not close the EUR 66M gap. A missed gate is described as an automatic 12-month deferral in some places and as a halt in others. No document names the committed money that pays for an early architecture switch. The other remaining items are repairable date, threshold-timing and arithmetic slips.

How the canonical facts were reconciled

Arithmetic was recomputed for all products, sums and ratios (T0 bottom-up EUR 15.0M, tranches to EUR 2,500M, 1,050 implants, 52% active users, EUR 45M revenue, EUR 111M opex, EUR 66M gap, 1,125 break-even, EUR 30k reserve) and these were correct. Corrections: the sovereignty basis wrongly said Month 30 (2029-04-30) precedes design lock (Months 24-30 = 2028-10-31 to 2029-04-30), so Month 36 (2029-10-31) is rejected as falling after design lock; the fallback fact claimed both fallbacks drew on the contingency while also saying dual-sourcing is in the base case, and the EUR 2M site fallback exceeds the EUR 0.8M T0 contingency by EUR 1.2M (the programme contingency exists only in T3/T4, so an early advance needs a board decision); the CE basis mixed slip assumptions with the bottom-up 132 and was rewritten. A new fact gives the free contingency (about EUR 219M central) after the architecture switch and early advance, with the reserve floor and dual-sourcing transfer funded inside the tranches; the bandwidth target's 3-participant minimum is flagged as proposed, and the stability fact notes that the 36-month retention check falls after the pivotal start.

Initial Prompt

Plan:
Create a European brain-computer interface company that can compete with leading US and Chinese players such as Neuralink, Synchron and Chinese state-backed programs. The long-term motivation is a possible merging of humans and AI, which needs high-bandwidth communication between brain and machine, since today a person can intentionally output only a very limited stream of information. The first product competes on clinical benefit; output bandwidth is the long-term technical edge. The company starts with only the founders, but licensing or acquiring existing EU neurotech assets, teams or companies is allowed and should be compared with building in-house.

Hard requirements are patient safety and valid consent, EU control of the delivered clinical system by the pivotal trial, and no assumed funding, political exemptions, supplier commitments or breakthroughs. The budget, milestones, patient numbers and bandwidth figures are soft targets, reported as met or missed with ranges. The plan must contain a feasibility verdict on the original mission, judged on the hard requirements and separating scientific, engineering, clinical, regulatory, supply-chain and financing feasibility: achievable as specified, achievable only with changes, or not credibly achievable. Any revised mission is presented separately, each change justified with its effect on the original objectives, and never counts as achieving the original. A well-supported decision not to proceed is acceptable. Beyond the verdict, the plan must be goal-seeking: for each critical obstacle, the most credible route past it (research, competing suppliers, partnerships, acquisitions, investment or institutional action), the evidence that would validate it, its cost and its decision date. Where several routes are credible, rank them by probability of success, time to decisive evidence, capital required and preservation of the original mission, and recommend one primary route and a contingency. Evaluate the recommended routes together as one integrated strategy whose architecture, supply chain, clinical evidence, financing and timeline are mutually compatible. It must separate a minimum viable programme for the first two years (founding team, hospital partner, architecture and supplier validation, funding to retire the first decisive risks) from the full industrial programme, and stage investment around demonstrated progress.

The first product is a Class III medical implant optimised for net clinical benefit and long-term safety; extra bandwidth justifies extra risk only under a documented benefit-risk assessment. Pick one initial indication, for example communication restoration in locked-in ALS or motor control in high spinal cord injury, and the clinical outcome that justifies brain surgery. Early participants will be people with severe, often progressive or terminal conditions with a defensible prospect of direct benefit; plan for consent when communication is impaired, independent ethics review and lifelong follow-up, and never recruit from coercive settings such as prisons. Compare penetrating cortical, endovascular and surface or thin-film architectures on clinical benefit, surgical risk, chronic stability, bandwidth and scalability, and choose one. Quality management, preclinical and biocompatibility evidence, sterilisation, manufacturing validation, human factors and risk management shape the design from the start; use existing EU mechanisms such as coordinated assessment of multinational clinical investigations. Human-AI enhancement is a separate research track sharing hardware and IP only where that does not compromise the medical device, and the plan should manage how it is communicated, since it could undermine trust in the medical programme.

Measure bandwidth as user-controlled information transfer rate: bits per second the person independently selects, decoded from neural signals, net of errors, sustained over sessions, excluding language-model expansion and autocomplete. Use a predefined protocol with held-out tasks, independent verification and multiple participants, reporting structured command selection separately from free communication, alongside words per minute, error rate, latency and calibration time. Target at least 10 bits per second in early trials; over 100 by year 15 is a stretch goal. Give pessimistic, central and optimistic scenarios for where the best US and Chinese systems will be by then, rather than a single forecast.

Sovereignty has three layers. The delivered clinical system (electrodes, implant electronics, encapsulation, any surgical robotics the architecture needs, decoding software and AI models, clinical data and hosting) must be EU-controlled by the pivotal trial. Critical design, software and IP must be EU-controlled, with foreign dependencies listed as explicit exceptions. Upstream equipment and tools, such as fab equipment and chip design software, are documented and mitigated rather than eliminated, and relabelling a dependency as upstream does not make it sovereign. Define EU-controlled with testable criteria: ownership, the ability to maintain the capability without foreign consent, and freedom from foreign export controls. EU member states are preferred for sovereignty-critical capabilities; EEA countries (Norway, Iceland, Liechtenstein) may be used where equivalent legal protection, control, funding eligibility and independence are demonstrated. Switzerland and the UK are outside the perimeter. Lock materials, chips and processes before the pivotal trial and budget bridging studies where sovereignty changes invalidate earlier evidence. Neural data stays in the EU by policy.

The company is based in Leuven, Belgium, close to the European institutions in Brussels. The local ecosystem includes imec, KU Leuven and the university hospital UZ Leuven, none of which has committed to partner. Headquarters and core R&D are in Leuven. Prefer local manufacturing and clinical capabilities where technically, commercially and regulatorily suitable; a research pilot line is not a validated Class III production line. Use other EU sites where they offer demonstrably better feasibility, cost, capacity, quality or speed, keeping a coherent Leuven-centred programme with each distributed facility justified, and say what happens if a local institution declines to partner. Later clinical trials and commercial rollout extend to other member states. Assess the Leuven site's long-term climate and infrastructure resilience, including multi-day heatwaves above 35°C, drought, flooding, power reliability, cooling and water for manufacturing and compute, thermal reliability of wearable hardware, and heat risk to patients with impaired thermoregulation.

Assume about €2.5 billion over 15 years for the company, from investors who need a return plus grants. Estimate shared European capabilities, such as a neural-implant foundry, separately, then give one programme total, distinguishing committed from hoped-for money. An Important Project of Common European Interest ordinarily involves at least four member states and is funded by them. Any unfunded prerequisite gets a financing gate and deadline, after which the plan stops, defers or switches to a named alternative. Seek Commission support for faster review, scientific advice and coordinated trials, but do not assume reduced evidence requirements. Cover AI Act obligations for high-risk AI in medical devices.

Assume US competitors may obtain CE marking and enter the EU market first: explain why EU patients, hospitals and payers would still choose this device, state whether the company also sells outside the EU, and include a freedom-to-operate assessment against existing BCI patents. Build a reimbursement and health-economic case against existing assistive technology, and plan for device lifetime, explantation, cybersecurity, long-term support, and reserves protecting implanted patients if the company fails.

The plan runs 15 years from now. First-in-human within about five years, CE marking within about ten and over 5,000 implanted patients by year 15 are targets: schedule bottom-up with uncertainty ranges, validate patient numbers against eligible populations, surgical centres and reimbursement, and distinguish cumulative implants from active users. Define kill gates for continuing, switching architecture, dropping an indication or terminating, for example if chronic signal stability proves insufficient. Stakeholders include investors, the Commission and member states, notified bodies, hospitals, patients, ethics committees, EU suppliers and a sceptical public; recruiting talent against US salaries is a constant constraint.

Success means a CE-marked EU implant with demonstrated clinical benefit, over 5,000 reimbursed patients, a sovereign clinical system and competitive bandwidth. Failure means dependence on US or Chinese technology in the delivered system, unacceptable patient harm, continuing when risks outweigh benefits, abandoning implanted patients, or running out of money before approval.


Today's date:
2026-Oct-31

Project start ASAP

Prompt Screening

Verdict: 🟢 USABLE

Rationale: The prompt describes a concrete, highly detailed project: founding a Leuven-based EU brain-computer interface company with a 15-year timeline, a €2.5B budget, a Class III implant, regulatory and sovereignty requirements, and kill gates. The ambitious scope is plannable. The "Numbers and provenance" and "Voice" sections are formatting guidance, not prompt injection.

Redline Gate

Verdict: 🟡 ALLOW WITH SAFETY FRAMING

Rationale: This is a strategic, regulatory and financing plan for a medical implant company with strong patient-safety and consent requirements. It touches human implants and human-subject trials, so help should stay at the level of governance, feasibility, ethics and planning. It should not include surgical protocols, device fabrication instructions or trial procedures.

Violation Details

Detail Value
Capability Uplift No

Premise Attack

Why this fails.

Premise Attack 1 — Integrity

Forensic audit of foundational soundness across axes.

[STRATEGIC] A founders-only Leuven start-up cannot credibly build a fully EU-sovereign Class III brain implant, from chips to AI models, to beat funded US and Chinese rivals who are already implanting humans, and the human-AI merger motive adds a trust liability without making the medical case any stronger.

Bottom Line: REJECT: Do not found this company. The mission needs funding, partners and technology that its own rules forbid assuming, and its 'merge with AI' motive endangers both the medical programme and the patients.

Reasons for Rejection

Second-Order Effects

Evidence

Premise Attack 2 — Accountability

Rights, oversight, jurisdiction-shopping, enforceability.

[STRATEGIC] — Flag-Before-Function Trap: the plan makes "EU-controlled" the hard requirement and a brain implant the vehicle, so a founder-only Leuven start-up with no committed hospital, fab, supplier or funder is asked to out-build Neuralink, Synchron and state-backed Chinese programmes on sovereignty first and patient benefit second, in service of a human–AI merger that the patients carrying the surgical risk never asked for.

Bottom Line: REJECT: The Flag-Before-Function Trap puts sovereignty and bandwidth ahead of patients' real needs, using a start-up with no committed partner or funder and a long-term motive the participants never agreed to. A premise that makes implanted people carry the risk of a geopolitical race should not be funded.

Reasons for Rejection

Second-Order Effects

Evidence

Premise Attack 3 — Spectrum

Enforced breadth: distinct reasons across ethical/feasibility/governance/societal axes.

[STRATEGIC] A founders-only Leuven start-up promising a sovereign Class III brain implant with a 100-bit-per-second stretch, on unfunded money, uncommitted partners and foreign-dependent chips, mistakes continental ambition for an executable company.

Bottom Line: REJECT: A founders-only European company cannot credibly deliver a fully sovereign, CE-marked, 5,000-patient brain implant that competes on bandwidth with US and Chinese leaders, on money, partners and supply chains that do not yet exist.

Reasons for Rejection

Second-Order Effects

Evidence

Premise Attack 4 — Cascade

Tracks second/third-order effects and copycat propagation.

Strategic flaw: the plan bolts a sovereignty-maximalist, no-assumed-funding, no-assumed-supplier, no-assumed-breakthrough constraint set onto the hardest category of medical device, then tries to beat better-funded rivals in clinical speed and bandwidth. The hard requirements cannot all hold at once. A €2.5B/15-year envelope is roughly two Neuralinks of cumulative cash spread over three times the horizon, while the mission also demands a sovereign foundry, an EU-only supply chain and 5,000 reimbursed patients in a market of a few thousand eligible people.

Bottom Line: Abandon the premise as specified: a sovereign, EU-only, founder-started company that must beat the US and China on bandwidth, reach 5,000 reimbursed patients and carry a lifelong implant-support liability on €2.5B of mostly hoped-for money is internally contradictory. The failure sits in the combination of hard requirements, which no implementation can reconcile, not in the execution. The defensible decision is not to proceed with the original mission.

Reasons for Rejection

Second-Order Effects

Evidence

Premise Attack 5 — Escalation

Narrative of worsening failure from cracks → amplification → reckoning.

[STRATEGIC] — Sovereign Cortex Mirage: the plan fuses a founders-only start-up, a full-stack EU-control mandate before the pivotal trial, and a human-AI merger ambition into one Class III implant programme, so every hard requirement (patient safety, valid consent, sovereignty, no assumed funding or suppliers) is in tension with the others, and the only way to keep the mission alive is to quietly bend the one that no regulator is watching yet.

Bottom Line: REJECT: A founders-only company cannot be trusted to build a sovereign, permanent brain implant while pursuing human-AI merging and promising no compromise on safety, consent, funding or control, and the premise deserves no go-ahead.

Reasons for Rejection

Second-Order Effects

Evidence

Overall Adherence: 86%

IMPORTANCE_ADHERENCE_SUM = (5×4 + 5×5 + 5×4 + 5×3 + 5×4 + 5×5 + 5×4 + 5×5 + 5×5 + 5×5 + 5×5 + 5×4 + 5×5 + 4×3 + 4×4 + 5×4 + 4×5 + 4×4 + 3×3 + 3×4) = 395
IMPORTANCE_SUM = 5 + 5 + 5 + 5 + 5 + 5 + 5 + 5 + 5 + 5 + 5 + 5 + 5 + 4 + 4 + 5 + 4 + 4 + 3 + 3 = 92
OVERALL_ADHERENCE = IMPORTANCE_ADHERENCE_SUM / (IMPORTANCE_SUM × 5) = 395 / 460 = 86%

Summary

ID Directive Type Importance Adherence Category
1 Create a European brain-computer interface company competitive with Neuralink, Synchron, Chinese state-backed programmes; long-term mission is high-bandwidth brain-machine communication enabling human-AI merging. Requirement 5/5 4/5 Partially honored
2 Hard requirements: patient safety, valid consent, EU control of delivered clinical system by pivotal trial, no assumed funding, political exemptions, supplier commitments or breakthroughs. Constraint 5/5 5/5 Fully honored
3 Plan must contain feasibility verdict (achievable as specified, achievable only with changes, or not credibly achievable) on original mission, separating scientific, engineering, clinical, regulatory, supply-chain and financing feasibility. Requirement 5/5 4/5 Partially honored
4 For each critical obstacle: identify most credible route (research, suppliers, partnerships, acquisitions, investment, institutional action), evidence to validate it, cost, decision date; rank credible routes by success probability, time to evidence, capital and mission preservation. Requirement 5/5 3/5 Partially honored
5 Separate minimum viable programme for first two years (founding team, hospital partner, architecture and supplier validation, funding to retire first risks) from full industrial programme; stage investment around demonstrated progress. Requirement 5/5 4/5 Partially honored
6 Class III medical implant optimised for net clinical benefit and long-term safety; pick one initial indication (e.g. communication restoration in locked-in ALS or motor control in spinal cord injury); early participants have severe, often progressive/terminal conditions with defensible prospect of direct benefit. Requirement 5/5 5/5 Fully honored
7 Compare penetrating cortical, endovascular and surface/thin-film architectures on clinical benefit, surgical risk, chronic stability, bandwidth and scalability; choose one. Quality management, preclinical and biocompatibility evidence, sterilisation, manufacturing validation shape design from start. Requirement 5/5 4/5 Partially honored
8 Measure bandwidth as user-controlled information transfer rate (bits/second, decoded from neural signals, net of errors, sustained over sessions, excluding language-model expansion/autocomplete). Target ≥10 bits/s in early trials; >100 by year 15 is stretch goal. Report with predefined protocol, independent verification, multiple participants. Requirement 5/5 5/5 Fully honored
9 Sovereignty: delivered clinical system (electrodes, implant electronics, encapsulation, surgical robotics, decoding software, AI models, clinical data/hosting) must be EU-controlled by pivotal trial. Define EU-controlled with testable criteria: ownership, maintainability without foreign consent, freedom from foreign export controls. Requirement 5/5 5/5 Fully honored
10 EU member states preferred for sovereignty-critical capabilities; EEA countries (Norway, Iceland, Liechtenstein) allowed if equivalent legal protection, control, funding eligibility and independence demonstrated. Switzerland and UK are outside perimeter. Neural data stays in EU by policy. Requirement 5/5 5/5 Fully honored
11 Company based in Leuven, Belgium; local ecosystem includes imec, KU Leuven and UZ Leuven, none of which has committed to partner. Headquarters and core R&D are in Leuven. Stated fact 5/5 5/5 Fully honored
12 Prefer local manufacturing and clinical capabilities where technically, commercially and regulatorily suitable; use other EU sites where demonstrably better feasibility, cost, capacity, quality or speed. Say what happens if local institution declines to partner. Assess Leuven's climate and infrastructure resilience (35°C heatwaves, drought, flooding, power, cooling, water, thermal reliability). Requirement 5/5 4/5 Partially honored
13 Assume about EUR 2.5 billion over 15 years from investors needing return plus grants. Committed funding at Month 0 (2026-10-31) is EUR 0; everything is hoped-for until written commitment closes. Any unfunded prerequisite gets financing gate and deadline; if not met, plan stops, defers or switches to named alternative. Constraint 5/5 5/5 Fully honored
14 Explain why EU patients, hospitals and payers would choose this device if US competitors obtain CE marking first. Include freedom-to-operate assessment against existing BCI patents. Build reimbursement and health-economic case against existing assistive technology. Requirement 4/5 3/5 Partially honored
15 Plan device lifetime, explantation, cybersecurity, long-term support and reserves protecting implanted patients if company fails. Define kill gates for continuing, switching architecture, dropping indication or terminating (e.g. if chronic signal stability proves insufficient). Requirement 4/5 4/5 Partially honored
16 15-year plan horizon from Month 0 (2026-10-31) to Month 180 (2041-10-31). First-in-human within about 5 years, CE marking within about 10 years, over 5,000 implanted patients by year 15 are targets; schedule bottom-up with uncertainty ranges. Constraint 5/5 4/5 Partially honored
17 Budget, milestones, patient numbers and bandwidth figures are soft targets, reported as met or missed with ranges. Feasibility verdict is separate from revised mission; any revised mission change is justified and never counts as achieving original. Well-supported decision not to proceed is acceptable. Requirement 4/5 5/5 Fully honored
18 Plan consent for impaired communication, independent ethics review and lifelong follow-up; never recruit from coercive settings such as prisons. Human-AI enhancement is separate research track sharing hardware and IP only where that does not compromise medical device; manage communication to avoid undermining trust. Requirement 4/5 4/5 Partially honored
19 Give pessimistic, central and optimistic scenarios for where best US and Chinese BCI systems will be by year 15, rather than single forecast. Compare against those scenarios to assess competitive feasibility. Requirement 3/5 3/5 Partially honored
20 Cover AI Act obligations for high-risk AI in medical devices. Estimate shared European capabilities (neural-implant foundry) separately, then give one programme total distinguishing committed from hoped-for money. Requirement 3/5 4/5 Partially honored

Issues

Issue 4 - For each critical obstacle: identify most credible route (research, suppliers, partnerships, acquisitions, investment, institutional action), evidence to validate it, cost, decision date; rank credible routes by success probability, time to evidence, capital and mission preservation.

Issue 14 - Explain why EU patients, hospitals and payers would choose this device if US competitors obtain CE marking first. Include freedom-to-operate assessment against existing BCI patents. Build reimbursement and health-economic case against existing assistive technology.

Issue 1 - Create a European brain-computer interface company competitive with Neuralink, Synchron, Chinese state-backed programmes; long-term mission is high-bandwidth brain-machine communication enabling human-AI merging.

Issue 3 - Plan must contain feasibility verdict (achievable as specified, achievable only with changes, or not credibly achievable) on original mission, separating scientific, engineering, clinical, regulatory, supply-chain and financing feasibility.

Issue 5 - Separate minimum viable programme for first two years (founding team, hospital partner, architecture and supplier validation, funding to retire first risks) from full industrial programme; stage investment around demonstrated progress.

Issue 7 - Compare penetrating cortical, endovascular and surface/thin-film architectures on clinical benefit, surgical risk, chronic stability, bandwidth and scalability; choose one. Quality management, preclinical and biocompatibility evidence, sterilisation, manufacturing validation shape design from start.

Issue 12 - Prefer local manufacturing and clinical capabilities where technically, commercially and regulatorily suitable; use other EU sites where demonstrably better feasibility, cost, capacity, quality or speed. Say what happens if local institution declines to partner. Assess Leuven's climate and infrastructure resilience (35°C heatwaves, drought, flooding, power, cooling, water, thermal reliability).

Issue 16 - 15-year plan horizon from Month 0 (2026-10-31) to Month 180 (2041-10-31). First-in-human within about 5 years, CE marking within about 10 years, over 5,000 implanted patients by year 15 are targets; schedule bottom-up with uncertainty ranges.

Issue 19 - Give pessimistic, central and optimistic scenarios for where best US and Chinese BCI systems will be by year 15, rather than single forecast. Compare against those scenarios to assess competitive feasibility.

Issue 15 - Plan device lifetime, explantation, cybersecurity, long-term support and reserves protecting implanted patients if company fails. Define kill gates for continuing, switching architecture, dropping indication or terminating (e.g. if chronic signal stability proves insufficient).

Issue 18 - Plan consent for impaired communication, independent ethics review and lifelong follow-up; never recruit from coercive settings such as prisons. Human-AI enhancement is separate research track sharing hardware and IP only where that does not compromise medical device; manage communication to avoid undermining trust.

Issue 20 - Cover AI Act obligations for high-risk AI in medical devices. Estimate shared European capabilities (neural-implant foundry) separately, then give one programme total distinguishing committed from hoped-for money.

Which generator version and models produced each part.

Generator

Stages

Stage Generated at Generator Models LLM calls
screen_planning_prompt 2026-10-31T23:19:13 v2.0.6-10-gfcdea47 claude-sonnet-5-5 1
setup 2026-10-31T23:19:09 v2.0.6-10-gfcdea47 - 0
extract_constraints 2026-10-31T23:19:43 v2.0.6-10-gfcdea47 claude-sonnet-5-5 1
identify_purpose 2026-10-31T23:19:14 v2.0.6-10-gfcdea47 claude-sonnet-5-5 1
premise_attack 2026-10-31T23:20:29 v2.0.6-10-gfcdea47 claude-sonnet-5-5 5
redline_gate 2026-10-31T23:19:22 v2.0.6-10-gfcdea47 claude-sonnet-5-5 1
classify_domain 2026-10-31T23:20:25 v2.0.6-10-gfcdea47 claude-sonnet-5-5 4
plan_type 2026-10-31T23:20:34 v2.0.6-10-gfcdea47 claude-sonnet-5-5 1
potential_levers 2026-10-31T23:25:29 v2.0.6-10-gfcdea47 claude-sonnet-5-5 23
potential_levers_constraint 2026-10-31T23:26:13 v2.0.6-10-gfcdea47 claude-sonnet-5-5 1
triage_levers 2026-10-31T23:25:58 v2.0.6-10-gfcdea47 claude-sonnet-5-5 1
enrich_levers 2026-10-31T23:26:29 v2.0.6-10-gfcdea47 claude-sonnet-5-5 3
triaged_levers_constraint 2026-10-31T23:27:05 v2.0.6-10-gfcdea47 claude-sonnet-5-5 1
enriched_levers_constraint 2026-10-31T23:27:06 v2.0.6-10-gfcdea47 claude-sonnet-5-5 1
focus_on_vital_few_levers 2026-10-31T23:26:54 v2.0.6-10-gfcdea47 claude-sonnet-5-5 1
candidate_scenarios 2026-10-31T23:27:44 v2.0.6-10-gfcdea47 claude-sonnet-5-5 1
strategic_decisions_markdown 2026-10-31T23:26:54 v2.0.6-10-gfcdea47 - 0
vital_few_levers_constraint 2026-10-31T23:27:56 v2.0.6-10-gfcdea47 claude-sonnet-5-5 1
candidate_scenarios_constraint 2026-10-31T23:28:48 v2.0.6-10-gfcdea47 claude-sonnet-5-5 1
select_scenario 2026-10-31T23:28:00 v2.0.6-10-gfcdea47 claude-sonnet-5-5 1
scenarios_markdown 2026-10-31T23:28:00 v2.0.6-10-gfcdea47 - 0
selected_scenario_constraint 2026-10-31T23:29:04 v2.0.6-10-gfcdea47 claude-sonnet-5-5 1
physical_locations 2026-10-31T23:28:15 v2.0.6-10-gfcdea47 claude-sonnet-5-5 1
currency_strategy 2026-10-31T23:28:28 v2.0.6-10-gfcdea47 claude-haiku-4-5-20251001 1
identify_risks 2026-10-31T23:32:23 v2.0.6-10-gfcdea47 claude-haiku-4-5-20251001 1
make_assumptions 2026-10-31T23:32:51 v2.0.6-10-gfcdea47 claude-sonnet-5-5 1
distill_assumptions 2026-10-31T23:33:02 v2.0.6-10-gfcdea47 claude-sonnet-5-5 1
review_assumptions 2026-10-31T23:33:51 v2.0.6-10-gfcdea47 claude-haiku-4-5-20251001 1
consolidate_assumptions_markdown 2026-10-31T23:35:56 v2.0.6-10-gfcdea47 claude-haiku-4-5-20251001 9
pre_project_assessment 2026-10-31T23:37:20 v2.0.6-10-gfcdea47 claude-haiku-4-5-20251001 1
canonical_facts 2026-10-31T23:43:02 v2.0.6-10-gfcdea47 claude-sonnet-5-5 2
project_plan 2026-10-31T23:43:58 v2.0.6-10-gfcdea47 claude-sonnet-5-5 1
create_wbs_level1 2026-10-31T23:44:02 v2.0.6-10-gfcdea47 claude-haiku-4-5-20251001 1
governance_phase1_audit 2026-10-31T23:44:43 v2.0.6-10-gfcdea47 claude-haiku-4-5-20251001 1
related_resources 2026-10-31T23:44:28 v2.0.6-10-gfcdea47 claude-sonnet-5-5 1
find_team_members 2026-10-31T23:44:58 v2.0.6-10-gfcdea47 claude-haiku-4-5-20251001 1
governance_phase2_bodies 2026-10-31T23:46:35 v2.0.6-10-gfcdea47 claude-haiku-4-5-20251001 1
swot_analysis 2026-10-31T23:44:55 v2.0.6-10-gfcdea47 claude-sonnet-5-5 1
enrich_team_members_with_contract_type 2026-10-31T23:46:14 v2.0.6-10-gfcdea47 claude-haiku-4-5-20251001 1
expert_review 2026-10-31T23:51:33 v2.0.6-10-gfcdea47 claude-haiku-4-5-20251001 10
governance_phase3_impl_plan 2026-10-31T23:50:00 v2.0.6-10-gfcdea47 claude-haiku-4-5-20251001 1
enrich_team_members_with_background_story 2026-10-31T23:47:13 v2.0.6-10-gfcdea47 claude-haiku-4-5-20251001 1
governance_phase4_decision_escalation_matrix 2026-10-31T23:52:21 v2.0.6-10-gfcdea47 claude-haiku-4-5-20251001 1
enrich_team_members_with_environment_info 2026-10-31T23:51:03 v2.0.6-10-gfcdea47 claude-haiku-4-5-20251001 1
governance_phase5_monitoring_progress 2026-10-31T23:53:21 v2.0.6-10-gfcdea47 claude-haiku-4-5-20251001 1
governance_phase6_extra 2026-10-31T23:54:19 v2.0.6-10-gfcdea47 claude-haiku-4-5-20251001 1
review_team 2026-10-31T23:53:05 v2.0.6-10-gfcdea47 claude-haiku-4-5-20251001 1
consolidate_governance 2026-10-31T23:54:19 v2.0.6-10-gfcdea47 - 0
team_markdown 2026-10-31T23:53:05 v2.0.6-10-gfcdea47 - 0
data_collection 2026-10-31T23:58:09 v2.0.6-10-gfcdea47 claude-haiku-4-5-20251001 1
identify_documents 2026-11-01T00:00:46 v2.0.6-10-gfcdea47 claude-haiku-4-5-20251001 1
create_wbs_level2 2026-10-31T23:58:40 v2.0.6-10-gfcdea47 claude-haiku-4-5-20251001 1
filter_documents_to_create 2026-11-01T00:01:15 v2.0.6-10-gfcdea47 claude-sonnet-5-5 1
filter_documents_to_find 2026-11-01T00:01:47 v2.0.6-10-gfcdea47 claude-haiku-4-5-20251001 1
draft_documents_to_create 2026-11-01T00:03:53 v2.0.6-10-gfcdea47 claude-haiku-4-5-20251001 5
draft_documents_to_find 2026-11-01T00:06:24 v2.0.6-10-gfcdea47 claude-haiku-4-5-20251001 10
identify_task_dependencies 2026-10-31T23:59:03 v2.0.6-10-gfcdea47 claude-haiku-4-5-20251001 1
wbs_project_level1_and_level2 2026-10-31T23:58:40 v2.0.6-10-gfcdea47 - 0
create_pitch 2026-10-31T23:59:15 v2.0.6-10-gfcdea47 claude-haiku-4-5-20251001 1
estimate_task_durations 2026-11-01T00:00:49 v2.0.6-10-gfcdea47 claude-haiku-4-5-20251001 19
markdown_with_documents_to_create_and_find 2026-11-01T00:06:24 v2.0.6-10-gfcdea47 - 0
convert_pitch_to_markdown 2026-11-01T00:00:46 v2.0.6-10-gfcdea47 claude-haiku-4-5-20251001 1
create_wbs_level3 2026-11-01T00:07:59 v2.0.6-10-gfcdea47 claude-haiku-4-5-20251001 48
wbs_project_level1_and_level2_and_level3 2026-11-01T00:07:59 v2.0.6-10-gfcdea47 - 0
create_schedule 2026-11-01T00:07:59 v2.0.6-10-gfcdea47 - 0
review_plan 2026-11-01T00:12:47 v2.0.6-10-gfcdea47 claude-haiku-4-5-20251001 16
executive_summary 2026-11-01T00:13:19 v2.0.6-10-gfcdea47 claude-haiku-4-5-20251001 1
questions_and_answers 2026-11-01T00:15:13 v2.0.6-10-gfcdea47 claude-haiku-4-5-20251001 2
premortem 2026-11-01T00:16:23 v2.0.6-10-gfcdea47 claude-sonnet-5-5 3
prompt_adherence 2026-11-01T00:15:05 v2.0.6-10-gfcdea47 claude-haiku-4-5-20251001 2
self_audit 2026-11-01T00:23:38 v2.0.6-10-gfcdea47 claude-haiku-4-5-20251001 20
consistency_review 2026-11-01T00:26:53 v2.0.6-10-gfcdea47 claude-sonnet-5-5 1
consistency_repair 2026-11-01T00:35:00 v2.0.6-10-gfcdea47 claude-sonnet-5-5 14
decision_register 2026-11-01T00:35:31 v2.0.6-10-gfcdea47 claude-sonnet-5-5 1
arithmetic_check 2026-11-01T00:35:31 v2.0.6-10-gfcdea47 - 0